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Abstract 
 The preparation and characterization of coordination complexes of Schiff-base 
and crown ether macrocycles is presented, for application as contrast agents for magnetic 
resonance imaging, Project 1; and single-molecule magnets (SMMs), Projects 2 and 3. 
 In Project 1, a family of eight Mn
II
 and Gd
III
 complexes of N3X2 (X = NH, O) 
and N3O3 Schiff-base macrocycles were synthesized, characterized, and evaluated as 
potential contrast agents for MRI. In vitro and in vivo (rodent) studies indicate that the 
studied complexes display efficient contrast behaviour, negligible toxicity, and rapid 
excretion.   
 In Project 2, Dy
III
 complexes of Schiff-base macrocycles were prepared with a 
view to developing a new family of mononuclear Ln-SMMs with pseudo-D5h geometries. 
Each complex displayed slow relaxation of magnetization, with magnetically-derived 
energy barriers in the range Ueff = 4 – 24 K.  
 In Project 3, coordination complexes of selected later lanthanides with various 
crown ether ligands were synthesized. Two families of complexes were structurally and 
magnetically analyzed: ‘axial’ or sandwich-type complexes based on 12-crown-4 and 15-
crown-5; and ‘equatorial’ complexes based on 18-crown-6. Magnetic data are supported 
by ab initio calculations and luminescence measurements. Significantly, the first 
mononuclear Ln-SMM prepared from a crown ether ligand is described. 
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1 INTRODUCTION 
 Over the last two decades, the field of molecular magnetism has enjoyed a surge 
of popularity. My research focusses on the development of new magnetic materials from 
macrocyclic ligands for application in two areas: the development of novel contrast 
agents for magnetic resonance imaging (MRI), and the study of lanthanide single-
molecule magnets (Ln-SMMs). The two classes of ligand utilized are Schiff-base 
macrocycles, and crown ethers. The division of my work into three projects based on 
ligand class and application is shown below. 
Project Class of cyclic ligand 
Metal ion(s) 
coordinated 
Magnetic behaviour 
studied 
Application 
1 (Ch. 2) 
Schiff-base 
macrocycles 
Mn
II 
 and Gd
III 
Relaxivity MRI contrast agents 
2 (Ch. 3) 
Schiff-base 
macrocycles 
Dy
III 
Dc and ac susceptibility Mononuclear SMMs 
3 (Ch. 4) Crown ethers 
Tb
III
, Dy
III
, 
Ho
III
, Er
III 
Dc and ac susceptibility Mononuclear SMMs 
 
This introductory section is divided into two parts. Firstly, the principles behind 
the two applications of my work are given: the theory of magnetic resonance imaging 
and recent advances in small-molecule contrast agents are discussed (Section 1.1), and an 
overview of the origins of magnetic behaviour, with a focus on mononuclear single-
molecule magnets, is presented (Section 1.2). Secondly, an introduction to the ligand 
classes is given: magnetic materials based on Schiff-base macrocycles are reviewed 
(Section 1.3), and a brief background to crown ethers is presented (Section 1.4). 
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1.1 MRI contrast agents  
1.1.1 MRI theory 
 Magnetic resonance imaging (MRI) is a medical technique used to provide 2- and 
3D images of tissues and organs in the body. This powerful tool is used to detect, 
diagnose and monitor diseases including cancer,
1
 Alzheimer’s2 and Parkinson’s.3 MRI 
offers several advantages over other imaging modalities such as X-ray, PET and CT 
scans in that it is a non-invasive technique, does not require high-energy radiation, and 
has excellent spatial resolution in the sub-millimeter range.
4
 
 An MRI image is generated from the nuclei of the hydrogen atoms of water 
molecules. Since the protons are spinning charged particles, each proton generates a 
small magnetic moment. In the absence of an applied magnetic field, the spins of these 
protons are randomly oriented. When a field is applied along, say, the z-axis, the 
individual moments align parallel or antiparallel to the z direction. Slightly more spins 
align parallel than antiparallel, resulting in an overall magnetic moment in the z direction 
(Figure 1).
5
 This is known as longitudinal magnetization, Mz. The presence of the field 
also causes the nuclei to ‘wobble’ on their axes. This ‘wobbling’ or precession, occurs at 
a characteristic frequency directly proportional to the strength of the magnetic field, B0 
(T). The characteristic frequency is called the Larmor frequency, ω0 (MHz).
5
 The ratio of 
ω0/B0 is given by the gyromagnetic ratio, γ0, which is specific to a given nucleus. The 
gyromagnetic ratio of 
1
H
 
is 42.58 MHz/T.
5
 
 Following alignment, an electromagnetic pulse is applied to the system with 
precisely enough energy to rotate the longitudinal magnetization vector by exactly 90°, so 
3 
 
that it lies in the transverse plane (Figure 1.1, right). This transverse magnetization, Mxy, 
precesses around the z axis, and this rotation gives rise to an alternating current which is 
the signal recorded as an MRI image.
5
  
 
Figure 1.1   a) In the absence of an applied field, the spins of the water protons are 
randomly oriented; b) when a field B is applied, the spins align in the z direction, 
resulting in longitudinal magnetization M; c) when a specific radiofrequency (RF) pulse 
is applied, the magnetization rotates 90° into the transverse plane. Adapted from 
Reference 5. 
 The transverse magnetization Mxy decays by two relaxation processes: 
longitudinal and transverse relaxation. Longitudinal relaxation, or spin-lattice relaxation, 
involves a loss of energy from the precessing magnetic vector to the surrounding 
environment, causing the signal to decay slowly from the xy plane back to the z direction. 
Transverse relaxation, or spin-spin relaxation, does not involve a loss of energy; rather, 
the precessing transverse moments lose their phase coherence, so the individual vectors 
in the transverse plane begin to cancel each other out, leading to a loss of the MRI signal. 
Longitudinal and transverse relaxation are described by the relaxation time parameters T1 
and T2 respectively (s), and are depicted in Figure 1.2.
5
 
4 
 
 
Figure 1.2   The two processes by which transverse magnetization relaxes: top, 
longitudinal relaxation; bottom, transverse relaxation. Adapted from Reference 5. 
 
 Water protons in different tissues and organs of the body have different intrinsic 
T1 and T2 relaxation times, as do healthy versus diseased portions of the same tissue. This 
results in the natural contrast on an MRI scan.  An MRI scan can be ‘weighted’ to T1 or 
T2, depending on which parameter would allow best visualization of the desired tissue.  
 Sometimes the natural contrast due to the differences in the biological 
environments of water protons does not provide enough intensity difference on an MRI 
image for sufficient detail to be seen. Contrast agents are compounds administered to 
enhance an MRI image, by increasing the signal intensity. Of the 1.5 million MRI scans 
performed in Canada each year, about a third use contrast agents. Contrast agents contain 
a paramagnetic ion or ions, which change the local magnetic field strength of a tissue, 
and interact with the surrounding protons of water molecules, shortening the T1 and T2 
relaxation times.
5
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 Contrast agents can be divided into small-molecule agents, and nanosized agents. 
‘Small-molecule’ agents are complexes smaller than 10 nm in diameter, usually 
comprising one metal center bound to an organic chelating ligand. In contrast, 
‘nanosized’ agents are the broad class of slightly larger compounds, including both 
macromolecular agents (liposomal systems, polymers and dendrimers), and inorganic 
bulk particles. Small-molecule agents are the first and largest class of compounds studied 
as potential imaging agents; they account for 90% of contrast agent use today; and are the 
focus of the work presented in Chapter 2 of this thesis. Therefore these agents will be 
the most thoroughly reviewed in this introductory section. 
1.1.2 Development of contrast agent theory: 
Dominated by Gd
III
(1980-2005)  
 From 1988, when the first contrast agent was approved for use in humans, until 
2006, research into small-molecule agents was focused primarily on complexes of Gd
III
. 
This ion has two important properties: seven unpaired electrons, the most of any metal 
ion; and a slow electronic relaxation time.
4
 This latter point sets Gd
III
 apart from other 
lanthanides which also have large numbers of unpaired electrons since its electronic spin 
states are much more long-lived, in the range 10
-8
-10
-9
 s, allowing sufficient interaction 
between the paramagnetic metal in a given electronic state, and the surrounding water 
molecules.
4
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 The effectiveness of a contrast agent is described by its relaxivity, r1 or r2 (s
-1.
mM
-
1
), where:  
r1 =  
1
T1
⁄
c
         and            r2 =  
1
T2
⁄
c
 
High values of r1 and r2 are desirable. The vast majority of small-molecule agents are 
utilized as T1 agents, in T1-weighted scans. Thus r1 is the relaxivity parameter usually 
reported in the literature, and unless otherwise stated, ‘relaxivity’ will refer to r1 in the 
following discussion. Relaxivity is dependent on both the magnetic field applied, and the 
temperature of the measurement, and so values for these parameters should accompany r1 
values. Most clinical MRI scans are performed in a field of 1.5 T (corresponding to a 
frequency of 64 MHz based on the 
1H Larmor frequency), however ‘low-field scans’ as 
low as 0.3 T (13 MHz) and ‘high-field scans’ up to 3 T (125 MHz) are also carried out.4  
 The relaxivity effect of a contrast agent is due to dipole-dipole interactions 
between the nuclei (protons) of water molecules, and the unpaired electrons of the metal 
center. Relaxation occurs via both an inner-sphere mechanism, through the direct 
interaction of coordinated water molecules with the metal center; and via an outer-sphere 
mechanism, through the indirect effect of the metal center on bulk, non-coordinated 
water. Based on the ‘Solomon-Bloembergen-Morgan Theory’ of relaxation, a thorough 
mathematical model for dipolar interactions developed between 1948 and 1961, the 
relaxivity of a contrast agent may be maximized by optimizing several key parameters: i) 
the number of inner-sphere water molecules, described by the hydration number q; ii) the 
length of time inner-sphere water molecules remain coordinated, given by the residence 
time τM, and reflected in the water exchange rate kex; and iii) the rate at which the 
molecule ‘tumbles,’ described by the rotational correlation time (time taken for a rotation 
7 
 
of 1 radian), τR.
4,5
 These parameters are summarized in Figure 1.3. Additional parameters 
include the interaction of the metal center with outer-sphere water molecules; and the 
electronic relaxation behaviour of the metal center.
4
   
 Relaxivity increases as q, τR, and kex increase: in other words, a good contrast 
agent will bind at least one water molecule, effectively cause it to relax, and then 
efficiently exchange that water molecule for another to repeat the process in a catalytic 
fashion.
6
  
 
Figure 1.3   Factors affecting relaxivity, where q is the hydration number, τM is the water 
residence time, kex is the water exchange rate, and τM is the rotational correlation time.
4,5
 
 
 The design of ligands for small-molecule contrast agents (specifically, Gd
III
 
agents during the development of the field from 1980-2005) has centered on two factors: 
optimizing the parameters described above, for high relaxivity/efficacy; and creating 
agents which will be stable in vivo. Free Gd
III
 has long been recognized as biologically 
toxic: studies in the 1990s in rats and mice showed significant dose-related toxic effects 
upon intravenous administration of GdCl3, particularly in the lungs, kidneys and spleen.
7,8
 
Thus the synthesis of complexes which are both thermodynamically stable and kinetically 
inert is very important.  
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1.1.2.1 DTPA and DOTA ligand systems 
  Two key ligand families have been thoroughly investigated with regards to Gd
III
 
contrast agents: the linear chelating ligand DTPA (diethylenetriaminepentaacetic acid) 
and its derivatives, and the macrocyclic ligand DOTA (tetraazacyclodecanetetraacetic 
acid) and its derivatives. 
 
 The chelating ligand DTPA binds in an octadentate fashion to Gd
III
 via the three 
backbone nitrogen atoms and five (deprotonated) oxygen atoms. One inner-sphere water 
molecule is also bound, resulting in a complex with distorted tricapped trigonal prismatic 
geometry (Figure 1.4, left).  
             
Figure 1.4   Left, crystal structure of [Gd(DTPA)]
2-
. Hydrogen atoms and silver counter 
ions are omitted for clarity.
9
 Right, Schematic showing the tricapped trigonal prismatic 
geometry of Gd
III
-DTPA type complexes. blue circles = backbone nitrogen atoms; open 
circles = donor atoms of pendant arms.
10
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 The Gd
III
-DTPA complex has a relaxivity of 3.4 mM
-1.
sec
-1
 (20 MHz, 37°C, in 
water).
4
 Along with DTPA itself, Gd
III
 complexes of five derivatives of this macrocycle 
are approved for clinical use, including ligands with pendant ether, phosphate, and amide 
groups (Figure 1.5). These derivatives exhibit similar distorted TTP geometries, with the 
single bound water molecule occupying a ‘capped’ position opposite the backbone 
nitrogen atoms (Figure 1.4, right).
4
  
 
Figure 1.5   Derivatives of DTPA approved for clinical use.
10
 
 
 The macrocyclic ligand DOTA also binds in an octadentate fashion, with the four 
nitrogen atoms forming a plane parallel to, but offset from, the four oxygen atoms of the 
pendant carboxylic arms. A coordinating water molecule binds above the O4 plane to give 
a capped square antiprismatic geometry (Figure 1.6). Complexes of DOTA and its 
derivatives may be described using three parameters: d, the distance between the N4 and 
O4 planes; ψ, the angle at which the O4 plane is rotated from the N4 plane; and ω, the 
10 
 
minimum O-Gd-O angle, also called the ‘opening angle.’4 The key parameter which 
determines whether a water molecule binds to the Gd
III
 in a DOTA-type complex is the 
opening angle: ω must be >135° in order for a water molecule to coordinate.4   
                 
Figure 1.6   Left, crystal structure of [Gd(DOTA)]
2-
. Hygrogen atoms and sodium 
counter ions are omitted for clarity.
11
 Right, schematic showing the capped square 
antiprismatic geometry of Gd
III
-DOTA type complexes. Red circles = backbone oxygen 
atoms; blue circles = pendant nitrogen atoms.
10
 
 
 Gd
III
 complexes of two derivatives of DOTA have been approved for clinical use 
in Canada, both of which have a carboxylic arm substituted by a pendant alcohol (HP-
DO3A and DO3A-butrol, Figure 1.7). 
 
Figure 1.7   Derivatives of DOTA approved for clinical use in Canada. 
10
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 The formula, drug name, active component and key MRI properties of each of the 
nine contrast agents approved for use in North America based on DTPA and DOTA are 
summarized in Table 1.1. 
        r1, r2 (s
-1.
mM
-1
)
12
 
Drug 
Name 
Formula 
Active Component 
H2O 
0.47T 
37° 
Plasma 
1.5 T 
37° 
Plasma 
3 T 
37° 
Clearance  Use 
Magnevist 
(MEG)2[Gd(DTPA)H2O] 
gadopentetate 
3.4, 4.0 4.1, 4.6 3.7, 5.2 
renal 
1.60 h 
CNS, 
whole body 
Eovist or 
Primovist 
Na2[Gd(EOB-DTPA)H2O] 
gadoxetate 
5.3, 6.2 6.9, 8.7 6.2, 11 
renal/hepatic  
50:50** 
liver 
Ablavar or 
Vasovist 
Na3[Gd(MS-325-L)H2O] 
gadofosveset 
5.8, 6.7 19, 34 9.9, 60 
renal/hepatic 
91:9 
18.5 h 
blood pool 
Multihance 
(MEG)2[Gd(BOPTA)H2O] 
gadobenate 
4.2, 4.8 6.3, 8.7 5.5, 11 
renal/hepatic 
96:4 
1.2-2 h 
CNS, 
liver 
Omniscan 
[Gd(DTPA-BMA)H2O] 
gadodiamide 
3.5, 3.8 4.3, 5.2 4.0, 5.6 
renal 
1.30 h 
CNS, 
whole body 
OptiMARK 
[Gd(DTPA-BMEA)H2O] 
gadoversetamide 
4.2, 5.2 4.7, 5.2 4.5, 5.9 
renal 
1.73 h 
CNS, 
whole body 
Dotarem* 
(MEG)[Gd(DOTA)H2O] 
gadoterate 
3.4, 4.1 3.6, 4.3 3.5, 4.9 renal** 
CNS, 
whole body 
Prohance 
[Gd(HP-DO3A)H2O] 
gadoteridol 
3.1, 3.7 4.1, 5.0 3.7, 5.7 
renal 
1.57 h 
CNS, 
whole body 
Gadavist 
[Gd(DO3A-butrol)H2O] 
gadobutrol 
3.7, 5.1 5.2, 6.1 5.0, 7.1 renal** 
CNS, 
whole body 
 
Table 1.1   Summary of the Gd
III
-based contrast agents (MEG = meglumine cation, 
C7H18NO5
+
).
4,10
 *Dotarem is not approved for use in Canada, but is approved for use in 
the USA. **Clearance time data unavailable. 
 
 The agents listed in Table 1.1 can be classified in several ways: linear vs. 
macrocyclic, ionic vs. neutral, and by site of action. All act as T1 contrast agents, but they 
can be divided into whole-body, vascular, and organ-specific agents. Whole-body agents 
such as Gd
III
-DOTA and Gd
III
-DTPA distribute into the intravascular and extracellular 
fluid space of the body post-injection, in contrast to vascular agents (Gd
III
-MS-325-L), 
which remain in the blood pool; and organ-specific agents, such as Gd
III
-EOB-DTPA, 
12 
 
which is selectively taken up by the liver.
4
 The most common dosage is 0.01 mmol
.
kg
-1
 at 
a concentration of 0.5 mol
.
L
-1
, administered intravenously.
4
 
 For decades, aqueous relaxivities measured in a field of 0.47 T (20 MHz) were the 
primary reported values with regards to a Gd
III
-based contrast agents.
10
 It is only in recent 
years that the  relaxivities of the approved agents in human plasma at much more 
clinically relevant fields of 1.5 and 3 T have been reported.
12-14
 For this reason, unless 
otherwise stated, quoted relaxivities of any agent refer to aqueous solutions. From the 
table above, it is clear that in spite of an increasing understanding of the factors affecting 
relaxivity, ligand design for the tuning of these parameters is non-trivial. Relaxivity 
values of small-molecule Gd
III
 agents have not been significantly improved since Gd
III
-
DTPA was first approved 25 years ago: 4.2 mM
-1.
sec
-1
 for the most powerful whole-body 
agent Gd
III
-BOPTA, versus 3.4 mM
-1.
sec
-1
 for Gd
III
-DTPA (aq., 20 MHz). The similarity 
in values is due to the single bound water present in each complex. When relaxivity is 
measured in plasma at stronger magnetic fields, slightly higher values are observed, with 
the exception of the vascular agent Gd
III
-MS-325-L (Ablavar), for which the r1 value 
increases from 5.8 to 19 mM
-1.
sec
-1
 (aq., 20 MHz → plasma, 64 MHz). The reason for 
this significant increase is that Gd
III
-MS-325-L binds with human serum albumin (HSA) 
in vivo, resulting in a macromolecular structure with very slow tumbling and thus 
drastically increased relaxivities.
15
  
 As mentioned earlier, along with exhibiting effective relaxivity behaviour, Gd
III
-
based complexes must be stable in vivo. Both the thermodynamic and kinetic stability of 
Gd
III
 complexes of DOTA and DTPA derivatives have been well-studied. Due to the 
chelate and macrocyclic effects, all nine complexes listed in Table 1.1 are very 
13 
 
thermodynamically stable, with stability constants logKGdL ranging from 16 – 24 
(measured in solutions of 0.1 mol
.
L
-1
 KCl of NMe4Cl).
4
 Gd
III
-DOTA is more stable than 
Gd
III
-DTPA: logKGdL
 
= 25.3 vs. 22.2.
16
 The replacement of a carboxylic group with a 
pendant alcohol to give Gd
III
-HP-DO3A and Gd
III
-DO3A-butrol leads to a small decrease 
in stability: logKGdL
 
= 23.8 and 20.8 respectively.
16,17
 With regards to derivatives of 
DTPA, the incorporation of pendant amide functionalities causes a more significant 
decrease in logKGdL (to 16.8 for both Gd
III
-DTPA-BMA and –BMEA),18 while the 
substitution of an organophosphate arm to give Gd
III
-MS-325-L resulted in a slight 
increase in stability (23.2).
19
 Most of these stability changes can be attributed to the effect 
of different substituents on the basicity of the backbone nitrogen atoms: more basic 
nitrogen atoms = a more thermodynamically stable complex.
4
  
 Although the small-molecule Gd
III
-based agents exhibit high thermodynamic 
stability, kinetic stability presents more of an issue. Two undesirable kinetic processes 
which lead to free Gd
III
 in vivo are transmetallation, and dissociation.
4
 With regards to 
transmetallation, the two ions most likely to compete with Gd
III
 in the body are Zn
II
 and 
Ca
II
. To this end, the stability of Gd
III
-DOTA and –DTPA type complexes have been 
investigated in aqueous solutions of neutral pH, in the presence of Zn
II
 ions.
20
 The most 
kinetically inert complexes with respect to transmetallation were Gd
III
 complexes of 
macrocyclic DOTA and its derivatives: less than 10% of Gd
III 
centers were displaced 
after 72 hours. Gd
III
-DTPA exhibited significantly more transmetallation, with 20% 
displacement in less than 5 hours. Systems with pendant amide arms resulted in even 
faster transmetallation, while functionalization on the ethylene linkers resulted in more 
stable complexes.
4,20
  The kinetics of the second process, acid-assisted dissociation, were 
14 
 
examined using solutions of the complexes in 0.1 mol
.
L
-1 
[H+]. Gd
III
-DTPA proved to 
have a dissociation rate constant k of 1.2 x 10
3 
s
-1
, two orders of magnitude higher than 
that of Gd
III
-DOTA: 0.021 x 10
3 
s
-1
.
4,10
 However, pre-clinical in vivo studies indicated 
that the rapid excretion of both families of small-molecule Gd
III
 agents would allow the 
vast majority of Gd
III
 ions to leave the body in chelated form. 
4
   
1.1.2.2 Non-DOTA/DTPA systems 
 Aside from derivatives of these two ligand families, few altogether new ligand 
systems have been investigated with a view to Gd
III
 agents. One new class of Gd
III
 agent 
was developed by Raymond and co-workers, based on hydroxopyridinone (HOPO) 
ligands. These systems comprise three bidentate HOPO moieties linked via a non-
coordinating amine backbone. The resulting hexadentate ligands have only oxygen 
donors, ideal for binding to the oxophilic Gd
III
 ion. The authors note that the mixed N/O 
donor set of the approved agents is due more to synthetic accessibility than design.
21
 The 
first HOPO system reported was Gd
III
-TREN-1-Me-3,2-HOPO (Figure 1.8), in which two 
water molecules are directly bound to the Gd
III
, resulting in a large increase in relaxivity 
compared to the DOTA and DTPA systems: r1 = 10.5 mM
-1.
sec
-1
 (20 MHz, 37°C).
22
 A 
further promising feature of this system was that the NMRD profile showed a maximum 
relaxivity at high, clinically relevant fields, in contrast to the approved systems which 
display their highest relaxivities below 10 MHz.
22
 This feature is due to the fact that the 
water exchange rate for the HOPO-based complexes is close to the optimal value 
associated with a water residence time of τR = 10 ns.
4
  In addition, the HOPO-based 
ligands exhibit good selectivity for Gd
III
 over competing ions such as Zn
II
 and Ca
II
.
22,23
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 In spite of its clear potential, the Gd
III
-TREN-1-Me-3,2-HOPO complex was not 
particularly water soluble. Thus Raymond and co-workers have developed an extended 
family of HOPO-based systems
23
 incorporating solubilizing functionalities, such as 
pendant hydroxyl groups, or  mixed ‘heteropodal’ HOPO ligands, with a second binding 
modality such as salicylamide.
24
 Although no pre-clinal studies have yet been performed, 
research into this promising family of systems is ongoing.
22
 
 
Figure 1.8   Left, the hexadentate TREN-1-Me-3,2-HOPO ligand; right, structure of 
Gd
III
-TREN-1-Me-3,2-HOPO.
22
 
1.1.2.3 Gd
III
-based agents and NSF 
 As described above, the physical factors governing relaxivity were investigated 
primarily via the study of small-molecule Gd
III
 agents. As noted earlier, a key additional 
feature of any compound intended for use in humans is that it be non-toxic. Although it 
was reported early on in contrast agent development that the free Gd
III
 ion had toxic 
effects in rats and mice,
7,8,25
 the chelating and macrocyclic ligands utilized in the 
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approved Gd
III
 ions were considered to confer sufficient stability on the resulting 
complexes for safe in vivo use.   
 However, in 2006, a link was found between Gd
III
-based agents and the acquired 
disorder nephrogenic systemic fibrosis, or NSF,
26
 a debilitating and sometimes fatal 
disorder in patients with suppressed renal function involving a hardening of the skin, 
joints, muscles of the heart, and the walls of organs such as the liver.
27
 A strong causative 
link was quickly established between this disease and Gd
III
-based agents, in particular 
Omniscan and Magnevist, with the absence of any other common factor between the 
hundreds of patients afflicted.
26
 A possible reason for the previous oversight of the link, 
in spite of the decades-long history of Gd
III
-based agent use, is the lag time of at least 25 
days before the onset of symptoms.   
 Following this discovery, there was an immediate surge in publications discussing 
the safety of Gd
III
-based agents, both with regards to NSF,
28-30
 and a more general 
investigation into the effects of these agents on heart and kidney health.
31,32
 In parallel, 
the discovery spurred a renewed interest in small molecule agents based on alternate 
paramagnetic ions: in particular, Mn
II
. 
1.1.3 Advances in small molecule agents:  
The rise of Mn
II
  
 Although Gd
III
-based small molecule agents were the focus of attention from 
1980-2005, Mn
II
 was actually the very first paramagnetic ion to be considered for 
enhancing MRI contrast, by the ‘Father of MRI’ himself, Lauterbur, in 1978.33 Lauterbur 
used MnCl2 to visualize diseased versus healthy heart tissue in dogs. Like Gd
III
, Mn
II
 has 
several attractive features: a large number of unpaired electrons (S = 5/2), and a long 
17 
 
electronic relaxation time. The key difference between the two ions is that unlike Gd
III
, 
Mn
II
 is a biologically essential element, acting as a cofactor for several important 
enzymes including arginase, the final enzyme in the urea cycle;
34
 and glutamine 
synthetase, which metabolizes nitrogen.
35
 The human body requires the maintenance of a 
serum concentration of at least 0.5 µg/L of Mn
II 
for optimal health.
36
 However, in excess, 
free Mn
II
 can cause toxic effects. Due to its size similarity to Ca
II
, Mn
II
 binds with ease to 
Ca
II
 binding sites and can be readily transported across the blood-brain barrier,
37
 where it 
accumulates and causes Parkinson’s-like symptoms, including tremors and muscle 
stiffness: a condition known as ‘Manganism.’38  
 The oral contrast agent Lumenhance
®
 was briefly approved by the FDA in 1997 
for use in gastrointestinal imaging, but was quickly removed from the market due to 
toxicity concerns: the active compound was the salt MnCl2, which becomes free Mn
II
 of 
the form [Mn(H2O)6]
2+
 in vivo.
39
 MnCl2 is now prohibited for use in clinical settings: 
although Mn
II
 is less toxic than Gd
III
, and as a free ion exhibits a high r1 relaxivity of 6.76 
mM
-1.
sec
-1
, it still requires chelation for biocompatibility.
40,41
 Currently, there is one 
Mn
II
-based MRI contrast agent which is not approved for use in Canada, but is approved 
for use elsewhere in North America. Teslascan
®
, or Mangafodipir, consists of a Mn
II
 ion 
bound to the linear chelating ligand DPDP
2-
 (dipyridoxyl diphosphate). Teslascan is 
administered intravenously, and acts as a positive-enhancement liver-specific agent.
42
 
The ligand DPDP
2-
 is a vitamin B12 analogue, which is retained by hepatocytes.
43
 At a 
frequency of 20 MHz in aqueous solution, Teslascan has relaxivity values of r1 = 2.8 and 
r2 = 3.7 mM
-1.
sec
-1
.
44
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Figure 1.9 Structure of the Mn
II
-based contrast agent Teslascan.
43
 
 
 Over the last decade, publications involving Mn
II 
MRI agents have soared, in 
parallel with publications discussing the safety concerns surrounding the use of Gd
III
-
based agents. As was the case with Gd
III
, the search for appropriate low molecular weight 
ligands centers on a balance between two factors: in order to prevent the release of free 
Mn
II
, a ligand system should confer both thermodynamic stability and kinetic inertness 
on the resulting complex, while still allowing at least one water molecule to directly 
coordinate to the metal center for high relaxivity.  
1.1.3.1 Classes of ligand 
 Like Gd
III
, Mn
II
 is a hard acid, and so both linear and macrocyclic ligands with N 
and O donor atoms have been investigated for Mn
II
, including the DOTA and DTPA 
systems exploited for Gd
III
 agents.  However, the two ions have several differences: Mn
II
 
has a lower charge, a smaller ionic radius, and a preference for coordination numbers of 6 
or 7. These differences mean that Mn
II
 and Gd
III
 complexes of the same or similar ligands 
may have very different properties.  
 Linear ligands investigated for use in Mn
II
-based agents are predominantly 
polyaminocarboxylates, with two or three amine groups: EDTA and DTPA derivatives 
19 
 
respectively (Figure 1.10). The monoamine derivative NTA (Figure 1.10) was 
determined to be too unstable for in vivo use, due to the rapidity of dissociation.
45
  
 
Figure 1.10 Linear chelating ligands studied for use in Mn
II
-based contrast agents.
40,41
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 The first of the polyaminocarboxylate family to be studied for its contrast 
potential was the EDTA complex of Mn
II
, Na2[Mn(EDTA)].
46
 The ligand binds in a 
hexadentate fashion, with the remaining coordination position filled by a bound water 
molecule. The high denticity of EDTA confers thermodynamic stability on the complex, 
and indeed an early toxicity study in rats showed that the LD50 for this compound was 
over 30x higher than that of MnCl2.
46
 Surprisingly, given the bound water, its r1 
relaxivity was low: 1.7 mM
-1.
sec
-1
 (130 MHz, 22°C).
47
 An array of EDTA derivatives 
have been investigated, all resulting in similar 7-coordinate Mn
II
 complexes with a single 
inner-sphere water molecule. The cyclohexyl derivative CyDTA yielded a comparable 
aqueous r1 value of 1.5 mM
-1.
sec
-1
, under a stronger magnetic field (500 MHz, 25°C).
48
 
The similar relaxivities are somewhat surprising, given that the water-exchange rate kex of 
the EDTA complex is 3x faster than that of the CyDTA complex.
48
 The benzyloxymethyl 
derivatives EDTA-BOM and EDTA-BOM2 resulted in Mn
II
 complexes with higher 
aqueous r1 relaxivities of 3.6 and 4.3 mM
-1.
sec
-1
 respectively (20 MHz, 37°C);
49
 however, 
the most important observation concerning these complexes was their tendency to bind to 
HSA in vivo, in an analogous fashion to the approved Gd
III
-agent Ablavar, resulting in 
massively increased relaxivities: 55.3 and 48.0 mM
-1.
sec
-1
 respectively (20 MHz, 37°C, 
HSA).
49
 A similar binding phenomenon was observed for the phosphate and phenoxy 
derivatives diPhEDTA
50
 and PhoEDTA
51
 (Figure 1.10), which have aqueous r1  
relaxivities of 5.8 and 3.7 mM
-1.
sec
-1
 respectively (20 MHz, 25 and 37°C). The latter 
species is based on the amino acid tyrosine, and was designed to target melanoma.
51
 The 
highest aqueous relaxivity of a Mn
II
 complex of an EDTA derivative was reported for the 
phytanyl ester of EDTA (PhyEDTA), where phytanyl is a diterpenoid alkane with the 
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formula C20H42. PhyEDTA is an amphiphilic ligand, and the resulting Mn
II
-PhyEDTA 
self-assembled into a liquid crystalline phase with high r1 and r2 relaxivities of 8.9 and 
11.6 mM
-1.
sec
-1
 (20 MHz, 25°C).
52
 Interestingly, the diester derivative Mn
II
- diPhyEDTA 
exhibited drastically lower relaxivity values, due to the lack of crystalline order.
52
  
 Like EDTA, the octadentate ligand DTPA forms a very thermodynamically stable 
complex with Mn
II
; however, this ligand coordinatively saturates the metal ion, 
preventing inner-sphere water binding. As in the case of Teslascan, the relaxivity effect 
of DTPA-Mn
II
 type complexes results from the slow release of free Mn
II
 ions in vivo. 
Various analogues of DTPA have been synthesized with a view to increased solubility, 
bulk, and targeting potential. Phenolic groups have been appended  (PhoDTPA, Figure 
1.10), modelled after the functional group of the amino acid tyrosine, resulting in low r1 
values of 1.6 – 1.7 mM-1.sec-1 (20 MHz, 25°C).51  Inositol, which has 6 hydroxyl groups 
for added hydrophilicity (inoDTPA),
53
 and isoniazid, an antituberculosis drug for organ-
specific imaging (isoDTPA) have also been appended.
54
 These modifications resulted in 
high relaxivity values of 5.6 (200 MHz) and 6.9 mM
-1.
sec
-1
(80 MHz) respectively. 
41,53,54
  
  
 There are three main classes of macrocyclic ligand which have been studied for 
use in Mn
II
-based agents: flexible cyclic polyamines (predominantly aza- and azaoxa-
crowns); rigid cyclic polyamines; and porphyrins. Macrocyclic ligands confer additional 
stability on their complexes due to the macrocyclic effect. 
 The class of flexible cyclic polyamine ligands predominantly comprises aza- and 
azaoxa-crown ethers (Figure 1.11).  
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Figure 1.11 Flexible cyclic polyamine ligands studied for use in Mn
II
-based contrast 
agents.
40,41
 
 
 NOTA and its derivatives have three donor nitrogen atoms in a nine-membered 
ring. NOTA forms a 6-coordinate complex with Mn
II
, coordinatively saturating the metal 
and leading to a very low relaxivity due to only outer-sphere contributions.
55
 However, 
when two NOTA units are covalently tethered via tertiary amine linkages, the resulting 
bicyclic ligand ENOTA has two pentadentate binding pockets, each of which may 
contain a single 6-coordinate Mn
II
 ion additionally bound to one water molecule.
56
 Mn
II
2-
ENOTA has an r1 value of 2.7 mM
-1.
sec
-1
 (20 MHz, 37°C), fairly low considering the 
total of two bound water molecules per dinuclear complex.
56
 The issue of coordination 
sphere saturation has also been addressed by the substitution of an oxygen for one of the 
backbone nitrogen atoms, forming N2O2A and its phosphonic derivative N2O2P.
57
 
17
O 
NMR measurements indicated that while Mn
II
-N2O2P is 6-coordinate, Mn
II
-N2O2A in 
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solution exists in equilibrium between the 6-coordinate monohydrated and 7-coordinate 
bishydrated species.
57
 In spite of the lower hydration number, Mn
II
-N2O2P has a 
significantly higher r1 relaxivity (4.29 vs. 3.20 mM
-1.
sec
-1
, 20 MHz, 37°C), due to its rate 
of water exchange being 100x faster than that of the carboxylate species Mn
II
-
N2O2A.
40,41
  
 Another family of macrocyclic N3 ligands include derivatives of the seven-
membered ring AAZTA (Figure 1.11), containing two in-ring nitrogen donors, with a 
third nitrogen present as a pendant amine. While the Mn
II
 complex of AAZTA is very 
stable, this 6-coordinate species has no inner sphere water molecules.
58
 The removal of a 
carboxylate group to give the three substituted amine derivatives shown in Figure 1.11 
allows for the potential binding of a water molecule; in fact, the Mn
II
 complexes of 
AAZ3A, MeAAZ3A and AAZ3AMA exist in equilibrium between the non-hydrated and 
monohydrated species.
59
 The relaxivities of the three derivatives depicted decrease in the 
order AAZ3A > MeAAZ3A > AAZ3AMA, in keeping with the extent of the hydration 
equilibrium observed via 
17
O
 
NMR measurements: the Mn
II
 complexes of the three 
ligands have hydration numbers of 0.63, 0.32 and 0.24 respectively, yielding r1 
relaxivities in the range 1.6 – 2.5 mM-1.sec-1 (20 MHz, 37°C).40,41,59 
 Several derivatives of the aza-crown cyclen have been studied. The 
tetracarboxylate ligand DOTA forms a stable 6-coordinate complex with Mn
II
, but like its 
N3 analogue NOTA, has no inner-sphere water molecules in solution and displays purely 
outer-sphere relaxation.
55
 A systematic study of several derivatives of DOTA was 
performed by Wang and Westmoreland in 2009, including the tricarboxylate and 
dicarboxylate ligands DO3A and DO2A, and the tetraamide and triamide derivatives 
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DOTAM, DO3AM and DO3AM-CyOH (Figure 1.11).
60
 The authors found that the 6-
coordinate complex Mn
II
-DO2A exhibited the highest relaxivity of 6.2 mM
-1.
sec
-1
 (20 
MHz, 37°C), while the 8-coordinate complex Mn
II
-DOTAM had the lowest relaxivity of 
0.9 mM
-1.
sec
-1
 (20 MHz, 37°C).
60
 The 7-coordinate complexes of DO3A, DO3AM, 
DO3AM-CyOH and DOTA-BOM3 exhibited intermediate values. The authors suggested 
that 6- and 7-coordinate complexes were able to temporarily widen their coordination 
spheres to accept an additional ligand (H2O) in solution, accounting for the higher 
relaxivities observed for these systems, while 8-coordinate complexes were unable to do 
so, as evidenced by the low relaxivity of Mn
II
-DOTAM.
60
 In addition, the authors 
suggested that increased steric bulk on the pendant arms of the macrocyclic ligand would 
hinder the expansion of the coordination sphere, a possible reason why the observed 
relaxivity of 7-coordinate Mn
II
-DOTA-BOM3 was 1.6 mM
-1.
sec
-1
 (20 MHz, 25°C),
49
 
lower than the less hindered 7-coordinate complexes DO3AM and DO3AM-CyOH (3.3 
and 4.7 mM
-1.
sec
-1
 at 20 MHz and 37°C respectively). This study was significant because 
it related the coordination number of a Mn
II
 complex to its relaxivity; and because it 
showed that complexes with no inner-sphere water molecules in the solid state were still 
worth investigating for relaxivity behaviour in solution.
40,41
 
 Closely related to this family of flexible cyclic polyamines are the rigid analogues 
shown in Figure 1.12, functionalized by the incorporation of a pyridine unit into the 
macrocyclic backbone. This class of macrocycle is most relevant to the systems described 
in Chapter 2. 
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Figure 1.12 Pyridine-functionalized macrocyclic ligands.
40,41
 
 
 In an early report by Jackels and co-workers in 1992, the NMRD profiles of 
several pyridine-functionalized N5 and N6 macrocycles were studied. NMRD, or nuclear 
magnetic resonance dispersion, relates the strength of an applied magnetic field to the 
observed r1 relaxivity of a system. Jackels performed NMRD experiments on the 
saturated systems 15-pyaneN5 and 16-pyaneN5, as well as the bis(imine) unsaturated 
systems 15-pydieneN5, 16-pydieneN5, 17-pydieneN5, and 18-pydieneN6 (Figure 1.12).
61
 
He noted several structure-activity relationships: higher relaxivity values were observed 
for the unsaturated systems over the saturated systems, and for the smaller macrocyclic 
cavity sizes over the larger cavity sizes (15 >16 >17 >18). Jackels also used EPR in 
conjunction with the relaxivity data to draw conclusions about the symmetry and 
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coordination environments of the Mn
II
 complexes. The smaller macrocyclic systems 15-
pyaneN5, 16-pyaneN6, 15-pydieneN5, and 16-pydieneN5 bound in a pentadentate fashion, 
equatorial to the Mn
II
 ion, with two axially-bound water molecules in solution; while the 
larger macrocycles were slightly puckered, and formed 6-coordinate complexes with a 
single water additionally bound.
61
 Two related saturated systems were studied in detail 
recently by Drahos and co-workers: 15-pyN5 and 15-pyN3O2.
62
 As previously observed 
by Jackels, these systems formed 7-coordinate complexes with Mn
II
 in solution, with r1 
relaxivities of 3.13 and 3.61 mM
-1.
sec
-1
 respectively (20 MHz, 37°C).
62
 Drahos also 
examined the pyridine-functionalized DOTA derivatives 12-pyN4 and 12-pyN4P.
63
 While 
the resulting Mn
II
 complexes exhibit high thermodynamic stability, the relaxivity values 
of 1.94 and 2.32 mM
-1.
sec
-1
  (20 MHz, 37°C) are not a marked improvement on 
previously published values, likely due to the very slow water exchange; and the two 
complexes are very kinetically labile, with instantaneous and rapid dissociation at pH = 6 
observed respectively.
63
 
 Although the Mn
II
 complexes of 15-pyN5 and 15-pyN3O2 were recently 
investigated with a view to understanding structure-relaxivity correlation, these systems 
act as very aggressive mimics of the important enzyme superoxide dismutase (SOD).
64
 
For this reason, they and related systems are not candidates for in vivo imaging.
40
 In 
contrast to the saturated macrocycles 15-pyN5 and 15-pyN3O2, the unsaturated bis(imine) 
derivative L1 does not act as a SOD mimic. However, somewhat surprisingly, after the 
initial NMRD study in 1992, this system has not been revisited as a potential contrast 
agent by Drahos and co-workers, or any other researchers to date, nor have any of its 
N3X2 or N3X3 analogues (X = NH, O).  
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 A third class of macrocyclic ligand which has been increasingly exploited for 
small molecule agents are the porphyrins. These conjugated, N-heterocyclic macrocycles 
were known to form complexes with high stability constants, and had been reported to 
selectively accumulate in tumours:
65
 two desirable traits. After the Mn
II
 complex of the 
tetraphenylsulfonated porphyrin TPPS4 (Figure 1.13) was observed to have a relaxivity of 
10.4 mM
-1.
sec
-1
 (20 MHz, 37°C), higher than MnCl2, a flurry of research activity into this 
family was sparked.
66
 The tri- and bi-sulfonated derivatives TPPS3
67
 and TPPS2
68
 were 
examined, with Mn
II
-TTPS3 yielding the most promising in vivo relaxivity results when 
tested with human breast carcinoma cells. In a similar study, the phthalocyanine 
derivative of TPPS4, PcS4, was reported to have a similarly high relaxivity of 10.4 mM
-
1.
sec
-1
 (10.7 MHz), and was selectively retained by tumor tissue over muscle or kidney 
tissue for 24 hours.
69
 An even higher aqueous relaxivity of 13.0 mM
-1.
sec
-1
 (20 MHz) was 
reported for the Mn
II
 complex tetraphenylporpyrin TPP, but surprisingly a study 
involving hepatocellular carcinomas did not show selective tumor enhancement until 
after 3 hours.
70
 The fully carboxylate-substituted derivative uroporphyrin (UROP-1) 
selectively accumulates in rat brain tumors, providing persistant image enhancement with 
an aqueous relaxivity of 4.75 mM
-1.
sec
-1
 (10 MHz).
71
 The related ligands 
mesoporphyrin
72
 and hematoporphyrin
73
 have also been studied, and although both allow 
for excellent tumour visualization, the toxicity of these compounds has remained an 
issue: a third of the rats injected with hematoporphoryn at a dosage of 38 μmol.kg-1 did 
not survive.
73
 A more recent porphyrin derivative is the amphiphilic ligand HOP-8P, 
which was studied in mice models and found to accumulate in cancerous cells in mice, 
while being thoroughly cleared from circulation after 24 hours.
74
 Mn
II
 metalloporphyrins 
28 
 
clearly have application for tumor-specific imaging, especially in brain, breast and liver 
tissue. Toxicity remains a noted concern, and significant in vivo work in this regard is 
required before these compounds are suitable for clinical trials.
40
 
 
Figure 1.13 Selected porphyrin-based macrocyclic ligands studied for use in Mn
II
-based 
contrast agents.
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1.1.3.2 Nanosized agents and small molecule agents 
 As well as the development of new small-molecule contrast agents, a variety of 
nanosized agents have also been investigated. These can be divided into macromolecular 
agents, and inorganic bulk particles. Macromolecular agents include liposomal systems, 
polymers and dendrimers. Liposomal systems involve the encapsulation of an MRI agent 
into a liposome. A major advantage of liposomal delivery is that liposomes can be 
temperature-sensitive, allowing for a thermal report via MRI; and a drug may be co-
29 
 
encapsulated, for dual-action imaging and therapy: theranostics.
75,76
 Dendrimeric and 
polymeric systems have the advantage of incorporating multiple paramagnetic centers, 
and having tunable substituents/peripheries, for desirable physical or functional 
properties such as solubility or selectivity.
40
 For instance, Mn
II
-DTPA units have been 
linked via water-soluble polysaccharides to give a multi-center MRI contrast agent;
77
 and 
a recent dendrimeric system incorporated the Mn
II
-DOTA moiety into a lysine-based 
nanoglobule, for targeted tumor imaging.
78
 From these examples, it can be seen that 
advances in small-molecule agents (higher relaxivity, lower toxicity) may be harnessed 
for use in many nanosized systems also: a new higher relaxivity small molecule agent 
may be encapsulated into a liposome, linked to a polymer chain, or appended to a 
dendritic branch.  
 
 As can be seen from the reports above, there is an ongoing search for effective 
paramagnetic contrast agents with high biostability. While there has been a dramatic shift 
in research interest towards Mn
II
-based agents in the face of increasing concerns about 
the toxicity of Gd
III
, the focus of ligand design for small molecule contrast agents has not 
changed: chelates which allow for high relaxivity via inner-sphere water molecules, fast 
water exchange, and slow tumbling; and which result in kinetically and 
thermodynamically stable systems. Chapter 2 focusses on the synthesis of a promising 
family of small molecule Mn
II 
and Gd
III
 agents formed from Schiff-base macrocycles 
using the technique of metal templation.  
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1.2 Molecule-based magnetism 
Lanthanide single molecule magnets (Ln-SMMs) are the second class of magnetic 
material involved in my research. An introduction to the origins of magnetic behaviour 
will be presented, and an overview of molecule-based magnets will be given, before the 
field of mononuclear Ln-SMMs is discussed. 
1.2.1 Origins of magnetic behaviour 
As early as 600 BC, the attraction of iron to lodestone was described by the 
ancient Greek philosopher Thales. Centuries later, around 1100 AD, the Chinese used 
this property to develop the first navigational compasses. Today, the applications of 
magnetism are astounding in number. From health care to entertainment, from a tiny 
USB key to a giant generator, magnetic devices are interwoven into our modern 
existence.  
1.2.1.1 Fundamental magnetic behavior: diamagnetism and paramagnetism 
The phenomenon of magnetism arises from the movement of electrons, which 
gives rise to spin angular momentum, S and orbital angular momentum L. The motion of 
each electron induces a small magnetic moment. The vector sum of these individual 
magnetic moments of electrons within an atom combine to give the overall magnetic 
moment of the atom.  
There are two kinds of magnetic phenomenon which may be exhibited by an 
individual atom or molecule: diamagnetism and paramagnetism. Diamagnetism is due to 
the presence of paired electrons in atomic or molecular orbitals. The magnetic moments 
of paired electrons within an orbital cancel each other out, giving a net magnetic moment 
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of 0 for paired electrons. Diamagnetism results in the slight repulsion of a substance from 
an applied magnetic field. It is a temperature independent behavior, exhibited by all 
atoms and molecules containing at least one pair of electrons.  
Paramagnetism results from the presence of one or more unpaired electrons in an 
atomic or molecular orbital, which gives rise to a net magnetic moment, or spin. 
Paramagnetism results in the attraction of a substance to an applied field, and is typically 
temperature dependent.
79
 
1.2.1.2 Bulk magnetic behavior: para-, ferro-, antiferro- and ferrimagnetism 
A bulk sample comprising multiple paramagnetic atoms or molecules with 
interacting spins will exhibit bulk magnetic behaviour. The magnetic behavior of a 
species can be determined by studying its magnetic susceptibility. Susceptibility, χ 
(dimensionless), describes the magnetization of a species in the presence of an external 
magnetic field (Eqn. 1.1):                  
𝛘 =
𝐌
𝐇
                         Eqn. 1.1 
where M is magnetization, and H is the applied magnetic field.
80
 This equation is valid 
for weak magnetic fields. 
 Susceptibility can be converted to mass susceptibility, χg (cm
3.
g
-1
), or molar 
susceptibility, χM (cm
3.
mol
-1
). Molar susceptibility is the measure of susceptibility most 
commonly used.  
There are four main classes of bulk magnetic behavior: paramagnetism, 
ferromagnetism, antiferromagnetism and ferrimagnetism (Figure 1.14). 
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Figure 1.14   The common types of bulk magnetic spin ordering, at absolute zero and in 
the absence of an external magnetic field.
81
 
 
Paramagnetic behavior in a bulk solid occurs when the spins of the paramagnetic 
atoms or molecules do not interact, but are randomly oriented. In the absence of an 
external magnetic field, a paramagnetic species will have no net magnetic moment. When 
an external field is applied, the spins of the atoms or molecules will align with the applied 
field, resulting in a weak attraction. The molar susceptibility of a paramagnetic material 
is both temperature dependent and field dependent.  
The temperature dependence of χM is described by the Curie law: 
    𝛘𝐌 =
𝐍𝐀𝐠
𝟐µ𝛃
𝟐
𝟑𝐤𝐁𝐓
𝑺(𝑺 + 𝟏)              Eqn. 1.2 
 
where NA is Avogadro’s number, g is the Landé g-factor, µβ is the Bohr 
magneton, kB is the Boltzmann constant, T is the temperature, and S is the spin quantum 
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number, equal to half the number of unpaired electrons.
80
 This expression is often 
simplified to:  
     𝛘𝐌 =
𝐂
𝐓                                    
Eqn. 1.3 
where C is the Curie constant (emu K mol
-1
). This version of the equation clearly shows 
the inverse relationship between χM and T for a paramagnetic material..
79
 
 The magnetization of a paramagnet is also field dependent. At low fields (keeping 
temperature constant), there is a linear relationship between magnetization and magnetic 
field. This is given by M = χH (Eqn. 1, rearranged; Figure 1.15). At higher magnetic field 
strengths, this relationship ceases to exist. Rather, as the field strength increases (keeping 
T constant), M approaches the saturation magnetization Ms (emu
.
G
.
mol
-1
) (Eqn. 1.4; 
Figure 1.15): 
𝐌𝐒 =  µ𝛃𝐍𝐀𝑺𝐠                   Eqn. 1.4 
 
 
 
Figure 1.15   Plot of M vs. H for a paramagnetic material.
79 
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A rearrangement of Eqn. 1.4 gives: 
      
MS
µβNA
=  𝑆g  = n    Eqn. 1.4b 
where 
MS
µβNA
 is the ‘reduced magnetization,’ and n is the number of unpaired electrons in 
the atom or molecule. Thus the saturation magnetization can be used to find the spin of a 
paramagnetic species.
80
  
 
The remaining three key types of bulk magnetic behavior (ferromagnetism, 
antiferromagnetism and ferrimagnetism), involve long-range ordering of magnetic spins.  
Ferromagnetic behavior occurs in a bulk solid when adjacent magnetic spins are 
aligned parallel to each other. In the absence of an external magnetic field, a 
ferromagnetic species will have a large net magnetic moment. However, ferromagnets 
usually exist as a group of domains. Each domain consists of a number of aligned spins. 
In the absence of a magnetic field, the domains are randomly oriented; so although each 
domain has a net magnetic moment, the bulk ferromagnet will appear to have a net 
magnetic moment of 0. In the presence of an external field, the domains align and the 
ferromagnet experiences a strong attraction to the field.
79
  
Antiferromagnetic behavior is observed when adjacent magnetic spins of the same 
magnitude are aligned antiparallel to each other. The magnetic moments of the adjacent 
spins cancel out, leading to a net magnetic moment of 0 in the absence of an applied 
field. In the presence of a magnetic field, 3D-ordered antiferromagnetic materials are 
weakly repelled, in a similar manner to diamagnetic materials.
79
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Ferrimagnetic materials also have an antiparallel arrangement of spins; however 
the spins differ in magnitude, leading to an overall net magnetic moment in the absence 
of a magnetic field. Like ferromagnets, ferrimagnets exist in domains, so a bulk 
ferromagnet may also appear to have no magnetic moment in the absence of an external 
field. In the presence of a field, the domains align, and the ferrimagnet is attracted to the 
magnetic field.
79
  
Ferromagnets, antiferromagnets and ferrimagnets only exhibit long-range 
ordering below specific temperatures. Above the Curie temperature Tc (for ferromagnets 
and ferrimagnets) and the Néel temperature TN (for antiferromagnets), the thermal energy 
is large enough to overcome the magnetic order present in the solids. Above Tc or TN, 
these classes of material lose their long-range ordering and act as paramagnets.  
 Bulk magnetic behavior can be described in terms of the relationship between 
magnetic susceptibility and temperature. As mentioned earlier, paramagnetic materials 
exhibit an inverse relationship between χM and T, given by the Curie law χM =
C
T
. Thus 
the plot of the susceptibility-temperature product χMT vs. T is a straight line for 
paramagnetic materials. Due to their long-range magnetic ordering, ferromagnets, 
antiferromagnets and ferrimagnets deviate from this line (Figure 1.16).
79
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Figure 1.16  Plot of susceptibility-temperature product χMT vs. T for the four main 
classes of bulk magnetic behavior. Redrawn from Reference 79. 
 
 A plot of inverse susceptibility 
1
χM
 vs. T is also informative. A pure paramagnet 
exhibits a linear relationship between 
1
χM
 and T, with a slope equal to the Curie constant 
C. Ferromagnets and antiferromagnets deviate from such linear behavior due to their 
spin-spin interactions (Figure 1.17).  
 
Figure 1.17 Plot of inverse susceptibility 
1
χM
 vs. T for paramagnetic, ferromagnetic and 
antiferromagnetic materials. Redrawn from Reference 79.   
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This deviation can be quantified using the Curie-Weiss law (Eqn. 1.5): 
                              χM =
C
(T−θ)                    
Eqn. 1.5 
where θ is the Weiss constant. The sign of the Weiss constant indicates whether the spin-
spin interactions are ferromagnetic (positive θ) or antiferromagnetic (negative θ). The 
magnitude of the Weiss constant is proportional to the strength of the interaction. 
Susceptibility data may be usefully fit to the Curie-Weiss equation in the temperature 
range T > 5 θ.79,81  
1.2.1.3  Hysteresis 
 Ferromagnetic and ferrimagnetic substances exhibit a property called hysteresis: a 
history-dependence to the magnetic behaviour. In the presence of an external magnetic 
field, as discussed above, the domains of these species align parallel to the field, and the 
ferromagnetic or ferrimagnetic material becomes magnetized, reaching a saturation of its 
magnetization. When the magnetic field is reduced to 0, the magnetization does not 
return to 0; instead, a ‘remnant magnetization’ Mr remains. This is due to some of the 
magnetic domains remaining in alignment. The magnetic field which must be applied in 
order to return the magnetization to 0 is the ‘coercive field,’ +/- Hc. This spontaneous 
magnetization after a magnetic field is applied and removed is known as hysteresis, and 
presents as a characteristic hysteresis loop on a plot of M vs. H (Figure 1.18). A broad 
hysteresis loop (large Hc) indicates a ‘hard’ magnet, or a permanent magnet: a substance 
which is magnetized in the presence of a magnetic field, and retains that magnetization 
long after the field is removed.  A narrow loop (small Hc) suggests a ‘soft’ magnet.
79
  
38 
 
 
Figure 1.18   Representation of a hysteresis loop, showing the remnant magnetization Mr 
and the coercive fields +/- Hc. 
  
 Hysteresis is a desirable quality of a magnetic material for device applications 
because it confers a bistability or magnetic memory on the compound. That is, at the 
same field, a species with hysteresis can exist in one of two magnetic states, depending 
on its immediate magnetic history.  
1.2.2 Classical magnets vs. molecule-based magnets  
Having discussed the origins of magnetic behaviour, it is worth clarifying the 
distinction between the terms classical magnets and molecule-based magnets. 
The magnets discovered by the ancient Greeks and Chinese were classical 
magnets. Classical magnets are inorganic network solids. They display bulk magnetic 
behaviour which is ‘atom-based,’ arising from the presence of unpaired electrons in the 
d-orbitals of transition metals, or the f-orbitals of lanthanides. The spins of these electrons 
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interact in 3-dimensions, often through direct bonds between spin centers. These 
materials are usually produced by high-temperature metallurgical methods. Examples 
include metals (Fe, Co, Ni), heterometallics (SmCo5, Nd2Fe14B), and  metal oxides 
(Fe2O3, Cr2O3).
82
 Until recently, classical magnets were the only type employed in 
technological applications.  
In the 1980s, the first molecule-based ferromagnet was reported: an organic-
based, zero-dimensional ferromagnet, [Fe(C5Me5)2]
.+
[TCNE]
.- 
(TCNE= 
tetracyanoethylene).
83
 In contrast to the ‘atom-based’ magnetism of classical magnets, 
molecule-based magnets such as this species display ‘molecule-based’ magnetism, with 
isolated spin centers not directly linked via covalent bonds. Molecular magnets may be 
organic radicals, coordination complexes, or hybrid organic/inorganic species; and may 
have unpaired electrons not only in d- or f-orbitals, but also in σ- and π-molecular orbitals 
formed from s- and p-atomic orbitals.
82
  
Molecule-based magnets have several advantages over classical magnets. 
Molecular magnets may be formed using the synthetic techniques of organic and 
coordination chemistry, an alternative to the harsh conditions required for the synthesis of 
classical magnets. These techniques also offer an increased ability to control and alter the 
magnetic properties of a species, because the magnetic properties of the bulk solid 
depend on the spatial relationship and co-operative interactions of the spin sites on a 
molecular level.
82
 Furthermore, it is proposed that these synthetic methods should allow 
for the facile combination of magnetic character with other useful or interesting features, 
such as electrical, optical and mechanical properties.
80
 Molecular magnets tend to be 
easier to process than classical magnets, as they are less dense and more soluble.
82
 As 
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well as these synthetic advantages, many molecule-based magnets also exhibit 
mechanical flexibility, high strength, and biocompatibility.
84
 Finally, molecule-based 
magnetism offers unique opportunities for the miniaturization of switching, sensing and 
data storage devices.  
Both classical and molecule-based magnets exhibit the major types of magnetic 
ordering: antiferromagnetism, ferromagnetism, and ferrimagnetism, as well as other 
cooperative behaviours (Table 1.2). 
Magnetic behaviour Classical magnet Molecule-based magnet 
Antiferromagnetic MnO
85
 Mn[N(CN)2]
86
 
Ferromagnetic CrO2
87
 [Fe(C5Me5)2]
.+
[TCNE]
.-
 
83
 
Ferrimagnetic Fe3O4
88
 Mn
II
 nitronyl nitroxide chains
89
 
 
Table 1.2 Examples of magnetic behaviour in classical vs. molecule-based magnets. 
Adapted from Reference 84. 
 
Molecule-based magnets can be classified in several ways, including: by the 
magnetic behaviour exhibited (some classes shown above in Table 1.2); by the nature of 
the molecules (organic radicals, coordination complexes, or hybrid organic/inorganic 
species); or by the dimensionality of the molecules (0-D, 1-D, 2-D or 3-D).
84,92,93
  
Two classes of molecule-based magnets which do not have a classical analogue 
are single-molecule magnets (SMMs) and single-chain magnets (SCMs). Chapters 3 and 
4 of my thesis focus on SMMs, so an introduction to this class of compound will now be 
presented. 
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1.2.3 Single-molecule magnets 
 Single-molecule magents (SMMs) are individual coordination complexes, which 
can be magnetized in the presence of an applied magnetic field, and exhibit slow 
relaxation of that magnetization below a certain temperature (the blocking temperature, 
TB). Like ferromagnets and ferrimagnets, SMMs display magnetic hysteresis. However, 
unlike ferromagnets and ferrimagnets, SMMs exhibit their slow relaxation on an 
individual molecular level, rather than as a property of the bulk solid.  In order to act as 
an SMM, a compound must have a bistable electronic ground state; that is, the lowest 
energy MJ or MS sub-level must exists as a doublet, with the two orientations of that 
ground state doublet separated by a large energy, or anisotropy barrier (U). The large 
barrier traps the magnetic moment of an SMM in one orientation, preventing rapid 
relaxation of its magnetization. This barrier results from the presence of magnetic 
anisotropy: a directional dependence to the magnetization. In the absence of a magnetic 
field, the direction in which the spin of a magnetically anisotropic material spontaneously 
wants to align is known as the ‘easy axis.’  
 Magnetic anisotropy is due to zero-field splitting (ZFS), described by the 
parameter D.  ZFS refers to the loss of degeneracy of the MS or MJ sub-levels, even in the 
absence of an applied magnetic field. ZFS is due to: spin-orbit coupling (rare for 
transition metals); the coordination geometry of the metal center(s); the overall symmetry 
of the molecule; and bulk crystal packing. It is easiest to talk about ZFS in terms of 3d 
transition metals, for which a ‘spin only’ approximation may often be made: the 
magnetism can be considered as being due solely to spin angular momentum, because of 
the quenching of orbital angular momentum in many cases. ZFS for a transition metal is 
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primarily due to the coordination environment and molecular symmetry. A transition 
metal ion, complex or cluster may thus be described primarily by its total spin quantum 
number, S, and by its spin multiplicity: (2S+1). The spin multiplicity is equal to the 
number of MS sub-levels the system has, ranging in value from –S to S.  
 Let us consider a system with S = 1. The three MS sub-levels are +1, 0 and -1. If 
there is no ZFS, the MS sub-levels are degenerate in the absence of a magnetic field, and 
are split only once an external field is applied (Zeeman splitting). When ZFS is present 
(D ≠ 0), the MS sub-levels are not degenerate, even in the absence of an applied field. The 
energy of each sub-level is given by Eqn. 1.6: 
            E(MS) = g
.
µβ
.
H
.
MS + DMS
2              
Eqn. 1.6 
Each MS sub-level is populated by a different number of spins at a given temperature. The 
difference between the populations of each sub-level is what gives rise to magnetization 
in the sample. Species with large values of S have greater magnetization, because the MS 
levels are further apart in energy.       
 If there is no applied field (i.e. H = 0), then the g
.
µβ
.
H
.
MS term = 0. In that case, if 
D is positive, the MS = 0 is the sub-level which is lowest in energy, while if D is negative, 
then the MS = +1 and MS = -1 sub-levels are lowest (Figure 1.19).
94
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Figure 1.19   Depiction of the lowest-lying sub-levels when D is positive or negative, 
and how the energies of the states change when a magnetic field is applied. Adapted from 
Reference 94. 
 
 Considering the case when D is positive: when a field is applied, the MS = -1 state 
crosses the MS = 0 state and is populated because it is lowest in energy, resulting in 
sample magnetization (Figure 1.9). When the field is removed, the system readily relaxes 
(depopulates) from MS = -1 to MS = 0. From the MS = 0 level, the MS = +1 and MS = -1 
states can be equally thermally populated, because at 0 field they are degenerate. 
 Considering the case when D is negative: when a field is applied, the MS = -1 state 
loses degeneracy with the MS = +1 sub-level, and becomes populated, leading to 
magnetization (Figure 1.9). When the field is removed, the system must go through the 
higher energy MS = 0 state before it can return to the lower energy MS = +1 state. Thus 
when D is negative, there is an energy barrier between -1 and +1 magnetization states. 
This energy barrier (U, cm
-1
) causes the slow relaxation of magnetization in SMMs.
94
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 The accepted equation for U (for transition metal SMMs) is given by Eqn. 1.7: 
    Ueff =│D│S
2
       Eqn. 1.7 
for integer spins; |D|(S
2
-1/4) for non-integer. 
 Each MS state corresponds to a specific orientation of the magnetization (or 
projection of the total spin angular momentum S) with repect to the easy axis of 
anisotropy, with a specific energy (Figure 1.20). Alignment of the magnetization parallel 
to the axis of anisotropy (0° or 180°, Figure 1.20) is energetically preferred.
95
 
 
 
Figure 1.20 Schematic showing the preference of an SMM system for the 
magnetization to be aligned parallel to the easy axis of anisotropy. Adapted from 
Reference 95. 
  
 The MS = +S and MS = -S states can be thought of as lying on either side of a 
‘double well potential’ (shown in Figure 1.21 for an S = 10 system), with the energy 
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barrier │D│S2 between them. Overcoming U by thermal excitation to go from MS = -S to 
MS = +S is the ‘classical’ process by which magnetic relaxation occurs (purple arrows, 
Figure 1.21). A second mechanism of relaxation involves the phenomenon of quantum 
tunnelling of magnetization (QTM), which occurs when electrons ‘tunnel’ between 
degenerate mS states without overcoming the anisotropy barrier.
94
 Quantum tunnelling is 
present at low temperatures when there is significant mixing between energetically 
degenerate microstates, and results in an ‘effective’ anistropy barrier Ueff which is lower 
than the anisotropy barrier U. It is desirable that QTM be non-existent, or very slow, in 
order for the energy barrier Ueff to be as high as possible.
95
 
 
  
Figure 1.21   Depiction of classical relaxation (purple arrows), quantum tunneling (QT, 
blue arrows), and thermally-assisted QT (orange arrows) in an S = 10 system. 
  
 The first SMM was reported by Sessoli and Christou in 1993,
96
 who described a 
cluster which has come to be known as Mn12-acetate, comprising eight Mn
III
 ions (S = 2) 
and four Mn
IV 
ions (S = 3/2), giving rise to an MS = +/-10 ground state. The cluster 
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displayed slow relaxation of magnetization below a blocking temperature of 10 K, with 
an energy barrier Ueff = 51 cm
-1
.  
  
Figure 1.22   Structure of the first reported SMM, Mn12-Ac.
96,97
. Dark purple = Mn
IV
, 
light purple = Mn
III
. 
 
 When this intriguing behaviour was described, the research interest of the 
magnetic community was thoroughly piqued and a large number of SMMs have since 
been reported. The majority are clusters formed from transition metals such as 
manganese, iron or nickel, with oxo or acetate ligands.
98,99
 Although over 20 years have 
now passed, the record barrier for a polynuclear transition metal complex is 62 cm
-1
, for a 
dinuclear Co
II
 complex
100
 – similar in magnitude to that of the first Mn12 system 
investigated. However, although a major improvement in anisotropy barrier has not been 
realized for TM clusters, the many clusters which have been reported have been vital for 
the development of SMM theory, especially with regards to the relationship between the 
size of the energy barrier, the total molecular spin, and the easy axis anisotropy. In 
addition, the synthetic strategies used to make these clusters are now finding application 
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in fields such as magnetic refrigerants.
101
 High nuclearity clusters have the major 
advantage of reaching nanoscale proportions via a ‘bottom-up’ rather than ‘top-down’ 
approach.
102
  
 Since the size of the energy barrier for transition metal clusters is given by U 
=│D│S2, initial efforts in the development of TM-SMMs focussed on maximizing the 
total spin, S, by incorporating a large number of metal centers in a single complex. 
However, the importance of also optimizing D became increasingly clear when a 
complex containing 19 manganese centers was found to have a very small Ueff due to its 
high symmetry.
103
 The anisotropy of a system is, however, much more difficult to design 
and control, especially in a polynuclear cluster. Due to their large intrinsic single-ion 
anisotropy, lanthanides quickly emerged as key metal centers for the development of 
SMMs. Lanthanides have now been employed in both mixed d-f and pure 4f clusters, 
leading to energy barriers up to 5x higher than those observed for TM-cluster-SMMs 
(Table 1.3).
104,105
 Research into lanthanide-containing clusters is moving increasingly 
towards the formation of multifunctional molecular magnetic materials, incorporating a 
second useful or interesting physical property such as optical activity.
106,107
 
 In addition, the use of lanthanide ions has driven the emergence of an entirely 
new class of SMM: SMMs containing a single metal center, or mononuclear SMMs. 
Mononuclear lanthanide SMMs (Ln-SMMs) will be discussed in the following section. 
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 Class 
Metal  
ion(s) 
Formula 
Ueff  
(cm
-1
) 
Ref. 
Polynuclear 3d Co2 [Co(hfpip)2(L′)]2 62 
100
 
  Mn6 [Mn6O2(L′′)6(O2CPh)2(EtOH)4]  60 
108
 
 mixed d-f Fe2Dy [Fe2Dy(L′′′)2(H2O)]ClO4
.
2H2O  319 
104
 
 4f Dy5 [Dy5(μ5-O)(μ3-O
i
Pr)4(O
i
Pr)5]) 367 
105
 
Mononuclear 3d Fe
 
[Fe(C(SiMe3)3)2]
−
 226 
109
 
 4f Tb [Tb(Pc)(
t
BuPc)] 652 
110
 
 
Table 1.3 A comparison of the largest anisotropy barrier observed for different classes of 
SMM. Key: hfpip = 1,1,1,5,5,5- hexafluoro-4-(4-tert-butylphenylimino)-2-pentanonate; 
L′ = a didiazo-dipyridine ligand; L′′H2 = salicylaldoxime; L′′′=2,2′,2′′-
(((nitrilotris(ethane-2,1-diyl))tris(azanediyl))tris(methylene))tris(4-chlorophenol). 
1.2.4 Lanthanide single-molecule magnets (Ln-SMMs) 
1.2.4.1 Electronic structure and anisotropy of Ln
III
 ions 
 Unlike transition metals, the orbital angular momenta of lanthanide ions often 
large and unquenched, and thus spin-orbit coupling must be considered. For this reason, 
the electronic states of the lanthanides are best described by a 
2S+1
LJ ‘term symbol.’ The  
2S+1
L  ‘term’ describes inter-electronic interactions: spin-spin coupling and orbit-orbit 
coupling, given by the total spin and orbital angular momentum quantum number S and L 
respectively. S is given in the form of the spin multiplicity (2S+1), while L is represented 
by letters, where 0, 1, 2, 3, 4 = S, P, D, F, G. Each term is split into 
2S+1
LJ ‘levels’ by spin-
orbit coupling, where J is the Russell-Saunders coupled total angular momentum 
quantum number, and may take values from J = |S+L| to |S-L|.   
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Table 1.4, below,  gives relevant parameters for each Ln
III
 ion, including the ground state 
term symbol and g value of each free ion.
95
  
Ln
III Atomic 
number 
Configuration 
Ground state 
term symbol 
(
2S+1
LJ) 
Landé 
g-factor 
Distribution of 
f electron density 
La
III 
57 [Xe]4f
0
 
1
S0 - n/a 
Ce
III
 58 [Xe]4f
1
 
2
F5/2 6/7 Oblate 
Pr
III
 59 [Xe]4f
2
 
3
H4 4/5 Oblate 
Nd
III
 60 [Xe]4f
3
 
4
I9/2 8/11 Oblate 
Pm
III
 61 [Xe]4f
4
 
5
I4 3/5 Prolate 
Sm
III
 62 [Xe]4f
5
 
6
H5/2 2/7 Prolate 
Eu
III
 63 [Xe]4f
6
 
7
F0 - Isotropic 
Gd
III
 64 [Xe]4f
7
 
8
S7/2 2 Isotropic 
Tb
III
 65 [Xe]4f
8
 
7
F6 3/2 Oblate 
Dy
III
 66 [Xe]4f
9
 
6
H15/2 4/3 Oblate 
Ho
III
 67 [Xe]4f
10
 
5
H8 5/4 Oblate 
Er
III
 68 [Xe]4f
11
 
4
I15/2 6/5 Prolate 
Tm
III
 69 [Xe]4f
12
 
3
H6 7/6 Prolate 
Yb
III
 70 [Xe]4f
13
 
2
F7/2 8/7 Prolate 
Lu
III
 71 [Xe]4f
14
 
1
S0 - Isotropic 
 
Table 1.4 Parameters for the Ln
III
 ions. Adapted from Reference  95. 
  
 Each 
2S+1
LJ level is composed of (2J+1) MJ microstates or sub-levels. The 
presence of a crystal field causes a slight but non-negligible perturbation of the energy 
levels, resulting in ‘Stark’ splitting of the MJ microstates.
111
 Splitting of the terms due to 
spin-orbit coupling is of the order ~10,000 cm
-1
 in magnitude, while splitting of the levels 
into MJ
 
microstates due to crystal field splitting is of the order ~100 cm
-1
. It is the energy 
barrier between the two orientations of the lowest-energy MJ microstate that causes the 
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slow relaxation in Ln SMMs. For Ln
III
 ions with an odd number of electrons (Kramers 
ions), the MJ microstates are arranged as doublets: these ions always meet the 
requirement of an SMM for a bistable electronic ground state. For non-Kramers Ln
III
 
ions, the MJ states may be arranged as singlets or doublets, and thus these ions may not 
necessarily meet the bistability requirement. It should be noted that the highest value MJ 
state is not necessarily the lowest in energy. The splitting of the 
6
H
 
term of Dy
III
 into the 
6
HJ levels by spin-orbit coupling, and the splitting of the ground state 
6
H15/2 level into the 
(2J+1) MJ microstates by the crystal field, is depicted below (Figure 1.23).  
 
Figure 1.23 The splitting of the 
6
H
 
term of a Dy
III
 ion by spin-orbit coupling and crystal 
field. Only the MJ microstates of the lowest-energy 
6
H15/2
 
level are shown. Adapted from 
Reference 95. 
 As was mentioned earlier, the magnetic anisotropy (due to ZFS) of a transition 
metal cluster arises primarily as a result of the structural arrangement of the metal ions 
and ligands: the coordination geometries, molecular symmetry, and crystal packing; 
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while the intrinsic anisotropy of most lanthanide ions is primarily due to the presence of 
spin-orbit coupling (SOC). In addition, the large ground state S of transition metal cluster 
SMMs arises from the coupled spins of multiple metal centers, whereas the large ground 
state J of the lanthanides utilized in Ln-SMMs is a feature of the individual metal ions. 
For these reasons, lanthanide-based SMMs allow for the presence of SMM behaviour in 
complexes containing just one metal ion, referred to as single ion magnets (SIMs), or 
mononuclear SMMs.   
1.2.4.2 Observing SMM behaviour 
 The presence of SMM behaviour is usually determined by performing low-
temperature magnetic measurements using a SQUID or PPMS magnetometer. The most 
common method involves measuring the susceptibility response of the sample in an 
oscillating magnetic field, produced by an alternating current (ac). In an SMM, the 
anisotropy barrier U causes the magnetization to lag behind the oscillating field, resulting 
in a phase shift, φ, relative to the field. Ac susceptibility can therefore be separated into 
two components, the in-phase, or real, component χ′, and the out-of-phase, or imaginary, 
component χ″. These two components are given by Eqns. 1.8a and b, below.112  
     χ′ = χcosφ            Eqn. 1.8a 
     χ″ = χsinφ           Eqn. 1.8b 
 The amount of ‘lag’ for a given SMM depends upon the frequency of the 
oscillation of the field: the faster the ac field oscillates, the less opportunity the 
magnetization has to overcome the anisotropy barrier and relax. For this reason the 
hallmark of an SMM is a frequency-dependence to the out-of-phase component of the ac 
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susceptibility, usually observed in a plot of χ″ vs. T (Figure 1.25, later) or χ″ vs. 
frequency.  
 A second method for determining the presence of SMM behaviour involves 
performing a dc field scan at one or more very low temperatures. The field is increased 
from 0 to +H, and then cycled back from +H to –H to +H again.95 The presence of a 
hysteresis loop in the plot of M vs. H indicates the presence of an energy barrier to 
magnetic relaxation. 
 The key parameters used to describe SMM behaviour may be extracted from the 
magnetic data. The effective anisotropy barrier Ueff, as well as a number of other 
parameters, may be calculated from the ac susceptibility data. This is discussed in 
Chapters 3 and 4. The blocking temperature TB can be directly seen as the temperature at 
which a hysteresis loop is observed in a plot of M vs. H. It should be noted that TB 
depends on the measurement sweep rate, for which there is no standard value; so it can be 
difficult to compare TB values between complexes.
111
  
1.2.4.3 
1.2.4.4 Mononuclear Ln-SMMs 
 The first Ln-SMMs, which were also the first mononuclear SMMs, were 
published by Ishikawa in 2003.
113
 He described two double-decker phthalocyanine-based 
complexes, [Bu4N][Pc2Ln], where Ln = Dy
III
 and Tb
III 
(Figure 1.24).  
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Figure 1.24   Structure of the anion portion of the first two reported SMM complexes, 
where lavender = N, green = Tb
III
, Dy
III
.
113,114
 
 
 The Ln
III
 metal centers (Ln = Tb, Dy) exhibited 8-coordinate, square antiprismatic 
geometries. The slow relaxation of magnetization was observed by applying an 
alternating current of various frequencies to a crystalline sample of each complex at low 
temperature. Figure 1.25 depicts the magnetic behaviour of the Dy
III
 complex. The χ″ vs. 
T plot clearly shows the frequency-dependence of the magnetization of this compound, 
which is the characteristic mark of an SMM.
113
  The Tb
III
 complex displayed a barrier to 
relaxation of Ueff = 566 cm
-1
, significantly higher than any barrier which had been yet 
observed for a transition metal cluster SMM. 
 
Figure 1.25   χ″ vs. T plot for [Bu4N][Pc2Dy]. Reproduced from Reference 113. 
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 Since Ishikawa’s initial work, now over ten years ago, interest in Ln-SMMs has 
grown exponentially. Well over 100 such complexes have now been reported. The class 
of Ln-SMMs of interest with respect to my research is that of mononuclear Ln-SMMs: 
those which contain a single Ln metal ion. These mononuclear Ln-SMMs are typically 
classified according to three criteria: (i) the type of metal ion; (ii) the geometry, and/or 
(iii) the class of ligand.  
 The five lanthanide ions which have utilized in the synthesis of mononuclear Ln-
SMMs are Tb
III
, Dy
III
, Ho
III
, Er
III
 and Yb
III
.
111
 Since the f-orbitals of these lanthanides are 
more than half-filled, they have large spin-orbit coupled J values in the ground state 
(ranging from 6 to 8). Of these five, Dy
III
, Er
III
 and Yb
III
 are Kramers  ions, while Tb
III
 
and Ho
III
 are not. Dy
III
 and Tb
III
 are by far the most exploited, with over 30 examples of 
each reported; while there are fewer than 10 mononuclear SMMs based on Ho
III
, Er
III
 and 
Yb
III
.
95
 
 The most common class of ligand exploited in Ln-SMM synthesis comprises 
phthalocyanine and its derivatives. Bis(phthalocyanine) complexes with the same double-
decker structure and square antiprismatic geometry as the complexes reported by 
Ishikawa have continued to lead the field. Phthalocyanine may be derivatized in 
numerous ways, yielding Pc ligands substituted with nitrile groups, long alkyl chains, 
bulky aromatic esters, and trifluoromethane moieties.
95
 The resulting [LnPc]2 complexes 
may be positive, negative, or neutral in charge; and most are redox active. Another major 
class of ligand is acetylacetonate (acac) and its β-diketonate derivatives. Several SMMs 
have been reported comprising a Ln
III
 ion surrounded in a distorted square antiprismatic 
geometry with three β-diketonate ligands and two mono- or one bidentate neutral 
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donor.
115
 Other studied ligand classes include nitronyl-nitroxide ligands, carbon-donor 
ligands such as cyclopentadienide ([Cp]
−
) and cyclooctatetraenide ([COT]
2−
), and 
organometallic  polyoxometallate ligands.
116
 An additional array of ligands with O 
(hydroxy and carboxy) and N (amine, oxime, imine, pyridine) donors have been utilized 
also, and have been thoroughly reviewed by Layfield and co-workers.
111
 
 
Figure 1.26 Representative ligands from (left to right) the phthalocyanine, β-diketone 
and nitroxyl radical families. Adapted from Reference 111. 
 
 There is a reason why bis(phthalocyanine) complexes dominate the Ln-SMM 
landscape. Recently, Rinehart and Long presented a simple model to help predict ligand 
geometries which would enhance the single-ion anisotropy of the lanthanides.
117
 The 
model is based on the fact that the f orbitals have a strong angular dependence; that is, the 
charge cloud for a given f orbital may be described as prolate (elongated along the z-
axis), oblate (expanded in the xy plane), or isotropic/spherical.
117
 Since the population of 
the f orbitals for a given lanthanide is readily determined using Hund’s rules, the overall 
shape of the 4f cloud of each lanthanide may in turn be described as prolate, oblate or 
spherical. The distribution of the electron density for each lanthanide is presented in 
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Table 1.4. Long postulated that the magnetic anisotropy of an oblate lanthanide ion 
would be enhanced by the presence of a crystal field with electron density located axially, 
above and below the xy plane; while the anisotropy of a prolate ion would be enhanced 
by electron density located equatorially, in the xy plane (Figure 1.27).
117
 These 
arrangements would minimize the repulsive interactions between the electron clouds of 
the metal ion and ligand(s), giving rise to MJ = J states parallel and antiparallel to the 
molecular axis, or z-axis. 
117
 As can be seen in Table 1.4, both Tb
III
 and Dy
III
 have oblate 
electron clouds, and thus their anisotropy would theoretically be enhanced by the axially 
located charge density of ligands bound in a sandwich-type conformation. 
117
 
 
 
Figure 1.27 Representation of low and high energy states for (left) an oblate charge 
cloud in an axial crystal field, and (right) a prolate charge cloud in an equatorial crystal 
field. The blue ovals represent the 4f electron density, the black circles represent ligand 
electron density, and the red arrows represent the orientation of the projection of the spin-
orbit coupled J state: large MJ values are lowest in energy for the depicted crystal fields. 
Adapted from Reference 117. 
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 The enhancement of the anisotropy of Tb
III
 and Dy
III
 by the square antiprismatic 
environment of a bis(phthalocyanine) ligand field helps to explain why D4d complexes of 
these two ions are so ubiquitous amongst Ln-SMMs. The record Ueff barrier of ~650 cm
-1
 
is held by a substituted bis(phthalocyanine) complex of Tb
III
,
110
 and in fact, the vast 
majority of the mononuclear Ln-SMMs with the top twenty highest anisotropy barriers 
(>390 cm
-1
) are such complexes. Tb
III
 is responsible for the highest barriers, likely 
because its f electron cloud has more angular dependence; but Dy
III
 has been utilized in 
more SMMs, because it always has a doubly degenerate ground state. Although the 8-
coordinate, square antiprismatic geometry associated with the bis(phthalocyanine) 
complexes is by far the most common geometry, a number of other coordination 
environments have been reported for the metal centers of Ln-SMMs (Table 1.5). 
Reported barriers for non-phthalocyanine mononuclear lanthanide complexes range in 
magnitude from 130 cm
-1
 to 3 cm
-1
.
95. 111 
Coord.  
No. 
Reported geometries 
6 trigonal prism, octahedron 
7 capped octahedron, capped trigonal prism 
8 
square antiprism, cube,  
biaugmented trigonal prism, triangular dodecahedron 
9 capped square antiprism, muffin, hula hoop 
10 sphenocorona, tetradecahedron 
12 icosahedron 
 
Table 1.5 Coordination geometries reported for Ln-SMMs.
95 
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1.2.4.5 Rational design of Ln-SMMs 
 The exciting potential uses for SMMs as high density information storage devices, 
as qubits for quantum computing, and in molecular spintronics, have been well-
described.
118-123
 However, before these species can be practically applied, the 
temperatures at which SMM behaviour is observed must be significantly increased, to at 
least liquid nitrogen levels. Currently, the highest TB (temperature at which hysteresis is 
observed) reported for a Ln-SMM, mononuclear or otherwise, is 8.3 K.
124
 In order to 
rationally design SMM systems with predictable, applicable magnetic properties, a 
greater understanding of the relationship between structure and magnetism is required. In 
this regard, mononuclear SMMs are very desirable, because their comparable simplicity 
makes magneto-structural correlation more achievable.  
 The electrostatic theory of Long, described above, is useful in helping to explain 
the relaxation behaviour of many Ln-SMMs. However, as interest in ligand design for 
rational synthesis of SMMs increases, so does the importance of an even more detailed 
understanding of magneto-structural correlation. The effect of even minute changes in 
coordination geometry on the anisotropy of a system was shown by Sessoli and co-
workers in their wonderfully detailed magnetic and electronic study on the Dy
III
 complex 
of the macrocyclic ligand DOTA.
125
 Rare geometries, such as those discussed in Chapter 
3, and tunable systems in which one or more structural parameters can be systematically 
modified, such as those discussed in Chapter 4, offer a unique opportunity to examine 
the subtleties of magneto-structural correlation.  
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1.3 Schiff-base macrocycles: 
Applications in molecule-based magnetic materials 
 As mentioned earlier, my work involves two classes of macrocyclic ligand. The 
complexes synthesized in my first and second projects (Chapters 2-3) are Schiff-base 
macrocycles, based on a 15-membered, pentadentate macrocyclic system (Figure 1.28). 
 
Figure 1.28   The ‘parent’ pentadentate macrocycles L1 and L2. 
 
 A brief overview of complexes based on this macrocyclic system will now be 
presented. Firstly, mononuclear complexes of macrocycles L1 and L2 are discussed, with 
emphasis on the early structural elucidation and coordination geometries of the transition 
metal complexes; the unique SCO transition of a [Fe(L2)CN)2] complex; and a 
discussion of related rare earth complexes.  Secondly, selected higher-order magnetic 
structures based on complexes of these ligands are presented.
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Schiff bases containing an imine or azomethine group (-R2C=N-R; where R = an 
aryl or alkyl group) formed via the condensation of a primary amine with an active 
carbonyl are named after the Italian chemist Hugo Schiff who first discovered them.
127
 
The reaction to prepare a Schiff base is reversible, occurring via a carbinolamine 
intermediate which typically requires the removal of water to push the equilibrium to the 
right in order to obtain the compounds in good yields (Scheme 1.1). 
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Scheme 1.1 Schiff-base formation. 
 
 The 15-membered Schiff-base macrocycles discussed in this section are formed 
by the [1+1] metal-templated condensation of a diamine and a diketone (Scheme 1.2). 
The role of the metal ion in the cyclization reaction is to pre-organize the molecular 
precursors via the formation of a metal complex, thus the size and charge of the metal 
ions employed are important considerations. The pyridyl head groups serve to increase 
the rigidity of the ligand which is kinetically favourable for the templation reaction. 
 
Scheme 1.2 General synthesis of a 15-membered N3X2 Schiff-base macrocycle via metal 
templation around a metal chloride salt. 
1.3.1 Mononuclear complexes 
Transition metal complexes: structural reports 
The N5 macrocycle L1 was first reported in 1967, when Hawkinson described the 
crystal structure of an [Fe(L1)(NCS)2]ClO4 complex (Figure 1.29), and noted the unusual 
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seven coordinate pentagonal bipyramidal geometry of the central Fe
III
 ion.
128
 The 
macrocycle was synthesized following Scheme 1.2, above, via the condensation of 2,6-
diacetylpyridine and triethylenetetramine. At this time, L1 was only the second reported 
example of a macrocyclic ligand prepared via a metal templation strategy. 
 
Figure 1.29 The molecular structure of the first N5 macrocyclic complex  
[Fe(L1)(NCS)2]ClO4.
128,129
 The ClO4
-
 counter ion and H-atoms are omitted for clarity. 
 
Ten years later, Nelson and co-workers described the preparation of a family of 
coordination complexes of L1 via templation by a series of metal cations, where M
II
  = 
Mn, Fe, Co, Ni, Cu, Zn, and Mg.  Interestingly, when X = O and M = Ag
I
 or Pb
II
, the 
related 30-membered [2+2] macrocycle formed in high yield, indicating that both the size 
of the cation and its affinity for the X substituents on the diamine precursor direct the 
preferred course of the condensation reaction. 
Following the synthesis of the [Mg(L1)(H2O)Cl]Cl complex, the Mg
II
 cation was 
exploited as a template for the synthesis of the chloride, perchlorate, tetraphenylborate 
and thiocyanate derivatives of L1 and L2.
130
 Although no single crystal X-ray diffraction 
data were collected for this series of complexes (other than the Mg
II
 complex), imine 
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bond formation was confirmed by IR spectroscopy, with each complex exhibiting a C=N 
stretch at 1650 cm
-1
, consistent with formation of the Schiff base bis(imine) bond. The 
templating role of the Mg
II
 cation was demonstrated by the failure of the macrocycle to 
form in the absence of a metal cation. For these reactions, in the absence of any metal 
ion, an oily product or a mixture of products was obtained in which the carbonyl groups 
of the diketone starting material were observed in the IR spectra. The IR spectra also 
indicated the presence of bound water molecules for each of the complexes with the 
exception of the thiocyanate derivative. Consistent with this, the electronic spectra 
indicated that the chloride, perchlorate and tetraphenylborate derivatives were salts, with 
non-coordinating counter ions balancing the charge of the bis(aqua) complexes; while the 
thiocyanate derivative was a neutral complex, with two coordinating counter ions. Mass 
spectra of the complexes did not show parent ion peaks, but the spectra of the chloride 
derivatives did contain fragment ions corresponding to the loss of a single chloride ion 
from complexes of L1 and L2
 
respectively. 
1
H and 
13
C NMR data for selected complexes 
were in agreement with the suggested macrocyclic structures. Given the data, a seven-
coordinate pentagonal-bipyramidal geometry was assigned to all of the complexes.
130
  
A second series of studies were then carried out where the counter ion and axial 
ligands were kept constant, while the nature of the templating metal ion was varied. 
Following this strategy, the thiocyanate derivatives of the Mn
II
, Fe
II
, Zn
II
 and Cd
II
 
complexes of L1 and L2 were prepared.
131
 This family of complexes was similarly 
characterized by IR and electronic spectroscopy, elemental analysis and mass 
spectrometry. The crystal structure of [Mn(L2)(NCS)2] was determined and was the first 
reported structure of a macrocyclic complex of L2. This complex, like other members of 
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the series, has a pentagonal bipyramidal geometry with axial thiocyanate ligands, similar 
to the [Fe(L1)(NCS)2]ClO4 complex presented in Figure 1.29. Given that the IR spectra 
of the Fe
II
, Zn
II
, and Cd
II
 dithiocyanate complexes were almost identical, a pentagonal 
bipyramidal geometry was assigned to all four complexes.
131
 
 
Fe
II
 complex: SCO behaviour  
Of all the structurally described transition metal complexes, by far the most 
magnetically interesting and well-studied is the Fe
II
 bis(cyanide) complex of L2: 
[Fe(L2)(CN)2]. Following the structural reports by Nelson and Drew described above, 
attention shifted towards the magnetic properties of the Fe
II
 complexes of L1 and L2. 
Nelson reported that while the metal center of [Fe(L1)(CN)2] exhibited a low spin (LS) 
ground state at ambient temperatures, the N3O2 analogue displayed a thermally-induced 
spin crossover (SCO) transition.
132
 At low temperatures (<150 K), the system adopts a 
low spin (LS), S = 0 state, while at high temperatures (>230 K), the complex was present 
solely in the HS S = 2 state. The thermal transition was reversible, with Tc
↑
 = 222 K, 
giving a hysteresis loop with a width 15 K. The LS complex was assumed to be 6-
coordinate; but the HS geometry could not be assigned due to the lack of X-ray quality 
crystals.
132
 Powder diffraction data suggested that the transition was accompanied by a 
change in unit cells likely due to a change in geometry. After Nelson’s initial work, 
investigation into the unusual SCO behaviour of [Fe(L2)(CN)2]  lay largely dormant for 
twenty years until it was revisited by Sato in 2001, who confirmed that the room 
temperature crystal structure of the HS [Fe(L2)(CN)2]∙H2O complex was  7-coordinate, 
as postulated earlier by Nelson, with the macrocycle acting as an essentially planar 
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pentadentate ligand, and the two cyanide ligands occupying the axial positions.
133
 Several 
years later, Letard conclusively proved the presence of a structural transformation when 
he reported the LS molecular structure of the complex, with the Fe
II
 ion in a 6-coordinate, 
distorted octahedral environment following the breaking of an Fe-O bond.
134
 This 
conversion is particularly interesting since it is completely reversible in the solid state. 
Such a structurally characterized, reversible change in coordination geometry 
accompanying a thermal SCO transition (Figure 1.30) was unprecedented in the chemical 
literature.  
Sato and co-workers also studied the photomagnetism of this complex, and found 
that the complex also exhibits a photo-induced SCO transition, displaying the LIESST 
effect. The observed Tc(LIESST) of 130 K is currently one of the highest relaxation 
temperature reported for any mononuclear Fe
II
 complex, and represents an important step 
towards the application of such compounds in molecular devices.  
 
Figure 1.30 Molecular structures of [Fe(L2)(CN)2]∙H2O, in the HS (left) and LS (right) 
states showing the reversible transition from 7-coordinate to 6-coordinate geometry, H-
atoms are omitted for clarity.  
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Rare earth complexes  
For more than a decade, the Radecka-Paryzeck group has been working towards 
incorporating rare earth elements into L2 and other Schiff base macrocyclic systems. 
Initially, the Y
III
 chloride and perchlorate complexes of L2 were formed via metal 
templation.
135
 A 7-coordinate geometry was assigned to the complexes with two water 
molecules filling the axial positions and the chloride and perchlorate anions acting as 
counter ions. Seven coordinate complexes of Y
III
 are quite rare,
136
 and this was the first 
reported example of a Y
III
 ion acting as the templating agent for the synthesis of a 
pentadentate Schiff base macrocycle. Soon after these studies, the metal-templated 
synthesis of several lanthanide complexes of L2 were reported.
137
 The heavier 
lanthanides (Dy
III
, Tm
III
, Lu
III
 and Er
III
) were found to template the formation of L2.
137
 
Characterization by IR, mass spectrometry and elemental analysis suggested that the 
complexes have 7-coordinate pentagonal bipyramidal geometry with the five donor atoms 
of the macrocyclic ring bound to the lanthanide ion, along with two water molecules in 
the axial positions. The chloride and perchlorate anions were concluded to be present as 
non-coordinating counter ions, although there was no crystallographic evidence available 
to corroborate this. The lighter lanthanide ions (La
III
, Sm
III
, and Eu
III
) proved to be less 
effective as templating agents, yielding acyclic products.
137
 These results confirmed the 
dependence of metal templation on the ratio of metal ion size to potential macrocyclic 
cavity with the larger early lanthanides unable to template macrocycle formation. A 
similar study was performed by Bastida and co-workers with regards to the related  
hindered macrocycle L3, as well as its formyl derivative L3b.
138
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Attempts were made to template the formation of each macrocycle around the 
trivalent lanthanide series La
III
-Er
III
 with nitrate and perchlorate counter ions. Although 
no X-ray quality crystals could be isolated, the resulting products were characterized by 
elemental analysis, conductance, infrared spectroscopy, FAB mass spectrometry, and 
magnetic moment. Elemental analysis gave varying degrees of fit for complexes with the 
formulae [Ln(L)]X3
.
xH2O
.
yEtOH, where L = L3 or L3b, and X = NO3
-
 or ClO4
-
. FAB 
mass spectrometry proved uninformative, with no clear molecular ion peaks apparent. IR 
spectroscopy confirmed imine bond formation, and indicated that in complexes of both 
L3 and L3b, bound perchlorate ions were present, due to the splitting of the peak around 
1114 cm
-1
. However, no firm coordination assignments could be made due to the lack of 
X-ray structural data.
138
 
1.3.2 Polynuclear complexes 
 Over the last two decades, mononuclear complexes of L1 and L2 have been 
increasingly exploited as building blocks for the development of more structurally 
complex magnetic materials, including 1-D linear chains, as well 2-D and 3-D higher 
order structures. The majority of the compounds within this class are heterometallic 
materials assembled via the reaction of L1 or L2 with a secondary polycyanometalate 
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building block. Mn
II
 complexes of either L1 or L2 are by far the most commonly 
exploited; Fe
II
 complexes of L1 were also utilized along with three examples of higher 
order structures assembled from Co
II
 macrocycles of L2. In each case the macrocyclic 
bound metal center possesses pentagonal bipyramidal geometry and the 
polycyanometalate building blocks include di-, tetra-, or hexacyano 3d ions, as well as 
hepta- or octacyano 4d and 5d linkers. Additionally, cyanometalate precursors with 
blocking ligands, as well as non-polycyanometalate linkers such as azide, dicyanamido 
and a TCNQ radical have also been employed. 
   The magnetic properties of the resulting 1-, 2- and 3-D structural topologies are 
summarized in Table 1.6.
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[ML]n+ Linker Dimensionality 
Metal Center / 
Geometry 
 M-NC 
(°)†† 
Exchange 
Interactions 
|J| (cm-1) 
Magnetic 
Behaviour 
Ref. 
Dicyanometalates 
 
 
       
[Mn(L1)]2+ [Ag(CN)2]
- 1D – infinite 
MnII PB-7 
AgI  L-2 
166 AF MnII-MnII 0.065(2) - 139 
[Mn(L1)]2+ [Au(CN)2]
- 1D – infinite 
MnII PB-7 
AuI  L-2 
166 AF MnII-MnII 0.23(3) - 139 
[Mn(L2)]2+ [Ag(CN)2]
- 1D – infinite 
MnII PB-7 
AgI  L-2 
165 AF MnII-MnII 0.15(6) - 139 
[Mn(L2)]2+ [Au(CN)2]
- 1D – infinite 
MnII PB-7 
AuI  L-2 
164 AF MnII-MnII 0.13(5) - 139 
Tetracyanometalates         
[Mn(L2)]2+ [M(CN)4)]
2- 1D – infinite 
MnII  PB-7 
Ni/Pd/PtII  SP-4 
 
151 - 154 
 
P n/a - 140 
Hexacyanometalates         
[Mn(L2)]2+ [Fe(CN)6]
4- 
 
1D – trinuclear 
 
MnII PB-7. 
LS FeII  OC-6 
156 F MnII-MnII 0.045 - 140 
[Mn(L2)]2+ [Cr(CN)6)]
3- 
1D – infinite and 
trinuclear 
MnII PB-7 
CrIII  OC-6 
156 - 159 F/AF MnII-CrIII 7.5(7) - 140 
[Mn(L2)]2+ [Fe(CN)6)]
3- 
 
1D – infinite and 
trinuclear 
 
MnII PB-7 
LS FeIII  OC-6 
 
159 - 160 
 
F MnII-FeIII 
not 
modelled 
- 140 
[Mn(L2)]2+ [Cr(CN)6)]
4- 
 
1D – trinuclear 
 
MnII  PB-7 
CrII  OC-6 
145 - 157 AF MnII-CrII 9.8 - 141 
[Mn(L2)]2+ [Cr(CN)6)]
3- 
 
1D – trinuclear 
 
MnII PB-7 
CrIII  OC-6 
162 AF MnII-CrIII 6.52 - 141 
[Mn(L2)]2+ [Fe(CN)6)]
3- 
 
1D – trinuclear 
 
MnII  PB-7. 
LS FeIII  OC-6 
165 F MnII-FeIII not given - 141 
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[Fe(L2)]2+ [Cr(CN)6]
3- 
 
1D – trinuclear 
 
HS FeII  PB-7 
CrIII  OC-6 
155 F FeII-CrIII 3.76(6) 
SMM 
Ueff = 44.3 K 
142 
[Mn(L1)]2+ [Fe(CN)6]
3- 
 
1D – pentanuclear 
 
MnII PB-7 
LS FeIII  OC-6 
144 - 155 3 AF, 1 F MnII-FeIII 
0..3, 1.5, 
1.6, 2.6 
- 143 
{[Co(L2)]2+} 
2 
[Fe(CN)6]
4- 
 
1D – infinite 
 
CoII  PB-7 
LS FeII  OC-6 
161 F CoII-CoII 5.4 - 144 
[Mn(L2)]2+ [Co(CN)6)]
4- 1D – trimer 
MnII PB-7 
CoIII  OC-6 
166 P n/a - 141 
[Mn(L2)]+ [Fe(CN)6)]
3- 
 
2D – lattice 
 
MnII PB-7 
LS FeIII OC-6 
160 -161 
AF MnII-Fe1III 
AF MnII-Fe2III 
J1 = 2.1 
J2 = 1.6 
FI ordering 
Tc = 6.4 K 
140 
[Co(L1)]2+ [Cr(CN)6]
3- 
 
3D – nanotubular 
 
 
HS CoII PB-7 
LS CrIII OC-6 
155 F CoII-CrIII 1.2 
F ordering 
< 12 K 
145 
[Fe(L1)]2+ [Co(CN)6]
3- 
 
2D – brickwall 
 
 
HS FeII PB-7 
LS CoIII  OC-6 
 
154 - 165 
 
P n/a - 146 
[Co(L2)]2+ [Fe(CN)6]
3- 2D – honeycomb 
HS CoII  PB-7 
LS FeIII  OC-6 
150 - 159 
 
F CoII-FeIII not given 
F ordering 
< 3K 
146 
Heptacyanometalates         
[Mn(L2)]2+ [Mo(CN)7]
4- 1D – trimer 
MnII PB-7 
MoIII PB-7 
146 - 150 AF MnII-MoIII not given - 147 
[Mn(L2)]2+ [Mo(CN)7]
4- 2D - network 
MnII PB-7 
MnII PB-7 
MoIII PB-7 
MoIV SA-8 
 
143 - 151 
 
F (148), 
AF (149) 
MnII-MoIII 
not given 
(148) 
6.9 (149) 
F ordering 
< 3K (148)† 
148, 
149 
[Mn(L1)]2+ [Mo(CN)7]
4- 0D – cluster 
MnII BP-7 
MoIII PB-7 
140 -160 AF overall not given 
glassy 
behaviour 
150 
[Mn(L2)]2+ [Mo(CN)7]
4- 2D – layers 
MnII PB-7 
MoIII  PB-7 
134 - 151 AF MnII-MoIII not given 
F ordering 
< 3 K 
149 
[Mn(L2)]2+ [Mo(CN)7]
4- 2D – ladder MnII  PB-7 143 - 156 AF MnII-MoIII not given SMM 149 
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MoIII   CTP-7. 
MoIV   SA- 8 . 
 Ueff = 8.1 K 
[Mn(L2)]2+ [Mo(CN)7]
4- 1D - trinuclear 
MnII PB-7 
MoIV SQ-8 
145 AF MnII-MnII 1.46 × 10−2 - 149 
Octacyanometalates         
[Mn(L1)]2+ [Nb(CN)8]
4- 
1D – infinite 
 
MnII PB-7 
NbIV SQ-8 
151- 155 
 
AF not given - 151 
[Fe(L1)]2+ [Nb(CN)8]
4- 1D – infinite 
FeII PB-7 
NbIV SQ-8 
153 - 160 AF 20 
SCM 
Ueff = 7.4 K 
152 
[Mn(L1)]2+ [Mo(CN)8]
4- 1D – infinite 
MnII PB-7 
MoIV → MoV  
SQ-8 
155 
151 
before illumination: 
AF MnII-MnII 
after illumination: 
AF MnII-MoV 
not given 
after 
illumination/ 
photo-oxidation: 
ferromagnetic 
chain 
153 
[Fe(L1)]3+ [W(CN)8]
4- 
2D – honeycomb 
 
HS FeIII PB-7 
WIV DD-8 
161 
158 
AF FeIII-FeIII not given - 154 
‘Blocked’ complexes         
*[Fe(L2)](CN)2 [Mn(hfac)2] 1D – infinite 
LS/HS FeII PB-7 
HS MnII OC-6 
no single 
crystal data 
AF HS FeII-MnII 
(after illumination) 
0.10 LIESST effect 155 
[Mn(L1)]2+ [Fe(bpb)(CN)2]
- 1D – infinite 
MnII PB-7 
LS FeIII OC-6 
162, 155 AF MnII-FeIII 
|J1| = 
1.16(2), |J2| 
= 0.10(3) 
- 156 
[Mn(L2)]2+ [Fe(bpb)(CN)2]
- 1D – infinite 
MnII PB-7 
LS FeIII OC-6 
159, 147 AF MnII-FeIII 
|J1| = 
3.10(1), |J2| 
= 0.25(1) 
- 156 
[Mn(L1)]2+ [Fe(bpClb)(CN)2]
- 1D – infinite 
MnII PB-7 
LS FeIII OC-6 
163, 155 AF MnII-FeIII 
|J1| = 
1.10(1), |J2| 
= 0.139(8) 
- 156 
[Mn(L2)]2+ [Fe(bpClb)(CN)2]
- 1D – infinite 
MnII PB-7 
LS FeIII OC-6 
148, 167 AF MnII-FeIII 
|J1| = 
1.99(6), |J2| 
= 0.57(1) 
- 156 
[Mn(L2)]2+ [Fe(bpBrb)(CN)2]
- 1D – infinite 
MnII PB-7 
LS FeIII OC-6 
167, 153 AF MnII-FeIII 
|J1| = 
1.23(1), 
|J2| = 
- 156 
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Table 1.6 Summary of the magnetic properties of the polynuclear structures based on L1 and L2.
126
 
††
 This M-NC angle is that involving the macrocyclic metal center. 
* = cyanide bridges initially coordinated to macrocyclic complex 
PB-7 = pentagonal bipyramidal   HS = high spin   SMM = single-molecule magnet  
OC-6 = octahedral   LS = low spin    SCM = single chain magnet 
SA-8 = square antiprismatic  FI = ferrimagnetic                           dist. = distorted                   
DD-8 = triangular dodecahedral               AF = antiferromagnetic  
CTP-7 = capped trigonal prism                      F = ferromagnetic  
0.13(5) 
*[Fe(L1)(CN2)] [Mn(saltmen)(H2O)]
+ 1D – trinuclear 
HS FeII PB-7 
HS MnIII OC-6 
174, 176 AF FeII-MnIII 0.66(9) - 157 
*[Fe(L1)(CN2)] [Mn(saltmen)(H2O)]
+ 1D – infinite 
LS FeII OC-6 → 
HS FeII PB-7 
HS MnIII OC-6 
168, 175 
dominant AF, 
very weak F 
MnIII-MnIII 
(when FeII is LS) 
|J1| = 
0.76(4), |J2| 
= 0.02(8) 
SMM 
(when FeII is 
LS) 
Ueff = 13.9 K 
photoswitchable 
157 
[Mn(L1)]2+ [Fe(salen)(CN)2]
+ 1D – infinite 
MnII PB-7 
LS FeIII  OC-6 
152, 149 AF MnII-FeIII 
|J1| = 
3.25(1) |J2| 
= 0.78(5) 
- 158 
[Mn(L2)]2+ [Fe(salen)(CN)2]
+ 
1D – infinite 
 
MnII PB-7 
LS FeIII  OC-6 
154 AF MnII-FeIII 
|J1| = 
2.67(6)  |J2| 
= 0.46(5) 
- 158 
Other  
 
 
      
[Mn(L1)]2+ N3
- 1D – infinite MnII  PB-7 n/a AF MnII-MnII 4.8 - 159 
[Mn(L1)]2+ [N(CN)2]
- 1D – infinite MnII  PB-7 n/a AF MnII-MnII 0.49 - 160 
[Mn(L1)]2+ TCNQ.- 1D – infinite MnII  PB-7 n/a AF MnII-MnII 
0.18 
(theoretical)
0.15 (EPR) 
- 161 
[Fe(L1)]2+ CN- 1D- infinite FeII PB-7 158.35 
AF FeII-FeII 
canted 6.3 ° 
J = -4.37 
AF; spin 
canting; 
metamagnet  
SCM 
162 
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 From Table 1.6, it can be seen that the most common metal-metal interaction 
displayed by the polynuclear structures is the M-NC-M′ superexchange interaction, 
between the M of the [M(N3O2)]
n+
 unit  and the M′ of the secondary [M′(CN)x]
m-
  
building block. The strength and sign of these interactions are dictated by the nature of 
the orbital overlap between the bridging ligand, and both the geometry and d
n
 
configurations of the two metal ions.
163
 
 As well as the more common ferromagnetic and antiferromagnetic ordering, 
several polynuclear species based on L1 and L2 have been reported which display SMM 
or SCM behaviour. Sato and co-workers treated an [Fe(L2)]
2+ 
building block with a 
[Cr(CN)6]
3-
 salt to afford the trinuclear complex [(Fe(L2)(H2O))2Cr(CN)6]ClO4∙3H2O.  
The complex demonstrates slow relaxation of magnetization above 2 K, displaying 
frequency dependence in both the in- and out-of-phase components of the ac 
susceptibility (Figure 1.31). The relaxation time follows the Arrhenius law with an 
energy barrier of Ueff = 44 K and a relaxation time, 0= 1.4 x 10
-9
 s.
142
 This complex was 
the first example of an Fe
II
-based cyano-bridged SMM.  
 
Figure 1.31 Frequency dependence of the imaginary susceptibility (χ″M) versus 
temperature for Sato’s trinuclear SMM in an applied field of 3 Oe. Adapted from 
Reference 142. 
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 More recently, Clerac ́ and co-workers formed the first photomagnetic chain 
comprising SMM units linked by SCO complexes.
157
 The bis(cyanide) complex 
[Fe(L1)(CN2)] was mixed with [Mn(saltmen)(H2O)]
+
 (saltmen =  N,N-(1,1,2,2-
tetramethylethylene)bis(salicylideneiminate) to afford the linear chain 
[{Mn(saltmen)}2Fe(L1)CN)2](ClO4)2·0.5C4H10O·0.5H2O, with a wave-like topology 
comprising trinuclear Mn
III
-NC-Fe
II
  subunits.
157
   
 
Figure 1.32 A representation of the coordination chain [Mn2(saltmen)2Fe(L1)(CN)2]
2+
  
with hydrogen atoms, perchlorate anions, and interstitial solvent molecules omitted for 
clarity.
157
   
 
 Dc and ac magnetic measurements were performed, and the complex exhibited a 
χMT value of 5.9 cm
3.
K
.
mol
-1
, indicating  that the Fe
II 
 ion in each trinuclear subunit is LS 
(S = 0). The complex comprises two crystallographically distinct [Mn2(saltmen)2] units, 
each dominated by a different exchange interaction: one ferromagnetic, one 
antiferromagnetic.
157
  Ac magnetic measurements reveal slow relaxation of magnetization 
arising from the {Mn2(saltmen)2} units, with an energy barrier of 13.9 K.  Photomagnetic 
studies show that the LS [Fe(L1)(CN)2] unit can be reversibly converted to the HS state, 
allowing for a photoswitchable magnetic interaction between the HS Fe
II
 and Mn
III
 
ions.
157
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 Dunbar and co-workers have utilized the low symmetry/high spin building block 
[Mo
III
(CN)7]
4-
 to synthesize two species with SMM properties.  The anaerobic reaction of 
[Mo(CN)7]
4-
 with [Mn(L1)(H2O)2]
2+
 afforded a docosanuclear Mo8Mn12 cluster (Figure 
1.33).
150
 Not only is this compound the first discrete complex based on a [Mo(CN)7]
4- 
building block, but it also has the most paramagnetic centers together with one of the 
largest ground-state spin values (S = 31) reported for a cyanide cluster to date, again 
emphasizing the enormous potential of the pentadentate macrocyclic building block as a 
precursor to magnetically interesting topologies. 
 
Figure 1.33 Ball and stick representation of complete (left) and skeleton (right) depiction 
of the backbone of the magnetic Mo8Mn12 cluster.
150
 
 Detailed magnetic studies of the cluster between 2 and 300 K revealed 
antiferromagnetic interactions between spin carriers, slow relaxation of magnetization, 
and a hysteresis loop at 1.8 K. The broad maxima in the ac susceptibility data is 
consistent with glass-like behaviour.
150
 The reaction of the same 
heptacyanometalate with [Mn(L2)(H2O)2]
2+
 yielded several different condition-
dependent species, including a ladder-like complex with the formula 
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{[(L2)Mn(H2O)][Mo
III
(CN)7][Mn(L2)]3[Mo
IV
(CN)8]·29H2O}n, with alternating Mo
III
 
and Mo
IV
 units in a 1:1 ratio.
149 
Ac studies (1.8-5 K, 5.0 Oe ac field, zero applied dc field) 
revealed a frequency dependence in the out-of-phase susceptibility, consistent with SMM 
behaviour. The energy barrier to relaxation was estimated to be 8.0 K.
149
 
 Venkatakrishnan and co-workers used an [Nb(CN)8]
4-
 building block in 
conjunction with the [Fe(L1)]
2+
 macrocycle to synthesize a an infinite polymeric species 
with the stoichiometry [(H2O)Fe(L1)(Nb(CN)8)Fe(L1)]n, comprising both left-handed 
and right-handed helical chains.
152
 As intended, the complex demonstrated SCM 
properties with a magnetic hysteresis loop observed between 2 and 10 K. Slow relaxation 
of the magnetization was observed  due to the high energy barrier for magnetic reversal 
resulting from the strong exchange interactions between the Fe
II
 and Nb
IV
 centers, and the 
structural anisotropy associated with the incorporation of the low-symmetry 
heptacoordinate [Fe(L1)]
2+
 complex.
152
 These significant and predicted SCM properties 
highlight the potential of the [Fe(L1)]
2+
 building block for the self-assembly of molecule-
based magnets. 
 
It can thus be seen that the Fe
II
 complex of the macrocycle L2 has been well-
studied as a SCO system, and that Fe
II
, Mn
II
, Cr
II
 and Co
II
 complexes of L1 and L2
 
have 
been exploited for the synthesis of higher-order magnetic structures with a variety of 
topologies and behaviours.  
Two areas of magnetic interest which have not yet been explored are: testing the 
relaxivities of Mn
II
 and Gd
III
 complexes of an extended family of these macrocycles as 
potential contrast agents; and studying high anisotropy mononuclear lanthanide 
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complexes of the macrocycles as possible single-molecule magnets. These topics are the 
focus of Chapters 2 and 3 respectively.   
1.4 Crown ethers: A brief background 
1.4.1 Historical perspective 
Cyclic polyethers, or crown ethers, were accidentally discovered by Pederson in 
the 1960s, while he was attempting to synthesize multidentate phenolic ligands.
164,165
 
Pederson very quickly realized the unprecedented stability with which his first crown 
ether ligand, dibenzo 18-crown-6, bound the alkali cations, K
+
 and Na
+
. Embarking on a 
detailed study of the hitherto unknown cyclic ethers, Pederson synthesized dozens of 
ligands with ring sizes up to 60 atoms, containing up to 10 oxygen atoms; as well as 
nitrogen and sulphur derivatives.
164
 His general synthetic method, still employed today, 
involved Williamson ether synthesis – the reaction of a bis(chloro)ether with a 
dihydroxyether in the presence of a base.
164,165
 Some of his extended family of cyclic 
polyethers were excellent complexing agents; many were not. Pederson identified the 
best candidates for complexation as the crown ethers with up to 10 oxygen atoms, 
separated by ethylene linkers.
164
 Representative examples of this class are shown below. 
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These simple cyclic ligands demonstrate remarkable selectivity and specificity, 
and due to the chelate effect are able to bind with varying degrees of strength to both 
metal and non-metal cations, including alkali and alkaline earth metals, ammonium ions, 
and certain transition metal ions. Pederson found that a given cation had an optimal 
crown ether ring size for preferred binding within the plane of the crown ring, based on 
the relationship between cavity diameter and cation ionic radius. Pederson also noted that 
cations were able to form complexes with crown ethers smaller than this optimal size by 
forming ‘sandwich’ structures of two cyclic ethers per cation. For his seminal work in 
this field, Pederson was awarded the 1987 Nobel prize for Chemistry, together with Cram 
and Lehn.
164
 
Since their discovery, crown ethers have played an important role in the 
advancement of supramolecular chemistry, particularly in the area of host-guest 
chemistry.
166
 The ability of crown ethers to mimic the host-guest behaviour of biological 
molecules such as enzymes has made them a useful model for processes like cross-
membrane cation carriage
167
 for pharmaceutical development. Crown ethers have been 
largely employed in the areas of ion extraction and transport,
168
 uses which point to their 
promise as ion scavengers within the body or environment. Other uses include 
application as phase transfer catalysts,
169,170
 as well as in chiral recognition and 
enantiomeric resolution.
171,172
 Along with the thia-crown and aza-crown species first 
described by Pederson himself, well-studied derivatives of the crown ethers include lariat 
ethers (crown ethers with a pendant side arm)
173
 and cryptands (bi- and polycyclic crown 
derivatives).
174
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1.4.2 Lanthanide complexes of crown ethers 
Chapter 4 of this thesis focusses on a thorough exploration of certain later 
lanthanide (Tb
III
, Dy
III
, Ho
III
, and Er
III
) complexes of 12-crown-4, 15-crown-5 and 18-
crown-6. Lanthanide complexes of these crown ethers are relatively rare. The majority of 
the almost 400 12-crown-4 complexes reported in the literature contain alkali or alkali 
earth metals. Fewer than 20 publications describe Ln
III
-12C4 complexes. Many of these 
lanthanide complexes were reported by Rogers and coworkers in a succession of papers 
in Inorg. Chim. Acta in the late 1980s.
175-178
 Rogers’ work included a series of complexes 
of the form [Ln(12-crown-4)(H2O)5]Cl3
.
nH2O, synthesized using hydrated LnCl3 salts 
(Ln = every trivalent lanthanide but Pm
III
).
178
 Each complex in the series exhibited a 
‘half-sandwich’ structure, with the lanthanide ion lying out of the plane of the crown – 
perhaps predictably, as the ionic radii of these ions when 9-coordinate range from 1.03-
1.22 Å, unlikely to allow in-plane binding within the 12-crown-4 macrocyclic cavity, 1.2-
1.5 Å in diameter.
164
 Aside from this report, there are five additional 12-crown-4 
structures of the four later lanthanides noted above: additional half-sandwich complexes 
of Dy
III
, Ho
III
, and Er
III
 with both chloride and water bound;
178
 and two 9-coordinate full-
sandwich reports of a Ho
III
 complex, with a coordinated methyl group and Al(CH3)4
-
 
counter ions;
179
 and an Er
III
 complex, with a bound acetonitrile and three SbCl6
-
 counter 
ions.
180
 
79 
 
 
         
Figure 1.34 Left, representative half-sandwich complex from the [Ln(12-crown-
4)(H2O)5]Cl3
.
nH2O series;
178
 right, full-sandwich Ho
III
 complex.
179
 Hydrogen atoms, 
lattice water molecules, and non-coordinating counter ions are omitted for clarity.  
 
Although slightly more lanthanide complexes of 15-crown-5 are reported, none at 
all contain Tb
III
, Dy
III
, Ho
III
, or Er
III
. The lanthanide complexes of 15-crown-5 which are 
described, however, also show out-of-plane lanthanide binding, in keeping with the ionic 
radius of 1.7-2.2 Å for this macrocycle.
164
  Three distinct topologies have been reported 
for these complexes: half-, full- and pseudo-sandwich structures. Half-sandwich 
complexes of the Ln
III
 ions Ce-Nd, Sm-Eu, and Yb-Lu have been described, the majority 
of which include bidentate coordinating nitrate counter ions, giving an 11-coordinate 
geometry;
181,182
 or coordinating chloride ions, giving an 8-coordinate geometry.
183
 Three 
10-coordinate full-sandwich structures have been published: complexes of Sm
II
 and Eu
II
 
with perchlorate counter ions;
184,185
 and a complex of Pr
III
 with Al(CH3)4
-
 counter ions.
186
 
Pseudo-sandwich complexes of La
III
 and Sm
III
 were described,
187
 in which one 15-crown-
5 ligand is directly coordinated to the lanthanide ion, with the remaining four positions of 
the 9-coordinate binding sphere filled with water molecules, which in turn are hydrogen-
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bound to a second crown ether. The hydrated perchlorate salts of the metals were used for 
the formation of these complexes. Figure 1.35 illustrates the three binding topologies 
described above.  
                
 
Figure 1.35 Left, a Nd
III
 half-sandwich complex;
183
 center, a Pr
III
 full-sandwich 
complex;
186
 right, a Sm
III
 pseudo-sandwich complex.
187
 Hydrogen atoms, lattice water 
molecules and non-coordinating counter ions are omitted for clarity. 
 
In contrast to the out-of-plane binding exhibited by the lanthanide complexes of 
12-crown-4 and 15-crown-5, the lanthanide complexes of 18-crown-6 show in-plane 
binding of the metal ions, in keeping with the ligand’s larger ionic radius of 2.6-3.2 Å. 
Two Tb
III
 and two Dy
III
 complexes have been reported, each showing the crown ether 
bound in a slightly puckered fashion, equatorial to the lanthanide ion.
175,177,188,189
 Three 
additional monodentate ligands (water, chloride, thiocyanate) are bound in each case: one 
above, and two below the plane (Figure 1.36). To the best of my knowledge, there are no 
structural reports of Ho
III
 or Er
III
 complexes of 18-crown-6 published to date. 
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Figure 1.36 Equatorially-bound Tb
III
-18-crown-6 complex.
175
 Hydrogen atoms, lattice 
water molecules and non-coordinating counter ions are omitted for clarity. 
1.4.3 Luminescence of lanthanide-crown ether complexes 
 The majority of the lanthanide-crown reports noted above detailed synthetic and 
crystallographic information without a detailed discussion of the physical properties.
185-
187,190,191 
 In particular, a discussion of magnetic properties remains entirely absent to date 
from this class of compound. There are, however, several reports describing the emission 
properties of the complexes.
192,193
  
1.4.3.1 Introduction to lanthanide luminescence 
 Luminescence refers to the emission of light as an excited molecule returns to its 
ground state. In photoluminescence, the excited state is generated by the absorption of 
light in the UV-visible region of the electromagnetic spectrum (λ = 1–700 nm, or 14.3–
10,000 × 10
3
 cm
-1
). Following absorption of light of a certain energy, non-radiative 
vibrational relaxation to the emitting state occurs, before a lower-energy photon is 
emitted. The resulting difference in wavelength of the absorbed and emitted photons is 
called the Stokes shift.
194
 Photoluminescence is fluorescent if it does not involve a change 
in spin (for instance, ligand S1→S0, or Yb
III
 
2
F5/2→
2
F7/2), while phosphorescence 
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describes transitions involving a spin-flip, and intersystem crossing between states of 
different multiplicities (such as ligand T1→S0, or Dy
III
 
4
F9/2→
6
H5/2). The timescale of 
fluorescence is 10
-9
 – 10-7 sec, while the timescale of phosphorescence is much longer 
(10
-3 – 102 sec).195  
 
Figure 1.37 Jablonsky diagram showing absorption (A), vibrational relaxation (V), 
fluorescence (F), intersystem crossing (IC), and phosphorescence (P).  
 
     Electronic transitions within lanthanide ions may be intra-configurational 4f-4f, inter-
configurational 4f-5d, or charge-transfer transitions between the metal and ligand. The 
transitions of particular interest in lanthanide luminescence are the 4f-4f transitions, 
because these transitions produce extremely sharp, narrow emission bands characteristic 
of a given metal. Although 4f-4f transitions are ‘forbidden’ (highly improbable) by the 
Laporte parity selection rule, they can still occur in the presence of a ligand field which 
disrupts the orbital symmetry in an analogous fashion to ‘forbidden’ d-d transitions for 
transition metal ions. The main luminescent transitions for each lanthanide from Pr
III 
to 
Yb
III
 are listed below, along with an energy diagram showing partial splitting of the Ln
III
 
electronic energy levels. 
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Table 1.7 Luminescent f-f transitions of the lanthanides, where P = phosphorence and F = 
fluorescence. Adapted from Reference 196.    
 
 
 
 
 
 
 
 
Figure 1.38 Splitting of the electronic energy levels of the lanthanides. Adapted from 
Reference 196. 
 
Ln
III 
Excited state Final state J Type of lum. Color of emission 
Pr
III
 
1
G4 
3
HJ 4-6 P NIR 
 
1
D2 
3
FJ 2-4 P NIR 
 
3
P0 
3
HJ 2-6 F orange 
Nd
III
 
4
F3/2 
4
IJ 9/2-15/2 F NIR 
Sm
III
 
4
G5/2 
6
HJ 5/2-15/2 P orange 
Eu
III
 
5
D0 
7
FJ 0-6 P red 
Gd
III
 
6
P7/2 
8
S7/2  P UV 
Tb
III
 
5
D4 
7
FJ 6-0 P green 
Dy
III
 
4
F9/2 
6
HJ 15/2-5/2 P yellow/orange 
Ho
III
 
5
F5 
5
IJ 8-4 F NIR 
 
5
S2 
5
IJ 8-4 F green 
Er
III
 
4
S3/2 
4
IJ 15/2-9/2 F  
 
4
I13/2 
4
I15/2  F NIR 
Tm
III
 
1
G4 
3
HJ 6-4 P  
Yb
III
 
2
F5/2 
2
F7/2  F NIR 
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The main issue in lanthanide luminescence is the weakness of their emission, due to the 
forbidden nature of the 4f-4f transitions. The emission efficiency of a given complex is 
described by the quantum yield, φ, where φ =  
number of photons emitted
number of photons absorbed
. A large 
quantum yield corresponds to a high intensity band. Sensitization is the process of 
enhancing the quantum yield of an emission band, via ‘the antenna effect’; a strongly 
absorbing chromophore transfers energy to the lanthanide excited states, which undergo 
quick internal conversion to the emitting state (Fig. 6). The emission band occurs at the 
characteristic wavelength for a given metal, but with much greater intensity than normal. 
Two common energy transfer pathways are the Dexter mechanism, involving double-
electron exchange; and the through-space electrostatic multi-polar Forster mechanism.
195
 
An effective antenna should have a high molar absorptivity ε, and the triplet state of the 
ligand should be at least 1850 cm
-1 
higher in energy than the metal ion emitting state, to 
avoid re-population of the ligand triplet.
197
  
 To date, lanthanide luminescence has been predominantly exploited in medicinal 
biotechnology due to the pure-colour and tunable emission, and the long excited-state 
lifetimes. Eu
III
 and Tb
IIII 
are the most commercially exploited lanthanides, because they 
have both long lifetimes and quantum yields typically greater than 10%.
197
 The 
applications of these compounds include use in bioimaging and sensing, luminescent 
stains, optical amplifiers, and lighting devices and displays.
198-200
 These applications 
make use of the sharp emission bands corresponding to transitions between electronic 
terms or levels (a change in L or J).
201
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1.4.3.2 Emission of Ln-crown complexes 
 Over the past decade, Belian and co-workers have published a number of papers 
discussing the luminescent properties of lanthanide complexes of crown ethers, utilizing 
additional chromophoric ligands as antennae. In a 2011 study, Eu
III
, Tb
III
 and Gd
III
 were 
complexed to 12-crown-4 and 15-crown-5, in addition to water, phenanthroline (phen), 
2,2′-bipyridine (2,2′-bipy), or a combination of these ligands.202 The solid state crystal 
structures of the complexes were not measured, but the compositions were determined by 
elemental analysis. Due to the non-chromophoric nature of the crown ether ligands, as 
well as the quenching effect of bound water molecules, the complexes in which the 
coordination sphere involved a crown and water molecules displayed quantum 
efficiencies as low as 15.7%.
202
 The two N-heterocyclic ligands served as effective 
antennae. The Tb
III
 complexes displayed the most consistently intense emission, while an 
Eu
III
 complex had the highest quantum efficiency of 71.6%, observed for the [Eu(15-
crown-5)(phen)2]Cl3 complex.
202
 
 In a similar study, Eu
III
, Gd
III
 and Tb
III
 complexes of 12-crown-4 and 15-crown-5 
with terpyridine (terpy) antennae ligands were studied.
203
 Both solid state and aqueous 
emission properties were examined. Aqueous luminescence is particularly important for 
potential biological applications, such as in immunoassays. In a comparison of the 
quantum yields for aqueous solutions of [Eu(12-crown-4)(terpy)(H2O)]Cl3 and [Eu(15-
crown-5)(terpy)]Cl3, the respective values of φ = 7.4% and 4.3% suggest that the 12-
crown-4 complex is of more biological interest.
203
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Figure 1.39 Antennae ligands utilized in lanthanide-crown ether luminescence. 
 
 Belian and co-workers also reported the luminescent properties of a novel 
dinuclear, mixed-crown system: a Eu
III
-12C4 complex and a Tb
III
-18C6 complex bridged 
by a 4,4′-bipyridyl (4,4′-bipy) ligand.204 Although single crystals were not studied, the 
proposed structure is shown below (Figure 1.40). Interestingly, the complex emitted 
yellow light in the solid state, in contrast to the usual red and green emission exhibited by 
mononuclear Eu
III
 and Tb
III
 complexes respectively. In the same work, mononuclear 12-
crown-4 and 18-crown-6 complexes of Eu
III
, Tb
III
 and Gd
III
 were studied, with water 
molecules filling the remaining positions in the coordination spheres. Although quantum 
yields were not discussed, the expected transitions between the lanthanide energy levels 
were observed; in particular, the 
5
D0→
7
F0-2 transitions for Eu
III
, and the 
5
D4→
7
F6-3 
transitions for Tb
III
.
204
  
 
Figure 1.40 The heterodinuclear lanthanide-crown ether complex reported by Belian et 
al; chloride counter ions omitted.
204
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 An additional report by Belian and co-workers involved supramolecular 
lanthanide-crown ether systems, in which the effect of a crown ether (18-crown-6 or 
dibenzo-18-crown-6) on the luminescence of a Eu
III(β-diketonate) complex was 
studied.
205
 In these complexes, the crown ether was not directly coordinated, but was 
present as a lattice molecule. The supramolecular complexes displayed quantum yields of 
approximately 26% (vs. 29% for the complex in the absence of a crown); and were 
photochemically stable. Tris(β-diketonate) lanthanide complexes were mentioned in 
Section 1.2.4, in the context of mononuclear single-molecule magnets; however, β-
diketonate complexes of Eu
III
 and Sm
III
 in particular have been studied for their 
luminescent properties, because conjugated β-diketonates act as strong antennae.205  
 The research impetus behind the reports discussed above was to probe the effect 
of ligand field on lanthanide luminescence, with a view to luminescent probe 
development. Crown ethers were chosen as ligands for study in spite of their non-
chromophoric nature because of the stability they confer upon their complexes both in 
solid and solution states due to the macrocyclic effect.
202,204
 However, as well as the 
emission bands corresponding to transitions between terms and levels, mentioned in the 
above reports,  lanthanide emission can also provide information regarding the energy 
differences between electronic microstates or sublevels, which are important in single-
molecule magnetism. That is, emission spectra can show the Stark splitting of the ground 
state 
2S+1
LJ multiplet into its component MJ microstates/sublevels. This electronic 
structural information is gleaned from the fine structure of the highest-energy emission 
band in a luminescence spectrum. The relationship between magnetic behaviour and 
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luminescence-derived MJ energies in the context of lanthanide-crown complexes has not 
yet been explored, and is discussed in Chapter 4.   
 
1.4.4 Crown ethers in molecular magnetism 
 Most of the structural reports described in Section 1.1.2 were published 
before 2003, when the anisotropy of lanthanide ions first began to be harnessed for the 
synthesis of SMMs. For this reason, the potential of crown ether-lanthanide complexes 
for use as molecule-based magnetic materials has not been investigated.   
 However, the first report of a transition metal-crown ether complex 
displaying slow magnetic relaxation was reported during the preparation of this thesis.
206
 
An 8-coordinate ‘sandwich’ complex with the formula [Co(12-crown-4)2](I3)2(12-crown-
4) (Figure 1.41) was reported by Chen and co-workers, which exhibited SMM behaviour 
in an applied field of 500 Oe. The barrier to relaxation was calculated to be 17.0 cm
-1
. 
Although this Ueff value is not an improvement on the highest barrier observed for a 
mononuclear transition metal complex (226 cm
-1
, for a 2-coordinate Fe
I
 complex
109
), the 
report is significant as it represents the highest coordination number of any mononuclear 
transition metal SMM.
206
 In addition, the metallocrown derivative of 12-crown-4, 12-
metallocrown-4, has been increasingly exploited in single-molecule magnetism over the 
past five years.
207
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Figure 1.41 Structure of the Co
II
-crown ether SMM reported by Chen and co-workers 
Hydrogen atoms, non-coordinating lattice molecules and counter ions are omitted for 
clarity.
206
 
 To date, crown ethers have remained unexplored as a class of ligand for 
the synthesis of lanthanide-based SMMs. However, the wide array of known and 
commercially available crown derivatives suggest that lanthanide-crown ether 
compounds may represent a tunable family of complexes, through which the effects of 
structural variation on magnetic behaviour may be investigated with unprecedented ease. 
This topic is the focus of Chapter 4. 
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2 RESULTS AND DISCUSSION FOR PROJECT 1: 
Mn
II
 and Gd
III
 complexes of Schiff-base macrocycles as potential MRI contrast 
agent
*
 
2.1 Introduction  
 Project 1 involves the synthesis of Mn
II
 and Gd
III
 complexes of Schiff-base 
macrocycles as potential MRI contrast agents. As discussed in Section 1.1, the majority 
of the contrast agents clinically approved for use in Canada are ‘small-molecule’ agents: 
mononuclear complexes of Gd
III
 with a chelating or macrocyclic ligand.  
To briefly re-iterate the requirements for a contrast agent: in order to display 
relaxivity behaviour, a contrast agent must have at least one paramagnetic metal center, 
whose magnetic moment can interact with the moment of water protons; and at least one 
coordinated water molecule in aqueous solution. Relaxivity can be maximized by 
increasing the number of bound water molecules, increasing the water exchange rate, and 
decreasing the rate of molecular tumbling. Along with efficiently relaxing water protons, 
a contrast agent must also be stable in vivo with regards to both dissociation and 
transmetallation, due to the bio-toxicity of free Gd
III
 and Mn
II
. There is an on-going 
search for new MRI contrast agents which are both effective and safe; in particular, in the 
field of small-molecule agents there is a renewed interest in complexes based on Mn
II
, 
                                                 
*
 Note concerning labelling: Macrocyclic ligands are labelled L1-L6. Organic building 
blocks for a given ligand LX are labelled Xa, Xb etc. Inorganic complexes based on a 
given ligand LX are labelled X.1, X.2 etc.  
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due to the recent discovery of the link between the disorder nephrogenic systemic fibrosis 
and Gd
III
-based agents.  
Small [1+1] Schiff-base macrocycles, or bis(imine) macrocycles, have been 
heavily underutilized in this regard. These macrocycles are formed via the metal-
templated condensation of a diamine and a diketone (Scheme 2.1). As mentioned earlier, 
a great deal of research effort has been invested worldwide on the synthesis and 
characterization of coordination complexes of 15- to 18-membered bis(imine) or Schiff-
base macrocycles with N3X2 or N3X3 donor atom sets (X = O, NH).
126
 These complexes 
have been thoroughly and cleverly exploited as building blocks for the formation of 
higher order magnetic structures (Section 1.4). However, very few macrocyclic 
complexes within this class have been explored as possible MRI contrast agents.  
 
Scheme 2.1 Metal-templated synthesis of a [1+1] Schiff-base macrocycle from 
diacetylpyridine and a generalized diamine. 
 
 Section 1.1 detailed a 1992 study concerning the field-dependent relaxivity 
profiles of four Mn
II
 complexes of Schiff-base macrocycles: 15-, 16- and 17-membered 
N5 systems, and an 18-membered N6 system (Figure 1.12). Higher relaxivity values were 
observed for these unsaturated systems in comparison to their saturated (amine) 
analaogues, due to the enhanced rigidity provided by the pyridine head-unit. Furthermore, 
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higher relaxivities were also observed for the 15- and 16-membered rings when compared 
to the 17- and 18-membered rings. This second observation was attributed to the planar, 
equatorial binding mode of the smaller macrocycles, allowing for the coordination of two 
axial water molecules in solution. 
 In spite of the promising relaxivities observed, to-date these systems have not 
been investigated further. This is surprising, given that the amine analogue of L1 was 
recently re-examined, in spite of the fact that this system displays lower relaxivity than 
L1, and is well-known to be a superoxide dismutase mimic.
40,64
 In addition, bis(imine) 
macrocycles with mixed N3O2 or N3O3 donor groups have never been considered for 
MRI applications, which is again surprising, given that both Mn
II
 and Gd
III
 are highly 
oxophilic, so the incorporation of oxygen into the macrocyclic backbone should enhance 
the stability of the resulting complexes. 
 
Figure 2.1 N5 and N6 Schiff-base macrocycles.
61
 
   
We thus decided to first re-visit the most effective bis(imine) system described in the 
1992 report, the 15-membered N5 system L1; and subsequently, to investigate for the first 
93 
 
 
time an expanded family of bis(imine) systems with N3O2 and N3O3 donor sets, L2-L7 
(Figure 2.2) as potential MRI contrast agents.    
2.1.1 Target family of macrocycles 
The target family of Schiff-base macrocycles, L1-L7, is shown below (Figure 2.2). 
 
Figure 2.2 Proposed family of macrocycles L1-L7. 
L1
 
is an N5 macrocycle, the first of the family to be reported in the literature in 
any context, and also the only one of the family to have been suggested as a ligand for 
potential use in MRI contrast agent development. It has a 15-membered macrocyclic 
backbone.  L2 is the N3O2 analogue of L1, differing only in the nature of its donor atoms. 
L3 and L4 maintain the size and donor character of the N3O2 macrocyclic cavity, but 
have increased rigidity (L3) and steric bulk (L4). Additionally, macrocycle L4 is an 
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optically active system, with two adjacent chiral centres on the central ethylene linker. L5 
and L6 have an expanded cavity, with an additional O donor atom and an 18-membered 
backbone. L5 is the larger analogue of L2, with flexible ethylene linkers, while L6 is the 
analogue of the more rigid L3. Finally, L7 is comprised of two covalently-tethered L2 
macrocycles, linked via the pyridine head units. By studying this expanded family of 
macrocyclic systems, we hoped to be able to investigate the effect of the number and 
nature of donor atoms, and the cavity size, steric bulk and rigidity on the relaxivities of 
the resulting complexes. Complex L7 is particularly noteworthy in that it provides an 
opportunity to explore how the presence of two metal centers would affect the relaxivity 
behavior of the complex. 
Diacetylpyridine was selected as the diketone building block for macrocycles L1-
L6 rather than its dialdehyde analogue diformylpyridine, because Schiff-base 
macrocycles based on the former have been shown to be more resistant to hydrolysis.
208-
213
 This is likely because the methyl side-arms of the resulting complexes provide a steric 
protection. 
  There were several reasons why we hypothesized that the proposed family of 
macrocycles would be useful for the formation of contrast agents. Firstly, the planarity of 
the bis(imine) macrocyclic rings allows for the binding of monodentate ligands in the 
axial position. In aqueous solution, these positions could potentially be filled by aquo 
ligands, which may undergo unhindered, fast water exchange. Secondly, the known 
complexes of these Schiff-base macrocycles appear to be very water soluble, which is an 
important property of an in vivo imaging agent. Thirdly, none of the target 15- to 18-
membered [1+1] Schiff-base macrocycles had ever been formed or found to exist in the 
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absence of a metal ion. Thus the metal centers in these templated macrocycles could be 
less prone to dissociation of the metal ions, leading to complexes with a more favourable 
toxicity profile than the currently approved agents.  
 Our short term objectives were therefore to template macrocycles L1-L7 around 
Mn
II
 and Gd
III
, and study the in vitro relaxivities of any soluble, analytically pure 
complexes which resulted.  Longer term, our objective was to identify the most 
promising candidate(s) for further in vivo toxicity and imaging studies. 
2.2 Organic synthesis: macrocyclic building blocks 
As mentioned earlier, complexes of L1 (N5) and L2 (N3O2) were formed by the 
metal-templated Schiff-base condensation of 2,6-diacetylpyridine (1a) and a diamine.
126
 
The diamines used for the preparation of L1 and L2 were tris(ethylenetetramine) (1b) 
and 2,2’-(ethylenedioxy)bis(ethylamine) (2a), respectively. All three compounds are 
commercially available. 
 
Figure 2.3 The organic building blocks required for the synthesis of L1 and L2.  
 
 Modifications to the macrocyclic structure may be introduced by altering either 
the pyridine-based diketone unit, or the ether-containing diamine unit. In order to 
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synthesize L3-L6, different diamines were needed, whereas the synthesis of L7 requires a 
different ketone unit (Figure 2.4). 
 
Figure 2.4   Diamines required for the synthesis of L3-L6, and the tetraketone required 
for the synthesis of L7. 
 
 These building blocks are not commercially available, and so were synthesized 
following a variety of modified literature procedures
214-218
 as well as two synthetic 
pathways developed previously by the Pilkington group.
219-221
 Each known organic 
intermediate and product was  characterized by 
1
H- and 
13
C-NMR spectroscopy, mass 
spectrometry and melting point (if solid). In addition, the purity of each final product 
shown in Figure 2.4 was confirmed via elemental analysis. The success of the metal-
templated condensation reaction depends upon the 1:1:1 stoichiometry of the 
amine/ketone/metal salt (in the case of complexes of L7, the ratio would be 2:1:2 
amine/ketone/metal salt), so confirmation of the purity of the building blocks was vital. 
The synthetic pathways utilized are detailed below, followed by a summary of 
experimental data for the final product in each pathway (Table 2.1).  
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Diamine 3b was synthesized following the literature procedure shown in Scheme 
2.1.
214
 Two equivalents of p-nitrophenol were deprotonated using potassium carbonate 
and refluxed with one equivalent of dibromoethane in a dual Williamson ether synthesis 
to give the dinitro compound 3a. The two aryl nitro groups were subsequently reduced to 
amines in the presence of stannous chloride in acidic conditions, to afford the desired 
diamine 3b as a beige solid in 47% yield. 
 
Scheme 2.2 Synthetic pathway for the formation of diamine 3b.
214
 i) K2CO3, DMF, 
reflux, 18 h; ii) SnCl2, HCl/H2O, reflux, 18 h. 
 
Diamine 4d was previously unreported in the literature. The synthetic procedure 
shown in Scheme 2.3 was developed by the Pilkington group.
219
 The commercially 
available chiral starting material, hydrobenzoin, is available as the R,R′-, S,S′- or meso 
isomer. For this project, the R,R′- isomer was used. For the purposes of this research, the 
chirality was not of particular interest; the additional bulk conferred by the phenyl groups 
was the parameter being studied. R,R′-hydrobenzoin underwent a Williamson ether 
synthesis with allyl bromide to form diene 4a, which was then subjected to Lemieux-
Johnson oxidation by reaction with OsO4/NaIO4 to give diol 4b. The diol was then 
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converted to the diphthalimide via the Mitsunobu reaction, namely by reaction with 
triphenylphosphine, phthalimide and DIAD. Compound 4c was finally subjected to 
hydrazinolysis to afford the desired diamine 4d as an oil in 56% yield.  
Scheme 2.3   Synthetic procedure for the synthesis of diamine 4d.
219
 i) NaH, allyl 
bromide, THF, reflux, 18 h; ii) OsO4, NaIO4, THF/H2O, r.t., 18 h; iii) NaBH4, 
DCM/MeOH, r.t., 18 h; iv) PPh3, phthalimide, DIAD, THF, r.t., 4 d; v) hydrazine 
monohydrate, EtOH, reflux, 18 h. 
 
 The synthesis of 5c was carried out via the literature procedure shown in Scheme 
2.4.
215,216
 Commercially available tetra(ethylene)glycol reacted with tosyl chloride to 
give the ditosyltate 5a, which then underwent a simple substitution with potassium 
phthalimide to give 5b via Gabriel synthesis. Diphthalimide 5b then underwent 
hydrazinolysis to afford diamine 5c as an oil in excellent yield.   
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Scheme 2.4   Synthetic procedure for the synthesis of diamine 5c.
215,216
 i) Tosyl chloride, 
KOH, DMF, 0°C-r.t., 18 h; ii) potassium phthalimide, DMF, 80°C, 18 h; iii) hydrazine 
monohydrate, THF/MeOH, reflux, 18 h. 
  
 Diamine 6c was synthesized via the pathway given in Scheme 2.4.
217
 Amide 6a 
was formed from aminophenol and acetic anhydride. Diamide 6b was synthesized in a 
dual Williamson ether reaction between bis(2-chloroethyl) ether and 2 equivalents of 6a. 
The amide groups were then cleaved under basic conditions to give the desired diamine 
6c as a solid in 75% yield.  
 
Scheme 2.5   Synthetic procedure for the synthesis of diamine 6c.
217
 i) Acetic anhydride, 
MeOH/H2O, r.t., 5 h; ii) bis(2-chloroethyl)ether, K2CO3, DMF, 80°C, 30 min; iii) NaOH, 
EtOH/H2O, reflux, 3 d. 
Tetraketone 7d was formed from the known diacyl chloride 7c,
220
 following a 
procedure previously published by the Pilkington group (Scheme 2.6).
221
 Two 
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commercially available lutidine precursors were covalently tethered via a reductive 
coupling with sodium metal to give a non-aromatic anionic intermediate, which after 
bubbling-through with SO2 afforded the aromatic tetramethyl species 7a. This compound 
was then converted to the tetraacyl chloride 7b by reaction with thionyl chloride which 
was activated by DMF. The desired tetraketone 7d was formed by the reaction of 7c with 
deprotonated Meldrum’s acid, followed by an acidic work-up. 
Scheme 2.6 Synthetic procedure for the synthesis of tetraketone 7d developed by 
Pilkington and co-workers
220,221
 i) Na, THF, r.t., 7 d; ii) SO2, 0°C, 5 h; iii) CrO3, H2SO4 
(conc.), 75°C, 2 h; iv) SOCl2, DMF, reflux, 4 h; v) pyridine, DCM, 0°C-r.t., 2 h; vi) HCl, 
DCM, 0°C, 5 min; vii) acetic acid, H2O, reflux, 18 h. 
 
During the course of this project, an alternative synthetic pathway for the 
formation of 7d was reported in the literature by Lieb and co-workers, shown in Scheme 
2.7.
218
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Scheme 2.7 Synthetic procedure for the synthesis of tetraketone 7d developed by Lieb 
and co-workers
218 
i) Peroxydisulfate, silver nitrate, H2SO4 (1 M), r.t., 24 h. 
 
 This pathway offers significant advantages over that shown in Scheme 2.6, 
including reduced overall reaction time (two days for the conversion of 4,4′-biyridine to 
7d, compared with 11 days for the conversion of lutidine to 7d), milder reagents (Scheme 
2.6  involves the use of toxic and corrosive SO2, CrO3, and SOCl2), and higher overall 
yields (overall yield for  Scheme 2.6 was 4%, compared with an overall yield of 25% for 
Scheme 2.7). For these reasons, the latter pathway was subsequently adopted as our 
preferred method of choice for the synthesis of 7d. 
 Experimental data for each of these starting materials, 3b, 4d, 5c, 6c and 7d, are 
summarized in Table 2.1. The relevant numbering scheme is included to aid in 
interpretation of the NMR data. 
 
102 
 
 
 
Cmpd. 
1
H NMR data 
(CDCl3, 300- 400 MHz) 
13
C NMR data 
(CDCl3, 300 - 400 MHz) 
 C H N Melting point (°C) FAB-MS data 
3b 
6.87-6.73 (m, 8H, H2-4), 4.37 
(s, 4H, H7) 
146.3 (C6), 136.9  (C1), 122.0 (C3), 
118.5 (C4), 115.5 (C2), 112.6 (C5), 
67.6 (C7) 
Found 
Calcd. 
65.73 
66.09 
6.11 
6.33 
10.82 
10.93 
126°C 
(Lit. 129-132°C
214
) 
m/z = 245 
[M+H]
+
 (100%) 
4d 
7.14-7.03 (m, 10H, H5-7), 4.41 
(s, 2H, H3), 3.46-3.29 (m, 4H, 
H2), 2.78 (s, 4H, H1) 
138.6 (C4), 127.9 (C6), 127.6 
(C7), 127.5(C5), 86.0 (C3), 71.1 
(C2), 41.5 (C1) 
Found 
Calcd. 
68.39 
67.90 
8.04 
8.23 
8.34 
8.80 
oil at r.t. 
m/z = 301 
[M+H]
+
 (27.1%) 
5c 
3.64 (m, 8H, H3-4), 3.52 (t, J = 
5.1 Hz, 4H, H2), 2.87 (t, J = 
5.9, 4H, H1) 
73.3 (C2), 70.4 (C4), 70.7 (C3), 
41.8 (C1) 
Found 
Calcd. 
- - - oil at r.t. 
m/z = 194 
[M+H]
+
 (2.9%) 
6c 
6.84-6.69 (m, 8H, H2-5), 4.18 
(t, J = 4.7 Hz, 4H, H7), 3.93 (t, 
J = 4.8 Hz, 4H, H8) 
146.4 (C6), 137.2 (C1), 122.1 (C4), 
118.5 (C2), 115.5 (C5), 113.2 (C3), 
70.0 (C8), 68.6 (C7) 
Found 
Calcd. 
66.71 
66.65 
6.82 
6.99 
9.72 
9.53 
64°C 
(Lit. 65°C
217
) 
m/z = 289 
[M+H]
+
 (94.4%) 
7d 
8.56 (s, 4H, H4), 2.85 (s, 12H, 
H1) 
198.8 (C2), 154.0 (C3), 146.7 (C5), 
122.3 (C4), 25.7 (C1) 
Found 
Calcd. 
63.70 
63.15 
5.37 
5.30 
7.80 
8.18 
260°C, decomp. 
(Lit. 262°C
222
) 
m/z = 324  
[M]
+
 (28.3%) 
 
Table 2.1 Selected characterization data for the organic building blocks 3b, 4d, 5c, 6c and 7d. 
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2.3 Inorganic synthesis: Mn
II
 and Gd
III
 complexes 
 Following the synthesis of the required organic building blocks, templation of 
macrocycles L1-L7 was attempted around Mn
II
 and Gd
III
. Both of these ions have a large 
number of unpaired electrons (S = 5/2 and 7/2 respectively), and a long electronic 
relaxation time, making them the most utilized paramagnetic ions in MRI contrast agent 
development. 
The choice of which salts of these ions to employ as templating agents was 
influenced by the potential biological applications.  Schiff-base macrocycles have been 
previously templated around chloride, perchlorate, bromide, iodide, triflate, and nitrate 
salts of metal ions.
126
 However, since the contrast agents must be non-toxic, several of 
these anions were ruled out. For example, perchlorates affect the production and secretion 
of thyroid hormones;
223
 and nitrates are readily reduced to nitrite in the stomach or saliva, 
which binds with hemoglobin and disrupts its ability to carry oxygen.
224
 Chloride was 
therefore selected as a biologically-present anion, which had previously proven efficient 
as an anion in the synthesis of other analytically pure Schiff-base macrocyclic 
complexes.
126
 Thus MnCl2
.
4H2O and GdCl3
.
6H2O were selected as the metal salts around 
which this family of macrocycles would be templated.  
  The Mn
II
 chloride complexes of L1
 
and L2 have been well-reported in the 
literature due to their application as building blocks for magnetically interesting clusters, 
chains and networks,
126
 and the Mn
II
 chloride complex of L7 was reported previously by 
the Pilkington group.
221
 The Mn
II
 chloride complexes of L3-L6 and the Gd
III
 chloride 
complexes of all the ligands are unreported to date. 
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 Unless otherwise stated, each complex was synthesized in the following way. One 
equivalent each of the metal salt, diketone and diamine were refluxed at 85°C for 4-18 h. 
The solution was cooled, and diethyl ether was added, causing the complex to precipitate 
out of solution. After the solid was collected by Büchner filtration, it was washed very 
thoroughly with diethyl ether and allowed to air dry. The complexes were collected as 
powders in low to good yields (10 – 84%).   
2.3.1 Mn
II
 complexes  
Our attempts to template L1-L7 around MnCl2
.
4H2O resulted in the isolation of 
six analytically pure complexes with the formula [Mn(L)Cl2]·xH2O, summarized in Table 
2.2, below.  
Complex; 
Abbrev. 
Formula  C H N 
v(C=N) 
(cm-1) 
λmax (ε) 
(nm,  
L.mol-1.cm-1) 
ΛM (aq.) 
(S.cm2.mol-1) 
1.1* 
MnII-N5 
[Mn(L1)Cl2]·2H2O 
Found 
Calcd. 
45.01 
45.13 
5.88 
5.81 
17.21 
17.54 
1649 
250 (5110) 
300 (3070) 
254.3 
2.2* 
MnII-N3O2 
[Mn(L2)Cl2]·2H2O 
Found 
Calcd. 
41.19 
41.21 
5.69 
5.76 
9.43 
9.61 
1645 
250 (6350) 
300 (4240) 
194.4 
3.1 
MnII-dbN3O2 
[Mn(L3)Cl2]·2H2O 
Found 
Calcd. 
55.72 
55.55 
4.65 
4.26 
8.39 
8.45 
1617 
252 (11060) 
284 (7670) 
- 
4.1 
 
MnII-dpN3O2 
[Mn(L4)Cl2]·2H2O 
Found 
Calcd. 
55.15 
55.02 
5.63 
5.64 
6.79 
7.13 
1650 
252 (5840) 
301 (3240) 
293.4 
6.1 
MnII-dbN3O3 
[Mn(L6)Cl2]·2H2O 
Found 
Calcd. 
51.88 
52.01 
4.98 
5.06 
7.31 
7.28 
1618 
251 (10520) 
282 (6470) 
186.2 
7.1** 
(MnII-N3O2)2 
[Mn2(L7)Cl4]·5H2O 
Found 
Calcd. 
40.27 
40.47 
5.49 
5.66 
9.52 
9.44 
1647 
252 (18060) 
311 (3820) 
320.4 
 
Table 2.2 Summary of Mn
II
 complex formulae, elemental analyses, IR and UV-visible 
spectroscopic data, and conductance measurements. Key: *denotes previously reported 
complexes; **denotes a complex previously reported by the Pilkington group. 
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In each case, imine formation was confirmed by the key observation of the 
appearance of a band in the IR spectrum around υ = 1620-1670 cm-1, corresponding to 
imine (C=N) stretch. Elemental analysis was used to determine the total number of water 
molecules associated with each complex, both bound and unbound; and conductivity data 
was employed to establish the hydration number of each complex in aqueous solution. 
Where possible, X-ray diffraction was used to determine the structure of the complex: in 
particular, to confirm the planar, equatorially-bound nature of the macrocycle. Additional 
characterization included FAB mass spectrometry, where in each case a major peak 
corresponding to [M-2H2O-Cl]
+
 was observed; and UV-visible spectroscopy, which 
showed two strong absorption bands in the 250-300 nm, corresponding to π to π* 
electronic transitions of the coordinated macrocyclic ligand. A discussion of these factors 
in relation to each complex is presented below. 
As mentioned earlier, complexes 1.1 (Mn
II
-N5) and 2.1 (Mn
II
-N3O2) have been 
reported previously.
139
 Macrocyclic formation was confirmed for both complexes by IR 
spectroscopy, with the appearance of an imine peak at υ = 1649 and 1645 cm-1 
respectively, and by the absence of a ketone peak. Elemental analysis gave an excellent 
fit for formulae of [Mn(L)Cl2]·2H2O (L = L1, L2), with maximum differences of 0.33% 
and 0.14% for Mn
II
-N5 and Mn
II
-N3O2 respectively. The largest peak on the FAB-MS 
spectrum occurred at m/z = 363 for Mn
II
-N5, and at m/z = 365 for Mn
II
-N3O2, 
corresponding to [M-2H2O-Cl]
+
 in both cases. The UV-visible spectra of the two systems 
in methanol were very similar, with each solution absorbing strongly at  = 250 and 300 
nm. The crystal structures of 1.1 (Mn
II
-N5) and 2.1 (Mn
II
-N3O2) were previously 
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characterized by X-ray crystallography.
139
 The molecular structures show that in each 
complex, the Mn
II
 ion is coordinated in a 7-coordinate, pseudo-pentagonal bipyramidal 
geometry. The five donor atoms of the macrocyclic ring (N5 for 1.1 and N3O2 for 2.1) 
coordinate in the equatorial  plane, with the maximum deviation of a donor atom from the 
best plane through the donor set in each case equal to 0.083 Å for N(5) of Mn
II
-N5 and 
0.086 Å for O(3) of Mn
II
-N3O2. Each macrocycle binds to Mn
II
 in an equatorial fashion, 
with the metal ion offset from the N3X2 plane by a negligible distance of 0.003 and 0.001 
Å for Mn
II
-N5 and Mn
II
-N3O2 respectively. 
       
Figure 2.5 View of the molecular structures of complexes 1.1 (Mn
II
-N5, left) and 2.1 
(Mn
II
-N3O2, right).
139
 Hydrogen atoms and water molecules are omitted for clarity. 
Thermal ellipsoids are shown at 50%. 
 
The published crystal data for 2.1 (Mn
II
-N3O2) was collected on a single crystal 
grown via evaporation of an ethanol solution in the presence of NaCl.
139
 In order to 
determine whether the presence of excess Cl
-
 anions in the solution influenced the nature 
of the axial liagnds, we grew single crystals of 2.1 via the diffusion of diethyl ether into a 
methanol solution of the complex. The measured X-ray crystal structure was the same as 
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the literature structure (Figure 2.5), showing that both axial positions are occupied by 
chloride ions even when crystallization occurs in the absence of excess chloride.  
Initial attempts to form 3.1 (Mn
II
-dbN3O2) from diamine 3b and diacetylpyridine 
in a refluxing methanolic solution were unsuccessful. The IR spectrum of the isolated 
product showed amine peaks in the 3300-3400 cm
-1
 region, as well as imine peaks; 
furthermore, additional bands in the C-O stretch region (around 1100 cm
-1
) suggested an 
asymmetric product. When the reaction was carried out in EtOH rather than MeOH, and 
refluxed for just 4 hours rather than 18 hours, no N-H stretch peaks were visible in the IR 
spectra. The imine stretch for Mn
II
-dbN3O2 was visible at υ = 1617 cm
-1
. Intense bands 
on the UV-visible spectrum at λ = 252 and 284 nm, corresponding to a macrocyclic π → 
π* transition. Elemental analysis gave an excellent fit for the formula [Mn(L3)Cl2]·2H2O, 
and a peak was observed on the FAB-MS spectrum at m/z = 461 corresponding to [M-
2H2O-Cl]
+
. However, this complex proved to be completely insoluble in water, so was 
not pursued further as an MRI contrast agent. 
Prior attempts within the Pilkington group to synthesize 4.1 (Mn
II
-dpN3O2) from 
diamine 4d and diacetylpyridine in ethanol had not been entirely successful.
219
 Red single 
crystals of the resulting complex were grown from acetonitrile, and showed that although 
macrocyclization had occurred, half of the complexes were present as a dimer, with one 
Mn
II
 centre connected to an oxidized Mn
III
 center via a bridging chloride ion; while half 
were present as the expected monomer.
219
 Each unit cell comprised four independent 
macrocyclic complexes. The resulting compound, with the formula 
{[Mn(L4)Cl2][Mn(L4)-μ-ClMnCl3]}2, is depicted in Figure 2.6.  
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Figure 2.6 View of the asymmetric unit of {[Mn(L4)Cl2][Mn(L4)-μ-ClMnCl3]}2 (4.2).
219
 
Hydrogen atoms and lattice water molecules are omitted for clarity. Thermal ellipsoids 
are plotted at 50%.  
 
To prevent oxidation of the Mn
II
 centres, the reaction was repeated under nitrogen 
using degassed MeOH.  Under these conditions, a yellow rather than red product was 
isolated, and the elemental analysis of the resulting complex was an excellent fit for 
[Mn(L4)Cl2]·2H2O with a maximum difference of 0.34%. The imine stretch was present 
in the IR spectrum at υ = 1650 cm-1, the UV-visible absorption maxima occurred at λ = 
252 and 301 nm, and the major peak in the mass spectrum at m/z = 517 corresponded to 
[M-2H2O-Cl]
+
. Repeated attempts were made to crystallize 4.1 (Mn
II
-dpN3O2), but these 
were unsuccessful; however, a planar, equatorial, pentadentate binding mode may be 
assigned to this macrocycle, given that this complex likely has a similar structure to the 
Mn
II
-dpN3O2 units within the structure of the mixed valence system 4.2 (Figure 2.6). 
Within these units, the macrocycle L4 (dpN3O2) is essentially planar: the maximum 
109 
 
 
deviation from the N3O2 plane of a contributing atom is 0.078 Å, observed for O(8). The 
Mn
II
 ions binds within the plane of the ring, with a deviation of 0.010 Å.
219
 
 Attempts were made to template the formation of macrocycle L5 (N3O3) around 
Mn
II
, from diamine 5c and diacetylpyridine. However, only oligomeric products could be 
obtained, with both ketone (υ = ~1700 cm-1) and amine stretches present in the IR 
spectra. The increased cavity size of this N3O3 system, and the flexibility of its aliphatic 
backbone, are likely the reasons this macrocycle did not template around the Mn
II 
ion.  To 
the best of my knowledge, there are no structural reports of complexes of this ligand, or 
its N6 analogue, in the literature. 
Complex 6.1 (Mn
II
-dbN3O3) was successfully prepared from diamine 6c and 
diacetylpyridine in the presence of MnCl2. An imine stretch was visible in the IR 
spectrum at υ = 1618 cm-1, and the elemental analysis was an excellent fit for 
[Mn(L6)Cl2]·2H2O, with a maximum difference of  0.13%  for C.  It is interesting to note 
that the macrocycle L6 (dbN3O3) was able to template around Mn
II
, while the more 
flexible macrocycle L5 (N3O3) was not, although the macrocycles have a similar cavity 
size and the same donor atom set. The enhanced rigidity of L6 due to the two benzene 
rings inserted into the backbone presumably facilitates the templation process even 
around a small ion like Mn
II
. The FAB-MS spectrum of Mn
II
-dbN3O3 exhibited a 6% 
peak at m/z = 505, corresponding to [M-2H2O-Cl]
+
; however a much larger peak was 
visible at m/z = 289, corresponding to protonated diamine 6c. The UV-visible spectrum 
most closely resembled that of the smaller dibenzo system 3.1 (Mn
II
-dbN3O2): the 
absorption bands occurred at  = 251 and 282 nm, with the second band blue shifted 
when compared to the non-rigid macrocyclic complexes described above ( = ~300 nm).  
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Despite repeated attempts, X-ray quality single crystals of 6.1 (Mn
II
-dbN3O3) 
could not be grown. There are no crystal structures reported for any metal complexes of 
this macrocycle; however, the formyl derivative f-dbN3O3 has been templated around 
Pb
II
, with coordinated nitrate counter ions (Figure 2.7).
225
 The macrocycle binds in a 
hexadentate fashion, through all six of its donor atoms; and is fairly planar, with a 
maximum deviation of a donor atom from the N3O3 plane of 0.24 Å; the pyridyl nitrogen 
and three oxygen atoms lie on one side of the N3O3 mean plane, while the imine 
nitrogens, as well as both benzyl groups, lie on the other. The Pb
II 
ion (ionic radius = 1.49 
Å) deviates from the plane by 0.12 Å. Interestingly, in a Cd
II
 (ionic radius = 1.17 Å) 
complex of the related macrocycle f-dbN4O2, the macrocycle binds equatorially in a 
pentadentate fashion, via the four nitrogen atoms, with axial water ligands bound above 
and below the plane, giving a seven-coordinate geometry. One oxygen, O(1) remains 
unbound, and deviates from the pentadentate N4O donor plane by 1.49 Å.
226
 The Cd
II
 ion 
lies within the plane, with a maximum deviation of 0.14 Å.
226
 Although the semi-metals 
Pb
II
 and Cd
II
 cannot be considered a perfect model for the transition metal Mn
II
, these 
structures do confirm that macrocycles with the same cavity size and rigidity can bind 
equatorially to ions with a larger radius than Mn
II
 (1.04-1.10 Å).  
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Figure 2.7 Left, molecular structure of Pb
II
-f-dbN3O3;
225
 right, molecular structure of 
Cd
II
-f-dbN4O2.
226
 
 
It is thus uncertain whether the macrocycle binds in a penta- or hexadentate 
fashion to the Mn
II
 ion in 6.1.  It is, however, probable that the macrocycle binds 
equatorially, given that the similarly sized Cd
II
 ion and larger Pb
II
 ion are equatorially 
encapsulated by structurally related macrocycles; leaving the axial positions available for 
water binding. 
As mentioned in Section 1.3, complex 7.1 [(Mn
II
-N3O2)2] was first reported 
several years ago by the Pilkington group.
221
 (Mn
II
-N3O2)2 was synthesized from 
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MnCl2
.
4H2O, the tetraketone 7d and 2,2’-(ethylenedioxy)bis(ethylamine) in a 2:1:2 
stoichiometric ratio, following the general synthetic method described at the beginning of 
Section 2.3. Imine formation was confirmed once again by the absence of a ketone peak, 
and by the presence of an imine stretch at υ = 1647 cm-1. The UV-visible spectrum 
showed the expected two absorption bands, with a particularly intense peak at  = 252 
nm (ε = 18060 L.mol-1.cm-1), and a second weaker absorption at  = 311 nm (ε = x L.mol-
1.
cm
-1
), blue shifted when compared to the absorption band associated with the ‘half’ 
version of this complex, 1.1 (Mn
II
-N3O2). The elemental analysis data for 7.1 was an 
excellent fit for the formula [Mn2(L7)Cl4]·5H2O, in agreement with the major peak on 
the FAB-MS spectrum at m/z = 728, corresponding to [M-4H2O-2Cl]
+
. The crystal 
structure of (Mn
II
-N3O2)2 is presented in Figure 2.5.
221
 Both macrocyclic rings are almost 
planar, with maximum donor-atom deviations of 0.099 and 0.097 Å for N(6) and N(2); 
and the two macrocyclic rings are offset with a dihedral angle of 41.25°. Each Mn
II
 ion is 
equatorially bound by the macrocycle, with deviations of the metal ions from the 
pentadentate planes of 0.034 and 0.046 for Mn
II
(1) and (2) respectively.
221
 Interestingly, 
while the crystal structure of 2.1 (Mn
II
-N3O2) shows that in the solid-state, the axial 
positions are occupied by chloride ions,
139
  the reported crystal structure of 7.1 [(Mn
II
-
N3O2)2] shows one chloride anion and one water molecule coordinated to each metal 
center (Figure 2.5).
221
 This is surprising because L7 [(N3O2)2] is simply two covalently 
tethered L2 (N3O2) macrocycles.  
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Figure 2.8 Crystal structure of [Mn2(L7)Cl4]
.
5H2O (7.1).
221
  Hydrogen atoms, chloride 
counter ions and lattice water molecules are omitted for clarity.  
 
Thus six of the seven target macrocycles were successfully templated around 
MnCl2. Of the resulting complexes, five complexes were water soluble and consequently 
of interest as potential MRI contrast agents. As discussed above, an examination of the 
solid-state structures of the previously reported complexes 1.1 (Mn
II
-N5), 2.1 (Mn
II
-N3O2) 
and 7.1 [(Mn
II
-N3O2)2] show that the macrocycles bind in an equatorial, pentadentate 
fashion, with two axial monodentate ligands.  Although solid-state structures of 4.1 
(Mn
II
-dpN3O3) and 6.1 (Mn
II
-dbN3O3) could not be measured, the partially dimerized 
system 4.2 [Mn(L4)Cl2][Mn(L4)-μ-ClMnCl3] clearly showed the ability of macrocycle 
L4 (dpN3O3) to bind in a pentadentate, planar fashion; and a similar equatorial binding 
mode was assigned to 6.1 (Mn
II
-dbN3O3) based on transition metal structures of related 
ligands.  
 These solid-state structures were primarily important in that they confirmed the 
equatorial nature of the macrocyclic binding, allowing for the presence of axially binding 
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ligands. Although in each solid-state structure, chloride anions were observed to bind, 
what is more important for the biological application of these compounds is the nature of 
the ligands bound to each Mn
II
 center in aqueous solution, as a model for the in vivo 
structure.  
 In order to investigate the nature of the axial ligands in solution, conductance 
measurements in aqueous solution were performed on all five complexes. Conductance 
measurements provide information concerning the electrolytic nature of complexes in 
solution. The formula unit of each mononuclear complex includes two chloride ions: if 
both are coordinated in aqueous solution, the complex will be neutral; if one chloride and 
one water are coordinated, the complex will be a 1:1 electrolyte; and if two water 
molecules are coordinated and both chloride ions are non-coordinating, the complex will 
be a 1:2 electrolyte. 
 Following literature precedence for this family of systems,
208-213
 conductance 
measurements were carried out on 0.5 mM solutions of the complexes in water. 
Measurements were obtained in triplicate with precision >99%. The recorded values of 
conductance (G, in μS) were converted to molar conductivity (ΛM, in S
.
cm
2.
mol
-1
) via the 
equation below: 
         ΛM =
G ×K
c
     Eqn. 2.1 
where K is the cell constant (1 cm
-1
) and c is the concentration. The average molar 
conductivity (ΛM) of each complex is presented in Table 2.2 and again in Table 2.3, 
along with the hydration number q. 
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Complex Formula 
q 
(solid-state) 
ΛM (H2O) 
(S
.
cm
2.
mol
-1
) 
q 
(solution) 
1.1 
Mn
II
-N5 
[Mn(L1)Cl2]·2H2O 0 254.3 2 
2.2 
Mn
II
-N3O2 
[Mn(L2)Cl2]·2H2O 0 194.4 2 
4.1 
Mn
II
-dpN3O2 
[Mn(L4)Cl2]·2H2O 0 293.4 2 
6.1 
Mn
II
-dbN3O3 
[Mn(L6)Cl2]·2H2O - 186.2 2 
7.1 
(Mn
II
-N3O2)2 
[Mn2(L7)Cl4]·5H2O 2 320.4 3 
 
Table 2.3 Summary of molar conductivity values (S
.
cm
2.
mol
-1
) in aqueous solutions at 
25°C for the Mn
II
 complexes. 
 
 The aqueous molar conductivities of the mononuclear complexes fall in the range 
190-290 S
.
cm
2.
mol
-1
, indicative of 1:2 electrolytic behaviour, which is consistent with the 
displacement of both coordinated chloride ions by water in aqueous solution. A similar 
phenomenon was reported by Nelson and co-workers in his series of papers on 
pentadentate macrocyclic complexes of transition metals in the 1970s.
208-213
  With a focus 
on 7-coordinate, pentagonal bipyramidal complexes of Fe
II
 and Mg
II
, he found that 
conductivity measurements in the poorly coordinating solvent acetonitrile were consistent 
with one or two bound counter ions in the axial positions (1:1 electrolytes or non-
electrolytes in solution), while aqueous conductivity measurements indicated complete 
displacements of both axial ligands by water (1:2 electrolytes in solution).
208-211
 The 
aqueous hydration number of q = 2 observed for the mononuclear complexes in Table 2.3 
is higher than that of all the approved agents: 1 for the Mn
II
 agent Teslascan (in solution 
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only), and 1 for the Gd
III
 complexes. The dinuclear complex 7.1 (Mn
II
-N3O2)2 exhibited a 
molar conductivity of 320 S
.
cm
2.
mol
-1
 in aqueous solution, suggesting that one of the two 
coordinated chloride ions was displaced by a water molecule. It is somewhat surprising 
that both coordinated chloride ions were not displaced by water, given the complete 
displacement observed for the mononuclear complexes. Nevertheless, the resulting 
hydration number of q = 3 is still very high. 
 Other Mn
II
 complexes with no coordinated waters in the solid state have been 
shown to exhibit aqueous relaxivity behaviour, by various means. In the case of 
Teslascan, the solid-state structure shows a hydration number of q = 0. In aqueous 
solution, and in vivo, the observed relaxivity behaviour is due to the complete 
dissociation of the DPDP ligand (Figure 2.9), yielding small amounts of free Mn
II
, which 
becomes fully hydrated; the contrast behaviour of Teslascan is thus due to the species 
[Mn(H2O)6]
2+
.
40,41
 A similar full-dissociation is observed for the 8-coordinate, q = 0 
complex Mn
II
-DTPA (Figure 2.9).
40,41
 In contrast, the 6-coordinate complex Mn
II
-DO2A 
(Figure 2.9) is also coordinatively saturated by the ligand in the solid state with q = 0, but 
in solution, the ligand remains fully bound, and the coordination sphere transiently 
increases to 7, as one water binds, giving q = 1 and accounting for the observed relaxivity 
of this system.
60
 Thus full dissociation of a chelating ligand to give hydrated Mn
II
, and a 
widening of the coordination sphere to accept a water molecule, have both been described 
for q = 0 structures. However, the retention of a fully-bound macrocyclic ligand, 
accompanied by an increase in hydration number without increasing the coordination 
number, due to axial ligand displacement, has not been discussed in the context of 
contrast agent development. 
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Figure 2.9 Selected ligands which form q = 0 complexes with Mn
II
 in the solid state. 
  
 Based on their high water solubility, aqueous hydration numbers of q = 2 and 3, 
and the planar, equatorial nature of the macrocycles which should allow for ready water 
exchange, the five Mn
II
 complexes listed above were selected as promising candidates for 
further investigation as MRI contrast agents.  
2.3.2 Gd
III
 complexes  
 Although small-molecule agent research has focused in recent years on complexes 
of  Mn
II
, Gd
III
 contrast agents are still of interest: the lanthanide ion has a higher 
paramagnetic moment and a slower electronic relaxation time than the transition metal – 
which is why Gd
III
 was the ion which dominated the first 25 years of contrast agent 
development. In addition, the link between NSF and Gd
III
 has been observed only in 
patients with already compromised kidney function, which is why Gd
III
-based agents are 
still on the market, although more stringent safety measures surrounding their use are in 
place. The search for Gd
III
-based agents with non-DOTA or DTPA scaffolds, which have 
a high relaxivity and an acceptable toxicity profile, is still ongoing.
227
   
 Our attempts to template L1-L7 around GdCl3
.
6H2O resulted in the isolation of 
five novel, previously unreported complexes with the formula [Gd(L)Cl3]·xH2O, 
summarized in Table 2.4. Three of these complexes had a high degree of purity and were 
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water soluble (complexes 1.2, 2.2, and 6.2), while two were insoluble (3.2 and 5.2). This 
stands in contrast to the ready synthesis of analytically pure complexes of Mn
II
 with all 
but one of the target macrocycles.  
Complex; 
Abbrev. 
Formula  C H N 
v(C=N) 
(cm-1) 
λmax (ε) 
(nm,  
L.mol-1.cm-1) 
ΛM – H2O 
(S.cm2.mol-1) 
1.2 
GdIII-N5 
[Gd(L1)Cl3]·3H2O 
Found 
Calcd 
30.48 
30.48 
5.21 
4.95 
11.95 
11.85 
1631 
250 (5860) 
281 (4020) 
316.7 
2.2 
GdIII-N3Os 
[Gd(L2)Cl3H2O]·6H2O 
Found 
Calcd 
27.89 
27.84 
5.23 
5.14 
6.35 
6.49 
1620 
250 (4560) 
274 (2730) 
- 
3.2 
GdIII-
dbN3O2 
[Gd(L3)Cl3]·0.5H2O 
Found 
Calcd 
43.71 
42.89 
4.01 
3.44 
5.63 
6.52 
1661 
250 (7200) 
275 (5160) 
- 
5.1 
GdIII-N3O3 
[Gd(L5)Cl3]·2H2O 
Found 
Calcd 
32.83 
32.98 
4.10 
4.72 
5.95 
6.79 
1659 
251 (10520) 
282 (6470) 
277.9 
6.2 
GdIII-
dbN3O3 
[Gd(L6)Cl3]·6H2O 
Found 
Calcd 
38.50 
38.14 
4.39 
4.74 
5.14 
5.34 
1628 
254 (8501) 
277 (8038) 
346.8 
 
Table 2.4 Summary of Gd
III
 complex formulae, elemental analyses, IR and UV-visible 
spectroscopic data, and conductance measurements.  
 
Gd
III
 readily templated the formation of macrocycles L1 (N5), L2 (N3O2) and L6 
(N3O3), yielding the pure, soluble complexes 1.2, 2.2, and 6.2. Imine formation was 
confirmed in each case by appearance of band at υ = 1630, 1620 and 1628 cm-1 
respectively, corresponding to the imine stretch. Elemental analysis fit for the formulae 
[Gd(L)Cl3]·xH2O, where x = 3 for l.2 (Gd
III
-N5) and x = 6 for 2.2 (Gd
III
-N3O2) and 6.2 
(Gd
III
-dbN3O3).  In contrast to the FAB mass spectra of the Mn
II
 complexes, in which 
major peaks corresponding to the intact complex were observed, fragmentation of the 
Gd
III
 complexes occurred much more readily under FAB, EI and ESI conditions. A small 
peak at m/z = 465 observed for 1.2 corresponding to [M-H-2Cl]
+
, but no peaks 
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corresponding to the intact complex were observed for 2.2 and 6.2, only peaks at m/z = 
297 and 289, corresponding [L2+Na]
+
 (6.6%) and  289 [L6+H]
+
 respectively. All three 
complexes exhibited similar UV-visible behaviour, with two maxima within the ranges 
250-254 and 274-281 nm observed for each. The bands correspond to π to π* electronic 
transitions or the coordinated macrocycle – comparable to those observed for the MnII 
complexes, for which the bands were found at  = 250-252 and 280-311 nm. 
 Macrocycles L3 (dbN3O2) and L5 (N3O3) were successfully templated around 
Gd
III
, evidenced by imine stretches in their IR spectra at  = 1661 and 1659 cm-1 
respectively, and macrocyclic π to π* transitions in their UV-visible spectra at  = 250 
and 275, and 251 and 282 nm respectively.  The formation of complex 3.2 (Gd
III
-dbN3O2) 
was carried out in ethanol rather than methanol, as this macrocycle had proven 
susceptible to hydrolysis during the formation of the related Mn
II
 complex 3.1. The 
successful formation of complex 5.1 (Gd
III
-N3O3) stands in contrast to the inability of 
macrocycle L5 to template around Mn
II
 as noted in Section 2.3.1, presumably due to the 
smaller size of that ion. The best fit for elemental analysis was for complexes of the 
formulae [Gd(L)Cl3]·xH2O, where x = 0.5 for 3.2 and x = 2 for 5.1. Both complexes were 
initially formed with a lower degree of purity (maximum difference between observed 
and calculated C, H, and N elemental analyses was >0.8%); and in spite of repeated 
attempts to wash and recrystallize the product from methanol and ethanol, a higher 
degree of purity could not be achieved. Due to their water insolubility, these two 
complexes are not suitable for development as MRI contrast agents, and so were not 
pursued further.  
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An attempt was made to prepare the Gd
III
 complexes of the dimeric macrocycle 
L7 [(N3O2)2]. However, when the tetraketone 7d was added to a methanolic solution of 
Gd
III
, a precipitate immediately formed, in contrast to all the other systems in which the 
intermediate metal-ketone species remained in solution. Upon addition of the diamine, 
the precipitate remained. It was collected and isolated, but the IR spectrum showed the 
presence of ketone peaks around 1700 cm
-1
, and the elemental analysis could not be fit to 
any number of variations of the metal/tetraketone/diamine mixture. It appears that if the 
dinuclear Gd
III
 complex is to be formed, a suitable solvent must be found in which the 
intermediate metal-ketone complex is soluble. However, solubility tests on the 
precipitating species failed to reveal a common solvent in which the compound was 
soluble. 
 
 Although many attempts were made to crystallize each synthesized Gd
III
 complex 
from a variety of solvents via evaporation, vapour diffusion, and layered systems, no X-
ray quality crystals were successfully formed. For this reason, although imine bond 
formation can be confirmed by IR spectroscopy, and elemental analysis can indicate the 
formula, the coordination geometry of the metal center and the nature of the anions and 
water molecules (axially bound, or unbound) could not be definitively determined in the 
solid state. There is strong literature precedence for this difficulty in growing X-ray 
quality single crystals of lanthanide complexes of [1+1] Schiff-base macrocycles.  
Radecka-Paryzek and co-workers attempted to template L1 (N5) around the series of 
lanthanide chloride and perchlorate salts.
137
 Only two analytically pure complexes were 
isolated, template by LuCl3 and La(ClO4)3. Evidence of macrocycle formation was 
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observed in the isolated products of the reactions with LnCl3 (Ln = Dy, Tm) and 
Ln(ClO4)3 (Ln = Sm, Tm).  Bastida and co-workers attempted the synthesis of L6 
(dbN3O3) via templation around the whole lanthanide series of nitrate and perchlorate 
salts. Analytically pure complexes of a number of nitrates (La
III
, Ce
III
, Pr
III
, Nd
III
, Sm
III
, 
Eu
III
, Gd
III
, Tb
III
 and Dy
III
) and two perchlorates (La and Ce) were isolated.
138
 In both 
reports, a range of spectroscopic data, molar conductance values, and thermogravimetric 
analyses were presented; but the possible coordination numbers and geometries of the 
metal centers were not speculated upon, and no single crystal structural data was 
reported.
137,138
 
 Although X-ray quality crystals of the three complexes of interest (Gd
III
-N5, Gd
III
-
N3O2 and Gd
III
-dbN3O2) could not be grown, and in fact no rare-earth structures of any of 
the three macrocycles L1, L2, or L6 are known, an examination of related rare earth 
macrocyclic structures suggests that all three macrocycles bind in an equatorial fashion 
around the metal ion. Planar, equatorial binding of a pentadentate macrocylic ring to a 
lanthanide was described for the 16-membered analogue of L1, p-N5, which binds to both 
Yb
III
 and Lu
III
 (Figure 2.10).
228-230
 Although p-N5 is larger than L1 and L2 by one –CH2- 
unit, this macrocycle confirms that a lanthanide ion may be bound within an N5 donor 
plane. In addition, 15-membered N5 and N3O2 macrocycles have been reported to bind in 
a pentadentate fashion to ions with a larger ionic radius than Gd
III
 (1.00 Å when seven-
coordinate to 1.11 Å when nine-coordinate), such as Cd
II
.
231
 
 Equatorial binding of a related hexadentate macrocyclic ring to a rare-earth metal 
was reported for the La
III
, Ce
III
, Pr
III
, Nd
III
, and Lu
III
 complexes of the pyridine-
functionalized macrocycle f-N6 (Figure 2.10). In each case, the macrocycle is puckered. 
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A representative Nd
III
 complex is shown in Figure 2.10, in which the pyridine nitrogen 
N(1) lies 0.85 Å Ln
III
 away from the mean N6 plane; the N(1)---N(4) angle is 145.5°. The 
Nd
III
 ion lies just 0.07 Å out of the macrocyclic plane. These structures provide evidence 
that a lanthanide ion may be equatorially encapsulated by a hexadentate, 18-membered 
macrocyclic ring. In addition, as was noted in Section 2.3.1 during a discussion of the 
Mn
II
 complex of L6, ions with a larger ionic radius than Gd
III
 (Pb
II
 and Cd
II
) are 
equatorially bound by the rigid hexadentate macrocycles f-dbN3O3 and f-dbN4O2.
225,226
  
     
 
Figure 2.10 Left, molecular structure of the Yb
III
-p-N5;
229
 right, molecular structure of 
the Nd-f-N6 complex.
232
 
 
 It can thus be assumed that the pentadentate macrocycles L1 (N5) and L2 (N3O2), 
and the hexadentate macrocycle L6 (dbN3O3), are capable of binding in an equatorial 
fashion to Gd
III
 via five and six donor atoms respectively. Of the rare earth complexes 
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with pentadentate and hexadentate macrocyclic ligands, most are at least seven- and 
eight-coordinate respectively: they have at least two axially-bound ligands.
228,229,233-235
  
 A detailed discussion of additional rare earth structures is presented in Section 3.2 
of Chapter 3, in the context of SMMs for which an understanding of the solid-state 
structure is very significant. However for the purposes of contrast agent development, as 
was noted for the Mn
II
 complexes above, the key structural point for this family is that 
the macrocycles bind in an equatorial fashion, allowing for the potential of fast, 
unhindered water exchange, and thus efficient (high) relaxivity – as long as at least one 
water molecule is directly coordinated to the Gd
III
 center in aqueous solution. 
 As was noted above for the Mn
II
 complexes, information about the nature of the 
axial ligands may be gleaned from conductance measurements. Conductance 
measurements were performed in both water and in the poorly coordinating solvent 
methanol, as the number of unbound chloride ions in methanol may be representative of 
the number unbound in the solid state.
208-213
  The average molar conductivity (ΛM) of 
each complex is presented in Table 2.4 and again in Table 2.5, along with the indicated 
electrolytic behaviour. 
Complex Formula 
ΛM (MeOH) 
(S
.
cm
2.
mol
-1
) 
electrolytic  
behaviour  
(MeOH) 
ΛM (H2O) 
(S
.
cm
2.
mol
-1
) 
electrolytic  
behaviour  
(H2O) 
1.2 
Gd
III
-N5 
[Gd(L1)Cl3]·3H2O 95.6 1:1 316.7 1:2-3 
2.2 
Gd
III
-N3O2 
[Gd(L2)Cl3H2O]·6H2
O 
171.9 1:2 277.9 1:2-3 
6.2 
Gd
III
-dbN3O3 
[Gd(L6)Cl3]·6H2O 164.0 1:2 346.8 1:3 
 
Table 2.5 Summary of molar conductivity values (S
.
cm
2.
mol
-1
) in aqueous solutions at 
25°C for the Gd
III
 complexes. 
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 The molar conductivity data in methanol was interpreted in light of the useful 
review by Geary.
236
 This was the paper used by Nelson and Drew in their original series 
on pentadentate Schiff-base macrocycles, to justify their conclusions regarding the 
coordination numbers of transition metal complexes in the solid state. Geary gives an 
expected range of values of 80-115 S
.
cm
2.
mol
-1
 for a 1:1 electrolyte in methanolic 
solution, 160-220 S
.
cm
2.
mol
-1
 for a 1:2 electrolyte, and 290-350 S
.
cm
2.
mol
-1
 for a 1:3 
electrolyte. The ΛM (MeOH) value for complex 1.1 (Gd
III
-N5) is indicative of 1:1 
electrolytic behaviour, while the values for 2.2 (Gd
III
-N3O2) and 6.2 (Gd
III
-dbN3O3) 
suggest a 1:2 electrolyte in solution. This conductance data suggests that in the solid state 
(represented by methanolic solution), two chloride ions are directly coordinated in 1.2 
while one chloride ion is directly coordinated in 2.2 and 6.2. Given that each complex is 
likely to be at least seven-coordinate, at least one water molecule is likely bound to the 
metal centers of 2.2 and 6.2 in the solid state. 
 Thermogravimetric analysis (TGA) of complex 2.2 (Gd
III
-N3O2) was utilized in 
order to confirm the reliability of methanolic solution as a model for the solid state 
structure, and in order to gather further information concerning the nature of the axial 
ligands (Figure 2.11). 
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Figure 2.11 TGA plot for complex 2.2 (Gd
III
-N3O2). 
  
 Water is present, bound in at least two different ways. An initial water molecule is 
lost by 60°C, suggesting a weakly bound lattice solvent. Three additional waters are lost 
by 300°, suggesting strong hydrogen bonding; along with two non-coordinating chloride 
ions, lost in the form of HCl. Decompositon occurs by ~545°C, and one chloride ion is 
not observed to leave. Thus the TGA data for 2.2 supports the binding of a single chloride 
ion to the Mn
II
 centre in the solid state, consistent with the molar conductivity data 
measured for 2.2 (Gd
III
-N3O2) in methanol. 
 The aqueous molar conductivity data suggested that complexes 1.2 (Gd
III
-N5) and 
2.2 (Gd
III
-N3O2) are both either 1:2 or 1:3 electrolytes in aqueous solution, while 6.2 
(Gd
III
-dbN3O3) acts as a 1:3 electrolyte.  That is, in aqueous solution, at the most, one 
chloride ion is coordinated to 1.2 and 2.2, and no chlorides are coordinated to the metal 
center of 6.2, confirming displacement of axial chloride ligands by water. Again, since 
126 
 
 
each complex is likely to be at least seven-coordinate, in aqueous solution at least one 
water molecule is bound to the metal center of 1.2 and 2.2, and at least two waters are 
bound to the metal center of 6.2. Thus the primary requirement for efficient relaxivity 
behaviour – inner-sphere water molecules – is met by all three soluble, pure GdIII 
complexes.  
2.4 Relaxivity studies 
A collaboration was initiated with the STTARR Innovation Centre in Toronto, in 
order to acquire aqueous relaxivity data on the family of complexes at a clinically 
relevant magnetic field. Under the guidance of Dr. Warren Foltz, a Bruker minispec 
mq60 Contrast Agent Analyzer was used to measure the T1 and T2 relaxation time 
constants of all eight pure, water soluble compounds: the Mn
II
 compounds of N5, N3O2, 
dpN3O2, dbN3O3, and O2N3-N3O2; and the Gd
III
 complexes of N5, N3O2, and dbN3O3. The 
measurements were carried out in a magnetic field of 1.4 T (corresponding to a 
1
H 
nuclear resonant frequency of 60 MHz), at 37°C.  
 Interestingly, although 60 MHz is the most common clinical field utilized in MRI, 
the relaxivity values of both the approved agents and compounds being investigated as 
potential agents tend to be reported in a field of 20 MHz. For this reason, the r1 and r2 
values of the complexes were measured in an additional field of 20 MHz, using a 
minispec mq20 Contrast Agent Analyzer.   
The formulae for the r1 and r2 relaxivities are: 
r1 =  
1
T1
⁄
c
          and            r2 =  
1
T2
⁄
c
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In order to calculate the r1 and r2 relaxivities of each complex, a series of 5-6 dilutions of 
each complex were prepared immediately prior to the measurements. The T1 and T2 
relaxation time constants of each dilution of the 8 analytically pure, water soluble 
compounds were measured at a temperature of 37°C, as this temperature has the most 
biological relevance. Then 
1
T1
 or 
1
T2
 (s
-1
) was plotted against c (mM), to give a series of 
linear plots, whose slopes gave the values of r1 and r2 (mM
-1.
sec
-1
) respectively.  
 
 Table 2.6, below, summarizes the clinical field (60 MHz) and low-field (20 MHz) 
relaxivity results. 
Complex Formula 
r1 
(60 MHz) 
r2 
(60 MHz) 
r1 
(20 MHz) 
r2 
(20 MHz) 
1.1 [Mn(L1)Cl2]·2H2O 2.76 ± 0.02 10.7 ± 0.2 3.77 ± 0.02 6.07 ± 0.03 
2.1 [Mn(L2)Cl2]·2H2O 2.78 ± 0.03 12.7 ± 0.12 3.58 ± 0.02 6.67 ± 0.06 
4.1 [Mn(L4)Cl2]·2H2O 4.00 ± 0.03 23.0 ± 0.2 5.34 ± 0.08 14.8 ± 0.2 
6.1 [Mn(L6)Cl2]·2H2O 2.78 ± 0.02 31.1 ± 1.4 7.22 ± 0.12 42.9 ± 0.5 
7.1 [Mn2(L7)Cl2(H2O)2]Cl2 7.36 ± 0.05 30.7 ± 0.8 10.0 ± 0.79 26.8 ± 1.5 
1.2 [Gd(L1)Cl3]·6H2O 5.58 ± 0.10 6.77 ± 0.04 6.43 ± 0.41 6.85 ± 0.47 
2.2 [Gd(L2)Cl3]·6H2O 6.04 ± 0.10 7.67 ± 0.13 - - 
6.2 [Gd(L6)Cl3]·6H2O 2.78 ± 0.23 8.68 ± 0.11 8.05 ± 0.15 8.60 ± 0.27 
 
Table 2.6  Summary of 20 and 60 MHz r1 and r2 (mM
-1.
sec
-1
) relaxivity data.  
 
128 
 
 
A sample relaxivity plot for 1.1 (Mn
II
-N5) at 60 MHz, 37°C is shown in Figure 2.12, 
below. Relaxivity plots for additional compounds and fields are provided in the 
Appendix. 
 
 
Figure 2.12 Relaxivity plot for 1.1 (Mn
II
-N5) at 60 MHz, 37°C, showing an r1 of 2.76 and 
an r2 of 10.7 mM
-1.
sec
-1
, given by the slopes of the lines. 
 
From this data it can be seen that all eight complexes displayed efficient 
relaxation of water protons. The measured values of r1 for the Mn
II
 complexes 6.1 and 7.1 
and the Gd
III
 complexes 1.2 and 6.2 are higher than the majority of the r1 values of the 
FDA-approved agents at 20 MHz, which tend to be between 3 and 5.5 s
-1.
Mm
-1
 (see 
Section 1.1). The r1 values for the remaining complexes are within the range of the 
approved agents. All of the r2 values are remarkably high, in particular those of the Mn
II 
complexes 4.1, 6.1 and 7.1, which are above 30 s
-1.
Mm
-1
. Teslascan, the T2-reducing 
Mn
II
-based agent on the market in the USA, has an r2 of 3.7 s
-1.
Mm
-1
. The increased bulk 
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of 4.1 and 6.1 resulting in slower rotation,  and the presence of two metal centers in 7.1, 
may be responsible for the extraordinary r2 values of these systems.  
2.5 In vitro toxicity study 
 Following the success of the aqueous relaxivity measurements, an in vitro toxicity 
study was performed in order to evaluate the cytotoxic potential of several of the agents. 
The primary purpose of this study was to aid in the selection of a test compound for a 
pilot in vivo study, by confirming that at least one of the agents was not significantly 
more toxic than an agent already approved for use. It is important to note that direct 
conclusions about in vivo toxicity cannot be drawn from in vitro toxicity results, chiefly 
because prior to studies on the biodistribution, pharmacokinetics and excretion 
timeline/pathway of a compound, it is impossible to say what concentration of the 
compound would be present in a given tissue or organ at a given time point. However, in 
vitro studies do offer a way to compare a compound approved for human use with one or 
more test substances, with a view to preventing unnecessary pain and distress on an 
animal due to unforseen acute toxicity during an in vivo study. 
 The study was performed using primary rat renal proximal tubule epithelial cells 
(RPTECs), which were chosen because excretion occurs primarily via the kidneys in all 
but one of the approved small molecule contrast agents.
4,10
 Six agents were selected for in 
vitro testing: the Mn
II
 and Gd
III
 complexes of L1 (N5), L2 (N3O2) and L6 (dbN3O3); that 
is, complexes 1.1 and 1.2, 2.1 and 2.2, and 6.1 and 6.2. The compounds were evaluated at 
seven concentrations (30 mM, 10 mM, 3.3 mM, 1.1 mM, 0.36 mM, 0.12 mM and 0.04 
mM) after 2, 4, 10 and 24 hours of treatment in rat RPTECs. The MTT assay was used as 
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an indicator of viability.  MTT, or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, is a yellow tetrazole. Living cells reduce MTT to the purple compound 
formazan, and thus the proportion of viable cells can be assessed using a 
spectrophotometer. The cytotoxic potential of the test articles was compared to the 
toxicity observed in the presence of the approved agent Omniscan (or Gadodiamide, 
Gd
III
-DTPA-BMA). The results are summarized in Table 2.7, where the inhibitory 
concentration (IC50, the concentration resulting in 50% toxicity) was determined by 
plotting log concentration vs. relative viability.   
   2 hr 4hr 10 hr 24 hr 
1.1 [Mn(L1)Cl2]·2H2O ND ND ND 5.47 
2.1 [Mn(L2)Cl2]·2H2O 3.88 2.56 14.66 0.68 
6.1 [Mn(L6)Cl2]·2H2O 1.25 0.67 1.39 0.21 
1.2 [Gd(L1)Cl3]·3H2O 8.15 3.37 8.53 0.92 
2.2 [Gd(L2)Cl3H2O]·6H2O 9.39 3.65 5.32 1.1 
6.2 [Gd(L6)Cl3]·6H2O 2.9 2.19 2.195 1.27 
 Omniscan ND ND >30mM 31.05 
 
Table 2.7 Inhibitory concentrations (IC50, mM). ND = not determined due to lack of 
dose response. 
 As shown in Table 2.7, following 2 and 4 h of treatment, complex 1.1 and 
reference article Gadodiamide did not show significant cytotoxicity at the concentrations 
tested. However, a decrease in viability was observed in the cells which were treated with 
the other five complexes, suggesting a degree of toxicity at these time points. At the 10 
hour time point, complex 1.1 (Mn
II
-N5) still did not display significant cytotoxicity. 
Complexes 1.2 (Gd
III
-N5), 2.1 (Mn
II
-N3O2), 2.2 (Gd
III
-N3O2), and 6.1 (Mn
II
-N3O2), 
exhibited a slight reduction in toxicity, suggesting that the cells might be recovering from 
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the effects of the test articles. Complex 6.2 (Gd
III
-N3O2) did not show a significant 
change in toxicity from the 4 to the 10 h time point. Reference article Gadodiamide 
showed more toxicity after 10 hours of treatment than at earlier time points. Following 24 
hours of treatment, all six test articles and the reference article showed some level of 
toxicity, with 1.1 (Mn
II
-N5) and Gadodiamide exhibiting the least cytotoxic effects. It 
should be noted that the most of the approved small-molecule contrast agents have a 
clearance time of under 2 hours, so the 10 and 24 hour time points may not be relevant to 
the in vivo toxicity of the test compounds if they are excreted with similar efficiency.  
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Figure 2.13 Cell viability plots for 1.1 (Mn
II
-N5) and Omniscan at the 2 and 4 hour time 
points, showing high cell viability over the studied concentration range.  
 
 Based on the results described above, 1.1 (Mn
II
-N5) was selected as the initial 
agent for in vivo testing because it displayed the least cytotoxic activity in rodents 
RTEPCs. In addition, as was discussed in Section 1.1, there is a current focus on Mn
II
-
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based small molecule agents, due to the recent discovery of the link between Gd
III
-based 
agents and the disorder NSF.
26
 Since the one Mn
II
-based agent Teslascan was removed 
from the market, there is a clear need for alternatives to Gd
III
 for patients with 
compromised renal function. For this additional reason, the Mn
II
 compounds in our 
family were of particular interest. 
In the approved agents, the in vivo stability and thus the toxicity is limited by 
acid-assisted dissociation of the metal ions.
4,10
  In contrast, we were anticipating that the 
in vivo stability of our templated Schiff-base macrocyclic complexes would be limited by 
the kinetics of the cleavage of the imine bonds. However, although the addition of water, 
methanol and ethanol to the imine bonds of transition metal complexes of Schiff-base 
macrocycles has been reported in the literature, these reactions are not necessarily or even 
usually accompanied by a change in the coordination sphere of the metal ion.
237,238
 For 
instance, the base-catalysed addition of water to the imine bonds of complex 1.1 (Mn
II
-
N5) was reported as part of a study on Mn
II
 complexes as superoxide dismutase mimics, 
and  UV-visible measurements indicated no change in the Mn
II
 coordination sphere 
during  the addition.
64
 Thus even if a certain amount of imine bond cleavage were to 
occur in vivo, the Mn
II
 or Gd
III
 ions would potentially remain coordinated to the now-
amine nitrogens of the macrocycle until excreted. It is also important to note that high 
stability constants are not a representative measure of in vivo non-toxicity.
239
 The overall 
in vivo toxicity of small-molecule agents is determined by numerous factors, including 
the concentration and nature of the dose administered; the biodistribution, excretion 
pathway and excretion time; as well as interactions with biological molecules and ions to 
give free Mn
II
 or Gd
III
, and/or degradation products with their own toxicity profiles. For 
134 
 
 
these reasons, preliminary acute toxicity studies were amongst the earliest data reported 
for the now-approved Gd
III
-based agents.
240
 Thus a pilot in vivo acute toxicity study on 
representative compounds from our family was an important next step. 
2.6 In vivo study 
 Small-scale pilot in vivo toxicity and imaging studies were performed first on 
complex 1.1 (Mn
II
-N5) and then on 7.1 [(Mn
II
-N3O2)2] as part of a collaboration with the 
Animal Resource Centre (ARC) and STTARR Innovation Centre in Toronto. Compound 
1.1 (Mn
II
-N5) was selected due to its particularly low cytotoxicity as noted above, and 
following the success of that initial study, 7.1 [(Mn
II
-N3O2)2] was chosen because it 
displayed the highest r1 relaxivity and one of the highest r2 relaxivity values; and because 
as a dinuclear system, it is the most novel of the complexes. Compound 2.1 (Mn
II
-N3O2) 
was also included in the imaging portion of the study, for comparison as a mononuclear 
analogue of 7.1. 
2.6.1 Acute toxicity 
The acute toxicities of 1.1 (Mn
II
-N5) and 7.1 [(Mn
II
-N3O2)2] were studied in 8 
week old male Sprague-Dawley rats. The toxicity of 1.1 was studied over a period of 14 
days, in four rats; while the toxicity of 7.1 [(Mn
II
-N3O2)2] was studied over a period of 8 
days, in 8 rats. Compound 1.1 was injected intravenously at a dosage of 0.02 mmol/kg (c 
= 12.5 mM), while 7.1 was injected at a dosage of 0.01 mmol/kg (c = 6.25 mM). These 
dosages were chosen because the dosage for the only Mn
II
-based compound approved in 
North America, Teslascan, was 0.005 mmol/kg; and we were anticipating a lower degree 
of toxicity.  
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We were excited to find that based on clinical observations, hematology, and 
gross and microscopic examination, complex 1.1 at the studied dosage can be considered 
minimally- to non-acutely toxic to rats over the initial two week period post-dose. No 
clinical signs of toxicity were observed throughout the period of the study, and healthy 
weight gain by all four rats was recorded. Blood was collected and analyzed on study 
days 7 and 14. There were no statistically significant deviations in the hematological and 
biochemical parameters measured on days 7 and 14 in comparison to the baseline 
measurements taken prior to the study.  
Following euthanasia on day 14, necropsy was performed. The heart, lungs, liver, 
kidneys, spleen, thyroid and pituitary glands of each rat were observed to be grossly 
unremarkable. A very small adhesion between the ling and thoracic wall was observed in 
one rat, possibly reflecting a previous localized pleural inflammation. A small degree of 
variation was found among the organ weight for the four rats, and in comparison to the 
organ weights reported in a historical database.
241
 Tissue samples from the brain, heart, 
lungs, liver, kidneys, spleen and thymus were examined histopathologically. Renal 
tubular necrosis was evident in kidney tissue harvested from three of the four rats, 
attributable to the administration of compound 1.1. The necrosis spared the epithelial 
basement membrane of the affected tubules, allowing for repair by re-epithelialization 
instead of fibrosis and scarring, a characteristic typical of nephrotoxic injury. The amount 
of injury was very minimal, with less than approximately 1-2% of the renal tubules 
affected (Figure 2.14) 
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Figure 2.14 Evidence of renal cortical tubular necrosis and regeneration in a kidney of a 
rat following euthanasia 14 days after administration of compound 1.1. The cortical 
tubules are lined with attenuated epithelial cells (red arrows) or large epithelial cells with 
open nuclei (asterisks). Individual dead epithelial cells (yellow arrows) are interspersed 
and the surrounding interstitium is expanded by a small number of lymphocytes and 
plasma cells (black arrow). 
 
Like complex 1.1, complex 7.1 displayed minimal to no acute toxicity during the 
first 8 days post-dosage, with no clinical observations of toxicity and no significant 
hematological or biochemical deviations noted during blood analysis on study days 1 and 
8 in comparison to the baseline values recorded pre-study. Following euthanasia on day 
8, necropsy was performed. The heart, liver, kidneys, spleen, thyroid and pituitary glands 
of each rat were observed to be grossly unremarkable. Six of the eight rats displayed 
minor pulmonary lesions: areas of subtle depression which were red/purple in colour, 
consistent with atelectasis, or partial lung collapse.  However, these lesions may have 
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resulted from the euthanasia process: during exsanguination under isoflurane anesthesia, 
respiration is slow and shallow. Histopathological analysis of the tissue samples from the 
liver, kidneys, lungs, spleen and brain of two rats were examined histopathologically. No 
significant lesions were observed in the liver, spleen and brain samples. Renal tubular 
necrosis was evident in kidney tissue harvested from one of the two rats, similar in scope 
(1-2%) to that observed after administration of compound 1.1; and similar epithelial 
regeneration had occurred 
 
Figure 2.15 Evidence of renal cortical tubular necrosis and regeneration in a kidney of a 
rat #8, following euthanasia 8 days after administration of compound 7.1. The cortical 
tubules are lined with attenuated epithelial cells (red arrows) and some contain luminal 
protein (asterisk). A few dead epithelial cells (yellow arrows) are interspersed and a small 
number of lymphocytes and macrophages expand the surrounding intertitium (black 
arrow). (G = glomeruli.) 
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2.6.2 Imaging  
The in vitro contrast potential of 1.1 (Mn
II
-N5), 2.1 (Mn
II
-N5) and 7.1 
(Mn
II
-N3O2)2 were studied via the collection of fast-spin-echo images for 30-45 minutes 
immediately following injection of an aqueous solution of each complex. The dosage 
chosen for 1.1 was 0.02 mmol/kg (c = 12.5 M) while the dosage chosen for 2.1 and 7.1 
was 0.01 mmol/kg (c = 6.25 mM). 
Predominantly T1-weighted scans with some T2-weighting were performed on 
two rats injected with 1.1 (Mn
II
-N5). The compound was observed to appear in the 
bladder within 5 minutes (Figure 2.16). A slow increase in the renal cortical signal was 
apparent over the first 45 minutes ( 
Figure 2.17), along with a gradual liver hypoenhancement (darkening), reflecting 
an increase in T2 relaxivity in this organ.  
 
Figure 2.16 Coronal slices at the level of the bladder, showing enhancement due to 
complex 1.1 (Mn
II
-N5). Top left to right: 0, 2, 10, 15; bottom left to right: 20, 30, 45 
mins.  
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Figure 2.17 Coronal slices at the level of the kidneys, showing enhancement due to 
complex complex 1.1 (Mn
II
-N5). Top left to right: 0, 2, 10, 15; bottom left to right: 20, 
30, 45 mins.  
 The signal alteration can be quantified by the mean voxel intensities measured in 
each tissue. The time point at which the maximum intensity difference was observed is 
bolded in Table 2.9, along with the change as a percentage of the initial intensity. The 
signal alteration is also visually represented in Figure 2.18. 
Minutes -10 2 10 20 30 45 
Max. 
intensity change 
Renal  
cortex 
579.1 635.2 683.4 717.0 775.4 804.1 39% 
Renal  
medulla 
480.8 608.9 561.8 502.9 512.6 520.6 27% 
Renal  
pelvis 
465.7 881.1 920.7 733.9 704.7 666.1 98% 
Liver 498.6 458.8 436.2 424.5 398.0 369.8 -26% 
Bladder 414.3 454.3 1093.1 1046.4 970.1 1030.1 177% 
Skeletal  
muscle 
432.1 358.5 354.3 337.5 330.6 351.0 -23% 
 
 
Table 2.8 Change in MRI signal intensity (arbitrary units of voxel intensity) in various 
tissues following injection of 1.1 (Mn
II
-N5). 
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Figure 2.18 Change in MRI signal intensity over the first 45 minutes post-injection of 1.1 
(Mn
II
-N5). The baseline scan was collected at t = 10 mins.  
 
Scans collected 3 hours post-injection showed no evidence of 1.1 (Mn
II
-N5) being 
retained by any tissue or organ at this time point, indicating rapid excretion.  
Both T1- and T2-weighted scans were performed on two rats injected with 2.1 
(Mn
II
-N3O2) and its dimeric analogue 7.1 [(Mn
II
-N3O2)2] respectively.  
T1-weighted scans showed both compounds appearing in the bladder within 10 
minutes, with 2.1 (Mn
II
-N3O2) appearing before 7.1 [(Mn
II
-N3O2)2], suggesting slightly 
faster excretion of this monomeric system. Interestingly, while both complexes cause an 
increase in signal intensity in the renal medulla (Figure 2.20, Figure 2.19), compound 2.1 
(Mn
II
-N3O2) causes an enhancement in the renal cortex and has negligible effect on liver 
and lean muscle tissue; while 7.1 [(Mn
II
-N3O2)2] causes a decrease in signal intensity in 
141 
 
 
all three of these tissues.  These results are summarized in Table 2.9 – Table 2.10 and 
Figure 2.21 – Figure 2.22. 
 
Figure 2.19 Coronal slices at the level of the kidneys, showing enhancement of the T1-
weighted MRI signal due to complex 2.1 (Mn
II
-N3O2). Top left to right: -10, 0 15; bottom 
left to right: 30, 44 mins.  
 
Figure 2.20 Coronal slices at the level of the kidneys, showing enhancement of the T1-
weighted MRI signal  due to complex 7.1[(Mn
II
-N3O2)2]. Top left to right: -10, 1; bottom 
left to right: 16, 29 mins.  
142 
 
 
 
 
Minutes 
-10 1 15 30 45 
Max. 
intensity 
change 
Renal 
cortex 
8005 9368 10144 10702 11485 43% 
Renal 
medulla 
7725 9169 8472 7969 8615 19% 
Liver 7276 7568 7385 7812 7683 7% 
Bladder 5085 5155 16182 11996 13104 218% 
Lean 
muscle 
5640 5841 5696 5569 5574 3% 
Fat 14509 15671 15845 15745 15860 9% 
 
Table 2.9 Change in T1-weighted MRI signal intensity (arbitrary units of voxel intensity) 
in various tissues following injection of 2.1 (Mn
II
-N3O2). 
 
 
 
Figure 2.21 Change in T1-weighted MRI signal intensity over the first 45 minutes post-
injection of 2.1 (Mn
II
-N3O2). The baseline scan was measured at t = 10 mins.  
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Minutes -10 1 16 29 
Max.  
intensity change 
Renal 
cortex 
8324 7160 6355 7030 -24% 
Renal 
medulla 
7439 9222 7008 7345 24% 
Liver 7948 6234 5508 5838 -31% 
Bladder 6374 4991 8171 10143 59% 
Lean 
muscle 
6710 4720 4284 4095 -39% 
Fat 16614 12834 13248 13001 -23% 
 
Table 2.10 Change in T1-weighted MRI signal intensity (arbitrary units of voxel 
intensity) in various tissues following injection of 7.1[(Mn
II
-N3O2)2]. 
 
 
Figure 2.22 Change in T1-weighted MRI signal intensity over the first 30 minutes post-
injection of 7.1 [(Mn
II
-N3O2)2]. The baseline scan was measured at t = 10 mins.  
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 T2-weighted scans showed a decrease in signal intensity in the bladder, as well as 
kidney, liver and muscle tissue over the 30-40 minutes following injection of each 
compound (Figure 2.23). The hypoenhancement due to 7.1 [(Mn
II
-N3O2)2] was greater 
than that due to 2.1 (Mn
II
-N3O2), unsurprising given that the compounds were 
administered at equimolar concentrations and 7.1 contains double the number of metal 
centers (Figure 2.24-Figure 2.25; Table 2.11-Table 2.12) 
 
Figure 2.23 Coronal slices at the level of the kidneys, showing hypoenhancement of the 
T2-weighted MRI signal due to complex 7.1 [(Mn
II
-N3O2)2]. Top left to right: -10, 9; 
bottom left to right: 22, 35 mins.  
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Minutes -10 8 22 37 
Max.  
intensity change 
Renal 
cortex 
4759 3367 3307 3034 -36% 
Renal 
medulla 
6454 5342 5306 4215 -35% 
Liver 965 788 577 400 -59% 
Bladder 12921 7977 667 512 -96% 
Lean 
muscle 
2673 2386 2451 2377 -11% 
Fat 14834 14550 12923 13440 -13% 
 
Table 2.11 Change in T2-weighted MRI signal intensity (arbitrary units of voxel 
intensity) in various tissues following injection of 2.1 (Mn
II
-N3O2). 
 
 
Figure 2.24 Change in T2-weighted MRI signal intensity over the first 40 minutes post-
injection of 2.1 (Mn
II
-N3O2). The baseline scan was measured at t = 10 mins.  
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Minutes -10 1 16 29 
Max.  
intensity change 
Renal 
cortex 
7718 4270 4640 2963 -62% 
Renal 
medulla 
12041 7869 7063 2770 -77% 
Liver 739 588 498 408 -45% 
Bladder 16247 14484 13169 10727 -34% 
Lean 
muscle 
3053 2707 2399 2063 -32% 
Fat 15094 9718 10027 8525 -44% 
 
Table 2.12 Change in T2-weighted MRI signal intensity (arbitrary units of voxel 
intensity) in various tissues following injection of 7.1 [(Mn
II
-N3O2)2]. 
 
 
Figure 2.25 Change in T2-weighted MRI signal intensity over the first 40 minutes post-
injection of 7.1 [(Mn
II
-N3O2)2]. The baseline scan was measured at t = 10 mins. 
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The results from these small pilot studies on the Mn
II
 complexes 1.1, 2.1 and 7.1 
were very promising, showing negligible toxicity, rapid excretion, and obvious MRI 
signal enhancement in each case. 
 
2.7 Ongoing and future work 
The two clear directions this research will take in the future involve: continuing in 
vivo studies on the extended family of compounds; and pursuing the development of 
dual-property (‘second generation’) contrast agents based on this family.  
2.7.1  In vivo stability studies 
 To date, a pilot imaging study has been carried out on three of our family of 
potential agents (Mn
II
-N5, Mn
II
-N3O2 and (Mn
II
-N3O2)2), and a pilot toxicity study has 
been performed on two of these (Mn
II
-N5 and (Mn
II
-N3O2)2). These very promising initial 
investigations confirmed that the complexes can enhance both T1- and T2-weighted 
signals in vivo, are rapidly excreted, and are minimally- to non-toxic at a clinical dosage. 
Similar studies will be performed on the remaining complexes in the family, including 
the Gd
III
 species, in order to identify the most promising candidates for more detailed 
study. Larger scale, GLP (‘good laboratory practice’) studies will then be performed in 
rodents for a full investigation of the biodistribution, excretion mechanism, and 
biological interactions / pharmacokinetics of the lead compound(s), as well as the longer 
term toxicity, and dose-responsive toxicity. In addition, a variety of MRI fields, scanning 
sequences and parameters will be tried, in order to determine the optimal conditions for 
the imaging of different tissues and organs  
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2.7.2 Bio-targeting: development of a model targeted complex 
In parallel with pursuing in vivo studies, we were intrigued by the possibility of 
attaching a second functionality to the macrocycle, to allow for a ‘second generation’ of 
dual-property agents. Additional functionalities such as a bio-targeting group for directed 
contrast agent delivery; a therapeutic group, towards a ‘theranostic’ agent; or a moiety 
allowing for a second imaging modality, are all of current research interest. Recent 
examples include contrast agents targeted to specific proteins such as collagen for the 
detection of fibrosis,
242
 serum albumin for angiography,
243
 or fibrin for the selective 
imaging of thrombosis. The recently reported chitosan-functionalized magnetic graphene 
nanoparticle (CMG) is an example of a theranostic system with the potential to deliver 
both an iron oxide MRI contrast agent and an anti-cancer drug to a tumor site.
244
  Dual-
imaging species explored include fluorescence labelled agents,
245
 and combination 
MRI/PET (positron emission tomography) agents.
246
  
We proposed that the copper-catalyzed azide-alkyne cycloaddition (CuAAC) 
reaction could be utilized to attach a bio-active group to the macrocycle.  The CuAAC 
‘click’ reaction involves the reaction of an organic azide with a terminal alkyne, in the 
presence of a Cu
I
 catalyst. The product is a 1,4-substituted-1,2,3-triazole (Scheme 2.8).
247
 
 
 
Scheme 2.8   The CuAAC ‘click’ reaction. 
 
149 
 
 
 A ‘click’ reaction is a reaction which is powerful and reliable. To be classified as 
‘click’, a reaction must be high yielding, stereospecific, and applicable to a wide range of 
starting materials. Solvents must be easily removable, products must be readily isolated, 
and there must be no offensive byproducts produced.
248
 The CuAAC reaction qualifies as 
a ‘click’ reaction, and has its own particular advantages. The reaction is applicable to 
virtually any azide and alkyne pairing, is not affected by the electronic or steric properties 
of any groups which are attached, and produces a chemically stable triazole product.
247
  
 The backbone of macrocycles L1 to L6 includes a substituted pyridine head-unit. 
We proposed that if the diacetylpyridine building block could be functionalized with an 
azide group, then essentially any alkyne-functionalized unit could be ‘clicked’ on via the 
CuAAC reaction. In order to address these objectives, we developed a strategy for the 
synthesis of the key intermediate in this process: the novel azide 2,6-diacetyl-4-
azidopyridine, 8e (Scheme 2.9).  
 
Scheme 2.9   Synthetic procedure for the synthesis of 2,6-diacetyl-4-azidopyridine, 
8e.
249-253
 i) Br2/PBr3, 90°C, 3 h; ii) EtOH, r.t., 1 h.; iii) NaOH, H2O, 115°C, 1 h., iv) HCl, 
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H2O, r.t., 5 min., v) SOCl2, DMF, reflux, 4 h.; vi) Meldrum’s acid, pyridine, DCM, 
0°C→r.t., 18 h., vii) HCl, H2O, 0°C, 5 min., viii) acetic acid, H2O, 115°C, 18 h., ix) 
NaN3, DMF, 85°C, 48 h.   
 
 Following literature methodologies, commercially available chelidamic acid was 
treated with phosphorus pentabromide, formed in situ from bromine and phosphorus 
tribromide.
249
 Subsequent treatment with methanol at 0°C yielded the dimethylester 8a, 
which was subjected to basic hydrolysis to regenerate the carboxylic acid functionalities 
in 8b,
250
 which were then activated by conversion to the acyl chloride derivatives via 
reflux in thionyl chloride to give 8c. To synthesize the rare bromodiketone 8d we 
employed a tri-step procedure involving reaction with Meldrum’s acid, HCl and acetic 
acid (Scheme 2.9)
251,252
 which had not previously been applied to this starting material, to 
give 8d with an overall yield of 35% after purification via a silica column with pet. 
ether/ethyl acetate (8:2).  
 Due to the explosive nature of organic azides, those used in the CuAAC reaction 
are not usually isolated. Rather, following formation of the azide, the species is reacted in 
situ with the desired terminal alkyne in the presence of a Cu
I 
catalyst. However, since the 
desired pyridyl azide 8e was a new compound, we decided to isolate the species before 
carrying out the ‘click’ reaction. Conversion of the bromo-diketone 8d to the desired 
azido-diketone 8e was non-trivial. Formation of an azide for use in the CuAAC reaction 
is commonly carried out by a simple nucleophilic substitution, by the reaction of a 
chloro-, bromo- or iodo-species with NaN3 in DMF. In fact, initially we had searched for 
a pathway which would allow the attachment of the bromide group to the pyridine head-
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unit via an alkyl linker, for this very reason. The 4-position of a pyridine ring is activated 
with respect to nucleophilic substitution. However, the ketone substituents at the 2- and 
6-positions have deactivating effect on this position. A key consideration was the extreme 
toxicity of sodium azide, as well as the explosive potential of both this species and any 
organic azides formed. Minimal exposure to heat, pressure, and chlorinated solvents was 
prioritized. We were able to synthesize the novel azide 8e via nucleophilic substitution, 
by carefully heating a small quantity of 8d with a large excess of sodium azide and 
monitoring the reaction progress using tlc.
253
 The desired product was purified via 
column chromatography; degeneration on the column was possibly partially responsible 
for the low yield of 29%. 
 Preliminary 
1
H and 
13
C-NMR data was gathered on the new compound , and the 
proton and carbon spectra of 8d and 8e in d6-acetone were compared. The singlet peak 
corresponding to the six ketone protons, H1, remained at approximately the same 
chemical shift in both compounds (δ = 2.74 ppm for H1 of 8d, δ = 2.64 ppm for H1 of 8e). 
However the singlet corresponding to the aromatic proton H4 shifted from δ = 8.26 ppm 
in the spectrum of 8d to δ = 7.39 ppm in the spectrum of 8e (deuterated acetone). This 
upfield shift indicates that the azido group is slightly less electron-withdrawing than the 
bromo substituent. A similar shift was observed for the peak corresponding to C5 on each 
spectrum: the peak occurred at 135.5 ppm for 8d but was shifted upfield to 126.0 ppm on 
the spectrum of 8e. 
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Further characterization techniques were not carried out, due to the very low molecular 
weight of this azide, and the reported decomposition danger of dry, isolated organic 
azides with C/N ratios ≤ 3. This new organic azide is an important prescursor for the 
synthesis of a mononuclear contrast agent functionalized for targeting, therapy or dual-
imaging. The next steps will be the ‘clicking’ on of a model alkyne such as 
ethynyltoluene (Figure 2.27, left) to establish the conditions necessary for the CuAAC 
reaction, and to provide proof of principle that the click will work with this building 
block; followed by the formation of a metal complex, using either Mn
II
 or Gd
III
, and a 
diamine. Assuming a model click reaction occurs successfully, the attachment of more 
complex (bio)molecules will be investigated. For example, ethynylestradiol (Figure 2.27, 
center) is a commercially available, alkyne-functionalized synthetic estrogen mimic 
previously employed in click chemistry.
254,255 
Functionalization of the macrocyclic 
backbone by the attachment of this compound should facilitate the passive targeting of 
breast cancer cells.
256
 Other clickable functionalities with targeting potential include 
protein-targeted imaging probes such a 4,4ʹ-diphenylcyclohexyl moiety which has been 
shown to bind to albumin for blood pool imaging to detect the presence of albumin in the 
lymphatics, tumour interstitium and in artherosclerotic plaque;
257,258
 and as a fibrin-
specific cyclic peptide, important for detecting blood clots.
259
 Alkyne-functionalized 
species for dual-property imaging include commercially available water soluble 
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fluorescent probes such as boron-dipyrromethene (BODIPY, Figure 2.27, right) 
derivatives which have been previously appended to Gd
III
-DOTA.
260
  
 
Figure 2.26 Left to right: model alkyne ethynyltoluene; the synthetic estrogen mimic 
ethynylestradiol; and the fluorescent moiety BODIPY. 
 
2.8 Conclusion 
During this project, a family of Mn
II
 and Gd
III
 complexes of N3X2 (X = NH, O) 
and N3O3 Schiff-base macrocycles were synthesized, characterized, and analyzed as 
potential contrast agents for MRI.  Of the 8 proposed macrocyclic systems, 6 formed 
analytically pure complexes with Mn
II
 and 3 formed analytically pure complexes with 
Gd
III
. The in vitro relaxivities of the soluble, pure complexes were studied at clinical 
magnetic fields, with very promising results: the Mn
II
 complexes, in particular, displayed 
relaxivities up to 7x as high as those of the best approved agent. A pilot in vivo toxicity 
and imaging study in rats on Mn
II
-N5 indicated that the complex displays negligible 
toxicity at the studied dosage; effectively enhances the kidneys, bladder and vasculature; 
and is fully excreted within 3 hours – an extremely encouraging result. Future directions 
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include ongoing in vivo studies, as well as the development of a dual-property agent for 
targeting, therapy, or bimodal imaging. 
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3 RESULTS AND DISCUSSION FOR PROJECT 2: 
Dy
III
 complexes of Schiff-base macrocycles: towards mononuclear SMMs 
3.1 Introduction 
My second area of research involves working towards the development of a new 
family of mononuclear lanthanide single-molecule magnets (Ln-SMMs) with pseudo-D5h 
geometries, formed via the templation of Schiff-base macrocycles around Dy
III
. SMMs 
are compounds which exhibit slow relaxation of magnetization due to the presence of a 
large energy barrier (Ueff) between the two orientations of the electronic ground state. As 
was discussed in Section 1.2.4, the crystal field of a lanthanide ion plays a key role in the 
splitting of the MJ microstates, and thus in the size of Ueff for Ln-SMMs. Emerging 
principles of rational design in the field of L-SMMs include the simple electrostatic 
model of Long and co-workers, who postulated that the intrinsic anisotropy of oblate 
lanthanide ions such as Dy
III
 and Tb
III
 may be enhanced by axially-located charge 
density; while the anisotropy of prolate lanthanide ions such as Er
III
 may be enhanced by 
equatorially bound ligand charge density (discussed in more depth in Section 1.2.4).
117
  
In addition, the size of Ueff is affected in a large way by the presence or absence, 
and the degree, of quantum tunneling: a phenomenon arising from the overlap of wave 
functions, which allows magnetic relaxation to occur ‘through’ rather than thermally 
‘over’ the anisotropy barrier.261 Suppression of quantum tunneling via structural design 
remains a key focus of synthetic magneto-chemists. As was succinctly described by Tong 
and co-workers, certain high-symmetry coordination environments have been 
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theoretically shown to allow for the control of quantum tunneling by the disappearance of 
certain terms (B
k
q) in the crystal field Hamiltonian (ĤCF = ΣB
k
qÕ
k
q, where Õ
k
q are the 
Stephen operators).
104
 These high-symmetry cases include C∞v, D∞h, S8, D4d, D5h, 
and D6d.
104
 The D4d geometry is ubiquitous in the field of Ln-SMMs, with an impressive 
number of bis(phthalocyanine) complexes with this symmetry displaying some of the 
highest reported energy barriers to date.
113,114
  
 Of the desirable high-symmetry geometries, one which is extremely rare amongst 
Ln-SMMs is the 7-coordinate pseudo-D5h geometry. To the best of my knowledge there 
are only four examples in the literature of SMMs containing lanthanide ions in pseudo-
D5h geometries, including a dinuclear Dy2 SMM
262
 and two M
II
2Dy
III
 complexes: a 
Zn2Dy trimer and an Fe2Dy trimer.
104,263
   The two Dy
III
 centers in the asymmetric SMM 
reported by Powell both lie in pentagonal bipyramidal environments (Figure 3.1, right), 
with N2O5 and NCl2O4 donor sets respectively. Although at low temperatures, the 
observed slow relaxation is due to the exchange-coupling interaction between the dimeric 
centres, bridged by two O donors, at high temperatures, the SMM behaviour is due to the 
anisotropy of each ion acting individually. The relaxation process due to each ion in the 
high temperature regime is characterized by a separate relaxation time, and the energy 
barriers were found to be 198 and 150 K respectively. The Dy
III
 center in the Zn2Dy 
complex reported by Tang undergoes a reversible change in coordination geometry upon 
desolvation, from 7-coordinate pseudo-D5h (Figure 3.1, center) to 6-coordinate pseudo-
Oh. 
263
 When the Dy
III
 is pseudo-D5h, the complex behaves as an SMM with a high energy 
barrier of 439 K, and after the geometry change, the SMM behaviour is switched off.
263
 
When the two Zn
II
 ions are replaced with Fe
II
 ions to give an Fe2Dy trimer, the energy 
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barrier of the resulting SMM increased to 459 K, due to the change in the immediate 
environment of the Dy
III
 ion when exchanging diamagnetic for paramagnetic ions.
104
 This 
confirms the vital role that the coordination environment plays in SMM behaviour, as 
well as the ability of Dy
III
 ions in pentagonal bipyramidal environments to display 
significant anisotropy barriers. An additional example is a layered Er
III
 phosphonate 
structure which exhibits field-induced SMM behaviour.
264
 The energy barrier Ueff was 
determined to be 34.8 K in an applied dc field of 0.1 T. Unlike the oblate Dy
III
 ion, Er
III
 is 
prolate, so these results are consistent with the theory of Long described above:
117
 that a 
ligand environment providing equatorial electron density would enhance or confer SMM 
properties upon an Er
III
 system.  
 
Figure 3.1 Crystal structures of: left, a Zn2Dy SMM;
263
 center, a layered erbium(III) 
phosphonate complex;
264
 and right, a Dy2 dimer
262
 in which the Ln
III
 species have 
pseudo-D5h geometry. Counter ions and non-coordinating solvent molecules are omitted 
for clarity. 
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With these exciting but rare examples in mind, we proposed that the templation of 
equatorially-binding Schiff-base macrocycles around lanthanide ions could confer such 
high symmetry coordination geometries upon the metal centers, and might afford a new 
family of mononuclear Ln-SMMs.  
Macrocycles L1 (N5), L2 (N3O2) and L6 (dbN3O3) were selected as the target 
macrocycles for this study. The pentadentate macrocycles L1 and L2 were chosen due to 
their potential ability to confer pseudo-pentagonal bipyramidal geometry on the resulting 
complexes. These two macrocycles differ only in the nature of their donor atom sets (N5 
vs. N3O2), and thus should allow the effect of donor atom strength on the magnetic 
properties to be examined. The potentially hexadentate macrocycle L6 was also selected 
for examination, in order to probe the effect of a larger cavity size and additional steric 
bulk on the properties of the resulting complex.  
 
 Dy
III
 was chosen as the templating cation because it has a large inherent magnetic 
anisotropy, as well as 5 unpaired electrons, allowing for a high ground state MJ value of 
15/2. As well, because it is a Kramers ion with an odd number of unpaired electrons, 
Dy
III
 always has a doubly degenerate ground state. In addition, the uniaxial anisotropy of 
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Dy
III
 has been shown to be enhanced by a pseudo-D5h crystal field, in the examples given 
above. 
 Our objectives were therefore to template the formation of selected Schiff-base 
macrocycles around Dy
III
 and study the magnetic properties of the resulting complexes, 
as potential Ln-SMMs.  
3.2 Synthesis and characterization 
 In light of the successful metal templation reactions using Gd
III
 chloride salts 
detailed in Chapter 2, DyCl3
.
6H2O
 
was chosen as the initial templating agent. The same 
general synthetic procedure outlined in Section 2.3 described for the synthesis of the Mn
II
 
and Gd
III
 complexes was followed: stoichiometric amounts of  the metal salt, diketone 
and diamine were refluxed in methanol, followed by precipitation and copious washing 
by diethyl ether.  
 Each of the three macrocycles was successfully templated around DyCl3
.
6H2O, 
giving macrocyclic complexes 1.3 (Dy
III
-N5), 2.3 (Dy
III
-N3O2) and 6.3 (Dy
III
-dbN3O3) 
respectively as powders in low to average yields (20 – 50%). Key characterization data 
for the three complexes are summarized in Table 3.1, below. 
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Complex; 
Abbrev. 
Molecular 
Formula 
 C H N 
v(C=N) 
(cm-1) 
λmax (ε) 
(nm,  
L.mol-1.cm-1) 
ΛM – MeOH 
(S.cm2.mol-1) 
1.3 
DyIII-N5 
[Dy(L1)Cl3]·4H2O 
Found 
Calcd 
29.76 
29.33 
4.91 
5.09 
10.87 
11.40 
1631 
250 (6590) 
281 (3820) 
160.4 
2.3 
DyIII-N3Os 
[Dy(L2)Cl3]·6H2O 
Found 
Calcd 
27.94 
27.62 
4.92 
5.10 
6.39 
6.44 
1625 
250 (5140) 
274 (4050) 
180.0 
6.3 
DyIII-dbN3O3 
[Dy(L6)Cl3]·6H2O 
Found 
Calcd 
37.94 
37.89 
4.44 
4.71 
4.95 
5.30 
1620 
- 
276 (4966) 
125.6 
 
Table 3.1 Summary of Dy
III
 complex characterization data: complex formulae, elemental 
analyses, IR and UV-visible spectroscopic data, and conductance measurements. Note: 
the formulae in Column 2 are not structural formulae denoting the coordination 
environment of the Dy
III
 centers; but rather, molecular formulae determined via elemental 
analysis.  
 
 The peaks corresponding to an imine stretch in the IR spectrum of each complex 
were found at v = 1631 cm
-1
, 1625 cm
-1
 and 1620 cm
-1
 for 1.3 (Dy
III
-N5), 2.3 (Dy
III
-N3O2) 
and 6.3 (Dy
III
-dbN3O3) respectively, consistent with the values reported for similar rare 
earth complexes of Schiff-base macrocycles.
137,265
 The importance of the IR data cannot 
be overstated, as it provides evidence for the formation of the macrocyclic ring, 
templated by the metal ion, and for the absence of amine and ketone starting materials. A 
representative IR spectrum is presented in Figure 3.2 for the Dy
III
-N5 complex 1.3.  
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Figure 3.2 IR spectrum of 1.3 (Dy
III
-N5), showing the absence of a C=O stretch 
corresponding to the ketone starting material, and the presence of a C=N stretch for the 
Schiff-base macrocycle.  
 
 The elemental analysis data for 1.3 (Dy
III
-N5) fit for the presence of three chloride 
ions and four H2O molecules, with a maximum difference of 0.53% for nitrogen. This 
offers a significant improvement over the attempted synthesis of this complex by 
Radecka-Paryzek and co-workers in 1998, for which a maximum difference of 2.4% was 
reported.
137
 The elemental analysis data for complexes 2.3 (Dy
III
-N3O2) and 6.3 (Dy
III
-
dbN3O3) fit for three chloride ions and six H2O, and were both within the acceptable +/- 
0.4% limit for C, H and N. Both of these complexes are previously unreported.  
 The mass spectrum of 1.3 (Dy
III
-N5) displays a peak at m/z = 471 assigned to [M-
H-2Cl]+. The mass spectrum of 2.3 (Dy
III
-N3O2) displays a peak at m/z = 297 assigned to 
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[L2+Na]
+
, while the most intense peak in the spectrum of 6.3 (Dy
III
-dbN3O3) 
corresponded to [L7+H]
+
. Similar macrocycle-only peaks were reported in the mass 
spectra of Ln
III
 complexes of the related 19-membered N5 Schiff-base macrocycle.
266
  
The UV-visible spectra of all three complexes show maximum absorption bands at λ = 
250-280 nm, once again corresponding to the π to π* electronic transition of the 
macrocyclic ligand in each instance.  The absorption bands are consistent with those for 
the corresponding Gd
III
 complexes described in Chapter 2. A representative UV-visible 
spectrum is shown below (Figure 3.3) for the Dy
III
-N5 complex 1.3.   
 
Figure 3.3 UV-visible spectrum of 1.3 in MeOH showing λmax at 288 nm, corresponding 
to the π to π* transition of the macrocyclic ligand. 
 
From this data we can therefore conclude that the three Dy
III
 complexes 1.3 (Dy
III
-N5), 
2.3 (Dy
III
-N3O2) and 6.3 (Dy
III
-dbN3O3) have been successfully isolated as pure solids. 
 
 In the field of molecular magnetism, having a specific knowledge of the 
coordination geometry, bond lengths, and bond angles present in a (para)magnetic 
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complex is very important, in order to draw conclusions about the relationship between 
structure and magnetic behaviour. Numerous attempts were made to crystallize the three 
Dy
III
 complexes described above. Solutions of the complexes in methanol, ethanol, and 
DCM were used, in various concentrations. Solvents including diethyl ether, pentane, 
hexane, THF, acetone, toluene, acetonitrile and mixtures of these were layered over the 
complex solutions, or allowed to vapour-diffuse into the complex solutions at various 
rates. Vials, test tubes, and H-tubes were utilized. The crystallizations were carried out at 
room temperature and in the refrigerator.   
 In spite of my best attempts, no X-ray quality crystals of these complexes have 
yet been grown. For this reason we decided to template the macrocycles around 
alternative Dy
III
 salts, thinking that different anions might favour the growth of single 
crystals due to a more efficient solid state packing of the anions in the crystal lattice. 
Following this methodology, perchlorate, triflate and nitrate salts of Dy
III
 were also 
employed to template the formation of each macrocycle. Templating the macrocycles 
around these salts resulted in solids which were much more difficult to isolate as pure 
samples: the only compound which could be isolated pure was [Dy(L6)(OTf)3]
.
6H2O 
(6.4), the triflate derivative of Dy
III
-dbN3O3 (6.3). As previously described, the complex 
was characterized first by IR spectroscopy and displayed the characteristic imine stretch 
at 1653 cm
-1
. The elemental analysis of 6.4 (Dy
III
-dbN3O3-OTf) indicated the presence of 
three triflate anions and six H2O molecules within the acceptable +/-0.4% difference. The 
mass spectrum showed a peak at m/z = 289 corresponding to [L6+H]
+
. Unfortunately, 
attempts to crystallize 6.4 also met with no success; thus, our attention remained focused 
on the original three complexes Dy
III
-N5 (1.3), Dy
III
-N3O2 (2.3) and Dy
III
-dbN3O3 (6.3).  
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 As was discussed in Chapter 2 (Section 2.3.2), crystal structures of rare earth 
complexes of 15- to 18-membered [1+1] Schiff-base macrocycles are extremely rare. 
Concerted efforts to synthesize rare earth complexes of these macrocycles by two 
research groups in particular have yielded very few crystalline compounds.
137,138
  Given 
the lack of structural information in the literature, we attempted to examine the 
crystallinity of our compounds by powder diffraction. The diffraction pattern for 1.3 
(Dy
III
-N5) is shown in Figure 3.4, and reveals no well-resolved features out to 33.5°, 
consistent with its amorphous nature. The powder patterns for complexes 2.3 (Dy
III
-
N3O2) and 6.3 (Dy
III
-dbN3O3) were very similar, and we thus concluded that all three 
complexes were amorphous, which accounts for the difficulties faced when trying to 
grow single crystals of this family of complexes. 
 
Figure 3.4 Powder diffraction pattern for 1.3 (Dy
III
-N5), showing the amorphous nature 
of the complex. Data were collected at room temperature in the range 2.5 < 2  < 33.5°, 
and were recorded in 0.05
°
 steps using Cu-K radiation ( = 1.54187 Å) with the tube 
operating at 40 kV and 40 mA with an initial beam diameter of 0.5 mm.  
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 In Chapter 2, our key structural concern was confirming the ability of the 
macrocycles to bind in an equatorial fashion around Mn
II
 and Gd
III
, allowing for axially-
bound waters and high relaxivity. For the Dy
III
 complexes in this chapter, our structural 
concern is determining whether the two pentadentate macrocycles N5 and N3O2
 
give rise 
to pseudo-pentagonal bipyramidal complexes when coordinated to Dy
III
; and to gain 
insight into the potential coordination environment of Dy
III
 in the larger, rigid macrocycle 
dbN3O3. We thus turned our attention once again to an analysis of related structures in the 
literature.  
 As noted earlier, two related lanthanide complexes for which the crystal structures 
have been measured are the Lu
III
 and Yb
III
 complexes of the 16-membered N5 macrocycle 
p-N5 (Figure 3.5, left), formed from a mixture of the chloride and perchlorate salts of 
each ion.
228-230
 In both cases, the lanthanide ions adopt a 7-coordinate, pseudo-D5h 
geometry, with the macrocycle coordinating in the equatorial plane, and two axially 
bound chloride ions. The flat nature of the macrocycle is confirmed by the near co-
planarity of the N5 donor set, and each lanthanide ion is very slightly displaced from the 
N5 plane by 0.114(2) and 0.104(2) Å for Yb
III
 and Lu
III
 (Figure 3.5, right) respectively.              
             
Figure 3.5 Left, 16-membered N5 macrocycle; right, the crystal structure of the 7-
coordinate Lu
III
 complex.
228
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This literature evidence confirmed that a lanthanide ion could accept an equatorial N5 
donor set, along with at least two axial ligands. In addition, a crystal structure of a 
pseudo-D5h Cd
II
 complex in which the metal ion is bound to a 15-membered N5 
macrocycle
231
 indicates that an even larger cation than Dy
III
 can coordinate in the plane of 
a macrocycle of this size. We thus propose that macrocycles L1 and L2 coordinate 
equatorially, via their full N5 and N3O2 donor sets, acting as pentadentate ligands.  
 However, the coordination of the dbN3O3 macrocycle L6 is less straightforward. 
There are no published crystal structures of complexes of L6, and the few reports of 
complexes of this macrocycle refrain from postulating on the binding mode of the 
macrocycle.
138
 However, a search of the literature yields several related complexes which 
shed some light on this question.  
 
Figure 3.6 Macrocycles discussed in this section. 
 There are a number of hexadentate macrocyclic ligands, with 18-membered 
backbones, which coordinate in a planar fashion to lanthanide ions, as well as alkali earth 
metals with larger ionic radii than Dy
III
. The La(NO3)3 complex of L5, the flexible 
analogue of L6, has been reported (Figure 3.7, left).
233
 The macrocycle coordinates in a 
hexadentate fashion, and although it binds equatorially, the macrocycle is puckered: 
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dihedral angle between the planes defined by the three N donors and La, and the three O 
donors and La, is 135.38º. The remaining 6 positions of the lanthanum coordination 
sphere are filled with donor O atoms from the three nitrate counter ions. Although L6 is 
more rigid than L5, due to the substituent benzo groups, so is unlikely to pucker in the 
same way, this demonstrates that an 18-membered N3O3 Schiff-base macrocycle can 
coordinate to a lanthanide equatorially. Further evidence for this was provided by 
Hursthouse and co-workers, who reported lanthanide complexes of an 18-membered N6 
macrocycle, [2+2]N6 (Figure 3.6) .
234
 The La
III
, Ce
III
 and Nd
III
 complexes of this [2+2] 
Schiff-base macrocycle were described (Figure 3.7, center). In each case, the macrocycle 
binds in a hexadentate fashion. Again, the macrocycle is puckered, with a fairly large 
interplanar angle of 26.7 – 73.9° observed between each N3-Ln plane. The angle increases 
as the ionic radii of the lanthanide decreases, presumably in order to optimize the Ln-N 
bond lengths. Since this is a [2+2] Schiff-base macrocycle, it is not completely analogous 
to L6, but does serve to suggest that to the extent that puckering is possible in the more 
rigid L6 macrocycle, this macrocycle will likely fold slightly to accommodate the smaller 
Dy
III
 ion.
234
  
           
Figure 3.7 Left, the La
III
 complex of L5;
233
 center, the Ce
III
 complex of [2+2]N6;
234
 right, 
the Sr
II
 complex of f-N2O4.
235
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 Fenton and co-workers report structures of the 18-membered N2O4 furan-based 
analogue of L5: f-N2O4 (Figure 3.6).
235
 The macrocycle is templated around the alkali 
earth metals Ca
II
, Sr
II
 and Ba
II
, in each case binding in a hexadentate fashion. 
Interestingly, Ca
II
 (1.00 Å)
267
 lies in the plane of the ring, and the two thiocyanates bind 
in a ‘trans’ conformation, occupying the two axial positions affording an 8-coordinate 
geometry. In contrast, the larger Sr
II 
and Ba
II
 cations (1.16 and 1.36 Å respectively)
267
 lie 
very slightly out of the plane of the macrocyclic ring, and the two thiocyanate ions bind 
in a ‘cis’ conformation on the out-of-plane side of the cation, with a water bound in the 
other axial position, conferring 9-coordinate geometry on the cations (Figure 3.7, 
right).
235
 This report further demonstrates that ions with larger radii than Dy
III
 may still 
be equatorially bound by 18-membered, hexadentate [1+1] Schiff-base macrocycles.  
Hence it seems probable that the full N3O3 donor set of L6 coordinates equatorially to the 
Dy
III
 in complex 6.3. 
 In light of these related structures, we are confident that the N5 (L1) and N3O2 
(L2) macrocyclic systems can support a pentagonal bipyramidal geometry by binding in a 
pentadentate, equatorial fashion to Dy
III
. The larger macrocycle dbN3O3 is also likely to 
bind equatorially, in a hexadentate fashion. In order to shed more light on the proposed 7-
coordinate geometry of Dy
III
-N5 and Dy
III
-N3O2, and to gain further information about the 
structure of Dy
III
-dbN3O3, several techniques were employed.   
 Given the intrinsic problem of a lack of single crystal data, we turned to other 
means to aid in the structural elucidation. Although imine bond formation was confirmed 
via IR measurements, and the formulae were elucidated by elemental analysis, these 
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techniques do not allow for a determination of the number and nature of axial ligands 
bound to the metal centre. Several additional techniques were thus employed to elucidate 
the coordination geometries of the three complexes, including thermogravimetric 
analysis, conductance measurements, and Raman and far-IR spectroscopy.  
 Thermogravimetric analysis or TGA, was utilized in order to glean information 
concerning the nature of the chloride anions and water molecules (coordinating vs.non-
coordinating) determined to be part of the formula unit by elemental analysis. TGA data 
was gathered on the two pentadentate systems: 1.3 (Dy
III
-N5) and 2.3 (Dy
III
-N3O2), and is 
presented in Figure 3.8. 
 
 
 
Figure 3.8 TGA plots for complex 1.3 (Dy
III
-N5, top) and 2.3 (Dy
III
-N3O2, bottom). 
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 The TGA plot for complex 1.3 (Dy
III
-N5) shows the loss of three water molecules 
and two chloride ions (as HCl) below 300°C, suggesting non-coordination of these 
species. The varying temperatures at which the water molecules leave may correspond to 
weakly bound lattice solvent vs. strongly hydrogen-bonded water molecules. An 
additional water molecule is lost by 400°C, which we postulate to indicate coordination 
of this molecule. The third chloride ion is not observed to leave, again indicative of 
coordination. The TGA plot for complex 2.3 (Dy
III
-N3O2) shows very similar behaviour: 
four water molecules and two chloride ions (as HCl) are lost below 300°C, with an 
additional water molecule, likely to be coordinated, lost by 350°C, and one chloride ion 
not observed to leave. Thus the TGA data is consistent with the present of one bound 
chloride and one bound water molecule in each complex. 
 Conductance measurements have historically been utilized to gain insight into the 
number of bound versus unbound counter ions in coordination complexes, particularly 
before X-ray crystallography became routine as a characterization method. In their 
original series on pentadentate Schiff-base macrocycles, Nelson and Drew utilized 
conductance measurements in poorly coordinating organic solvents to justify their 
conclusions regarding the coordination geometry of the complexes, under the assumption 
that the electrolytic behaviour of a complex in such a solvent would reflect its structure in 
the solid state.
208-213
 In particular, conductance has been very successfully employed to 
help determine the 7-coordinate geometry of transition metal complexes; an important 
example is the predicted pentagonal bipyramidal geometry of the Fe
II
 complex studied in 
171 
 
 
detail for its spin crossover properties;
132
 a postulation which was proven correct decades 
later by single crystal X-ray diffraction.
133
  
   
 Following literature precedence for this family of systems,
208-213
 conductance 
measurements were carried out on 0.5 mM solutions of the complexes in both water and 
methanol. The average molar conductivities (ΛM) of the three complexes in each solution 
are presented in Table 2.3. 
Complex Formula 
ΛM 
(MeOH) 
ΛM (H2O) 
1.3 
Dy
III
-N5 
[Dy(L1)Cl3]·4H2O 160.4 313.8 
2.3 
Dy
III
-N3O2 
[Dy(L2)Cl3]·6H2O 180.0 319.6 
6.3 
Dy
III
-dbN3O3 
[Dy(L6)Cl3]·6H2O 125.6 300.6 
 
Table 3.2 Summary of molar conductivity values (S
.
cm
2.
mol
-1
) in MeOH and aqueous 
solutions at 25°C for the Dy
III
 complexes. 
 
 As noted in Chapter 2, Geary gives an expected range of values of 80-115 
S
.
cm
2.
mol
-1
 for a 1:1 electrolyte in methanol, 160-220 S
.
cm
2.
mol
-1
 for a 1:2 electrolyte, 
and 290-350 S
.
cm
2.
mol
-1
 for a 1:3 electrolyte.
236
 The ΛM values for complexes 1.3 (Dy
III
-
N5) and 2.3 (Dy
III
-N3O2) in methanol are indicative of 1:2 electrolytic behavior, 
consistent with the presence of one bound and two unbound chloride ions.  The molar 
conductivity of 6.3 (Dy
III
-dbN3O3) in MeOH was between the range expected for a 1:1 
electrolyte and a 1:2 electrolyte, so a definite determination of the number of bound 
chloride ions was not clear in this case. In contrast, the molar conductivities observed for 
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the aqueous solutions range from 300-320 S
.
cm
2.
mol
-1
, consistent with 1:3 electrolytes in 
solution, due to the displacement of the one bound chloride ion (or possible two, in the 
case of 6.3) by water.  
 The conductance data thus indicates that in the solid state (represented by 
methanolic solution), one chloride ion is directly coordinated to the Dy
III
 center of 1.3 
(Dy
III
-N5) and 2.3 (Dy
III
-N3O2), in excellent agreement with the TGA data; and either one 
or two chloride ions are coordinated to 6.3 (Dy
III
-dbN3O3).  
 Raman and Far-IR spectroscopy are very useful techniques for determining the 
presence of M-O and M-Cl bonds in coordination complexes. Like conductance, these 
methods were commonly employed for the characterization of such complexes before X-
ray crystallography became so routine.
268
 Raman and FT-IR spectroscopic data were 
collected to provide further information concerning the ligands coordinated to the metal 
center, in order to corroborate the conclusions drawn from the conductivity and TGA 
measurements, and to confirm that conductance measurements in MeOH are in fact a 
valid model for the electrolytic nature of a compound in the solid state. 
 For complex 1.3 (Dy
III
-N5), the presence of a coordinated chloride ion, as 
predicted by both conductance and TGA, is confirmed by the observation of a strong 
Raman peak at 257 cm
-1
 corresponding to the v(Dy-Cl) stretching mode (Figure 3.9). In 
addition, a medium intensity band is visible in the far-IR spectrum at 207 cm
-1
 is 
attributed to the same stretching mode (Figure 3.10). A complex band in the Raman 
spectrum between 300-380 cm
-1
 is consistent with the presence of at least one 
coordinated water molecule.
269
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Figure 3.9 Raman spectrum for 1.3 (Dy
III
-N5). 
 
Figure 3.10 Far-IR for 1.3 (Dy
III
-N5). 
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Although literature concerning low-frequency IR and Raman spectra of Ln
III
-chloride 
bonds is scarce,
269-271
 the observed data do support the assignment of a 7-coordinate 
environment to the Dy
III
 center of 1.3 (Dy
III
-N5). For instance, the far-IR spectrum of the 
tentatively 7-coordinate Schiff-base complex [DyCl3(LH2)] (where LH2 = 
diethyl(ethylenebis-β-aminocrotonate) exhibits IR ν(Dy-Cl) bands between 230-240 cm
-1
, 
while the far-IR spectrum of the complex [DyCl2(H2O)6]Cl shows νas(Dy-Cl) and νs(Dy-
Cl) peaks at 219 and 162 cm
-1
 on the far-IR spectrum, and at 243 and 169 cm
-1
 on the 
Raman spectrum, respectively.
269
 The latter complex also exhibits a complex peak in the 
Raman spectrum between 290-360 cm
-1
, corresponding to the ν(Ln–O) stretching 
mode.
269
 Thus the observed Raman and FT-IR data for 1.3 (Dy
III
-N5) support the 
presence of a bound chloride ion and a bound water molecule to a Dy
III
 center; in 
agreement with the conductivity and TGA data.  
 Unfortunately, complex 2.3 fluoresced too intensely for the assignment of any 
useful bands. Like complex 2.3, complex 6.3 fluoresced intensely; but visible peaks in 
the Raman spectrum were present: a  peak at 242 cm
-1
 may be attributed to the v(Dy-Cl) 
stretching mode, in agreement with the 1-2 chloride ions predicted to be bound via 
conductance measurements; while the complex contour on the spectrum between 290-340 
cm
-1
 corresponds to the v(Dy-O) stretch of coordinated water.
269
 
 Based on the above evidence, we thus propose that complexes Dy
III
-N5 (1.3) and 
Dy
III
-N3O2 (2.3) are 7-coordinate, pseudo-pentagonal bipyramidal systems, with the 
pentadentate macrocycle bound in the equatorial plane, and a coordinated chloride ion 
and water molecule filling the axial positions; although without a crystal structure, this 
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cannot be conclusively proven. The third complex, Dy
III
-dbN3O3 (6.3), likely has 
geometry between 8-coordinate and 10-coordinate, with the potentially hexadentate 
macrocycle bound equatorially, and at least one water and one chloride bound axially. 
The conferral of anisotropy on a Dy
III
 ion via the equatorial binding of a pentadentate or 
hexadentate macrocycle has never before been explored, and thus the magnetic properties 
of these three complexes are of great interest.  
3.3 Magnetic studies 
Following the synthesis of complexes 1.3 (Dy
III
-N5), 2.3 (Dy
III
-N3O2), and 6.3 
(Dy
III
-dbN3O3), direct current (dc) and alternating current (ac) susceptibility 
measurements were carried out on each complex in order to probe their magnetic 
properties.  
  Dc magnetic data was collected using a Quantum Design MPMS system. 
Measurements were performed on a powder sample of each complex, in an applied field 
of 0.1T, from 300-2 K. The parameters of interest are the room temperature χT value, 
which should equal the Curie constant (C); and the Weiss constant (θ). The former values 
can be compared to the theoretical value for an isolated Dy
III
 ion; and the latter value 
indicates whether or not any weak intermolecular interactions are present.  The χT vs. T 
and 1/χ vs. T plots for each complex are presented in Figure 3.11, below. 
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Figure 3.11 χT vs. T (left) and 1/χ vs. T (right) plots for 1.3 (top), 2.3 (center), and 6.3 
(bottom). 
 The Curie and Weiss constants determined for each complex are summarized in 
Table 3.4, below. 
Complex Abbreviation C (cm
3.
K
.
mol
-1
) θ (K) 
1.3 Dy
III
-N5 14.88 ± 0.02 -4.35 ± 0.20 
2.3 Dy
III
-N3O2 14.89 ± 0.06 -5.86 ± 0.53 
6.3 Dy
III
-dbN3O3 15.15 ± 0.01 -3.35 ± 0.16 
 
Table 3.3 Summary of the parameters describing the dc magnetic susceptibility 
behaviour of 1.3, 2.3 and 6.3. 
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 The theoretical value of χT for a non-interacting DyIII ion (6H15/2, S = 5/2, L = 5, g 
= 4/3) is 14.17 cm
3.
K
.
mol
-1
, which is close to the high-temperature values observed for 
the three complexes (Figure 3.11, left). In each χT vs. T plot, the χT value remains 
constant as temperature decreases, until ~70 K, where the line begins to decrease, 
reaching a minimum value at 2 K. This decrease at low temperatures is most likely due to 
the depopulation of the Stark sublevels of each Dy
III
 center.
272
 The Curie constant, 
calculated from the inverse of the slope of each 1/χ vs. T plot, should also equal 14.17 
cm
3.
K
.
mol
-1
 for a mononuclear Dy
III
 complex which displays Curie-Weiss behaviour. The 
Curie constants for the three complexes were in reasonable agreement with the expected 
value (Table 3.4). The Weiss constants, calculated from the x-intercept of the same plot, 
were all low negative values, due to either the presence of weak antiferromagnetic 
interactions at low temperatures, or to the single-ion anisotropy of the Dy
III
 ions. 
Alternating current (ac) measurements were carried out on each complex at low 
temperatures (2-15 K), in an oscillating field of 3.5 Oe, over a range of frequencies 
between 25 and 10,000 Hz. As mentioned in Chapter 1, the rationale behind performing 
such ac measurements is that the magnetization of an SMM will lag behind an alternating 
current, so the measured magnetic susceptibility will incorporate a phase shift, φ. The ‘in-
phase’ or ‘real’ component of magnetic susceptibility is given by χ′ = χcosφ, while the 
‘out of phase’ or ‘imaginary’ component is given by χ″ = χcosφ.111 SMM behavior is 
usually identified by observing that the out-of-phase response has a frequency-
dependence, exhibited in a χ″ vs. T or χ″ vs. frequency plot. 
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 Initially, measurements on each complex were carried out in zero applied dc field. 
In-phase and out-of-phase susceptibility vs. temperature plots are given in Figure 3.12. 
 
 
 
Figure 3.12 In-phase (left) and out-of-phase (right) susceptibility as a function of 
temperature for 1.3, 2.3, and 6.3 from 2-15 K, in zero dc field. 
1.3 (DyIII-N5) 
2.3 (DyIII-N3O2) 
Cl3]
.4H2O 
Cl3]
.4H2O 
 
6.3 (DyIII-dbN3O3) 
Cl3]
.4H2O 
Cl3]
.4H2O 
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 Although a large number of ‘field-induced’ SMMs have been reported, 
compounds which display slow relaxation of magnetization in the absence of a static field 
are of primary interest.
111
 We were excited to observe that all three of the Dy
III
 complexes 
exhibit frequency-dependent magnetization, even in the complete absence of an applied 
dc field. In each set of χ′ and χ″ vs. temperature plots (Figure 3.12) a clear separation 
between the susceptibility curves for each frequency is observed at low temperatures. 
 While most SMM materials display a clear maximum in the out-of-phase 
component of the ac data, systems with a distribution of relaxation pathways may not 
show such well-defined behaviour.
273,274
 The absence of the typical maximum in ″ can  
be due to the presence of quantum tunneling, and has been observed for other lanthanide 
complexes including the Er
III
 polyoxometalate-based SMM [Er(2-SiW11O39)2]
13-
.
275
  
 In an attempt to resolve the emerging maxima in the χ″ vs. T plots (Figure 3.12, 
right), we collected further ac susceptibility data, in the presence of a series of applied dc 
fields ranging from zero to 0.5 T. Applying a static dc field serves to quench quantum 
tunneling processes by slightly altering the energies of the MJ microstates via the Zeeman 
effect, and removing the degeneracy of the spin states between which tunneling is 
occurring. It is desirable to use as small a dc field as possible to quench the tunneling, so 
that the MJ sublevels are shifted as little as possible, in order that any effective barrier Ueff 
calculated in the presence of a static field may be a good representation of the barrier U 
in zero field. In addition, using a small dc field helps to ensure that the magnetic response 
observed in the presence of a field is not due to any long-range ordering. Figure 3.13, 
below, shows the resolution of a maximum in the χ″ vs. T data for 1.3 (DyIII-N5). The 0.5 
T data shows that the maximum is best-resolved at lower frequencies (<500 Hz). At 
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higher frequencies, the maximum shifts to higher temperatures, and a shoulder to the left 
of the maximum emerges, suggesting the beginning of a second peak due to the presence 
of more than one relaxation pathway. Similar dynamic ac behaviour has been reported for 
various polynuclear and mononuclear SMMs, some in the absence and some in the 
presence of applied dc fields.
275-278
  
 
 
Figure 3.13 χ″ vs. T data for 1.3 (DyIII-N5) from 2-15 K in a series of applied dc fields 
from 0 to 0.5 T. 
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 Complexes 2.3 (Dy
III
-N3O2) and 6.3 (Dy
III
-dbN3O3) display a similar but smaller 
change over the series of applied dc fields. In static fields of increasing magnitude, a 
broad, shallow maximum resolves in the χ″ vs. T data for 6.3 (Figure 3.14, bottom right), 
but is barely detectable even in a field of 0.5 T for 2.3 (Figure 3.14, top right). Like 1.3, 
both complexes exhibit a shoulder or upswing as the temperature approaches 2 K.  
 
 
 
 
Figure 3.14 χ″ vs. T data for 2.3 and 6.3 from 2-15 K in applied dc fields of 0 (left) and 
0.5 T (right). 
 
2.3 (DyIII-N3O3) 
 
6.3 (DyIII-dbN3O3) 
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 The frequency dependence of the out-of-phase susceptibility is further evidenced 
when χ″ is plotted as a function of frequency. The χ″ vs. frequency plots are shown in 
Figures 3.15-3.17, below.  
 Resolved maxima are apparent at both low (2-5 K) and ‘high’ (11-15 K) 
temperatures for complex 1.3 (Dy
III
-N5, Figure 3.15). In each temperature regime, the 
position of the maximum shifts slightly, but distinctly between adjacent temperature 
curves, confirming the frequency-dependent nature of the response.   
 
 
Figure 3.15 χ″ vs. frequency data for 1.3 (DyIII-N5) in zero applied dc field, at low 
temperatures (2-5 K, left), and ‘high’ temperatures (11-15 K, right).  
 
 For complex 2.3 (Dy
III
-N3O2) maxima are only resolved below ~4 K (Figure 3.16, 
left), although there is a visible frequency-dependence to the out-of-phase response in the 
‘high’ temperature regime also (Figure 3.16, right).  
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Figure 3.16 χ″ vs. frequency data for 2.3 (DyIII-N3O2) in zero applied dc field, at low 
temperatures (<7 K, left), and ‘high’ temperatures (8-15 K, right).  
 
In contrast, complex 6.3 (Dy
III
-dbN3O3) exhibits resolved maxima only in the ‘high’ 
temperature regime, above ~11 K (Figure 3.17, right).  
 
 
Figure 3.17 χ″ vs. frequency data for 6.3 (DyIII-dbN3O3) in zero applied dc field, at low 
temperatures (2-5 K, left), and ‘high’ temperatures (11-15 K, right).  
 
 The χ′ and χ″ vs. frequency data for a system may be used to determine the 
parameters describing the mechanisms of relaxation, by a fit of this data to the Cole-Cole 
equations.  The Cole-Cole model describes ac susceptibility as: 
184 
 
 
χ(ω) =  χS + 
χ0− χS
1+(iωτc)1−α
    Eqn. 3.1 
where ω = 2πf, χ0 is the isothermal susceptibility, χS is the adiabatic susceptibility, τc is 
the temperature-dependent relaxation time, and α is a measure of the dispersivity of 
relaxation times.
273
 Dividing this equation into its real and imaginary parts gives: 
 
χ′ =  χS +  
(χ0− χS)
2
 {1 − 
sinh[(1−α)ln (ωτc)]
cosh[(1−α)ln(ωτc)]+cos[
1
2⁄ (1−α)π]
}   Eqn. 3.2 
χ′′ =  
(χ0− χS)
2
 {1 −  
sin[1 2⁄ (1−α)π]
cosh[(1−α)ln(ωτc)]+cos[
1
2⁄ (1−α)π]
}   Eqn. 3.3 
 
At a given temperature point, the experimental or observed values of χ′ and χ″ may be 
modelled using these equations, by assigning values to each of the four parameters (χ0, χS, 
α and τc) which minimize the error between the experimental and calculated values of χ′ 
and χ″ at each frequency for that temperature. Subsequently, the Arrhenius equation may 
be used to determine the tunneling rate, τ0, and the effective energy barrier, Ueff. The 
Arrhenius equation relates relaxation time c to temperature T, and is given by:   
τc =  τ0e
Ueff/kBT      Eqn. 3.4 
When the natural log of c is plotted against the inverse of temperature (lnc vs. 1/T), the 
energy barrier Ueff (K) is given by the slope of the line, and the tunneling rate τ0 (s) is 
given by exp(y-intercept).
273
    
 It is not uncommon for different relaxation domains to dominate in different 
temperature regimes. In addition, several relaxation pathways may contribute to a 
relaxation domain characterized by a single Ueff and τ0.  
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 In order to successfully use the Cole-Cole equations to model χ′ and χ″ data at a 
given temperature point, a resolved maximum must be observable in the χ″ vs. frequency 
plot at that temperature (which will also mean a resolved maximum in the χ′ vs. χ″ plot at 
that temperature). Thus, consistent with the χ″ vs. frequency plots above (Figures 3.15-
3.17), we were able to model both the high and low temperature regimes of the zero field 
χ′ vs. χ″ data for complex 1.3 (DyIII-N5), the low temperature regime for 2.3 (Dy
III
-N3O2), 
and the high temperature regime for 6.3 (Dy
III
-dbN3O3). An inability to utilize the Cole-
Cole and Arrhenius equations to extract the energy barrier and tunneling rate in the 
remaining temperature regimes does not mean that slow magnetic relaxation is not 
occurring; simply that the collected data does not lend itself to characterization via this 
method.  
 The Cole-Cole plots for each complex may be seen below (Figures 3.18-3.20). 
 As mentioned above, both the low and high temperature regimes may be 
modelled for complex 1.3 (Dy
III
-N5, Figure 3.18). 
 
Figure 3.18 χ″ vs. χ′ plot for 1.3 (DyIII-N5) in zero dc field from 2-5 K (left) and 11-15 
K(right), over the frequency range 25-10,000 Hz. Circles correspond to experimental 
data, lines correspond to a best fit to the Cole-Cole equation. 
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Figure 3.19 depicts the χ″ vs. χ′ data for 2.3 (DyIII-N3O2). The low temperature regime 
(left) was successfully modelled using the Cole-Cole equations; while the experimental-
only χ″ vs. χ′ data above 5 K (right) shows the lack of resolved maxima at higher 
temperatures which was also observed in the χ″ vs. frequency data. 
 
 
Figure 3.19 χ″ vs. χ′ plot for 2.3 (DyIII-N3O2) in zero dc field over the frequency range 
25-10,000 Hz. Left, temperature range 2-4 K; circles correspond to experimental data, 
lines correspond to a best fit to the Cole-Cole equation. Right, temperature range 5-15 K; 
circles correspond to experimental data only. 
 
 Complex 6.3 (Dy
III
-dbN3O3) presents an interesting case. As was indicated by the 
χ″ vs. frequency data, the low temperature region may not be modelled with ease, due to 
the lack of resolved maxima. This absence of resolved maxima is also apparent in the χ″ 
vs. χ′ data (Figure 3.20, left). However, the χ″ vs. χ′ curves do display a slight but distinct 
kink, corresponding to the presence of two separate relaxation domains contributing to 
the relaxation behaviour at each temperature. For similarly kinked but better resolved 
data, a fit to the two-component Debye equation allows for the determination of a Ueff 
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and τ0 parameter for each of the two domains; however, the lack of resolution prevented 
successful modelling of the low temperature data in this case. 
 The high temperature (11-15 K) region is readily modelled using a one-
component Cole-Cole equation, as shown in Figure 3.20, right. 
 
Figure 3.20 χ″ vs. χ′ plot for 6.3 (DyIII-dbN3O3) in zero dc field over the frequency range 
25-10,000 Hz. Left, temperature range 2-10 K; circles correspond to experimental data, 
black lines are  guide for the eyes only. Right, temperature range 11-15 K; circles 
correspond to experimental data only, lines correspond to a best fit to the Cole-Cole 
equation. 
 
 For each modelled temperature regime of each complex, a fit of the temperature 
dependence of the τc values to the Arrhenius equation allowed the energy barriers and 
tunneling rates to be determined. The Arrhenius plots are shown below (Figure 3.21), and 
the parameters describing their relaxation behaviour are presented in Table 3.5. 
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Figure 3.21 Arrhenius plots for (top to bottom) complexes 1.3, 2.3 and 6.3. Circles 
correspond to calculated values, black lines are a best fit to the Arrhenius equation.  
Complex Temperature Ueff (K) τ0 (s) α 
1.3 (Dy
III
-N5) 2 – 5 K 3.79 ± 0.07 (3.35 ± 0.08)  10
-5
 0.63-0.66 
 11 – 15 K 27.7 ± 0.2 (4.68 ± 0.07)   10-6 0.44-0.47 
2.3 (Dy
III
-N3O2) 2 – 4 K 7.75 ± 0.12 (7.52 ± 0.31)  10
-7
 0.57 
6.3 (Dy
III
-dbN3O3) 11 – 15 K 16.5 ± 0.9 (8.84 ± 0.59)   10
-6
 0.49-0.58 
Table 3.4 The energy barriers (Ueff) and tunelling rates/pre-exponential factors (τ0) for 
the modelled regions of the ac susceptibility data for complexes 1.3, 2.3 and 6.3. 
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 Thus it can be seen that all three complexes exhibit slow relaxation of magnetism 
in the absence of an applied magnetic field: they are zero field Ln-SMMs.  
 
 Complex 1.3 (Dy
III
N5) displays two clear relaxation domains or processes: a high 
and low temperature domain. The relaxation barriers calculated for 1.3 (shown in Table 
3.5: 4.13 and 23.7 K) and are very comparable to those of other Dy
III
 SMMs displaying 
two well-defined relaxation processes.
272,273,279
  In keeping with literature observations, 
we have tentatively assigned the high-temperature domain of the relaxation behaviour of 
1.3 to a predominantly thermal pathway, via classical crossing of the energy barrier. In 
the low temperature domain, the proportion of molecules able to overcome this energy 
barrier is small, and the dominant relaxation pathway is likely a temperature-independent 
pathway, such as quantum tunneling mechanism, ‘through’ the energy barrier.280 
 Only the 2-4 K temperature regime could be modelled for complex 2.3 (Dy
III
-
N3O2): a relatively low energy barrier of 7.25 K was calculated for this domain, again 
assigned to a quantum tunneling pathway. It was not visibly clear from the susceptibility 
plots (Figure 3.14 top, and Figure 3.16 right) whether a different relaxation process, or 
the same process, was occurring at temperatures above 4 K.  
 Complex 6.3 (Dy
III
-dbN3O3) exhibits a well-defined, readily modelled process in 
the high temperature region with an energy barrier of 16.5 K, comparable to that of 
complex 1.3, and probably also due to a classical thermal process. In the low temperature 
region, two separate relaxation domains are present as mentioned earlier, evidenced by 
the visibly kinked χ″ vs. χ′ data (Figure 3.14, left); although the energy barriers and 
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tunnelling rates could not be extracted for the two low temperature domains, each is 
likely due to a mixture of temperature-independent and temperature-dependent processes 
in different proportions. 
 
 Within each domain for each complex, multiple overlapping pathways contribute 
to the observed relaxation behaviour. This distribution of relaxation pathways is 
evidenced by the large α values given in Table 5, ranging from 0.44 to 0.66. An α value 
of 0 corresponds to one Debye-like relaxation pathway with a single relaxation time c, 
while a value of 1 indicates an infinitely wide range of relaxation pathways, characterized 
by an infinitely wide dispersion of c values. Clear visual evidence for the multiple 
pathways can be seen in the 0.5 T χ″ vs. T data for 1.3 (DyIII-N5, Figure 3.22), where at 
low temperatures the low frequency data displays a maximum corresponding to one 
pathway, and the higher frequency data begins to rise due to a second (or multiple) 
additional pathway(s).   
 
Figure 3.22 χ″ vs. T data for 1.3 (DyIII-N5) in 0.5 T dc field, with (at least) two separation 
relaxation pathways circled. Lines are a guide for the eye only.  
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 Unfortunately, for this system the lack of single crystal data makes it impossible 
to carry out detailed magneto-structural correlations in order to rationalize further the 
differences in the energy barriers and relaxation rates for the three complexes. However, 
in comparison to the four literature examples detailed at the beginning of this chapter 
(Section 3.1), our compounds are proposed to be unique in the use of equatorially-
binding macrocycles to control the geometry. Although our energy barriers do not 
represent an improvement on those of the compounds described above, our strategy for 
anisotropy enhancement is a novel one. 
3.4 Conclusion and future work 
To conclude, we have successfully synthesized three new mononuclear Dy
III
 Ln-
SMMs. Mono-cyclic mono-lanthanide SMMs such as these are a rarity, in a field 
saturated with bi-cyclic sandwich complexes and acyclic chelating ligands. Importantly, 
complexes  1.3 (Dy
III
-N5) and 2.3 (Dy
III
-N3O2) represent the first example of the 
exploitation of equatorially-binding pentadentate macrocycles to introduce anisotropy 
into an SMM system via the conferral of pseudo-pentagonal bipyramidal geometry. We 
have thus demonstrated a novel approach for the rational design of mononuclear SMMs, 
an area at the forefront of the field of molecular magnetism.  
 Due to the difficulties posed by the amorphous nature of the compounds in the 
project, future work involving the same design principles will involve a search of the 
Cambridge Structural Database in order to find macrocycles reported to bind to Ln
III
 ions 
in a pentadentate fashion, which are also well-known to confer crystallinity upon the 
resulting complexes. For instance, [1+1] Schiff-base macrocycles of the form below have 
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been reported to bind to various lanthanides, including Dy
III
.
281
 The two-compartment 
macrocycle where R = phenol has been reported to bind Dy
III
 in a pentagonal bipyramidal 
environment, with a sodium cation in the second binding pocket (Figure 3.23, right).
281
 
An array of structures based on this crystalline, double-pocket system could be 
synthesized and examined as potential Ln-SMMs.  
            
Figure 3.23 Left, general structure of the two-compartment Schiff-base macrocycle; 
right, the DyNa dimer reported by Tamburini and co-workers.
281
  
 
 In addition, an extension of this project involves the utilization of complexes 
Dy
III
-N5 and Dy
III
-N3O2 as building blocks for the synthesis of higher-order magnetic 
structures. As was discussed in detail in Section 1.3, transition metal complexes of L1 
(N5) and L2 (N3O2) have been exploited for use in chains, clusters and networks of 
varying topologies and magnetic properties. The majority of these structures were formed 
using layering and H-tube diffusion techniques, involving solutions of the macrocyclic 
complex and a bridging moiety such as a polycyanometalate. Utilizing similar 
techniques, attempts will be made to incorporate lanthanide complexes of these 
macrocycles into chains and clusters, with the aim of synthesizing novel higher-order 
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magnetic structures; including dual-property materials; such as the photomagnetic chain 
recently reported by Clerac ́ and co-workers, in which SMM units were linked via 
mononuclear spin-crossover (SCO) complexes of [Fe(L1)(CN2)].
157
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4 RESULTS AND DISCUSSION FOR PROJECT 3: 
Ln
III 
complexes of crown ethers: towards mononuclear SMMs  
4.1 Introduction 
 In Chapter 2, a family of mononuclear Dy
III
-SMMs were successfully prepared, 
demonstrating for the first time the use of equatorially-binding macrocycles to control the 
geometry, and thus enhance the intrinsic anisotropy of the Dy
III
 ion. However, the 
persistent amorphous nature of these complexes prevented a full magneto-structural 
correlation. 
We thus turned our attention toward a family of macrocycles well-known to 
confer crystallinity upon their complexes: the crown ethers. Crown ethers are a 
commercially available class of macrocyclic ligands in which both the cavity size and 
number of donor atoms can be structurally tuned. Surprisingly, crown ethers have thus far 
remained unexplored for the synthesis of Ln-SMMs.  
In this project, with a view to forming complexes with the ‘sandwich’-type 
geometries so ubiquitous in SMM chemistry, the 12-crown-4 (12C4) and 15-crown-5 
(15C5) macrocycles with cavity diameters between 1.2 and 2.2 Å were employed. For 
comparison, the larger 18-crown-6 macrocycle, with its cavity diameter of 2.7 Å, has also 
been utilized for the preparation of a family of complexes in which the macrocycle is 
equatorially-bound.  
A detailed introduction to the modest number of Ln
III
-crown ether complexes 
which have been structurally reported is presented in Section 1.4.2. The smaller crown 
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ether ligands, 12C4 and 15C5, tend to bind axially to the lanthanides. Predominantly half-
sandwich topologies have been reported for Ln
III
 complexes of 12C4, including a series 
of the form [Ln(12C4)(H2O)5]Cl3
.
nH2O (Ln = every trivalent lanthanide but Pm
III
) 
reported by Rogers and co-workers in the 1980s.
178
  The slightly larger 15C5 macrocycle 
is also reported to bind in an axial fashion. Three distinct topologies have been described 
for Ln
III
 complexes of 15C5 to date (Figure 4.1): half-sandwich,
181-183
 full-
sandwich,
184,185
 and pseudo-sandwich structures,
187
 with coordination numbers ranging 
from 8 to 11. Ln
III
 complexes of the larger 18C6 macrocycle show in-plane, equatorial 
binding, with three additional axial ligands bounds.
175,177,188,189
 
                 
                   
Figure 4.1 Representative topologies for Ln
III
-crown ether complexes. Top left: a Tb
III
-
12C4 half-sandwich;
178
 top right: a Tb
III
-18C6 equatorial complex;
175
 bottom: a Nd
III
-
15C5 half-sandwich,
183
 a Pr
III
-15C5 full-sandwich,
186
 and a Sm
III
-15C5 pseudo-
sandwich.
187
  Hydrogen atoms, lattice water molecules and non-coordinating counter ions 
are omitted for clarity. 
12C4 
15C5 
18C6 
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 The lanthanide ions selected for study were Tb
III
, Dy
III
, Ho
III
 and Er
III
. To date, 
there are no structural reports of 15C5 complexes of lanthanides in the Tb
III
-Er
III
 series; 
or of 18C6 complexes of Ho
III
-Er
III
. As a family, these ions provide a unique opportunity 
for observing the change in magnetic behaviour along the later lanthanides. All share 
similar preferences for high coordination geometries, as well as very similar, though 
slightly decreasing ionic radii (Table 4.1).
267
 All have high ground state J values, ranging 
from 6 to 8. However, their electron density distributions differ: Tb
III
, Dy
III
 and Ho
III
 are 
oblate ions, while Er
III
 is prolate.
95
 The degeneracy of the ground state also differs: Dy
III
 
and Er
III
 are Kramers ions, while Tb
III
 and Ho
III
 are non-Kramers ions.  
 
Ln
III 
Config. 
Ground state 
term symbol 
(
2S+1
LJ) 
Landé 
g-factor 
Distribution of 
f electron density 
Radii (Å) 
Coord. no. 6→9 
Tb
III
 [Xe]4f
8
 
7
F6 3/2 Oblate 0.92-1.10 
Dy
III
 [Xe]4f
9
 
6
H15/2 4/3 Oblate 0.91-1.08 
Ho
III
 [Xe]4f
10
 
5
H8 5/4 Oblate 0.90-1.07 
Er
III
 [Xe]4f
11
 
4
I15/2 6/5 Prolate 0.89-1.06 
  
Table 4.1 Selected parameters for Tb
III
-Er
III
.
95,267
 
 
 The magnetic properties of the selected crown ether complexes of these 
lanthanide ions are of particular interest due to the differing location of the ligand-
centered electron density: predicted to be axially located for the 12C4 and 15C5 
complexes, and equatorially centered in the 18C6 complexes. According to Long’s 
crystal field model, presented in Section 1.2.4, equatorial electron density is expected to 
enhance the anisotropy of the prolate Er
III
 ion, while axial electron density should serve 
to enhance the anisotropy of the oblate Tb
III
, Dy
III
 and Ho
III
 ions.
117
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 Our primary objective was therefore to utilize crown ethers as macrocyclic 
ligands for the formation of a ‘tuneable’ family of mononuclear SMMs based on TbIII, 
Dy
III
,  Ho
III
 and Er
III
. 
4.2 Lanthanide perchlorate series: structural elucidation 
 With the above goal in mind, a sequence of reactions was devised by which the 
later lanthanide series of perchlorates (Ln(ClO4)3 (aq), where Ln
III
 = Tb
III
, Dy
III
, Ho
III
 and 
Er
III
)
 
were reacted in succession with 12-crown-4, 15-crown-5, and 18-crown-6 ligands. 
The perchlorate salts of the lanthanides were chosen because perchlorate is a non-
coordinating anion, unlike chloride; and the larger size of the anion may afford well-
separated complexes in the solid state, a prerequistite for SMM behaviour. With a view to 
forming sandwich-type complexes, the lanthanide salts were combined with 12C4 and 
15C5 in both 1:1 and 1:2 Ln/crown ratios; while the lanthanide salts were reacted with 
the 18C6 in 1:1, 2:1 and 3:1 Ln/crown ratios, in an effort to determine whether the larger 
crown would bind to more than one Ln
III
 center. 
 Each reaction was carried out under the same set of conditions, based on a series 
of papers published by Rogers and co-workers in the 1980s.
175-178
 The aqueous lanthanide 
perchlorate salt and crown ether were combined in a 3:1 mixture of acetonitrile and 
methanol, and stirred vigorously at 55°C for 3 – 18 hours, followed by pipette filtration 
and slow evaporation of the reaction mixture. Each reaction was carried out in triplicate 
at least, allowing for several different rates of evaporation to be utilized for each 
Ln/crown type and ratio. The various combinations of reagents are summarized in Table 
4.2, along with the products of the 28 reactions types. Efforts were focussed on reactions 
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which yielded X-ray quality single crystals, since the goal of the project was, in part, to 
investigate the magneto-structural correlation of the resulting complexes. 
 
 Ln:crown Tb(ClO4)3(aq) Dy(ClO4)3(aq) Ho(ClO4)3(aq) Er(ClO4)3(aq) 
12C4 1:1 × 
 
half-sandwich 
(9.1) 
 
 
 
 
 
 
 
 
half-sandwich 
(9.2) 
 
 
 
 
 
 
 
× 
 1:2 
 
× × × × 
15C5 1:1 
 
 
pseudo-sandwich 
(10.3) 
 
 
pseudo-sandwich 
(10.1) 
 
 
 
 
 
 
× 
 
half-sandwich 
(10.2) 
 
 1:2 × 
 
× 
 
pseudo-sandwich 
(10.4) 
 
 
 
 
 
 
 
× 
18C6 1:1 × × × × 
 2:1 
 
eq. complex 
(11.1) 
 
 
 
 
 
 
 
 
eq. complex 
(11.2) 
 
 
 
 
 
 
 
 
eq. complex 
(11.3) 
 
 
 
 
 
 
 
 
eq. complex 
(11.4) 
 
 
 
 
 
 
 
 3:1 × × × × 
 
Table 4.2 The products of the reactions of the Ln
III
 series Tb
III
-Er
III
 with 12-crown-4, 15-
crown-5 and 18-crown-6. Hydrogen atoms, perchlorate counter ions and lattice solvent 
molecules are omitted for clarity. 
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 In the table above, the symbol × indicates that no X-ray quality single crystals 
were isolated from the given reaction type. Complexes which were analytically pure in 
bulk are presented in bold, italicized complexes were structurally characterized via X-ray 
diffraction, but were not analytically pure in bulk. 
 Single crystals of ten complexes were successfully obtained from this reaction 
series and their molecular structures were characterized by X-ray diffraction. In this 
context, isolation of the products of these reactions for X-ray crystallography involved 
storing the crystals in their mother liquor before measurement and then mounting the 
crystals in paraffin oil and flash cooling to 150 K on the X-ray diffractometer to prevent 
any decomposition of the crystals due to loss of solvent. The isolation of samples for 
characterization by elemental analysis and mass spectrometry was performed by the 
selection of individual single crystals from the crystallization vials, followed by washing 
with hexane and diethyl ether and then gently blotting dry with filter paper.  
4.2.1 Ln
III
-12C4 complexes 
Reaction of 1:1 and 2:1 mixtures of 12C4 with the lanthanide perchlorate salts described 
above resulted in the isolation of single crystals of two analytically pure complexes:  the 
Dy
III
 complex [Dy(12C4)(H2O)5](ClO4)3
.
H2O (9.1), and the Ho
III
 complex 
[Ho(12C4)(H2O)5](ClO4)3
.
H2O (9.2) (Figure 4.2). Unfortunately, under the reaction 
conditions described above, no single crystals of Tb
III
 or Er
III
 complexes with 12C4 were 
isolated. Selected characterization data is presented in Table 4.3, below. 
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Complex  C H N 
v 
(cm-1) 
λmax (ε) 
(nm,  
L.mol-1.cm-1) 
MS (m/z) 
9.1 
DyIII-12C4 
Found 
Calcd. 
12.90 
12.89 
3.79 
3.78 
0.00 
0.00 
3405, 2970,  
1050, 1027,  
929, 618 
269 (119) 
FAB: 
538 [M-6H2O-ClO4]
+  
(100%). 
9.2 
HoIII-12C4 
Found 
Calcd.  
(+0.1CH3CH) 
12.56 
12.80 
3.69 
3.97 
0.18 
0.18 
3405, 2970,  
1026, 929,  
616 
248 (37) 
MALDI-TOF: 
441 [M-5H2O-2ClO4-H]
+  
(100%). 
 
Table 4.3 Selected characterization data for complexes 9.1 (Dy
III
-12C4) and 9.2 (Ho
III
-
12C4). Calcd. formulae are based on the structures determined via single crystal X-ray 
diffraction. 
 
 The molecular structures of both complexes were characterized by X-ray 
crystallography. The complexes are isostructural, crystallizing in the monoclinic space 
group P21/c, with one independent molecule in the asymmetric unit. The O9 coordination 
geometry of each Ln
III
 center comprises four oxygen atoms of the tetradentate crown 
ether ligand (O1 to O4) and five water molecules (O5 to O9), to afford a half-sandwich 
type structural topology (Figure 4.2).  Selected bond lengths and angles for complex 9.1 
(Dy
III
-12C4) are presented in Table 4.4. 
 
Figure 4.2 View of the molecular structures of 9.1 (Dy
III
-12C4) and 9.2 (Ho
III
-12C4) 
showing their half-sandwich structural topologies. Hydrogen atoms bound to carbon 
atoms, perchlorate counter ions and lattice water molecules are omitted for clarity. 
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 Atom Atom 
Length 
(Å) 
Dy1 O1 2.513(6) 
Dy1 O2 2.420(6) 
Dy1 O3 2.495(5) 
Dy1 O4 2.457(6) 
Dy1 O5 2.446(6) 
Dy1 O6 2.337(6) 
Dy1 O7 2.386(6) 
Dy1 O8 2.372(6) 
Dy1 O9 2.344(5) 
  
Atom Atom Atom Angle (˚)  Atom Atom Atom Angle (˚) 
O2 Dy1 O1 62.74(19)  O7 Dy1 O4 111.2(2) 
O3 Dy1 O1 118.23(19)  O7 Dy1 O5 154.93(18) 
O3 Dy1 O2 62.79(18)  O7 Dy1 O6 70.3(2) 
O4 Dy1 O1 129.5(2)  O8 Dy1 O1 141.5(2) 
O4 Dy1 O2 121.6(2)  O8 Dy1 O2 142.2(2) 
O4 Dy1 O3 64.66(19)  O8 Dy1 O3 100.0(2) 
O5 Dy1 O1 65.2(2)  O8 Dy1 O4 70.0(2) 
O5 Dy1 O2 87.0(2)  O8 Dy1 O5 126.9(2) 
O5 Dy1 O3 85.2(2)  O8 Dy1 O6 81.9(2) 
O5 Dy1 O4 65.0(2)  O8 Dy1 O7 68.5(2) 
O6 Dy1 O1 66.8(2)  O9 Dy1 O1 79.3(2) 
O6 Dy1 O2 90.2(2)  O9 Dy1 O2 141.8(2) 
O6 Dy1 O3 138.1(2)  O9 Dy1 O3 143.0(2) 
O6 Dy1 O4 147.8(2)  O9 Dy1 O4 79.0(2) 
O6 Dy1 O5 127.1(2)  O9 Dy1 O5 72.68(19) 
O7 Dy1 O1 117.2(2)  O9 Dy1 O6 77.9(2) 
O7 Dy1 O2 74.0(2)  O9 Dy1 O7 132.13(19) 
O7 Dy1 O3 71.7(2)  O9 Dy1 O8 72.5(2) 
 
Table 4.4 Selected bond lengths and angles for 9.1 (Dy
III
-12C4). Additional 
crystallographic data for 9.1 and 9.2 (Ho
III
-12C4) are presented in the Appendix. 
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 The geometries of the Dy
III
 center of 9.1 and the Ho
III
 center of 9.2 were 
determined by calculating continuous shape measures (CSMs).
282
 The deviation from 
ideal C4v symmetry was described by CSMs of 0.52 and 0.51 for Dy
III
9.1 and Ho
III
9.2 
respectively (Table 4.5), indicating a very small deviation from a capped square 
antiprismatic polyhedron in each case (Figure 4.3).   
 
Figure 4.3 Coordination spheres of (left) Dy
III
9.1, and (right) Ho
III
9.2. Colour code: grey = 
Ln
III
, red = O, beige = idealized polyhedra. 
Polyhedron Dy
III
9.1 Ho
III
9.2 
EP-9 36.27 36.39 
OPY-9 23.11 23.28 
HBPY-9 18.48 18.48 
JTC-9 16.09 16.04 
JCCU-9 7.30 7.30 
CCU-9 6.22 6.22 
JCSAPR-9 1.37 1.35 
CSAPR-9 0.52 0.51 
JTCTPR-9 2.69 2.63 
TCTPR-9 1.49 1.49 
JTDIC-9 12.72 12.78 
HH-9 11.73 11.67 
MFF-9 1.13 1.14 
 
Table 4.5 Continuous shape measures (CSMs) of the 9-coordinate Ln
III
 coordination 
polyhedra in complexes 9.1 and 9.2. The values in red indicate the closest polyhedra for 
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each complex according to the CSMs. Abbreviations: EP-9, Enneagon; OPY-9, 
Octagonal pyramid; HBPY-9, Heptagonal bipyramid; JTC-9, Johnson triangular cupola 
J3; JCCU-9, Capped cube J8; CCU-9, Spherical-relaxed capped cube; JCSAPR-9, 
Capped square antiprism J10; CSAPR-9, Spherical capped square antiprism; JTCTPR-9, 
Tricapped trigonal prism J51; TCTPR-9, Spherical tricapped trigonal prism; JTDIC-9, 
Tridiminished icosahedron J63; HH-9, Hula-hoop; MFF-9, Muffin.  
 The crown ether ligand adopts a gauche conformation in both complexes, with all 
four O atoms of the crown lying on the same side of the ring. The Ln
III
 ion is displaced 
out of the best plane through the four crown ether oxygen atoms by 1.645 Å and 1.637 Å 
for Dy
III
 and Ho
III 
respectively. 
 The five coordinated water molecules, one uncoordinated water molecule, and 
three perchlorate counter ions form an extended, 3-D hydrogen-bonded network (Figure 
4.4). The hydrogen bonds for both complexes are in the range of 2.700 - 2.980 Å, the 
shortest being between the proton of the bound water O6 and the oxygen atom of a 
neighbouring solvent water molecule, O22. For complex 9.1, the shortest intermolecular 
Dy
III∙∙∙DyIII distances are 8.8750(5) Å, and for complex 10.1 the shortest HoIII∙∙∙HoIII 
distances are 8.831(3) Å (Figure 4.4). 
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Figure 4.4 Crystal packing of 9.1 (left) and 9.2 (right). View down the b-axis, showing 
H-bonds as blue dashed lines. The shortest Dy∙∙∙Dy distance of 8.8750(5) Å and the 
shortest Ho∙∙∙Ho distance of 8.831(3) Å are shown as black dashed lines. Right: Colour 
code: purple = Dy
III
, seafoam = Ho
III
, grey = C, green = Cl, red = O.  
4.2.2 Ln
III
-15C5 complexes 
 Reaction of 15C5 with aqueous Ln(ClO4)3 salts (Ln
III
 = Tb
III
, Dy
III
, Ho
III
 and Er
III
) 
under the previously described experimental conditions afforded single crystals of four 
different complexes. Reaction of Tb
III
 and Dy
III
 with 15C5 in a 1:1 ratio afforded the 
pseudo-sandwich structures [Tb(15C5)(H2O)4](ClO4)3
.
(15C5)
.
H2O (10.3) and 
[Dy(15C5)(H2O)4](ClO4)3
.
(15C5)
 .
H2O (10.1) respectively. Reaction of Ho
III
 with 15C5 
in a 1:1 ratio yielded no X-ray quality crystalline products; but the 2:1 ratio resulted in a 
similar pseudo-sandwich structure, [Ho(15C5)(H2O)4](ClO4)3
.
(15C5)
.
H2O (10.4). In 
contrast to the pseudo-sandwich complexes observed for Tb
III
-Ho
III
, the 1:1 reaction of 
Er
III
 with 15C5 afforded a half-sandwich complex with the formula 
[Er(15C5)(H2O)4](ClO4)3
.
H2O (10.2). Unfortunately, we were unable to isolate 
analytically pure samples of complexes 10.3 (Tb
III
-15C5) and 10.4 (Ho
III
15C5). 
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Nevertheless, the crystal structures of the major products from these reactions were 
characterized by X-ray diffraction, and a summary of selected structural data for all four 
complexes is presented in Table 4.6. 
 
10.1 
(Dy
III
-15C5) 
10.2 
(Er
III
-15C5) 
10.3 
(Tb
III
-15C5) 
10.4 
(Ho
III
-15C5) 
Topology 
pseudo-
sandwich 
half-sandwich 
pseudo-
sandwich 
pseudo-sandwich 
Space group 
Monoclinic 
P21/n 
Orthorhombic 
Pbcn 
Monoclinic 
P21/n 
Monoclinic 
P21/n 
a 
b 
c (Å) 
15.8533(14) 
14..6908(14) 
16.4867(15) 
17.6319(11) 
14.7648(8) 
9.5931(6) 
15.8302(11) 
14.7294(11) 
16.4864(12) 
15.7919(7) 
14.6637(6) 
16.4443(7) 
α 
β 
γ (°) 
90 
99.409(4) 
90 
90 
90 
90   
90 
99.488(4) 
90 
90 
99.3610(17) 
90 
Volume (Å
3
) 3788.1(6) 2497.4(3) 3791.5(5) 3757.26 
 
Table 4.6 Summary of parameters describing complexes 10.1 – 10.4. Additional 
structural data are presented in the Appendix section of the thesis.  
  Characterization data as well as a detailed discussion of the molecular structures 
of the Dy
III
 pseudo-sandwich and Er
III 
half-sandwich complexes 10.1 and 10.2 are 
presented below. 
Complex  C H N v (cm-1) 
λmax (ε) 
(nm, 
L.mol-1.cm-1) 
MS (m/z) 
10.1 
DyIII-15C5 
Found 
Calcd. 
(+4.5H2O) 
22.64 
22.40 
5.82 
5.54 
0.00 
0.00 
3355, 3241,  
2930, 2886,  
1050, 1028,  
939, 619 
250 (19) 
FAB: 
582 [M-4H2O-ClO4-15C5]
+  
(47%) 
10.2 
HoIII-15C5 
Found 
Calcd.  
(+0.1CH3CH) 
14.16 
14.79 
3.65 
4.22 
0.00 
0.00 
3395, 2947,  
1051, 951,  
932, 620 
246 (55) 
MALDI-TOF: 
676 [M-2H2O-ClO4]
+  
(68%) 
 
Table 4.7 Selected characterization data for complexes 9.1 (Dy
III
-12C4) and 9.2 (Ho
III
-
12C4).  
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 The Dy 15C5 complex 10.1 crystallizes in the monoclinic space group P21/n with 
one Dy
III
 ion and two unique 15-crown-5 molecules in the asymmetric unit: one directly 
coordinated, and one unbound. The Dy
III
 ion adopts a 9-coordinate pseudo-capped square 
antiprismatic geometry with the O9-donor set comprising five oxygen atoms from the 
bound pentadentate 15-crown-5 ether ligand, O1 to O5, along with four water molecules, 
O6 to O9. The bound crown adopts a puckered conformation, with an O5-Dy-O2 angle of 
86.82°.
[37]
 Three of the bound water molecules, O6, O7 and O8 are H-bonded to the five 
O atoms of the second, uncomplexed, crown, to afford a pseudo-sandwich type 
structure.
[35] 
The Dy
III
-crown complex is off-set from the hydrogen-bonded crown, 
enabling the coordinated water molecules O6 and O8 to form hydrogen-bonds to a 
perchlorate counter ion. The final coordinated water molecule O9, which is not H-bonded 
to the uncoordinated crown, is involved in two H-bonding interactions, the first to a free 
water molecule and the second to a perchlorate counter ion (O9∙∙∙O1S and O9∙∙∙O3 
respectively). Selected bond lengths and angles for this complex are summarized in Table 
4.8.  
 
Figure 4.5 View of the molecular structure of 10.1 (Dy
III
-15C5) showing the H-bonding 
interactions to the uncoordinated crown ether ligand as dashed blue lines. 
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Atom Atom Length (Å) 
Dy01 O1 2.4739(19) 
Dy01 O2 2.515(2) 
Dy01 O3 2.480(2) 
Dy01 O4 2.551(2) 
Dy01 O5 2.343(2) 
Dy01 O6 2.317(2) 
Dy01 O7 2.435(2) 
Dy01 O8 2.378(2) 
Dy01 O9 2.335(2) 
 
Atom Atom Atom Angle (˚)  Atom Atom Atom Angle (˚) 
O1 Dy01 O2 64.33(7)  O6 Dy01 O8 82.12(8) 
O1 Dy01 O3 96.51(7)  O6 Dy01 O9 140.67(8) 
O1 Dy01 O4 64.80(6)  O7 Dy01 O1 132.44(7) 
O2 Dy01 O4 99.25(7)  O7 Dy01 O2 130.12(7) 
O3 Dy01 O2 64.88(6)  O7 Dy01 O3 131.05(7) 
O3 Dy01 O4 63.78(7)  O7 Dy01 O4 130.61(7) 
O5 Dy01 O1 69.20(7)  O8 Dy01 O1 141.64(7) 
O5 Dy01 O2 79.90(7)  O8 Dy01 O2 130.09(7) 
O5 Dy01 O3 144.66(7)  O8 Dy01 O3 69.48(7) 
O5 Dy01 O4 128.61(7)  O8 Dy01 O4 77.16(7) 
O5 Dy01 O7 70.36(7)  O8 Dy01 O7 70.42(7) 
O5 Dy01 O8 140.64(7)  O9 Dy01 O1 78.91(7) 
O6 Dy01 O1 131.30(7)  O9 Dy01 O2 142.62(7) 
O6 Dy01 O2 69.92(7)  O9 Dy01 O3 129.38(7) 
O6 Dy01 O3 78.04(8)  O9 Dy01 O4 69.10(7) 
O6 Dy01 O4 140.91(7)  O9 Dy01 O5 80.98(8) 
O6 Dy01 O5 87.59(8)  O9 Dy01 O7 70.99(7) 
O6 Dy01 O7 69.72(7)  O9 Dy01 O8 83.35(8) 
Table 4.8 Selected bond lengths and angles for 10.1 (Dy
III
-15C5). Additional 
crystallographic data for complexes 10.1 and 10.2 (Ho
III
-12C4) are presented in the 
Appendix section. 
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Examining the crystal packing reveals that molecules of 10.1 are organized in a 
monoclinic space group, in a hexagonal arrangement with layers of Dy
III
 complexes 
separated by the hydrogen-bonded crowns (Figure 4.6 right). The shortest intermolecular 
Dy∙∙∙Dy contacts are 8.880(8) Å (Figure 4.6 left). 
 
Figure 4.6 a) View of the crystal packing of 10.1 down the b(1/2a+1/2c) plane, showing 
Dy
III∙∙∙
Dy
III 
distances as black dashed lines; b) view of the crystal packing down the b-
axis, showing the alternating layered arrangement of Dy
III
-bound crown ether ligands, 
free H-bonded crowns, ClO4
-
 counterions and lattice H2O molecules. Hydrogen bonds are 
shown as dashed blue lines. Colour code: purple = Dy
III
, grey = C, green = Cl, red = O.  
 
 In contrast, complex 10.2 (Er
III
-15C5) crystallizes as a half-sandwich structure in 
the orthorhombic space group Pnma. The lanthanide ion is nine coordinate, bound to the 
five oxygens of the crown ether, and four water molecules. The crown ether is puckered, 
with an O1-Er-O3 angle of 82.62(9)°. Due to the symmetric nature of the puckering 
(Figure 4.7), the asymmetric unit of the complex consists of an Er
III
 bound only to three 
of the oxygens of the crown ether, while there are four half-sandwiches in the unit cell.  
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The crystal packing of 10.2 reveals an extended 3-D hydrogen-bound network, with each 
of the coordinated water molecules hydrogen-bonded to three different perchlorate 
anions. The shortest Er∙∙∙Er distance is 8.22769(4) Å. Selected bond lengths and angles 
for the complex are presented in Table 4.9. 
           
Figure 4.7 View of the molecular structure of 10.2 (Er
III
-15C5) showing the 
symmetrically puckered nature of the 15-crown-5 ligand.  
 
Atom Atom Atom Angle (˚)  Atom Atom Atom Angle (˚) 
O1 Er1 O2 64.16(7)  O3 Er1 O1 82.62(9) 
O1 Er1 O3 82.62(9)  O3 Er1 O2 65.70(8) 
O1 Er1 O41 72.96(9)  O3 Er1 O42 129.49(8) 
O1 Er1 O42 142.06(7)  O41 Er1 O42 70.01(9) 
O1 Er1 O43 139.77(9)  O41 Er1 O43 135.8(1) 
O1 Er1 O1 64.48(7)  O41 Er1 O1 72.96(9) 
O1 Er1 O2 121.89(7)  O41 Er1 O2 114.66(9) 
O1 Er1 O42 96.53(7)  O41 Er1 O42 70.01(9) 
O2 Er1 O3 65.70(8)  O42 Er1 O43 76.12(8) 
O2 Er1 O41 114.66(9)  O42 Er1 O1 96.53(7) 
O2 Er1 O42 141.35(7)  O42 Er1 O2 68.75(7) 
O2 Er1 O43 76.58(8)  O42 Er1 O42 78.49(7) 
O2 Er1 O1 121.89(7)  O43 Er1 O1 139.77(9) 
O2 Er1 O2 129.30(7)  O43 Er1 O2 76.58(8) 
O2 Er1 O42 68.75(7)  O43 Er1 O42 76.12(8) 
O3 Er1 O41 151.0(1)  O1 Er1 O2 64.16(7) 
O3 Er1 O42 129.49(8)  O1 Er1 O42 142.06(7) 
O3 Er1 O43 73.2(1)  O2 Er1 O42 141.35(7) 
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Atom Atom Length (Å) 
Er1 O1 2.437(2) 
Er1 O2 2.443(2) 
Er1 O3 2.408(3) 
Er1 O41 2.392(3) 
Er1 O42 2.333(2) 
Er1 O43 2.316(3) 
 
Table 4.9 Selected bond lengths and angles for 10.2 (Er
III
-15C5).  
 The geometries of the lanthanide ions in 10.1 (Dy
III
-15C5) and 10.2 (Er
III
-15C5) 
were further investigated by calculating continuous shape measures (CSMs).
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Polyhedron Dy
III
10.1 Er
III
10.2 
EP-9 35.21 36.43 
OPY-9 24.16 23.53 
HBPY-9 14.51 15.77 
JTC-9 15.58 16.39 
JCCU-9 7.52 8.97 
CCU-9 6.38 7.78 
JCSAPR-9 2.57 2.43 
CSAPR-9 1.78 1.52 
JTCTPR-9 3.69 3.04 
TCTPR-9 2.59 1.70 
JTDIC-9 10.68 12.55 
HH-9 9.81 11.21 
MFF-9 1.27 1.10 
 
Table 4.10 Continuous shape measures (CSMs) of the 9-coordinate Ln
III
 coordination 
polyhedra in complexes 10.1 and 10.2.
282
 The values in red indicate the closest polyhedra 
for each complex according to the CSMs.  
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 The Dy
III
 center in complex 10.1 is closer to a muffin polyhedron with a CSM of 
1.27 than to a pseudo capped square antiprismatic topology, which has a larger CSM of 
1.78 (Table 4.10, Figure 4.8). The Er
III
 ion in complex 10.2 also most closely resembles a 
muffin-shaped polyhedron, with a CSM of 1.10, compared to CSMs of 1.52 and 1.70 for 
capped square antiprismatic and tri-capped trigonal prismatic geometries respectively 
(Table 4.10, Figure 4.8). 
 
Figure 4.8 Coordination spheres of (left) Dy
III
10.1, and (right) Er
III
10.2. Colour code: grey 
= Ln
III
, red = O, beige = idealized polyhedra. 
 
 As anticipated, based on the reported Ln
III
-12C4 and Ln
III
-15C5 structures, 
178,181-
185,187
 both 12C4 and 15C5 coordinate in an axial fashion to the lanthanide ions in the 
series Tb
III
-Er
III
, yielding half- and pseudo-sandwich topologies in which the Ln
III
 ions lie 
above the crown ether cavity. The presence of coordinating water molecules in each 
structure is due to the aqueous nature of the Ln(ClO4)3 salts used. In contrast, these ions 
would be expected to lie within the cavity of the larger 18C6 macrocycle, which should 
bind in an equatorial fashion.
175,177,188,189
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4.2.3 Ln
III
-18C6 complexes  
The 18C6 macrocycle readily forms mononuclear complexes with the perchlorate salts of 
all four lanthanide ions, yielding complexes 11.1-11.4 (Table 4.11). 
Complex  C H N v (cm-1) 
λmax (ε) 
(nm,  
L.mol-1.cm-1) 
MS (m/z) 
11.1 
TbIII-18C6 
Found 
Calcd. 
17.92 
18.16 
3.94 
4.06 
0.00 
0.00 
3406, 2956, 1049, 
1030, 950, 931, 619 
250 (29) 
MALDI-TOF: 
621 [M-4H2O-ClO4]
+ 
(100%) 
11.2 
DyIII-18C6 
Found 
Calcd. 
18.04 
18.08 
3.90 
4.05 
0.00 
0.00 
3422, 2951, 1050, 
1030, 952, 931, 619 
248 (46) 
MALDI-TOF: 
626 [M-4H2O-ClO4]
+ 
(100%) 
11.3 
HoIII-18C6 
Found 
Calcd. 
18.06 
18.44 
3.92 
3.87 
0.00 
0.00 
3397, 2955, 1049, 
1029, 951, 931, 619 
250 (57) 
MALDI-TOF: 
627 [M-4H2O-ClO4]
+ 
(100%) 
11.4 
ErIII-18C6 
Found 
Calcd.  
14.55 
17.97 
4.004.
02 
0.150.00 
3422, 2951, 1050, 
1030, 952, 931, 619 
247 (62) 
MALDI-TOF: 
630 [M-4H2O-ClO4]
+ 
(100%) 
 
 
Table 4.11 Selected characterization data for complexes 11.1-11.4.  
 
 X-ray quality single crystals were obtained and the molecular structures of all four 
complexes were determined by X-ray crystallography (Table 4.12). 
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11.1 
(Tb
III
-18C6) 
11.2 
(Dy
III
-18C6) 
11.3 
(Ho
III
-18C6) 
11.4 
(Er
III
-18C6) 
Space group 
Hexagonal 
P61 
Orthorhombic 
Pbcn 
Monoclinic 
Pc 
Monoclinic 
P21/c 
# Complexes  
in unit cell 
1 1 2 1 
a, b, c (Å) 
9.9031(5), 
9.9031(5), 
44.999(4) 
13.4884(9), 
22.4361(16), 
16.9130(12) 
9.7970(8), 
17.8698(15), 
14.8669(12) 
9.8027(6), 
17.8702(13), 
14.8422(11) 
α, β, γ (°) 
90, 
90, 
120 
90, 
90, 
90 
90, 
100.228(3), 
90 
90, 
100.180(3), 
90 
Volume (Å
3
) 3821.87 5118.33 2561.39 2559.07 
Min. 
Ln∙∙∙plane 
(Å) 
0.265 0.247 0.272 0.272 
Min. Ln∙∙∙Ln 
(Å) 
8.501 8.573 8.878 8.868 
Min. Ln-O-
Ln (°) 
102.9(2) 104.7(1) 98.3(2) 98.0(1) 
Ln∙∙∙Owater 
(Å) 
2.356(5)-2.365(4) 2.349(3)-2.377(3) 2.327(5)-2.357(8) 2.316(3)-2.336(3) 
Ln∙∙∙Ocrown 
(Å) 
2.431(7)-2.545(4) 2.435(4)-2.487(3) 2.397(7)-2.496(6) 2.397(4)-2.468(4) 
 
Table 4.12 Summary of parameters describing the crystal structures of 11.1 – 11.4. 
Additional structural data are presented in the Appendix section.  
 
 Somewhat surprisingly, each complex crystallizes in a different unit cell. 
Although the unit cells and volumes are different, the structural topologies of the four 
complexes are very similar. In each case, the Ln
III
 ion is 9-coordinate, bound to the six 
oxygen atoms of the equatorially-coordinating 18-crown-6 ligand, as well as three axially 
bound water molecules: one above, and two below the equatorial plane (Figure 4.9 and 
Figure 4.10).The crown ether is puckered in each complex, with minimum O-Ln-O 
angles in the range of 98.0(1) – 104.7(1)°. The LnIII lies in the mean plane formed by the 
6 crown ether oxygen atoms, with small deviations from the best plane in the range 0.247 
– 0.272 Å, Figure 4.9.  
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Figure 4.9 View of the molecular structures of 11.1 (Tb
III
-18C6), showing the very slight 
deviation of Tb
III
 from the mean plane formed by the crown ether oxygen atoms O(A), 
O(6), O(E), O(8), O(9), and O(G). Hydrogen atoms are omitted for clarity.  
              
Figure 4.10 View of the molecular structures of 11.2 (Dy
III
-18C6, left) and 11.4 (Er
III
-
18C6, right). Hydrogen atoms and perchlorate counter ions are omitted for clarity.  
 
 Complexes 11.1 (Tb
III
-18C6), 11.2 (Dy
III
-18C6), and 11.4 (Er
III
-18C6) contain 
one unique complex in each unit cell (Figure 4.9 and Figure 4.10), while the Ho
III
 
complex 11.3 has two independent complexes in the unit cell (Figure 4.11). Examining 
the crystal packing of each complex reveals that the molecules pack in a 3-D network, 
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with the directly coordinating water molecules hydrogen-bonded to perchlorate counter 
ions. The hydrogen bonds for all four complexes are in the range of 2.693-3.031 Å. 
 
Figure 4.11 View of the molecular structure 11.3, showing the two complexes of the unit 
cell, hydrogen-bonded via perchlorate counter ions, with O∙∙∙O distances ranging from 
2.750 Å (O14∙∙∙OJ) to 3.031 Å (O0B∙∙∙O0M).  
  
 The coordination geometry of each Ln
III
 center was investigated using CSMs, and 
the coordination sphere of each of the four complexes most closely resembled a muffin 
geometry (CSMs = 1.13 – 1.62, Table 4.13). The HoIII and ErIII complexes 11.3 and 11.4 
display a smaller deviation from the higher symmetry capped square antiprismatic 
geometry than the Tb
III
 and Dy
III
 complexes 11.1 and 11.2 (CSMs = 1.75 and 1.59 vs. 
2.26 and 2.12 respectively). 
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Polyhedron Tb
III
11.1 Dy
III
11.2 Ho
III
11.3 Er
III
11.4 
EP-9 32.49 33.32 34.44 34.30 
OPY-9 22.50 22.65 22.54 22.98 
HBPY-9 16.67 16.07 16.91 17.04 
JTC-9 13.89 14.55 14.91 15.10 
JCCU-9 7.63 8.86 7.18 7.84 
CCU-9 6.61 7.60 6.13 6.69 
JCSAPR-9 3.22 3.06 2.81 2.67 
CSAPR-9 2.26 2.12 1.75 1.59 
JTCTPR-9 3.36 4.08 3.21 3.20 
TCTPR-9 3.16 3.02 2.25 2.35 
JTDIC-9 11.7 12.66 12.78 12.38 
HH-9 6.26 6.41 7.48 7.66 
MFF-9 1.62 1.60 1.32 1.13 
 
Table 4.13 Continuous shape measures (CSMs) of the 9-coordinate Ln
III
 coordination 
polyhedra in complexes 11.1-11.4. The values in red indicate the closest polyhedra for 
each complex according to the CSMs.  
 
Figure 4.12 Coordination spheres of (left to right): Tb
III
11.1, Dy
III
11.2, Ho
III
11.3, and Er
III
11.4. 
Colour code: grey = Ln
III
, red = O, beige = idealized polyhedra. 
 Following the structural characterization of an array of Ln
III
-crown ether 
complexes, our next objective was to probe how turning the size of the macrocyclic 
cavity affects their electronic and magnetic properties. Given the observed structural 
topologies, we carried out physical studies in two parts: first, the magnetic and electronic 
properties of the half- and pseudo-sandwich structures 9.1 (Dy
III
-12C4) and 10.1 (Dy
III
-
15C5) were studied and compared; and secondly, the magnetic properties of the four 
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‘equatorial’ complexes 11.1 – 11.14 prepared from 18C6 and the later lanthanides TbIII-
Er
III
 were studied. These two families are pictorially summarized in Table 4.14. 
 
Table 4.14 The two families of Ln
III
-crown ether complexes selected for detailed 
analysis. 
4.3 Magnetic, electronic and luminescence studies on 9.1 and 
10.1 
4.3.1 Magnetic studies on 9.1 and 10.1 
 Both dc and ac magnetic measurements were performed on the ‘axial’ family of 
complexes: the half-sandwich 9.1 (Dy
III
-12C4) and the pseudo-sandwich 10.1 (Dy
III
-
15C5). 
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  Dc susceptibility measurements were carried out in an applied field of 0.1 T, over 
the temperature range 5 – 300 K. Above 100 K, χT values of 14.30 and 13.77 cm3.K .mol-
1
 were observed for 9.1 (Dy
III
-12C4) and 10.1 (Dy
III
-15C5) respectively (Figure 4.13). 
These values are in good agreement with the theoretical χT value of 14.17 cm3.K.mol-1 
for a non-interacting Dy
III
 ion (
6
H15/2, S = 
5
/2, L = 5, g = 
4
/3). The value of χT decreases 
rapidly below 40 K for complex 9.1 and 25 K for 10.1, due to thermal depopulation of the 
MJ sub-levels of the 
6
H15/2 ground multiplet.  
 
 
Figure 4.13 Plots of χT vs. temperature for 9.1 (top) and 10.1 (bottom) in a field of 0.1 T 
from 5 - 300 K. 
 
9.1 (Dy
III
-12C4) 
10.1 (Dy
III
-15C5) 
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 Plots of 1/χ vs. temperature were fit to the Curie-Weiss law, giving C = 14.33 ± 
0.01 cm
3
·K·mol
-1
 and C = 14.11 ± 0.01 cm
3
·K·mol
-1
 for 9.1 and 10.1 respectively.  
 
 
 
Figure 4.14 Plots of 1/χ vs. temperature for 9.1 (top) and 10.1 (bottom) in a field of 0.1 T 
from 5 - 300 K. Black lines are a best fit to the Curie-Weiss equation. 
 
9.1 (Dy
III
-12C4) 
10.1 (Dy
III
-12C4) 
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 In order to study the dynamic magnetic properties of the two half-sandwich 
complexes, ac susceptibility measurements were performed using an oscillating field of 
3.5 Oe in various applied static fields ranging from 0 to 5 kOe. Measurements were 
carried out from 2–15 K, over 10–17 frequencies ranging from 5–10,000 Hz. The pseudo-
sandwich complex 10.1 (Dy
III
-15C5) displayed a frequency-dependent χ″ signal in zero 
dc field, characteristic of an SMM. However, full maxima in the plot of χ″ vs. 
temperature were not observed (Figure 4.15). 
 
Figure 4.15 χ″ versus temperature for 10.1 (DyIII-15C5) in zero applied dc field, from 2-
15 K. 
 
 In order to resolve the maximum by removing the degeneracy of the MJ states 
between which quantum tunnelling might occur, a small static field of 300 Oe was 
applied. The frequency- and temperature-dependence of the out-of-phase component of 
the ac susceptibility is shown in Figure 4.16 and 4.17. The complex displayed classic 
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SMM behaviour below 15 K, with complete maxima emerging (Figure 4.16). Both the in-
phase (χʹ, Figure 4.16 top) and out-of-phase (χ″, Figure 4.16 bottom and Figure 4.17) 
components of the susceptibility show frequency dependence, consistent with slow 
relaxation of the magnetization. 
 
Figure 4.16 χ′ (top) and χ″ (bottom) versus temperature for 10.1 (DyIII-15C5) in 300 Oe 
applied dc field, below 10 K.  
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Figure 4.17 χ″ versus frequency for 10.1 (DyIII-15C5) in 300 Oe applied dc field, from 3-
15 K. 
 
 In order to probe the mechanisms of relaxation of the complex, the χʹ vs χ″ data in 
a 300 Oe static field were examined. Below 5 K, several of the χʹ vs χ″ semicircles are 
visibly kinked (Figure 4.18), indicative of two partially merged arcs, each corresponding 
to a distinct relaxation domain. That is, the sharp peak at low temperatures in χ″ (Figure 
4.16) comprises contributions from two relaxation pathways. As was discussed in 
Chapter 3, a single relaxation domain may be fit to the Cole-Cole model, which describes 
ac susceptibility as: 
χ(ω) =  χS +  
χT −  χS
1 + (iωτc)1−α
 
where ω = 2πf, χT is the equilibrium susceptibility, χS is the adiabatic susceptibility, τc is 
the temperature-dependent relaxation time, and α is a measure of the dispersivity of 
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relaxation times. In the case of complex 10.1, the susceptibility behaviour below 5 K is 
due to contributions from two distinct relaxation domains. The relaxation in this 
temperature region can thus be described by the sum of two combined, modified Debye 
functions:
273
  
 
χ(ω) =  χS1 +
χT1 −  χS1
1 + (iωτc1)1−α1
+ χS2 +
χT2 −  χS1
1 + (iωτc2)1−α2
 
  
 The χʹ vs χ″ data within 0.5 K of the sharp maximum at 4.0 K (10,000 Hz) was 
modelled using the above equation (Figure 4.18). 
 
Figure 4.18 χʹ versus χ″ for 10.1 in a 300 Oe dc field below 5 K. Open circles represent 
the observed data, while lines are the best-fit to a generalized two-component Debye 
model (see text).  
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The resulting calculated temperature-dependent relaxation times, τc, were subsequently fit 
to the Arrhenius equation, in order to extract the parameters describing each pathway. 
 
 
Figure 4.19 Plot of 1/T vs. τc for 10.1 (Dy
III
-15C5) below 5 K, under a static field of 300 
Oe and an oscillating field of 3.5 Oe. Points are calculated from experimental values, 
while lines are a best fit to the Arrhenius equation. 
 
 The two components of the magnetic relaxation comprise one domain with Ueff = 
48.9 ± 2.0 K (34.0 ± 1.4 cm
-1
) and τ0 = (8.52 ± 4.26) x 10
-11
 s (domain A), and a second 
domain with Ueff = 27.4 ± 1.4 K (19.0 ± 1.0 cm
-1
) and τ0 = (3.27 ± 1.09) x 10
-7
 s (domain 
B). The clear temperature dependence of both pathways shown in Figure 4.19 indicates 
that each domain has a thermal component; neither may be assigned to a pure quantum 
tunneling mechanism. The small α parameter for domain B (0.08) suggests that a single 
mechanism is at play within this domain, while an α value of 0.36 for domain A would 
indicate the presence of multiple overlapping relaxation mechanisms within this domain. 
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 Above 5 K, the magnetic behaviour may be modelled using a single-component 
Cole-Cole equation (Figure 4.20).  
 
Figure 4.20 χʹ versus χ″ for 10.1 (DyIII-15C5) in a 300 Oe dc field, above 5 K. Open 
circles represent the observed data, while lines are the best-fit to the Cole-Cole equation. 
 
 A fit of the 1/T vs. τc data to the Arrhenius equation (Figure 4.21) yielded an 
energy barrier of 21.2 ± 0.4 K (14.7 ± 0.3 cm
-1
) and a pre-exponential factor of (6.57 ± 
0.49)  10-7 s. An α value of 0.30 indicates that once again, several pathways are 
contributing to the observed magnetic behaviour characterized by these values. 
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Figure 4.21 Plot of 1/T vs. τc for 10.1 (Dy
III
-15C5) above 5 K, under a static field of 300 
Oe and an oscillating field of 3.5 Oe. Points are calculated from experimental values, 
while lines are a best fit to the Arrhenius equation. 
 
 The ac magnetic susceptibility response of complex 10.1 (Dy
III
-15C5) is 
summarized in Table 4.15.  
Temperature Domain Ueff (cm
-1
) τ0 (s) α 
3.5 – 4.5 K A 34.0 ± 1.4 (8.52 ± 4.26) x 10
-11
 0.36 
 B 19.0 ± 1.0 (3.27 ± 1.09) x 10
-7
 0.08 
5.5 – 7 K - 14.7 ± 0.3 (6.57 ± 0.49)  10-7 0.30 
 
Table 4.15 Summary of the parameters describing the slow relaxation of the 
magnetization of complex 10.1 (Dy
III
-15C5). 
  
 The values suggest that the dominant pathway above 5 K is the same pathway 
present in domain B below 5 K, while domain A is ‘switched off’ above 5 K. The 
observation of two distinct, well-resolved pathways for magnetic relaxation at a single 
temperature, seen below 5 K for 10.1 (Dy
III
-15C5), was first reported by Long in 2010,
283
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and remains a rarity among mononuclear SMMs,
125,272,284-286
 although similar divergent 
behaviour was observed for the family of Ln-POM SMMs which were magnetically 
characterized by Coronado and co-workers.
275,287,288
  
  
 To our surprise, the half-sandwich complex 9.1 (Dy
III
-12C4) displayed very 
different behaviour. The out-of-phase response of the ac susceptibility in the absence of 
an applied dc field appeared almost negligible (Figure 4.22) with no evidence of the 
maximum in χ′′ which would be expected for an SMM. In order to investigate how 
various static fields might affect the magnetic response, dc fields between 300 – 5000 Oe 
were applied. In an applied field of 800 Oe, a strong out-of-phase response is observed 
below 6 K, which resolves to give maxima in applied fields greater than 1500 Oe (Figure 
4.23). 
 
Figure 4.22 χ″ versus temperature for 9.1 (DyIII-12C4) in zero applied dc field, below 7 
K. 
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Figure 4.23 χ″ vs. temperature plots for 9.1 (DyIII-12C4) in various applied dc fields, 
below 7 K. 
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 Although the magnitude of the out-of-phase response increases significantly at 
higher frequencies, the temperature at which the maximum occurs is only very slightly 
frequency dependent, which is more characteristic of long range magnetic order than 
SMM-like behaviour. In order to rule out the presence of long-range ordering, zero-field 
heat capacity measurements were performed from 2-50 K, and showed no sign of any 
abrupt λ-type anomaly (Figure 4.24). In addition, M vs. H measurements were carried out 
at 3 K, and no hysteresis was observed, confirming the absence of ferromagnetic order.   
 
Figure 4.24 Plot of heat capacity vs. temperature for 9.1 (Dy
III
-12C4). The smooth 
increase in heat capacity upon warming is associated with the phonon (lattice) 
contribution to the specific heat. 
 
 As was described above, a strong out-of-phase susceptibility response with a 
frequency-dependent magnitude is observed as increasing dc fields are applied to 9.1 
(Dy
III
-12C4). However, the in-phase susceptibility displays no frequency dependence 
even in an applied field of 5 kOe, and a plot of χʹ vs. χ″ at various temperatures (Figure 
4.25) does not fit the Cole-Cole relaxation model traditionally applied to SMMs. 
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Figure 4.25 χʹ vs χ″ for 9.1 (DyIII-12C4)  in a 5 kOe dc field, from 2-15 K. Lines are a 
guide for the eyes only. 
 
 In light of these experimental observations we assign the unusual temperature 
independent behaviour of ′′ as being due to a quantum tunnelling mechanism that is very 
fast in comparison to what is usually observed for SMMs from Cole-Cole plots. Since the 
mechanism is a non-thermal process, the parameters describing the relaxation pathway 
are not temperature dependent; that is, a single value for the tunnelling rate τc 
characterizes the whole regime. In addition, when a single tunnelling mechanism is at 
play, the dispersivity variable α will equal 0. Given that the out-of-phase susceptibility 
may be described by the Cole-Cole function as: 
   𝛘″(𝛚) =  (𝛘𝐓 −  𝛘𝐒) 
(𝛚𝛕𝐜)
𝟏−𝛂𝐬𝐢𝐧 (𝛂𝛑 𝟐⁄ )
𝟏+(𝛚𝛕𝐜)
𝟐𝛂   ,               
since τc is fixed, and α = 0, the temperature dependence of χ″ depends solely on the 
temperature dependence of χT and χS. Whilst the adiabatic susceptibility χS does not 
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change significantly, the equilibrium susceptibility, χT, tends to follow Curie-like 
behaviour and we can approximate χ″  χT  1/T. In light of this, the zero-field ac data, 
in which only pure quantum tunnelling appears to occur, was re-examined. Although the 
out-of-phase signal is very small, a good linear fit to the experimental zero field χ″ vs. 
1/T data was observed (Figure 4.26), consistent with rapid relaxation via a single 
temperature-independent pathway. 
 
Figure 4.26 χ″ versus1/T for 9.1 (DyIII-12C4) at various frequencies in zero applied dc 
field, showing the linear, Curie-like relationship between χ″ and 1/T. Lines are a guide 
for the eyes only. 
 
 In addition, the slope of each χ″ and 1/T plot (dχ″/d(1/T)) was plotted as a 
function of frequency. The turning point of the plot at 3000 Hz corresponds to the point 
at which ωτc = 1. From this, the τc value for the pure quantum tunnelling mechanism of 
9.1 (Dy
III
-12C4) in zero field was determined: τc = ~0.3 ms.  This value is comparable to 
those reported by Coronado and co-workers for a series of polyoxometallate SMMs.
[24]
  
232 
 
 
 
Figure 4.27 Plot of dχ″/d(1/T) vs frequency for 9.1 (DyIII-12C4). Line is a guide for the 
eyes only. 
 In order to determine whether the relaxation in 9.1 (Dy
III
-12C4) is assisted by 
dipolar interactions between neighbouring Dy
III 
ions, complex 9.1 was doped into the 
analogous diamagnetic Y
III 
lattice in a ratio of Dy/Y = 12:88, as determined by ICP-MS 
measurements. The isostructural nature of the Dy
III
 complex 9.1, the analogous Y
III
 
complex 9.3, and the doped Dy
III
/Y
III
 sample 9.1b was confirmed by X-ray diffraction 
measurements (Table 4.16).  
 9.1
 
9.3 9.1b 
Crystal system monoclinic monoclinic monoclinic 
Space group P21/c P21/c P21/c 
a/Å 13.1195(7) 13.139(1) 13.10 
b/Å 10.2129(6) 10.2303(7) 10.19 
c/Å 17.5681(10) 17.5916(14) 17.55 
α/° 90 90 90 
β/° 93.941(2) 93.866(3) 93.72 
γ/° 90 90 90 
Volume/Å
3
 2348.4(2) 2359.2(3) 2342 
 
Table 4.16 Comparison of unit cell dimensions for 9.1, the yttrium
III
 analogue of 9.1 
(9.3), and the doped sample of 9.1 (9.1b). 
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 Ac susceptibility measurements were performed on the doped sample in a range 
of dc fields. Similar behaviour to that recorded for the undiluted sample of 9.1 (Dy
III
-
12C4) was observed, indicating that the magnetic response of 9.1 is associated with the 
behaviour of the single ion. A negligible out-of-phase response was observed in the 
absence of an applied static field, while a single strong response was induced by the 
application of a small static dc field (Figure 4.28). The lack of any observed frequency-
dependence in the magnetic response of the diluted sample suggests that the QTM is not 
assisted by dipolar interactions in the crystal lattice. In contrast, although identical ac 
susceptibility behaviour was recently reported for a mononuclear Dy
III
-tetramethyl-
aluminate complex, for that complex, dilution experiments suggest that dipolar 
interactions assisted the QTM.
116,289
 
 
Figure 4.28 χ″ vs temperature plot for a magnetically diluted sample of 9.1 (9.1b, Dy/Y = 
12:88) in a 1500 Oe applied dc field, below 7 K. 
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4.3.2 Ab initio studies on 9.1 and 10.1 
 As described above, ac magnetic measurements were used to experimentally 
determine the parameters surrounding the relaxation behaviour of 9.1 (Dy
III
-12C4) and 
10.1 (Dy
III
-15C5)  In particular, in zero dc field, no slow relaxation of magnetization was 
observed for 9.1, while two relaxation processes were observed for 10.1 below 5 K.  
 In order to further understand the relaxation behaviour of these complexes, and 
confirm the experimental results, ab initio calculations were carried out on 9.1 and 10.1 
using MOLCAS 7.8.
290
 The following methods were implemented, in order to determine 
the components of the g-tensors and the relative energies of the Kramers doublets in the 
6
H15/2 ground state of the Dy
III
 ions: SEWARD was used to compute the required one- 
and two-electron integrals; RASSCF was used to perform multi-configurational complete 
active space self-consistent field (CASSCF) calculation for the determination of the spin-
free eigenstates; RASSI was used to mix the RASSCF wavefunctions; and finally 
SINGLE_ANISO was used to determine the anisotropic magnetic properties for each 
mononuclear system.  
 The coordinates of the atoms in 9.1 and 10.1 as the input for SEWARD were 
determined crystallographically, and were used without further geometry optimization. 
The active space for both systems was chosen to be the 9 electrons in the 7 4f-orbitals of 
the Dy
III
 ion.  ‘Relativistic Atomic Natural Orbital’ (RCC-ANO) basis sets were selected 
to include the scalar relativistic terms where the dysprosium ions were treated at the 
VQZP level (9s8p6d4f3g2h), the coordinating oxygen atoms were treated at the VTZP 
level (4s3p2d1f) and all other atoms were treated at the VDZ level (3s2p for O and C, 
4s3p for Cl, and 2s for H) for all models. The Dy
III
 ions were assigned the pseudo-spin S 
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= ½ for the calculations of the g-tensors of the eight Kramers doublets, and the main 
magnetic axes.  
 In order to determine an accurate representation of the electronic structure of each 
complex within the crystal lattice, several models were investigated. For complex 9.1 
(Dy
III
-12C4), the first model (9.1A. Figure 4.30) was the immediate coordination sphere: 
the coordinated 12-crown-4 and five water molecules. The second model (9.1B, Figure 
4.30) involved the immediate coordination sphere as well as the three perchlorate anions 
and one water molecule in the asymmetric unit.  
 
 
 
 
 
Figure 4.29 The two models investigated for complex 9.1 (Dy
III
-12C4). 
 
 For complex 10.1 (Dy
III
-15C5), the first model (10.1A, Figure 4.30) was again the 
immediate coordination sphere: the coordinated 15-crown-5 and four water molecules. 
The second model (10.1B, Figure 4.30) involved the immediate coordination sphere 
along with a second crown ether, one hydrogen-bonded water molecule and three 
hydrogen-bonded perchlorate anions. The third model (10.1C, Figure 4.30) comprised the 
asymmetric unit of the crystal structure: the immediate coordination sphere, a second 15-
crown-5, and a lattice water molecule.  
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Figure 4.30 The three models investigated for complex 10.1 (Dy
III
-15C5). 
  
 For the calculations of models 9.1A, 9.1B, 10.1A and 10.1B, only the sextets were 
considered (that is, SDy = 
5
/2; 2SDy+1 = 6), with 21 roots and no mixing from the 
quadruplets and doublets. However, in the calculations of the full model 10.1C, mixing of 
the quadruplets (SDy = 
3
/2; 2SDy+1 = 4) was considered also, with the quadruplets given 
128 roots. No significant difference was observed in the energies of the 8 Kramers 
doublets calculated with and without the inclusion of quadruplets. 
 The Kramers doublets of the three lowest-lying energy states calculated for each 
of the models for 9.1 (Dy
III
-12C4) and 10.1 (Dy
III
-15C5) are presented in Table 4.9. 
Energies are given in wavenumbers. 
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J 9.1A 9.1B 10.1A 10.1B 10.1C 
 0.000 0.000 0.000 0.00 0.000 
15/2 34.386 33.083 20.560 58.224 45.528 
 67.185 66.942 59.050 68.724 77.849 
 98.283 89.758 104.802 112.954 110.527 
 137.295 131.235 146.372 177.132 180.244 
 153.553 159.251 172.515 234.354 239.466 
 211.099 198.393 236.856 268.554 276.889 
 269.128 245.699 319.435 369.180 376.751 
 3016.365 3011.050 3013.524 3525.412 3002.778 
13/2 3048.317 3049.813 3050.661 3578.595 3067.240 
 3058.381 3067.427 3080.949 3627.942 3113.915 
 3063.738 3091.087 3096.328 3647.843 3134.278 
 3118.191 3107.826 3135.303 3680.367 3171.549 
 3145.341 3129.249 3156.140 3699.792 3189.595 
 3169.155 3152.617 3205.383 3776.225 3263.081 
 5576.992 5575.112 5575.344 6071.999 5586.414 
11/2 5617.031 5617.497 5624.523 6116.250 5637.116 
 5647.751 5650.674 5656.378 6175.548 5699.984 
 5684.009 5671.289 5689.806 6189.807 5726.415 
 5717.813 5709.507 5740.490 6215.591 5756.563 
 5751.463 5733.642 5779.931 6292.237 5835.245 
 
Table 4.17 Energies (cm
-1
) of the microstates of the three lowest lying J electronic states 
for the three models of complexes 9.1 and 10.1. 
 
 The main components of the g-tensors for the 8 Kramers doublets of the 
6
H15/2 
level are shown below (Table 4.18). The values were calculated with strong spin-orbit 
coupling, for models 9.1A – 9.1B and 10.1A – 10.1C. 
 
Doublet 9.1A 9.1B 10.1A 10.1B 10.1C 
1 
0.617 
1.316 
18.190 
0.903 
1.156 
17.819 
0.809 
5.858 
13.131 
0.599 
0.190 
17.727 
0.258 
0.516 
17.492 
2 
0.539 
1.783 
16.314 
1.189 
1.871 
16.377 
1.522 
2.714 
13.384 
0.201 
0.729 
17.301 
0.835 
3.085 
15.442 
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Table 4.18 Main components of the g-tensors for the 8 Kramers doublets of the 
6
H15/2 
level. 
 
 The magnetic moments of both the ground (1) and first (2) excited states 
significantly depart from the Ising limit of gz = 20 with gx = gy = 0, thus displaying some 
transverse anisotropy, supporting the ac magnetic data which reveals fast quantum 
tunneling processes in both species. The angles (°) between the main magnetic axes (Zm) 
of successive states for the full models 9.1B and 10.1B are given in Table 4.19. The 
electronic ground state is denoted by 1, while 2, 3, 4 etc. refer to subsequent excited 
electronic states. 
 
 
 
3 
3.601 
5.139 
10.402 
8.115 
6.635 
3.002 
8.824 
5.784 
1.877 
10.261 
4.959 
2.439 
0.000 
2.252 
9.949 
4 
1.708 
2.829 
14.332 
0.486 
2.176 
14.629 
1.982 
4.355 
10.132 
1.522 
5.821 
8.527 
9.133 
6.306 
3.036 
5 
0.912 
4.937 
11.328 
1.515 
3.111 
10.822 
9.021 
6.266 
2.874 
0.730 
3.320 
12.314 
0.708 
3.468 
11.625 
6 
11.379 
5.819 
0.046 
10.089 
7.735 
0.391 
0.219 
1.340 
16.586 
0.329 
1.234 
17.749 
0.330 
1.122 
17.521 
7 
2.268 
2.499 
12.527 
7.600 
5.636 
3.587 
1.668 
2.223 
16.001 
1.125 
1.567 
16.293 
1.285 
1.985 
15.943 
8 
0.528 
1.726 
17.426 
0.817 
2.785 
16.888 
0.286 
0.790 
18.669 
0.214 
0.509 
18.774 
0.182 
0.424 
18.781 
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State 1 2 3 4 5 6 7 8 
9.1 --- 72.5 86.7 95.3 77.1 106.3 21.5 122.1 
10.1 --- 55.5 54.0 32.4 114.2 56.3 65.0 66.2 
 
Table 4.19 The angles between successive electronic states for 9.1 and 10.1.  
 
 The theoretically determined orientation of the magnetic moments for both the 
ground and first excited states of 9.1 (Dy
III
-12C4) and 10.1 (Dy
III
-15C5) are shown below 
(Figure 4.31). 
              
 
Figure 4.31 Calculated orientations of the principle magnetic axes of the Dy
III
 ions for 
the ground (A) and first excited (B) Kramers doublets for (left) 9.1 and (right) 10.1. The 
values of the components of the relevant g-tensors are given in Table 4.19.  
 
 From the data presented in Table 4.18 and Table 4.19, it is clear that a 
consideration of species beyond the immediate coordination environment must be 
considered for an accurate representation of the electronic structure of the Dy
III
 centers 
within the crystal lattice. In the case of the pseudo-sandwich complex 10.1 (Dy
III
-15C5), 
the model which best accounts for the experimental data is that which includes the 
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hydrogen-bonded water and perchlorate anions, as well as the second crown ether, since 
the Dy
III
 center is essentially encapsulated between the two crown ether ligands. For the 
half-sandwich complex 9.1 (Dy
III
-12C4), it becomes particularly important to include the 
perchlorate anions in the model, since they are tightly hydrogen-bonded to the 
coordinated water molecules.
125
  Thus models 9.1B and 10.1B most accurately describe 
the two complexes, and are thus considered to aid in the interpretation of the 
experimental magnetic data.   
 
 As Table 4.17 shows, the first excited state for the Dy
III
 ion in the pseudo-
sandwich complex 10.1 (Dy
III
-15C5), the ground state (1±) and the first (2±) and second 
(±3) excited states are well separated, consistent with the experimental observations of 
SMM behaviour. The theoretically calculated 1± → 2± energy gap of 58 cm-1 is larger 
than the magnetically-derived effective anisotropy barrier of 34.0 cm
-1
 for domain A of 
complex 10.1, but this discrepancy is consistent with the observations of Sessoli and co-
workers for the Dy
III
-DOTA complex, and is accounted for by the fact that a small 
applied dc field changes the energies of the MJ microstates; and in addition, the ab initio 
calculations do not take into account quantum tunneling.
291 
As previously discussed, 
complex 10.1 (Dy
III
-15C5) displays multiple relaxation pathways. The ab initio results 
described above support the propositions that the two closely spaced relaxation processes 
below 5 K are consistent with quantum tunneling and Orbach mechanisms likely 
involving both the ground and first excited state Kramers doublets (Figure 4.32).
292 
The 
much smaller 1± → 2± energy gap of calculated for the DyIII ion in the half-sandwich 
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complex 9.1 (Dy
III
-12C4) is consistent with the observation that this complex is not an 
SMM in zero dc field. 
 
 
Figure 4.32 The low lying electronic structure for 10.1, showing the lowest three 
Kramers doublets for the Dy
III 
ion and possible relaxation pathways (representative 
energies). The thick black lines represent the Kramers doublets as a function of their 
magnetic moment along the main axes of anisotropy. The green dashed line corresponds 
to quantum tunneling between the ground state doublets, while the solid red lines 
correspond to thermally assisted-QTM via the first and second excited state Kramers’ 
doublets. Dashed blue lines show possible Orbach processes. 
4.3.3 Luminescence properties of 9.1 and 10.1  
 The transitions of particular interest in lanthanide luminescence are the 4f - 4f 
transitions, because these transitions produce extremely sharp, narrow emission bands 
characteristic of a given metal. Although 4f - 4f transitions are ‘forbidden’ (highly 
improbable) by the Laporte parity selection rule, they can still occur in the presence of a 
ligand field which disrupts the orbital symmetry. As was discussed in depth in Section 
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1.4.3, the commercial applications of lanthanides exploit the sharp emission bands 
corresponding to transitions between electronic terms or levels (a change in L or J).
201
 
But lanthanide emission can also provide information regarding the energy differences 
between electronic MJ microstates: in theory, the fine splitting of the highest energy f – f 
transition in the emission spectrum of a lanthanide can be modelled to provide a direct 
picture of the splitting of the ground J multiplet.   
 However, examples of mononuclear SMMs for which the fine structure of the f - f 
transition is resolved well enough to extract this information are scarce in the literature. 
In the ground-breaking paper mentioned previously, Sessoli and co-workers reported a 
remarkably detailed magnetic and structural study of a Dy
III
 complex of tetraaza-
cyclododecanetetraacetate (DOTA).
293
 The complex displays SMM behavior, with an 
anisotropy barrier of 42 cm
-1
 calculated from the magnetic data. The luminescence 
emission spectrum of the complex showed well-resolved peaks at 20800, 17500, and 
15200 cm
-1
,  corresponding to 
4
F9/2→
6
HJ where J = 15/2, 13/2 and 11/2 respectively. The 
highest energy band shows well-resolved fine structure, corresponding to the Stark 
splitting of the ground state 
6
H15/2 multiplet. Importantly, the energy gap between the two 
highest energy peaks is 53 ± 8 cm
-1
, which is in reasonable agreement with the 
experimentally determined Ueff barrier of 42 cm
-1
. This unprecedented correlation 
between the anisotropy barrier and Stark splitting confirmed that population of the first 
excited doublet would be sufficient to reverse the magnetization.
293
 More recently, Long 
and coworkers synthesized a Dy
III
 complex incorporating a Zn
II
-Schiff base antenna to 
enhance the luminescence.
294
 The complex displayed SMM behavior, with Ueff = 27.38 
cm
-1
 calculated from the ac magnetic data. The fine structure in the high-energy 
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luminescence band was assigned to transitions between the Stark sublevels of the 
4
F9/2 
and 
6
H15/2 multiplets. The energy barrier to relaxation predicted from the sublevel 
separation was 44.1 ± 3.0 cm-1. Long postulated that the difference between the 
magnetically-calculated and spectrally-observed energy barriers indicates that quantum 
tunneling or dipolar interactions are occurring.
294
 Following this work, Long and co-
workers reported an additional chiral, ferroelectric Zn
II
/Dy
III
 complex displaying a rare 
combination of magnetism, Dy
III
 luminescence, and optical activity.
295
 
 With these examples in mind, the luminescence properties of complexes 9.1 
(Dy
III
-12C4) and 10.1 (Dy
III
15C5) were studied via collaboration with Dr. Rute Ferreira. 
Emission spectra of each complex excited at 280 and 340 nm were collected at room and 
low temperatures (300 and 14 K). The spectra are presented in Figure 4.33, and reveal the 
characteristic luminescence of Dy
III
 ions, assigned to the 
4
F9/2
6
H15/2-11/2 transitions. 
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Figure 4.33 Emission spectra measured at 14 and 300 K for (A) 10.1 and (B) 9.1 excited 
at 280 nm and 350 nm. 
 
 In order to experimentally investigate the crystal field splitting of the ground state 
of the Dy
III
 ions in 9.1 (Dy
III
-12C4) and 10.1 (Dy
III
15C5), a low temperature (14 K) 
emission spectra was acquired on single crystals of each complex in the spectral region of 
the 
6
F9/2→
6
H15/2 transition (Figure 4.34, Figure 4.35). The 
6
H15/2 level may undergo Stark 
splitting due to the crystal field to give a maximum of 8 microstates; this makes an 
unambiguous fit of the components of the transition difficult. For this reason, just the 
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high-energy region of the transition (20900-21100 cm
-1
) was analysed, in order to 
estimate the energy difference between the ground level and the first excited state. Using 
a multi-Gaussian function fit, this spectral region was fit to two Stark components 
(labelled A1 and A2 in Figures 4.35 and 4.36) which are ascribed to transitions from the 
first excited 
4
F9/2 Stark sublevel to the two lowest Stark levels of the 
6
H15/2 multiplet. A 
‘hot’ band (labelled A*) involving a microstate of the 7F9/2 level is also detected in each 
spectrum.  
 
Figure 4.34 (A) High-resolution emission spectra (14 K) for 9.1 excited at 351 nm. (B)  
Magnification of the 
4
F9/2
6
H15/2 transition and multi-Gaussian functions envelope fit 
(solid circles) and the components arising from the first 
4
F9/2 Stark sublevel to the 
6
H15/2 
multiplet in the energy interval 20950-21100 cm
-1
. (C) Regular residual plot (R
20.98) 
for a better judgment of the fit quality. 
 
20200 20450 20700 20950 21200
20900 21000 21100
20950 21000 21050 21100
-0.1
0.0
0.1 C
B
4
F
9/2
 
6
H
15/2
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
Energy (cm
-1
)
E
2
A
A
1
A
2
 
A
*
 
Energy / cm
-1
 Independent variable
 
495 490 485 480 475
Wavelength (nm)
0
20
40
60
80
20950
21000
21050
21100
E
n
e
rg
y
 /
 c
m
-1
4
F 9
/2
A1
A*
E2
A2
6
H
1
5
/2
246 
 
 
 
Figure 4.35 (A) High-resolution emission spectra (14 K) for 10.1 excited at 350 nm; (B)  
Magnification of the 
4
F9/2
6
H15/2 transition and multi-Gaussian functions envelope fit 
(solid circles) and the components arising from the first 
4
F9/2 Stark sublevel to the 
6
H15/2 
multiplet in the energy interval 20900-21100 cm
-1
. (C) Regular residual plot (R
20.98) 
for a better judgment of the fit quality. 
 
 From this data, the energy gap E10.1 between the ground and first excited state of 
the Dy
III
 ion in 10.1 (Dy
III
-15C5) was calculated to be E10.1 = 58 ± 3 cm
1
. This value is 
in excellent agreement with the energy gap determined from the ab initio calculations, 
but 24 cm-1 higher than the value determined from magnetic measurements. As 
previously mentioned, there are two contributions to this disagreement: 1) the 
magnetically-determined parameters were calculated from data collected in the presence 
of a small dc field, which alters the energies of the MJ microstates; and 2) the ab initio 
and luminescence methods do not take quantum tunnelling into account. As was 
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mentioned earlier, similar discrepancies have been noted before for both [DyDOTA]
3+
 
and [Zn(L)Dy]
3+
 SMMs.
24,44 
 
For 9.1, the luminescence-derived energy gap between the first and second 
excited state of the Dy
III
 ion was much lower, determined to E9.1 = 30 ± 3 cm
-1
, which 
again is in excellent agreement with the
 1± → 2± energy gap of 33 cm-1 predicted from 
the ab initio calculations. This smaller energy barrier (E9.1<E10.1) is qualitatively 
consistent with the lack of SMM behaviour for this compound.  
 As this work shows, luminescence can be used to probe the electronic structure of 
lanthanide centers in SMMs, providing information on the Stark splitting of the electronic 
ground state, as well as the relationship between this splitting energy and the magnetic 
relaxation behaviour. It should be emphasized that for 9.1 (Dy
III
-12C4), the lack of ac 
response prevents the experimental determination of the zero-field energy barrier from 
magnetic susceptibility data, highlighting the importance of photoluminescence data to 
experimentally probe the energies of the ground and low lying excited states in Ln-based 
SMMs.
 
The importance of magneto-electronic correlation was highlighted in a recent 
Nature review, in which Murugesu emphasized that studies such as these are vitally 
important in helping to understand and control the ‘elusive’ magnetism of SMMs, 
towards application in the technologies of tomorrow.
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4.4 Magnetic studies on the 18C6 complexes 11.1-11.4 
Dc magnetic measurements were performed on each of 11.1-11.4 between 5 and 300 K, 
in small fields of 1-2 kOe. In each case, the χT vs. T plots showed a low-temperature 
decrease in susceptibility, consistent with a slight depopulation of the Stark sublevels. 
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The decrease was slight for complex 11.1 (Tb
III
-18C6) occurring below 40 K, and more 
marked in the other three complexes, occurring in a gradual fashion below 100 K (Figure 
4.36 left).  
 
Figure 4.36 χT vs. T (left) and 1/χ vs. T (right) for: (top to bottom) 11.1-11.4 in a field of 
0.1 T from 5 - 300 K. 
 The parameters extracted from the dc data are summarized below in Table 4.20. 
11.1 (Tb
III
-18C6) 
11.2 (Dy
III
-18C6 
11.3 (Ho
III
-18C6) 
11.4 (Er
III
-18C6) 
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Complex Abbrev.
 
Expected χT 
(300 K, 
cm
3.
K
.
mol
-1
) 
C 
(cm
3.
K
.
mol
-1
) 
θ (K) 
11.1 Tb
III
-18C6 11.82 11.07 ± 0.01 -0.14 ± 0.05 
11.2 Dy
III
-18C6 14.17 14.89 ± 0.07 -13.9 ± 0.8 
11.3 Ho
III
-18C6 14.07 13.93 ± 0.01 -12.8 ± 0.1 
11.4 Er
III
-18C6 11.48 11.31 ± 0.03 -14.2 ± 0.4 
 
Table 4.20 Summary of the parameters describing the dc magnetic susceptibility 
behaviour of 11.1-11.4.  
 
The theoretical and experimental χT and C values, as well as the Weiss constants, 
are summarized in Table 4.20. The Curie constants, calculated from the inverse of the 
slope of each 1/χ vs. T plot (Figure 4.36 right), were in reasonable agreement with the 
theoretical values for each isolated Ln
III
 centre. The Weiss constants, calculated from the 
x-intercept of the same plot, were all small negative values (Table 4.20), indicating the 
presence of weak antiferromagnetic interactions at low temperatures. In the case of the 
Tb
III
 complex, the Weiss constant was negligible, indicating almost ideal Curie behaviour 
even at low temperatures.  
 Preliminary ac susceptibility measurements were carried out on polycrystalline 
samples of 11.1-11.4. An oscillating field of 3.5 Oe was applied, at various frequencies 
from 50 to 10,000 Hz, over the temperature range 2.8 – 15 K. 
 All four complexes displayed a negligible out-of-phase susceptibility response in 
zero dc field. It is perhaps unsurprising that 11.1-11.3 are not zero field SMMs, given that 
the intrinsic anisotropy of oblate metal ions is not enhanced by an equatorially-bound 
ligand field. Following the unremarkable zero field measurements, ac susceptibility data 
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was collected in the presence of static fields ranging from zero to 5 kOe. Upon initial 
inspection, there appeared to be a frequency-dependent out-of-phase susceptibility 
response in the ac data of all four complexes, in the presence of a 5 kOe field (Figure 
4.37).  
251 
 
 
 
Figure 4.37 χ″ versus temperature for (top to bottom) 11.1, 11.3, and 11.4 in a 5 kOe 
applied dc field, from 2-15 K.  
 
11.4 (Er
III
-18C6) 
11.3 (Ho
III
-18C6) 
11.1 (Tb
III
-18C6) 
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However, as can be seen by a glance at the y-axes of the plots in Figure 4.37, the scale on 
which each response occurs is so miniscule, that in effect the observed responses of 11.1 
(Tb
III
-18C6), 11.3 (Ho
III
-18C6), and 11.4 (Er
III
-18C6) in a 5 kOe field can be called 
negligible.  
 
 Of the four later lanthanide 18C6 complexes, the Dy
III
 complex 11.2 alone 
displayed a strong field-induced susceptibility response. In applied dc fields of increasing 
strength, a single fully resolved maximum appeared by 5 kOe (Figure 4.38).  
 
Figure 4.38 χ″ versus temperature for 11.2 in a 5 kOe applied dc field, from 2-15 K. 
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The frequency-independence of the position of the maximum is reminiscent of the Dy
III
-
12C4 structure 9.1, and again was assigned to a rapid relaxation pathway such as QTM. 
Assuming the same Curie-like relationship discussed earlier, that χ″  1/T, the slopes of 
the lines in a plot of χ″ vs. 1/T were plotted as a function of frequency (Figure 4.39). 
 
 
Figure 4.39 Plot of dχ″/d(1/T) versus frequency for 11.2 (DyIII-18C6), based on the zero 
field ac susceptibility data. Line is a guide for the eyes only. 
 
 The turning-point occurs at ~2300 Hz, which corresponds to the point at which 
ωτc = 1. This allows the determination of τc ~0.43 ms from the frequency dependent zero 
field data. 
 
 The observation of a temperature-independent quantum tunnelling process for 
11.2 (Dy
III
-18C6) in the presence of an applied field is of interest in the context of the 
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previously discussed complexes 9.1 (Dy
III
-12C4) and 10.1 (Dy
III
-15C5). All three of 
these complexes have Dy
III
 ions in O9 coordination environments.  
      
 
     9.1    10.1          11.2 
Figure 4.40 The immediate coordination spheres (top) and idealized polyhedra (bottom) 
for 9.1 (Dy
III
-12C4), 10.1 (Dy
III
-15C5) and 11.2 (Dy
III
-18C6). 
 
 Complexes 9.1 (Dy
III
-12C4) and 10.1 (Dy
III
-15C5) are most similar to one another 
in terms of their immediate coordination environment, with axially-bound crowns 
contributing 4 and 5 of the coordinated oxygens respectively. Geometrically, 10.1 (Dy
III
-
15C5) and 11.2 (Dy
III
-18C6) are most similar, with slightly distorted muffin-shaped 
topologies, in contrast to 9.1 (Dy
III
-12C4) which exhibits only a small deviation from a 
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capped square antiprismatic geometry. Yet magnetically, complex 9.1 (Dy
III
-12C4) 
closely resembles 11.2 (Dy
III
-18C6), with no magnetic relaxation observed in zero field, 
and the induction of QTM in the presence of a dc field. These observations point to the 
significant role that crystal packing plays in the magnetic behaviour of mononuclear 
lanthanide complexes. In the Dy
III
-DOTA SMM described by Sessoli and co-workers 
with similar capped square-antiprismatic geometry, the outer coordination sphere had an 
unexpectedly large effect on the axis of anisotropy.
125
 Additionally, the drastic effects of 
modifications to the peripheral ligand sphere in a family of Er
III
 SIMs was recently 
reported by Waldmann.
297
 It is increasingly clear that a systematic study of the effects of 
structural modification on magnetic and other properties is a necessary step towards the 
rational design of functional SMMs. In addition, it is apparent that while the electrostatic 
Long model is helpful in explaining the observed magnetic properties of many reported 
Dy
III
 and Tb
III
 ‘sandwich’ structures, the presence or absence of axial ligand electron 
density will not necessarily determine the presence or absence of slow magnetic 
relaxation. 
4.5 Conclusion  
 To conclude, reaction of the later lanthanides (Tb
III
, Dy
III
, Ho
III 
 and Er
III
) with the 
aliphatic crown ethers 12C4, 15C5 and 18C6 resulted in the formation of a number of 
new structures. Two families of compounds (the half- and pseudo-sandwich structures 
9.1 and 10.1, and the equatorial complexes 11.1-11.4) were analyzed as potential single 
molecule magnets. The correlation between the magnetic, electronic and spectroscopic 
properties  in 9.1 (Dy
III
-12C4) and 10.1 (Dy
III
-15C5) was discussed, which is a rare 
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approach in the ongoing conversation concerning Ln-SMMs. Complex 10.1 (Dy
III
-15C5) 
represents the first mononuclear Ln-SMM based on a crown ether, and displays dual 
properties: slow magnetic relaxation and photoluminescence. 
4.6 Future directions 
 Future work in this vein will include the use of rigorously dry conditions. Given 
the propensity for the oxophilic lanthanides to coordinate to water, a logical next step 
would be the exclusion of water from the reaction conditions. Although the lanthanide 
perchlorate salts are commercially available only as aqueous solutions, the in situ 
synthesis of anhydrous Ln(ClO4)3 from LnCl3 and NaClO4 in a dry, poorly coordinating 
solvent under glove-box conditions is possible. The reaction of the resulting anhydrous 
perchlorate salts with the various crowns would ideally result in full-sandwich topologies, 
which would provide an intriguing comparison to the half- and pseudo-sandwich 
structures analyzed thus far. 
 In addition, other classes of oxophilic macrocycle will be explored. The 
usefulness of the MOLCAS program has been demonstrated and will enable us to 
calculate the energy levels of coordination complexes prior to investing time and effort in 
the synthesis.  
 Finally, as mentioned above, the magneto-electronic-luminescence correlation 
work described herein is still rare for mononuclear lanthanide complexes. This approach 
to an examination of the relationship between molecular structure, electronic properties, 
and magnetic susceptibility behaviour will continue to be employed for the systems 
which emerge during the continuation of this project. 
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5 EXPERIMENTAL 
 
5.1 General Information 
All reagents were purchased from Sigma-Aldrich or Alfa Aesar and used without further 
purification.  Anhydrous solvents were obtained from a Puresolve PS MD-4 solvent 
purification system. Silica gel (75-250 mesh, 60 Å) and activated neutral alumina powder 
used for column chromatography were purchased from Desican Inc.  
5.2 Instrumentation 
Elemental analysis: Measurements were performed by Atlantic Microlab Inc. 
Mass spectrometry: Data was recorded on a Carlo Erba / Kratos EC/ms acquisition 
system and processed at a SPARC workstation. Samples were introduced through a direct 
inlet system, with tris(perflouroheptyl-S-triazine) as the internal standard.  
NMR spectroscopy: 
1
H- and 
13
C-NMR spectra were recorded at 300 MHz on a Bruker 
Advance AV 300 Digital NMR spectrometer in deuterated solvents. Data was analyzed 
using the Bruker TOPSPIN 2.1 PL6 software. 
Infrared spectroscopy: Infrared spectra were recorded on a Bruker Alpha FT-IR 
spectrometer.  
Far-IR spectroscopy: Far-IR spectra were collected on a Nicolet 6700 system equipped 
with the solid substrate beam splitter and a polyethylene detector, resolution 4 cm
-1
. The 
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system was purged with dry nitrogen gas before use and the data was smoothed during 
processing.   
Raman spectroscopy: Raman spectra were measured on a Renshaw in Via Laser Raman 
spectrometer with an attached Leica microscope and a red solid-state laser (785 nm). 
UV-visible spectroscopy: UV-visible data were obtained using a Beckman Coulter DU 
720 General-Purpose UV-visible spectrophotometer.  
Luminescence measurements: Luminescence data were recorded at 300 K and at 14 K 
with a modular double grating excitation spectrofluorimeter with a TRIAX 320 emission 
monochromator (Fluorolog-3, Horiba Scientific) coupled to a R928 Hamamatsu 
photomultiplier, using a front face acquisition mode. The excitation source was a 450 W 
Xe arc lamp. The emission spectra were corrected for detection and optical spectral 
response of the spectrofluorimeter and the excitation spectra were corrected for the 
spectral distribution of the lamp intensity using a photodiode reference detector.  The 
room temperature time-resolved emission spectra and emission decay curves (10
6
-10
9
 s) 
were recorded on a Fluorolog TCSPC spectrofluorimeter (Horiba Scientific) coupled to a 
TBX-04 photomultiplier tube module (950 V), 200 ns time-to-amplitude converter and 70 
ns delay. The excitation source was a Horiba-Jobin-Yvon pulsed diode (NanoLED-390, 
peak at 390 nm, 1.2 ns pulse duration, 1 MHz repetition rate and 150 ns synchronization 
delay). The emission decay curves (10
6
-10
2
 s) were recorded at room temperature with 
a Fluorolog TCSPC spectrofluorometer (Horiba Scientific) coupled to a TBX-04 
photomultiplier tube module (950 V), 50 μs delay. The exciting source was a Horiba 
Scientific pulsed diode light source (SpectraLED-355, peak at 356 nm). 
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ICP-MS: Inductively Coupled Plasma Mass Spectrometry (ICP-MS) measurements were 
carried out on a PerkinElmer-Sciex ELAN DRC II mass spectrometer. Measurements 
were carried out in triplicate.  Dy and Y standards were made from elemental 
stock solutions (1000 ppm), manufactured by High-Purity Standards (Charleston, SC, 
USA). Calibration range: 0-20 ppb. Samples of ca. 8 mg of were digested with 500 μL 
conc. HNO3 and 200 μL conc. HCl, then diluted with distilled water to a total volume of 
10.0 mL.  
Conductivity: Conductivity measurements were carried out using an Oakton CON 6+ 
Handheld Conductivity Meter with cell constant K = 1. The probe was calibrated using 
standard solutions of KCl at 20°C. Aqueous and methanolic 0.5 mM solutions of the 
complex were prepared, and measurements were obtained in triplicate with precision < 
1%.  
X-ray diffraction: Single crystals suitable for X-ray diffraction were mounted on a 
cryoloop with paratone oil and examined on a Bruker APEX-II CCD diffractometer 
equipped with a CCD area detector and an Oxford Cryoflex low temperature device. Data 
were measured at 150(2) K with Mo-Kα radiation (λ = 0.71073 Å) using the APEX-II 
software.
298
 Cell refinement and data-reduction were carried out by SAINT. An 
absorption correction was performed by the multi-scan method implemented in 
SADABS.
299
 The structures were solved by direct methods (SHELXS-97)
300
 and refined 
using SHELXL-2013 in the Bruker SHELXTL suite
 
and Olex2.
301
  
Powder diffraction: Powder X-ray diffraction experiments were performed on a Bruker 
D8 Discover powder diffractometer equipped with a Hi-Star detector and GADDS 
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software package. Data were collected at room temperature in the range 2.5 < 2Θ < 33.5°, 
and were recorded in 0.05
°
 steps using Cu-K radiation ( = 1.54187 Å) with the tube 
operating at 40 kV and 40 mA with an initial beam diameter of 0.5 mm. 
Magnetic susceptibility measurements:  Dc measurements were performed using a 
Quantum Design SQUID magnetometer MPMS. Temperature scans were performed at 
applied fields between 0.1 - 0.2 T, from 2 – 300 K. Field scans were performed over the 
range -5 to 5 T, at temperatures between 3 - 5 K. Ac measurements were carried out 
using a Quantum Design PPMS, with an oscillating field of 3.5 Oe over multiples 
frequencies between 25 and 1500 MHz. Static fields ranging from 0 to 0.5 T were 
applied, from 2 – 15 K. 
Computational details: Ab initio calculations were performed using the MOLCAS 7.8 
quantum chemistry software package.
290,302,303
 For all calculations, the multi-
configurational CASSCF/RASSI-SO approach was used. The spin-free eigenstates were 
calculated by the CASSCF method using the Douglas-Kroll-Hess Hamiltonian, followed 
by mixing via the RASSI-SO method to include spin-orbit coupling. The active space for 
9.1 and 9.2 was chosen to be the 9 electrons in the 7 4f-orbitals of the Dy
III
 ion.  The 
coordinates of the atoms were determined crystallographically, and were used without 
further geometry optimization. Relativistic basis sets of the type RCC-ANO were 
selected to include the scalar relativistic terms where the dysprosium ions were treated at 
the VQZP level (9s8p6d4f3g2h), the coordinating oxygen atoms were treated at the 
VTZP level (4s3p2d1f) and all other atoms were treated at the VDZ level (3s2p for O and 
C, 4s3p for Cl, and 2s for H) for all models. The Dy
III
 ions were assigned the pseudo-spin 
261 
 
 
S = ½ for the calculations of the g-tensors of the eight Kramers doublets, and the main 
magnetic axes.  
5.3 Organic building blocks 
5.3.1 Organic building blocks for L3 (dbN3O2) 
5.3.1.1 Synthesis of 1,4-bis-(2-nitrophenyl)-1,4-dioxabutane (3a)
214
 
 
A solution of 2-nitrophenol (2 eq., 20.0 g, 144 mmol) in dry DMF (20 mL) was heated to 
80°C. K2CO3 (1 eq., 9.93 g, 71.9 mmol) was added portionwise and the resulting bright 
red mixture was heated to 160°C and stirred for 5 min. 1,2-Dibromoethane (1 eq., 6.22 
mL, 71.9 mmol) was added dropwise with stirring over 30 min, after which the mixture 
was refluxed at 170°C for 2.5 h. The resulting orange mixture was poured into cold H2O 
and a granular yellow precipitate formed. The solid was collected by filtration and 
washed well with dilute NaOH(aq). The product was recrystallized from acetone to give 
3a as a crystalline beige solid (9.72 g, 45%). 
 
M.p.:      170°C (Lit. 169-170°C
214
). 
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EI-MS:      m/z = 304 [M]
+
 (14%). 
1
H NMR (CDCl3, 300 MHz) δ (ppm):  7.83 (dd, J = 8.2, 1.6 Hz, 2H, H2), 7.57 (td, J 
= 7.8, 1.7 Hz, 2H, H4), 7.23 (dd, J = 7.8, 0.9 
Hz, H3), 7.08 (td, J = 7.7, 1.0 Hz, H5), 4.54 
(s, 4H, H7) 
13
C NMR (CDCl3, 300 MHz) δ (ppm):  152.0 (C6), 134.4 (C1), 125.7 (C2), 121.5 
(C3), 116.0 (C5), 68.8 (C7) 
 
5.3.1.2 Synthesis of 1,4-bis-(2-aminophenyl)-1,4-dioxabutane (3b)
214
   
 
A solution of SnCl2 (10 eq., 24.9 g, 132 mmol) in conc. HCl (20 mL) was heated to 70°C. 
Compound 3a (1 eq., 4.00 g, 13.2 mmol) was added and the resulting mixture was 
refluxed at 110°C for 30 min. After cooling to room temperature, the reaction mixture 
was neutralized to pH = 7 by the addition of NaOH(aq). The product was extracted into 
CHCl3 (5 x 50 mL), washed with brine (3 x 50 mL), dried over Na2SO4 and concentrated 
under vacuum to give 3b as a cream solid (1.52 g, 47%). 
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M.p.:      126°C (Lit. 129-132°C
214
). 
FAB-MS:      m/z = 245 [M+H]
+
 (100%). 
1
H NMR (CDCl3, 300 MHz) δ (ppm):  6.87-6.73 (m, 8H, H2-4), 4.37 (s, 4H, H7). 
13
C NMR (CDCl3, 300 MHz) δ (ppm):  146.3 (C6), 136.9  (C1), 122.0 (C3), 118.5 
(C4), 115.5 (C2), 112.6 (C5), 67.6 (C7).  
CHN:  Found C: 65.73, H: 6.11, N: 10.82%; Calcd. 
for (C14H16N2O2)·0.1CHCl3 C: 66.09; H: 
6.33; N: 10.93%.  
 
5.3.2 Organic building blocks for L4 (dpN3O2) 
5.3.2.1 Synthesis of R,R-5,6-diphenyl-4,7-dioxa-1,9-decadiene (4a)
219
  
 
Sodium hydride (3.2 eq., 1.79 g, 74.7 mmol) was added in two portions to a solution of 
R,R-hydrobenzoin (1 eq., 5.00 g, 23.3 mmol) in dry THF (90 mL). The resulting 
purple/grey mixture was stirred at 30°C for 1 h, after which a solution of allyl bromide 
(3.5 eq., 6.90 mL, 81.6 mmol) in dry THF (20 mL) was added dropwise. The reaction 
mixture was stirred at 40°C for 2 h, and then refluxed at 95°C for 18 h. The mixture was 
cooled to room temperature, and passed through a Buchner funnel to remove the white 
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precipitate. The yellow filtrate was concentrated under vacuum, and then dissolved in 
DCM and washed well with H2O (2 x 50 mL) and brine (2 x 50 mL). The organic layer 
was dried over MgSO4 and concentrated under vacuum to give 4a as a yellow oil (5.63 g, 
82%). 
 
FAB-MS:       m/z = 295  [M+H]
+
 (16%). 
1
H NMR (CDCl3, 300 MHz) δ (ppm): 7.18-7.02 (m, 10H, H6-8), 5.92-5.80 (m, 2H, 
H2), 5.17 (dd, J = 17.1, 1.7 Hz, 4H, H1), 
4.53 (s, 2H, H4), 3.94 (dd, 4H, J = 12.6, 5.1 
Hz, H3). 
13
C NMR (CDCl3, 300 MHz) δ (ppm): 138.8 (C5), 135.1 (C2), 128.0 (C7), 127.8 
(C8), 127.6 (C6), 116.6 (C1), 85.0 (C4), 70.2 
(C3).  
5.3.2.2 Synthesis of R,R-4,5-diphenyl-3,6-dioxa-1,8-octanediol (4b)
219
 
 
 
Osmium(IV) tetroxide (0.03 eq., 133 mg, 0.524 mmol) was added to a solution of 4a (1 
eq., 5.14 g, 17.5 mmol) in THF/H2O (3:1, 200 mL). The dark purple mixture was stirred 
at room temperature for 2 h, and then sodium metaperiodate (5.8 eq., 21.70 g, 101.5 
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mmol) was added portionwise over 1 h. The mixture was stirred in the dark at room 
temperature for 18 h. The resulting creamy white mixture was concentrated under 
vacuum to give a cream residue, which was taken up into DCM/MeOH (1:1, 200 mL). 
The white precipitate was removed by Büchner filtration, and the yellow filtrate was 
cooled to 0°C in an ice bath. Sodium borohydride (6.8 eq., 4.50 g, 119 mmol) was added 
in two portions, and the reaction mixture was warmed to room temperature and stirred for 
18 h. The solvent was removed under vacuum to give a dark brown residue, which was 
stirred vigorously in distilled H2O (500 mL) for 1 h. The product was extracted with 
DCM (3 x 50 mL), and then washed with 1N HCl (3 x 50 mL), H2O (3 x 50 mL) and 
brine (3 x 50 mL). The organic layer was dried over MgSO4 and concentrated under 
vacuum to give 4b as a brown oil (7.42 g, 79%). 
 
1
H NMR (CDCl3, 300 MHz) δ (ppm): 7.17-7.02 (m, 10H, H5-7), 4.47 (s, 2H, H3), 
3.75-3.44 (m, 8H, H1-2).   
13
C NMR (CDCl3, 300 MHz) δ (ppm): 138.3 (C4), 128.2 (C7), 128.0 (C6), 127.7 
(C5), 86.9 (C3), 71.2 (C2), 61.9 (C1).  
5.3.2.3Synthesis of R,R-4,5-diphenyl-3,6-dioxa-1,8-octanediphthalimide (4c)
219
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A solution of 4b (1 eq., 3.72 g, 10.5 mmol) in dry THF (60 mL) was added to 
triphenylphosphine (2.2 eq., 3.41 g, 23.2 mmol) and phthalimide (2.2 eq., 6.07 g, 23.2 
mmol) under N2. The pale yellow mixture was briefly stirred, and then a solution of 
DIAD (2.2 eq., 5.05 g, 23.1 mmol) in dry THF (20 mL) was added dropwise. The 
resulting orange solution was stirred at room temperature for 4 d. The mixture was 
concentrated under vacuum, and the crude product was purified by silica gel column 
chromatography in hexane/EtOAc (2:1), followed by passage through a second silica gel 
column in pet. ether/EtOAc (3:1) to give 4c as a cream powder (1.70 g, 29%). 
 
M.p.       175°C. 
1
H NMR (CDCl3, 300 MHz) δ (ppm):  7.75 (ddd, J = 36.0, 5.2, 3.2 Hz, 8H, H1-2), 
7.00-6.78 (m, 10H, H9-11), 4.39 (s, 2H, H7), 
3.79 (q, J = 6.6 Hz, 4H, H5), 3.58 (t, J = 5.8 
Hz, 1H, H6). 
13
C NMR (CDCl3, 300 MHz) δ (ppm):  168.5 (C4), 137.9 (C8), 134.1 (C1), 133.2 
(C3), 127.8 (C2), 123.2 (C9-11), 85.7 (C7), 66.2 
(C6), 37.7 (C5). 
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5.3.2.4 Synthesis of R,R-4,5-diphenyl-3,6-dioxa-1,8-octanediamine (4d)
219
 
 
 
Hydrazine monohydrate (10 eq., 571 μL, 11.7 mmol) was added to a suspension of 4c (1 
eq., 563 mg, 1.17 mmol) in warm EtOH (75 mL). The mixture was refluxed at 80°C for 
18 h, and a fluffy white precipitate gradually formed. The mixture was cooled to r.t. and 
then further cooled to 0°C in the freezer. The precipitate was removed by Buchner 
filtration, and washed well with cold EtOH (3 x 25 mL) and DCM (3 x 25 mL). The 
combined organic solutions were concentrated under vacuum, to give a dark yellow 
residue which was dissolved in DCM (150 mL). The product was was extracted into 2N 
HCl (3 x 50 mL), and the aqueous phase was then basified to pH = 10 by the addition of 
NaOH(aq). After briefly stirring, the product was extracted into DCM (3 x 50 mL), washed 
with H2O (3 x 50 mL) and brine (3 x 50 mL), dried over Na2SO4 and concentrated under 
vacuum. Toluene (3 x 50 mL) was then added and removed under vacuum to give which 
was then dissolved in toluene (50 mL) and concentrated again  to give 4d as a yellow oil 
(196 mg, 56%). 
 
FAB-MS:      m/z = 301 [M+H]
+
 (27%). 
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1
H NMR (CDCl3, 400 MHz) δ (ppm):   7.14-7.03 (m, 10H, H5-7), 4.41 (s, 2H, H3), 
3.46-3.29 (m, 4H, H2), 2.78 (s, 4H, H1) 
13
C NMR (CDCl3, 400 MHz) δ (ppm):  138.6 (C4), 127.9 (C6), 127.6 (C7), 
127.5(C5), 86.0 (C3), 71.1 (C2), 41.5 (C1)  
CHN:  Found C: 68.39, H: 8.04, N: 8.34%; Calcd. 
for (C18H24N2O2)·H2O C: 67.90; H: 8.23; N: 
8.80%.  
 
5.3.3 Organic building blocks for L5 (N3O3) 
5.3.3.1 Synthesis of  tetra(ethylene glycol)-p-ditosylate (5a)
216
 
 
 
Tosyl chloride (2.2 eq., 86.4 g, 453 mmol) was added to a solution of 
(tetraethylene)glycol (1 eq., 40.00, 206 mmol) in dry DCM (120 mL). The mixture was 
cooled to 0°C in an ice bath and KOH (3 eq., 34.7 g, 618 mmol) was added portionwise 
over 30 min. The resulting beige mixture was stirred at 0°C for 1 h, and then warmed to 
room temperature and stirred for a further 18 h. DCM (50 mL) and H2O (200 mL) were 
then added to the reaction flask, and the mixture was stirred vigorously for 1 min. The 
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resulting layers were separated, and the aqueous layer was extracted with DCM (2 x 50 
mL). The combined organic layers were then washed with H2O (2 x 50 mL), dried over 
MgSO4 and concentrated under vacuum to give 5a as a yellow oil (95.6 g, 92%). 
 
FAB-MS:      m/z = 503 [M+H]
+
 (1.7%). 
1
H NMR (CDCl3, 300 MHz) δ (ppm):  7.78 (d, J = 8.0 Hz, 4H, H4), 7.33 (d, J = 8.2 
Hz, 4H, H3), 4.14 (t, J = 4.8, 4H, H6), 4.15 
(t, J = 5.5, 4H, H7), 3.55 (s, 8H, H8-9), 2.43 
(s, 6H, H1). 
13
C NMR (CDCl3, 300 MHz) δ (ppm):   144.9 (C5), 133.1 (C2), 129.9 (C3), 128.1 
(C4), 70.8 (C8/9), 70.7 (C8/9), 69.4 (C7), 68.8 
(C6), 21.8 (C1). 
 
5.3.3.2 Synthesis of 1,11-diphthalimido-3,6,9-trioxaundecane (5b)
215
 
 
 
Potassium phthalimide (2.5 eq., 9.73 g. 21.0 mmol) was added to a solution of 5a (2.5 
eq., 26.4 g, 52.5 mmol) in dry DMF (100 mL). The cream reaction mixture was heated to 
80°C and stirred for 18 h. After cooling to room temperature, the solvent was removed 
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under vacuum to give a tan residue. The crude product was purified by passage through a 
silica gel column in MeOH/CHCl3 (3:1), and concentrated under vacuum to give 5b as a 
cream solid (9.56 g, 98%). 
 
M.p.:      102°C (Lit. 104-105°C
304
). 
FAB-MS:      m/z = 453 [M+H]
+
 (1.0%). 
1
H NMR (CDCl3, 300 MHz) δ (ppm):  7.83-7.68 (m, 8H, H3-4), 3.76 (dt, J = 2.5 Hz, 
5.6 Hz, 8H, H7-8), 3.59-3.50 (m, 8H, H5-6). 
13
C NMR (CDCl3, 300 MHz) δ (ppm):   168.3 (C4), 134.0 (C1), 132.2 (C3), 123.3   
(C2), 70.7 (C7), 70.1 (C8), 68.0 (C6), 37.3 
(C5). 
5.3.3.3 Synthesis of 1,11-diamino-3,6,9-trioxaundecane (5c)
215
 
 
 
 
Hydrazine monohydrate (20 eq., 10.5 mL, 214 mmol) was added to a suspension of 5b (1 
eq., 5.01 g, 10.7 mmol) in dry MeOH/THF (1:1. 90 mL). The clear yellow mixture was 
refluxed at 95°C for 18 h, and a cream precipitate formed. The solvent volume was 
reduced by evaporation, and the flask was cooled to 0°C. The precipitate was removed by 
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filtration through a sintered funnel, and washed well with ice-cold MeOH/THF (3 x 10 
mL). The clear yellow filtrate was concentrated under vacuum to give 5c as a thick 
yellow oil (2.74 g, 89 %). 
 
FAB-MS:      m/z = 194 [M+H]
+
 (2.9%). 
1
H NMR (CDCl3, 300 MHz) δ (ppm):  3.64 (m, 8H, H3-4), 3.52 (t, J = 5.1 Hz, 4H, 
H2), 2.87 (t, J = 5.9, 4H, H1). 
13
C NMR (CDCl3, 300 MHz) δ (ppm):   73.3 (C2), 70.4 (C4), 70.7 (C3), 41.8 (C1).  
 
5.3.4 Organic building blocks for L6 (dbN3O3) 
5.3.4.1 Synthesis of 2-(acetylamino)phenol  (6a)
217
 
 
 
A solution of acetic anhydride (2.3 eq., 60 mL, 636 mmol) in MeOH (40 mL) was added 
dropwise to a suspension of 2-aminophenol (1 eq., 30.0 g, 275 mmol) in H2O (200 mL). 
The resulting mixture was stirred vigorously for 5 h at room temperature. The progress of 
the reaction was monitored by tlc (hexane/acetone (3:2)) (Rf = 0.2). The precipitate which 
formed was collected by Buchner filtration and washed well with EtOH to give 6a as a 
beige solid (40.7 g, 98%). 
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M.p.:      210°C (Lit. 209-210°C
305
). 
FAB-MS:      m/z = 152 [M+H]
+
 (52.2%). 
1
H NMR (d6-DMSO, 300 MHz) δ (ppm):  7.67 (d, J = 8.3 Hz, 1H, H4), 7.00-6.72 (m, 
3H, H5-7), 2.09 (s, 1H, H1). 
13
C NMR (d6-DMSO, 300 MHz) δ (ppm):    169.0 (C2), 147.9 (C8), 126.4 (C3), 124.6 
(C6),  122.4 (C5), 119.0 (C4), 115.9 (C7), 
23.6 (C1). 
 
5.3.4.2  Synthesis of  bis-(2-(2-acetylaminophenoxy)-ethyl) ether (6b)
217
 
 
 
Bis(2-chloroethyl) ether (1 eq., 10.3 g, 71.7 mmol) was dissolved in dry DMF (30 mL). 
K2CO3 (2 eq., 39.6 g, 143 mmol) was added and the resulting suspension was stirred at 
80°C for 30 min. A solution of 6a (2 eq., 21.6 g, 143 mmol) in dry DMF (10 mL) was 
added dropwise, with the temperature being maintained at 80°C, and the reaction mixture 
was stirred for a further 18 h. The mixture was then cooled to room temperature and the 
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inorganic solids were removed by Buchner filtration. The filtrate was concentrated under 
vacuum to give a dark red/brown liquid which quickly hardened into a brown solid. The 
product was washed well with acetone to give 6b as an off-white solid (12.6 g, 47%). 
 
M.p.:      132°C (Lit. 130-134°C
217
). 
FAB-MS:      m/z = 373 [M+H]
+
 (41.3%). 
1
H NMR (CDCl3, 300 MHz) δ (ppm):  8.35-8.32 (m, 2H, H4), 7.94 (s, 2H, H6), 
7.01-6.90 (m, 6H, H5,7), 4.22 (t, J = 5.7 Hz, 
4H, H9), 3.90 (t, J = 4.6 Hz, 4H, H10), 2.06 
(s, 6H, H1). 
13
C NMR (CDCl3, 300 MHz) δ (ppm):  168.3 (C2), 146.8 (C8), 128.9 (C6), 123.8 
(C3), 122.4 (C5), 120.5 (C4), 113.1 (C7), 69.5 
(C10), 68.9 (C9), 24.8 (C1). 
 
5.3.4.3 Synthesis of 1,5-bis(2-amino)-phenoxy-3-oxapentane (6c)
217
 
 
274 
 
 
A solution of NaOH (7.1 eq., 7.64 g, 191 mmol) in H2O (25 mL) was added dropwise to 
a suspension of 6b (1 eq., 10.0 g, 26.9 mmol) in EtOH (75 mL). The beige mixture was 
refluxed at 80°C for 3 d, then cooled to r.t. and concentrated under vacuum. The dark 
brown residue was dissolved in CHCl3, washed with H2O (3 x 50 mL), and concentrated 
under vacuum to give 6c as a dark brown liquid which solidified after several days into a 
light brown solid (5.80 g, 75%). 
 
M.p.:      64°C (Lit. 65°C
217
). 
FAB-MS:      m/z = 289 [M+H]
+
 (94.4%). 
1
H NMR (CDCl3, 300 MHz) δ (ppm):  6.84-6.69 (m, 8H, H2-5), 4.18 (t, J = 4.7 Hz, 
4H, H7), 3.93 (t, J = 4.8 Hz, 4H, H8). 
13
C NMR (CDCl3, 300 MHz) δ (ppm):  146.4 (C6), 137.2 (C1), 122.1 (C4), 118.5 
(C2), 115.5 (C5), 113.2 (C3), 70.0 (C8), 68.6 
(C7). 
CHN:  Found C: 66.71, H: 6.82, N: 9.72%; Calcd. 
for C16H20N2O3 C: 66.65; H: 6.99; N: 
9.53%. 
5.3.5 Organic building blocks for L7 (O2N3-N3O2) 
5.3.5.1 Synthesis of 2,2’,6,6’-tetramethyl-4,4’-bipyridine (7a)219,221 
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Sodium (2 eq., 3.98 g, 173 mmol) in paraffin oil was washed with hexane (3 x 50 mL) 
under N2. Dry THF (120 mL) and 2,6-dimethylpyridine (1 eq., 8.83 g, 82.4 mmol) were 
added, and the mixture was stirred vigorously for 7 d. The beige reaction mixture was 
cooled to 0°C, and SO2 gas was passed over the mixture for 5 h. Ethanol (150 mL) was 
then poured into the mixture, followed by sat. NaOH(aq) until the pH was ~8. The product 
was extracted with DCM (3 x 50 mL), dried over MgSO4 and concentrated under vacuum 
to give an amorphous cream solid, which was vigorously stirred in hot H2O for 5 min, 
and then cooled in the freezer. The product was collected by Buchner filtration and 
washed with water to give (8.1) as a white solid (4.24 g, 49%). 
 
M.p.:      151°C (Lit. 149°C
306
). 
FAB-MS:      m/z = 213 [M+H]
+
 (82.4%). 
1
H NMR (CDCl3, 300 MHz) δ (ppm):  7.19 (s, 4H, H3), 2.62 (s, 12H, H1). 
13
C NMR (CDCl3, 300 MHz) δ (ppm):   158.6 (C2), 146.8 (C4), 118.2 (C3), 24.6 (C1). 
 
5.3.5.2 Synthesis of 2,2’,6,6’-tetracarboxylic-4,4’-bipyridine (7b)221 
 
Chromium(VI) trioxide (12.2 eq., 11.0 g, 110 mmol) was added portionwise to a solution 
of 8.1 (1 eq., 1.91 g, 9.0 mmol) in conc. H2SO4 (32 mL). The reaction mixture was stirred 
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at r.t. for 1 h and then slowly heated to 75°C and stirred for a further 2 h. The mixture 
was cooled to r.t. and ~50 mL of ice chips were dropped in, with vigorous stirring. The 
mixture was then poured into ice water (300 mL) and left to cool in the fridge for 18 h. 
The resulting light green solid was collected by Buchner filtration and washed well with 
H2O to give 8.2 as an off-white solid (1.06 g, 34%). 
 
M.p.:      270°C, decomp.(Lit. 270°C
307
). 
FAB-MS:      m/z = 303[M+H]
+
 (100%). 
1
H NMR (d6-DMSO, 300 MHz) δ (ppm):  13.62 (s, 4H, HCOOH), 8.61 (2, 4H, H3). 
13
C NMR (d6-DMSO, 300 MHz) δ (ppm):   165.8 (C1), 150.1(C4), 146.7 (C2), 125.8 
(C3). 
 
5.3.5.3 Synthesis of 2,2’,6,6’-tetrachloroformyl-4,4’-bipyridine (7c)221 
 
 
SOCl2 (excess, 8 mL) and dry DMF (1 mL) were added to 8.2 (1 eq., 930 mg, 2.80 
mmol) under an atmosphere of N2. The mixture was heated to 80°C and vigorously 
stirred for 4 h, during which time it changed colour from green to pink. The solvent was 
removed by vacuum distillation to give a 8.3 as pale green solid (870 mg, 77%). 
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M.p.:      204°C (Lit. 205-206°C
307
). 
FAB-MS:      m/z = 406 [M+H]
+
 (0.4%). 
1
H NMR (d6-DMSO, 300 MHz) δ (ppm):  8.58 (s, 4H, H3). 
13
C NMR (d6-DMSO, 300 MHz) δ (ppm):   165.4 (C1), 149.6 (C2), 146.4 (C4), 125.5 
(C3). 
 
5.3.5.4 Synthesis of 2,2’,6,6’-tetraacetyl-4,4’-bipyridine (7d)  
 
METHOD 1
221
 
Meldrum’s acid (4.1 eq., 4.45 g, 30.9 mmol) was dissolved in dry DCM (25 mL) and dry 
pyridine (excess, 6 mL). The mixture was cooled to 0°C, and 8.3 (1 eq., 3.03 g, 7.46 
mmol) was added. After stirring for 1 h at 0°C and 1 h at r.t., DCM (40 mL) was added 
and the solution was poured into 2N HCl (50 mL) containing crushed ice. After vigorous 
stirring for 5 min, the layers were separated.  The aqueous layer was extracted with DCM 
(3 x 50 mL), and the combined organic layers were washed with 2N HCl (2 x 50 mL), 
dried over MgSO4 and concentrated under vacuum to give a dark brown solid. The solid 
was refluxed in acetic acid/H2O (1:1, 240 mL) at 115°C for 18 h. After the solution was 
cooled to r.t., H2O (150 mL) was added, and the product was extracted with DCM (6 x 50 
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mL), washed with 5% NaHCO3, dried over MgSO4 and concentrated under vacuum to 
give 8.4 as a light brown solid (770 mg, 32 %).  
METHOD 2
218
  
4,4′-Bipyridine (1 eq., 1.25 g, 8.0 mmol), pyruvic acid (7 eq., 3.95 mL, 56.0 mmol), and 
silver nitrate (0.075 eq., 0.102 g, 0.60 mmol) in H2O (5 mL) were stirred in a solution of 
H2SO3 (0.4 M, 150 mL) for 5 mins. Ammonium persulfate (8 eq., 14.6 g, 54.0 mmol) was 
added carefully in small portions over 30 min, and the resulting bright yellow mixture 
was vigorously stirred at r.t. for 18 h. The cream solid which precipitated was collected 
by filtration, and the same portions of pyruvic acid, silver nitrate, and ammonium 
persulfate were added to the filtrate again. Conc. H2SO4 (5 mL) was added, and the 
mixture was stirred for a further 18 h. The resulting precipitate was collected by filtration, 
and the combined precipitates were purified by column chromatography 
(EtOAc/hexane/DCM 1:2:7) to give 7d as a cream solid (285 mg, 11%). 
 
M.p.:      260°C, decomp.(262°C
222
). 
EI-MS:      m/z = 324 [M]
.+
 (28.3%). 
1
H NMR (CDCl3, 300 MHz) δ (ppm):  8.56 (s, 4H, H4), 2.85 (s, 12H, H1). 
13
C NMR (CDCl3, 300 MHz) δ (ppm):   198.8 (C2), 154.0 (C3), 146.7 (C5), 122.3 
(C4), 25.7 (C1). 
CHN:  Found C: 63.70, H: 5.37, N: 7.80%; Calcd. 
for (C18H16N2O4)·H2O C: 63.15; H: 5.30; N: 
8.18%.  
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5.3.6 Organic building blocks for targeted complex 
5.3.6.1 Synthesis of dimethyl-4-bromopyridine-2,6-dicarboxylate (8a)
308
 
 
Phosphorus tribromide (3.6 eq., 9.4 mL, 98.3 mmol) was added dropwise to a solution of 
bromine (3 eq., 4.2 mL, 81.9 mmol) in dry hexane (35 mL). The reaction mixture was 
vigorously stirred for 1 h, during which time a yellow solid precipitated. The dark red 
liquid was decanted, and the yellow solid was washed with dry hexane (4 x 50 mL). 
Chelidamic acid (1 eq., 5.00 g, 27.3 mmol) was added, and the reaction mixture was 
refluxed at 90°C for 4 h. After cooling to r.t., CHCl3 (75 mL) was added, and the dark 
purple mixture was passed through a Buchner filter. The brown filtrate was concentrated 
under vacuum, and then re-dissolved in CHCl3 (100 mL) and cooled in an ice-bath. EtOH 
(50 mL) was added dropwise, and the resulting brown mixture was allowed to warm to 
r.t. and stirred for 18 h. The solvent was removed under vacuum to give a thick brown 
oil. The product was extracted from the oil with hot hexane (6 x 50 mL), and crystallized 
upon cooling to 0°C. The desired product 8a was collected by filtration as white needles 
(1.39 g, 17%).  
 
M.p.:      93°C (Lit. 90-93°C
309
). 
ESI-MS:      m/z = 245 [M-2Et+2H]
+
 (4%). 
280 
 
 
1
H NMR (CDCl3, 400 MHz) δ (ppm):  8.42 (s, 2H, H5), 4.49 (dd, J = 14.3, 6.9 Hz, 
4 H, H2), 1.46 (t, J = 7.2 Hz, 6H, H3).  
13
C NMR (CDCl3, 400 MHz) δ (ppm):   163.7 (C3), 149.7 (C4), 135.0 (C6), 131.21 
(C5), 62.9 (C2), 14.3 (C1). 
5.3.6.2 Synthesis of 4-bromopyridine-2,6-dicarboxylic acid (8b)
308
  
 
NaOH(aq) (excess, 5M, 60 mL) was added to 9.1 (1 eq., 1.00 g, 3.3 mmol), and the 
resulting cloudy white mixture was refluxed at 115°C for 1 h. The mixture was cooled to 
r.t., and then acidified to pH = 2 by the addition of 3N HCl. The cream precipitate was 
collected by Buchner filtration and allowed to air dry, giving 9.2 as a white solid (420 
mg, 52.0%). 
 
M.p.:      211°C, decomp. (Lit. 205-209°C
310
). 
EI-MS:      m/z = 246 [M]
.+
 (4%). 
1
H NMR (d6-DMSO, 400 MHz) δ (ppm):  13.72 (s, 2H, HCOOH), 8.37 (2, 2H, H3). 
13
C NMR (d6-DMSO, 400 MHz) δ (ppm):   165.0 (C1), 149.7 (C2), 134.4 (C4), 130.2 
(C3). 
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5.3.6.3 Synthesis of 4-bromopyridine-2,6-dicarboxylic dichloride (8c)
311
 
 
Freshly distilled SOCl2 (excess, 10 mL) was added to 8b (1 eq., 1.23 g, 5.0 mmol) under 
N2. Dry DMF (0.5 mL) was added and the resulting yellow solution was refluxed for 2 h. 
After the mixture was cooled to r.t., the SOCl2 and DMF were removed by vacuum 
distillation to give 8c as a tan solid, which was used without further purification (1.32 g, 
93%). 
 
M.p.:      104°C (Lit. 105-108°C
310
). 
EI-MS:      m/z = 283 [M]
.+
 (1%). 
1
H NMR (CDCl3, 300 MHz) δ (ppm):  8.31 (s, 2H, H3). 
13
C NMR (CDCl3, 300 MHz) δ (ppm):   168.7 (C1), 150.2 (C2), 148.0 (C4), 129.0 
(C3). 
 
5.3.6.4 Synthesis of 2,6-diacetyl-4-bromo-pyridine (8d)
312,313
 
 
Meldrum’s acid (2 eq., 1.15 g, 8.0 mmol) was dissolved in dry DCM (10 mL) and 
pyridine (excess, 2 mL). The pale yellow solution was cooled to 0°C, and (8c) (1eq., 1.13 
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g, 4.0 mmol) was added in one portion. The resulting mixture was stirred at 0°C for 1 h, 
and then warmed to r.t. and stirred for a further 18 h. Dry DCM (50 mL) was added, and 
the mixture was poured onto 2N HCl (60 mL) containing crushed ice. The mixture was 
vigorously stirred for 5 min, and then the two layers were separated. The aqueous layer 
was extracted with DCM (3 x 50 mL), and the combined organic layers were washed 
with 2N HCl (2 x 50 mL), dried over MgSO4 and concentrated under vacuum to give a 
dark brown solid. The solid was refluxed in acetic acid/H2O (1:1, 240 mL) at 115°C for 
18 h. After the solution was cooled to r.t., H2O (150 mL) was added, and the product was 
extracted with DCM (6 x 50 mL), washed with 5% NaHCO3, dried over MgSO4 and 
concentrated under vacuum. The crude product was purified by a pipette-scale silica 
column in pet. ether/EtOAc (8:2) to give 8d as a light brown solid (340 mg, 35%).  
 
M.p.:      92-94°C. 
EI-MS:      m/z = 241 [M]
.+
 (100%). 
1
H NMR (d6-acetone, 400 MHz) δ (ppm):  8.26 (s, 2H, H4), 2.74 (s, 6H, H1). 
13
C NMR (d6-acetone, 400 MHz) δ (ppm):   198.0 (C2), 154.6 (C3), 135.5 (C5), 128.0 
(C4), 25.5 (C1). 
CHN:  Found C: 45.38, H: 3.44, N: 5.76%; Calcd. 
for C9H8BrNO2 C: 44.66; H: 3.33; N: 
5.78%. 
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5.3.6.5 Synthesis of 2,6-diacetyl-4-azido-pyridine (8e) 
 
NaN3 (10 eq., 0.209 g, 3.22 mmol) was added  to a vigorously stirred solution of 8d  (1 
eq., 0.078 mg, 0.322 mmol) in DMF/H2O (10 mL, 4:1). The resulting mixture was 
carefully stirred at 90°C for 48 h. After cooling to r.t., the dark red solution was poured 
slowly onto ice-cooled water. The product was extracted with EtOAc (6 x 10 mL), and 
the organic layers were concentrated carefully under vacuum. The crude product was 
purified via a pipette-scale silica column in pet. ether/EtOAc (8:2), to give the desired 
product 8e as a crystalline beige solid (19.4 mg, 29%).  
 
1
H NMR (d6-acetone, 400 MHz) δ (ppm):  7.39 (s, 2H, H4), 2.64 (s, 6H, H1) 
13
C NMR (d6-acetone, 400 MHz) δ (ppm):  200.0 (C2), 157.1 (C3), 138.2 (C5), 126.0  
      (C4), 25.6 (C1). 
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5.4 Schiff-base macrocyclic complexes 
5.4.1 Complexes of L1  
 
5.4.1.1 Synthesis of [Mn(L1)Cl2]·2H2O (1.1)  
Diacetylpyridine (1 eq., 329 mg, 2.01 mmol) was added in one portion to a solution of 
MnCl2·4H2O (1 eq., 349 mg, 2.01 mmol) in MeOH (30 mL). The solution was heated to 
50°C, and then triethyltetramine (1 eq., 300 μL, 2.01 mmol) was added in one portion. 
The reaction mixture was heated to 85°C and refluxed for 18 h. The solvent volume was 
reduced by half, and the mixture was cooled to r.t. An excess of Et2O was added, and the 
resulting precipitate was collected by Büchner filtration and washed well with cold Et2O 
to give 1.1 as a beige solid (530 mg, 60%). 
 
FAB-MS:       m/z = 363 [M-Cl]
+
 (100%). 
CHN:  Found C: 45.01, H: 5.88, N: 17.21%; Calcd. 
for C15H23N5Cl2Mn)·2H2O C: 45.13; H: 
5.81; N: 17.54%. 
IR (KBr, cm
-1
):  3330 (br, O-H), 3271 (m, N-H) , 2907 (s, C-
H), 2853 (s, C-H), 1649 (s, C=N), 1583 (s, 
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py), 1457 (s, C-H), 1201 (s, C-N), 1112 (m, 
C-N), 945 (w, py). 
UV-Vis (MeOH, nm):  λmax = 250 (ε = 5110), λ = 300 (ε = 3070). 
5.4.1.2 Synthesis of [Gd(L1)Cl3]·3H2O (1.2)   
Diacetylpyridine (1 eq., 329 mg, 2.01 mmol) was added in one portion to a solution of 
GdCl3·6H2O (1 eq., 749 mg, 2.01 mmol) in MeOH (30 mL). The solution was heated to 
50°C, and then triethyltetramine (1 eq., 300 μL, 2.01 mmol) was added in one portion. 
The reaction mixture was heated to 85°C and refluxed for 18 h. The solvent volume was 
reduced by half, and the mixture was cooled to r.t. After syringe flitration, an excess of 
Et2O was added, and the resulting precipitate was collected by Buchner filtration and 
washed well with cold Et2O to give 1.2 as a pale yellow solid (144 mg, 12%). 
 
FAB-MS:       m/z = 465 [M-H-2Cl]
+
 (2.9%). 
CHN:  Found C: 30.48, H: 5.21, N: 11.95%; Calcd. 
for (C15H23N5Cl3Gd)·3H2O C: 30.48; H: 
4.95; N: 11.85%. 
IR (KBr, cm
-1
):  3383 (br, O-H, N-H), 2961, (s, C-H), 1631 
(s, C=N), 1592 (s, py), 1458 (s, C-H), 1089 
(m, C-N), 1011 (w, py). 
UV-Vis (MeOH, nm):    λmax = 250 (ε = 5860), λ = 281 (ε = 4020). 
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5.4.1.3 Synthesis of [Dy(L1)Cl3]·4H2O (1.3)   
Diacetylpyridine (1 eq., 329 mg, 2.01 mmol) was added in one portion to a solution of 
DyCl3·6H2O (1 eq., 759 mg, 2.01 mmol) in MeOH (30 mL). The solution was heated to 
50°C, and then triethyltetramine (1 eq., 300 μL, 2.01 mmol) was added in one portion. 
The reaction mixture was heated to 85°C and refluxed for 18 h. The solvent volume was 
reduced by half, and the mixture was cooled to r.t. An excess of Et2O was added, and the 
resulting precipitate was collected by Buchner filtration and washed well with cold Et2O 
to give 1.3 as a beige solid (587 mg, 47.5%). 
 
FAB-MS:       m/z = 471 [M-H-2Cl] (6.6%). 
CHN:  Found C: 29.76, H: 4.91, N: 10.87%; Calcd. 
for (C15H23N5Cl3Dy)·4H2O C: 29.33; H: 
5.09; N: 11.40%. 
IR (KBr, cm
-1
):  3345 (br, O-H), 3246 (m, N-H), 1629 (s, 
C=N), 1591 (m, py), 1492 (m, py), 1111 (w, 
C-N), 1010 (w, py), 813 (w, O-H).  
UV-Vis (MeOH, nm):    λmax = 250 (ε = 6590), λ = 281 (ε = 3820). 
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5.4.2 Complexes of L2 
 
5.4.2.1 Synthesis of [Mn(L2)Cl2]·2H2O (2.1)   
Diacetylpyridine (1 eq., 412 mg, 2.53 mmol) was added in one portion to a solution of 
MnCl2·4H2O (500 mg, 2.53 mmol) in MeOH (30 mL). The solution was heated to 50°C, 
and then 2,2’-(ethylenedioxy)bisethylamine (1 eq., 370 μL, 2.53 mmol) was added in one 
portion. The reaction mixture was heated to 85°C and refluxed for 18 h. The solvent 
volume was reduced by half, and the mixture was cooled to r.t. An excess of Et2O was 
added, and the resulting precipitate was collected by Büchner filtration and washed well 
with cold Et2O to give 2.1 as a pale yellow solid (875 mg, 79%). 
 
FAB-MS:       m/z = 365 [M-2H2O-Cl] (100%). 
CHN:  Found C: 41.19, H: 5.69, N: 9.43%; Calcd. 
for (C15H21N3O2Cl2Mn)·2H2O C: 41.21; H: 
5.76; N: 9.61%. 
IR (KBr, cm
-1
):  3403 (br, O-H), 2923 (s, C-H), 2880 (s, C-
H), 1645 (s, C=N), 1586 (m, py), 1110 (m, 
C-O), 1018 (w, py). 
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UV-Vis (MeOH, nm):    λmax = 250 (ε = 6350), λ = 300 (ε = 4240).                                                                                                   
5.4.2.2 Synthesis of [Gd(L2)Cl3]·6H2O (2.2)   
Diacetylpyridine (1 eq., 329 mg, 2.02 mmol) was added in one portion to a solution of 
GdCl3·6H2O (1 eq., 749 mg, 2.02 mmol) in MeOH (30 mL). The solution was heated to 
50°C, and then 2,2’-(ethylenedioxy)bisethylamine (1 eq., 295 μL, 2.02 mmol) was added 
in one portion. The reaction mixture was heated to 85°C and refluxed for 18 h. The 
solvent volume was reduced by half, and the mixture was cooled to r.t. An excess of Et2O 
was added, and the resulting precipitate was collected by Büchner filtration and washed 
well with cold Et2O to give 2.2 as an orange/brown solid (287 mg, 22%). 
 
MS-FAB:       m/z = 297 [L2+Na]
+
 (6.6%). 
CHN:  Found C: 27.89, H: 5.23, N: 6.35%; Calcd. 
for (C15H21N3O2Cl3Gd)·6H2O C: 27.84; H: 
5.14; N: 6.49%. 
IR (KBr, cm
-1
):  3386 (br, O-H), 2924 (s, C-H), 1620 (m, 
C=N), 1595 (m, py), 1460 (m, C=C), 1095 
(m, C-O).  
UV-Vis (MeOH, nm):  λmax = 250 (ε = 4560), λ = 274 (ε = 3720). 
 
5.4.2.3 Synthesis of [Dy(L2)Cl3]·6H2O (2.3)  
Diacetylpyridine (1 eq., 612 mg, 3.76 mmol) was added in one portion to a solution of 
DyCl3·6H2O (1 eq., 1.41 g, 3.76 mmol) in MeOH (30 mL). The solution was heated to 
289 
 
 
50°C, and then 2,2’-(ethylenedioxy)bisethylamine (1 eq., 550 μL, 3.76 mmol) was added 
in one portion. The reaction mixture was heated to 85°C and refluxed for 18 h. The 
solvent volume was reduced by half, and the mixture was cooled to r.t. An excess of Et2O 
was added, and the resulting precipitate was collected by Büchner filtration and washed 
well with cold Et2O to give 2.3 as an orange solid (2.36 g, 96%). 
 
MS-FAB:       m/z = 297 [L2+Na]
+
 (9.1%). 
CHN:  Found C: 27.94, H: 4.92, N: 6.39%; Calcd. 
for (C15H21N3O2Cl3Dy)·6H2O C: 27.62; H: 
5.10; N: 6.44%. 
IR (KBr, cm
-1
):  3375 (br, O-H), 3007 (s, C-H), 1625 (m, 
C=N), 1593 (m, py), 1460 (w, C-H), 1095 
(m, C-O), 1017 (m, py).   
UV-Vis (MeOH, nm):  λmax = 250 (ε = 5140), λ = 274 (ε = 4050), λ 
= 315 (ε = 4410).  
5.4.3 Complexes of L3 
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5.4.3.1 Synthesis of [Mn(L3)ClH2O]Cl·H2O (3.1)   
Diacetylpyridine (1 eq., 134 mg 0.82 mmol) was added in one portion to a solution of 
MnCl2·4H2O (1 eq., 142 mg, 0.82 mmol) in EtOH (30 mL). The solution was heated to 
50°C, and then diamine 3b (1 eq., 200 mg, 0.82 mmol) was added in one portion. The 
reaction mixture was heated to 85°C and refluxed for 4 h. The solvent volume was 
reduced by half, and the mixture was cooled to r.t. An excess of Et2O was added, and the 
resulting precipitate was collected by Büchner filtration and washed well with cold Et2O 
to give 3.1 as an orange solid (62 mg, 14%). 
 
MS-FAB:       m/z = 461 [M-2H2O Cl]
+
 (10%). 
CHN:  Found C: 55.72, H: 4.65, N: 8.39%; Calcd. 
for (C23H21N3O2Cl2Mn)·2H2O C: 55.55; H: 
4.26; N: 8.45%. 
IR (KBr, cm
-1
):  3351 (br, O-H), 3072 (m, C-H ar.), 2968 (s, 
C-H), 2924 (s, C-H), 1617 (m, C=N), 1592 
(m, py), 1503 (m, C=C), 1362 (m, C-H), 
1087 (m, C-O).    
UV-Vis (MeOH, nm):  λmax = 252 (ε = 11060), λ = 284 (ε = 7670). 
 
5.4.3.2 Synthesis of [Gd(L3)Cl3]·0.5H2O (3.2)   
Diacetylpyridine (1 eq., 134 mg, 0.82 mmol) was added in one portion to a solution of 
GdCl3·4H2O (1 eq., 304 mg, 0.82 mmol) in EtOH (30 mL). The solution was heated to 
50°C, and then diamine 3b (1 eq., 200 mg, 0.82 mmol) was added in one portion. The 
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reaction mixture was heated to 85°C and refluxed for 4 h. The solvent volume was 
reduced by half, and the mixture was cooled to r.t. An excess of Et2O was added, and the 
resulting precipitate was collected by Büchner filtration and washed well with cold Et2O 
to give 3.2 as a brown solid (58 mg, 11%). 
CHN:  Found C: 43.71, H: 4.01, N: 5.63%; Calcd. 
for (C23H21N3O2Cl3Gd)·0.5H2O C: 42.89; H: 
3.44; N: 6.52%. 
IR (KBr, cm
-1
):  3342 (br, O-H), 2828 (m, C-H), 1632 (m, 
C=N), 1597 (s, py), 1503 (m, C=C), 1460 
(w, C=C), 1362 (w, C-H), 1082 (m, C-O). 
UV-Vis (MeOH, nm):  λmax = 250 (ε = 7200), λ = 275 (ε = 5160). 
5.4.4 Complexes of L4
 
 
5.4.4.1 Synthesis of R,R-[Mn(L4)Cl2]·2H2O (4.1)   
Diacetylpyridine (1 eq., 107 mg, 0.65 mmol) was added in one portion to a solution of 
MnCl2·4H2O (1 eq., 113 mg, 0.65 mmol) in bubbled MeOH (30 mL) under inert 
conditions. The solution was heated to 50°C, and then diamine 4d (1 eq., 196 mg, 0.65 
mmol) in MeOH (5 mL) was added in one portion. The reaction mixture was heated to 
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85°C and refluxed for 18 h under N2. The solvent volume was reduced by half, and the 
mixture was cooled to r.t. An excess of Et2O was added, and the resulting precipitate was 
collected by Büchner filtration and washed well with cold Et2O to give 4.1 as a beige 
solid (102 mg, 27%). 
 
FAB-MS:       m/z = 517 [M-2H2OCl]
+
 (100%). 
CHN:  Found C: 55.15, H: 5.63, N: 6.79%; Calcd. 
for (C27H29Cl2MnN3O2)·2H2O C: 55.02; H: 
5.64; N: 7.13%.  
IR (KBr, cm
-1
):  3371 (br, O-H), 3061 (m, C-H ar.), 2888 (m, 
C-H), 1650 (m, C=N), 1587 (m, py), 1454 
(m, C=C), 1079 (m, C-O), 929 (w, py). 
UV-Vis (MeOH, nm):  λmax = 252 (ε = 5840), λ = 301 (ε = 3240). 
 
5.4.5 Complexes of L5
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5.4.5.1 Synthesis of [Gd(L5)Cl3]·2H2O (5.1)   
Diacetylpyridine (1 eq., 620 mg, 3.80 mmol) was added in one portion to a solution of 
GdCl3·6H2O (1 eq., 1.412 g, 3.80 mmol) in MeOH (30 mL). The solution was heated to 
50°C, and then diamine 5c (1 eq., 731 mg, 3.80 mmol) in MeOH (5 mL) was added in 
one portion. The reaction mixture was heated to 85°C and refluxed for 18 h. The solvent 
volume was reduced by half, and the mixture was cooled to r.t. An excess of Et2O was 
added, and the resulting precipitate was collected by Büchner filtration and washed well 
with cold Et2O to give 5.1 as a yellow solid (136 mg, 6%). 
 
FAB-MS:       m/z = 193 [L5+H]
+
 (41%). 
CHN:  Found C: 32.83, H: 4.10, N: 5.95%; Calcd. 
for (C17H25N3O3Cl3Gd)·2H2O C: 32.98; H: 
4.72; N: 6.79%. 
IR (KBr, cm
-1
):  3289 (br, O-H), 1626 (s, C=N), 1595 (s, py), 
14534 (w, C-H), 1361 (m, C-H), 1118 (w, 
C-O), 1083 (m, C-O), 1012 (w, py), 814 (w, 
O-H).  
UV-Vis (MeOH, nm):  λmax = 251 (ε = 10520), λ = 278 (ε = 7480). 
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5.4.6 Complexes of L6
 
 
5.4.6.1 Synthesis of [Mn(L6)Cl2]·2H2O (6.1)   
Diacetylpyridine (1 eq., 417 mg, 2.55 mmol) was added in one portion to a solution of 
MnCl2·4H2O (1 eq., 505 g, 2.55 mmol) in MeOH (30 mL). The solution was heated to 
50°C, and then diamine 6c (1 eq., 736 mg, 2.55 mmol) was added in one portion. The 
reaction mixture was heated to 85°C and refluxed for 18 h. The solvent volume was 
reduced by half, and the mixture was cooled to r.t. An excess of Et2O was added, and the 
resulting precipitate was collected by Büchner filtration and washed well with cold Et2O 
to give 6.1 as a yellow solid (856 mg, 58%).  
 
FAB-MS:       m/z = 289 [L6+H]
+
 (60%), 505 [M-2H2O-
Cl]
 +
 (5.9%). 
CHN:  Found C: 51.88, H: 4.98, N: 7.31%; Calcd. 
for (C25H25N3O3Cl2Mn)·2H2O C: 52.01; H: 
5.06; N: 7.28%. 
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IR (KBr, cm
-1
):  3422 (br, O-H), 3069 (m, C-H ar.), 2872 (m, 
C-H), 1617 (m, C=N), 1586 (s, py), 1492 (s, 
C=C), 1116 (m, C-O), 1084 (m, C-O), 1011 
(w, py), 816 (w, O-H).  
UV-Vis (MeOH, nm):  λmax = 251 (ε = 10520), λ = 282 (ε = 6470). 
 
5.4.6.2 Synthesis of [Gd(L6)Cl3]·6H2O (6.2)   
Diacetylpyridine (1 eq., 97.9 mg, 0.60 mmol) was added in one portion to a solution of 
GdCl3·6H2O (1 eq., 223 mg, 0.60 mmol) in MeOH (30 mL). The solution was heated to 
50°C, and then diamine 6c (1 eq., 173 mg, 0.60 mmol) was added in one portion. The 
reaction mixture was heated to 85°C and refluxed for 18 h. The solvent volume was 
reduced by half, and the mixture was cooled to r.t. An excess of Et2O was added, and the 
resulting precipitate was collected by Büchner filtration and washed well with cold Et2O 
to give 6.2 as a brown solid (148 mg, 31%). 
 
FAB-MS:       m/z = 289 [L6+H]
+
 (100%). 
CHN:  Found C: 38.50, H: 4.39, N: 5.14%; Calcd. 
for (C25H25N3O3Cl3Gd)·6H2O C: 38.14; H: 
4.74; N: 5.34%. 
IR (KBr, cm
-1
):  3331 (br, O-H), 2868 (m, C-H), 1628 (m, 
C=N), 1594 (s, py), 1504 (s, C=C), 1362 (w, 
C-H), 1127 (m, C-O), 1055 (m, C-O), 957 
(w, py), 816 (w, O-H).  
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UV-Vis (MeOH, nm):    λmax = 254 (ε = 8501), λ = 277 (ε = 8038). 
 
5.4.6.3 Synthesis of [Dy(L6)Cl3]·6H2O (6.3)   
Diacetylpyridine (1 eq., 433 mg, 2.65 mmol) was added in one portion to a solution of 
DyCl3·6H2O (1 eq., 1.00 g, 2.65 mmol) in MeOH (30 mL). The solution was heated to 
50°C, and then diamine 6c (1 eq., 765 mg, 2.65 mmol) was added in one portion. The 
reaction mixture was heated to 85°C and refluxed for 18 h. The solvent volume was 
reduced by half, and the mixture was cooled to r.t. An excess of Et2O was added, and the 
resulting precipitate was collected by Büchner filtration and washed well with cold Et2O 
to give 6.3 as a dark brown solid (390 mg, 19%). 
 
FAB-MS:       m/z = 289 [L6+H]
+
 (100%). 
CHN:  Found C: 37.94, H: 4.44, N: 4.95%; Calcd. 
for (C25H25N3O3Cl3Dy)·6H2O C: 37.89; H: 
4.71; N: 5.30%. 
IR (KBr, cm
-1
):  3318 (br, O-H), 2936 (m, C-H), 1620 (m, 
C=N), 1594 (m, C=N), 1501 (s, C=C), 1360 
(m, C-H), 1117 (m, C-O), 1084 (m, C-O).  
UV-Vis (MeOH, nm):    λmax = 276 (ε = 4966). 
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5.4.7 Complexes of L7 
 
5.4.7.1 Synthesis of [Mn2(L7)Cl4]·5H2O (7.1)  
To a solution of MnCl2·4H2O (1 eq., 135 mg, 0.783 mmol) in MeOH (20 mL) was added 
7d (1 eq., 127 mg, 0.392 mmol) in one portion. The brown mixture was heated to 50°C, 
and then 2,2’-(ethylenedioxy)bisethylamine (1 eq., 116  μL, 0.783 mmol) was added. The 
reaction mixture was heated to 85°C and refluxed for 18 h. The solvent volume was 
reduced by half and the solution was passed through a syringe filter. An excess of Et2O 
was added, and precipitate was collected by Buchner filtration to give 7.1 as a beige solid 
(190 mg, 54%). 
 
FAB-MS:       m/z = 728 [M-4H2O-2Cl]
+
 (16.4%). 
CHN:  Found C: 40.27, H: 5.49, N: 9.52%; Calcd. 
for (C30H40N6O4Cl4Mn2)·5H2O C: 40.47; H: 
5.66; N: 9.44%. 
IR (KBr, cm
-1
):  3385 (br, O-H), 2932 (s, C-H), 1648 (s, 
C=N), 1596 (m, py), 1378, 1349, 1106 (m, 
C-O) 1071 (w, C-O). 
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UV-Vis (MeOH, nm):    λmax = 252 (ε = 18060), λ = 311 (ε = 3820). 
 
5.5Crown ether complexes 
5.5.1 Complexes of 12-crown-4 
5.5.1.1 Synthesis of [Dy(12C4)(H2O)5](ClO4)3
.
H2O (9.1)  
 
Dy(ClO4)3(aq) (40% w/w, 847 μL, 1.09 mmol) and 12-crown-4 (173 μL, 1.09 mmol) 
were vigorously stirred in MeOH/CH3CN (1:3, 6 mL) at 55 °C for 3 h. The reaction 
mixture was cooled to room temperature, filtered through cotton wool and left to 
crystallize by slow evaporation. Clear, colourless block-shaped crystals of 9.1 were 
isolated after 6 days (77.5 mg, 10%).  
 
FAB-MS:       m/z = 538 [M-6H2O-ClO4]
+
 (100%). 
CHN:  Found C: 12.90, H: 3.79, N: 0.00 %; Calcd. 
for C8H28Cl3O22Dy C, 12.89; H, 3.79; N, 
0.00%. 
IR (cm
-1
):  3405 (br, O-H), 2970 (w, C-H), 1050 (s, Cl-
O/C-O), 1027 (s, Cl-O/C-O), 929 (m, Cl-O), 
618 (m, Cl-O). 
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UV-Vis (MeOH, nm):  λmax = 269 (ε = 119). 
 
5.5.1.2 Synthesis of Y-doped [Dy(12C4)(H2O)5](ClO4)3
.
H2O (9.1b) 
Dy(ClO4)3(aq) (50% w/w, 57 μL, 0.098 mmol), Y(ClO4)3(aq) (50% w/w, 1.00 mL, 1.95 
mmol)  and 12-crown-4 (326 μL, 2.05 mmol) were vigorously stirred in MeOH/CH3CN 
(1:3, 6 mL) at 55 °C for 3 h. Clear, pale yellow block-shaped crystals of 9.1b were 
obtained via  slow evaporation after 6 days (260 mg, 19%).  
 
CHN:  Found C: C: 14.35, H: 3.81, N: 0.00%; 
Calcd. for C8H26Cl3O21Dy0.12Y0.88 C, 14.51; 
H, 3.95; N, 0.00%. 
5.5.1.3 Synthesis of [Ho(12C4)(H2O)5](ClO4)3
.
H2O (9.3) 
 
Ho(ClO4)3(aq) (40% w/w, 1 eq., 250 μL, 0.303 mmol) and 12-crown-4 (1 eq., 48.2 μL, 
0.303 mmol) were vigorously stirred in MeOH/CH3CN (1:3, 6 mL) at 55 °C for 3 h. The 
reaction mixture was cooled to room temperature, filtered through cotton wool and left to 
crystallize by slow evaporation. After 3 days, clear pale pink crystals of 9.3 were isolated 
(132 mg, 58%).  
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MALDI-TOF-MS:      m/z = 441 [M-5H2O-2ClO4-H]
+
 (100%). 
CHN:       Found C: C: 12.56, H: 3.69, N: 0.18%;  
      Calcd. for C8H28Cl3HoO22
.
H2O
.
0.1CH3CN  
      C, 12.80; H, 3.97; N, 0.18%. 
IR (cm
-1
):  3405 (br, O-H), 2970 (w, C-H), 1043 (s, Cl-
O/C-O), 1026 (s, Cl-O/C-O), 929 (m, Cl-O), 
616 (m, Cl-O). 
UV-Vis (MeOH, nm):  λmax = 248 (ε = 37). 
 
5.5.2 Complexes of 15-crown-5 
5.5.2.1 Synthesis of [Dy(15C5)(H2O)4](ClO4)3
.
15C5
.
H2O (10.1)  
 
Dy(ClO4)3(aq) (40% w/w, 847 μL, 1.09 mmol) and 15-crown-5 (215 μL, 1.09 mmol) 
were vigorously stirred in MeOH/CH3CN (1:3, 6 mL) at 55 °C for 3 h. The reaction 
mixture was cooled to room temperature, filtered through cotton wool and left to 
crystallize by slow evaporation. After 8 days, opaque white crystals of 10.1 were isolated 
(231 mg, 21%).  
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FAB-MS:       m/z = 582 [M-4H2O-ClO4-15C5]
+
 (47%).  
CHN:       Found C: C: 22.64, H: 5.82, N: 0.00%;  
      Calcd. for C10H30Cl3O22Dy
.
4.5H2O C, 22.40; 
      H, 5.54; N, 0.00%. 
IR (cm
-1
):  3355 (br, O-H), 3241 (br, O-H), 2930 (w, C-
H), 2886 (w, C-H), 1050 (s, Cl-O/C-O), 
1028 (s, Cl-O/C-O), 939 (m, Cl-O), 619 (m, 
Cl-O). 
UV-Vis (MeOH, nm):  λmax = 250 (ε = 19). 
5.5.2.2 Synthesis of [Er(15C5)(H2O)4](ClO4)3
.
3H2O (10.2)  
 
Er(ClO4)3(aq) (40% w/w, 149 μL, 0.178 mmol) and 15-crown-5 (35.3 μL, 0.178 mmol) 
were vigorously stirred in MeOH/CH3CN (1:3, 6 mL) at 55 °C for 18 h. The reaction 
mixture was cooled to room temperature, filtered through cotton wool and left to 
crystallize by slow evaporation. After 5 days, pink needle-like crystals of 10.2 were 
isolated (68 mg, 44%).  
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MALDI-TOF-MS:    m/z = 676 [M-2H2O-ClO4]
+
 (68%), 586  
      [M-7H2O-ClO4]
+
 (21%). 
CHN:  Found: C: 14.16, H: 3.65, N: 0.00%; Calcd. 
for C10H34Cl3ErO24 C, 14.79; H, 4.22; N, 
0.00%. 
IR (cm
-1
):  3395 (br, O-H), 2947 (w, C-H), 1051 (b, Cl-
O/C-O), 951 (m, Cl-O), 932 (m, Cl-O), 620 
(m, Cl-O). 
UV-Vis (MeOH, nm):  λmax = 246 (ε = 55). 
 
5.5.3 Complexes of 18-crown-6 
5.5.3.1 Synthesis of [Tb(18C6)(H2O)3](ClO4)3
.
H2O (11.1) 
 
Tb(ClO4)3(aq) (50% w/w, 2 eq., 547 μL, 0.757 mmol) and 18-crown-6 (1 eq., 100 mg, 
0.379 mmol) were vigorously stirred in MeOH/CH3CN (1:3, 6 mL) at 55 °C for 18 h. The 
reaction mixture was cooled to room temperature, filtered through cotton wool and left to 
crystallize by slow evaporation. After 6 days, 11.1 was isolated as clear, pale yellow 
crystals (232 mg, 77%).    
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MALDI-TOF-MS:     m/z = 621 [M-4H2O-ClO4]
+
 (100%) 
CHN:  Found: C, 17.92; H, 3.94; N, 0.00%; Calcd. 
for C12H32Cl3O22Tb: C: 18.16, H: 4.06, N: 
0.00%. 
IR (cm
-1
):  3406 (br, O-H), 2956 (w, C-H), 1049 (s, Cl-
O/C-O), 1030 (s, Cl-O/C-O), 950 (m, Cl-O), 
931 (m, Cl-O), 619 (m, Cl-O). 
UV-Vis (MeOH, nm):  λmax = 250 (ε = 29). 
 
5.5.3.2 Synthesis of [Dy(18C6)(H2O)3](ClO4)3
.
H2O (11.2) 
 
Dy(ClO4)3(aq) (50% w/w, 3 eq., 468 μL, 0.757 mmol) and 18-crown-6 (1 eq., 67 mg, 
0.252 mmol) were vigorously stirred in MeOH/CH3CN (1:3, 6 mL) at 55 °C for 18 h. The 
reaction mixture was cooled to room temperature, filtered through cotton wool and left to 
crystallize by slow evaporation. After 6 days, 11.2 was isolated as clear, colourless 
crystals (120 mg, 60%).   
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MALDI-TOF-MS:     m/z = 626 [M-4H2O-ClO4]
+
 (100%) 
CHN:  Found: C: 18.04, H: 3.90, N: 0.00%; Calcd. 
for C12H32Cl3O22Dy: C, 18.08; H, 4.05; N, 
0.00%. 
IR (cm
-1
):  3422 (br, O-H), 2951 (w, C-H), 1050 (b, Cl-
O/C-O), 1030 (b, Cl-O/C-O), 952 (m, Cl-O), 
931 (m, Cl-O), 619 (m, Cl-O). 
UV-Vis (MeOH, nm):  λmax = 248 (ε = 46). 
5.5.3.3 Synthesis of [Ho(18C6)(H2O)3](ClO4)3 (11.3) 
 
Ho(ClO4)3(aq) (40% w/w, 3 eq., 601 μL, 0.757 mmol) and 18-crown-6 (1 eq., 67 mg, 
0.252 mmol) were vigorously stirred in MeOH/CH3CN (1:3, 6 mL) at 55 °C for 18 h. The 
reaction mixture was cooled to room temperature, filtered through cotton wool and left to 
crystallize by slow evaporation. After 4 days, 11.3 was isolated as pink needle-like 
crystals (144 mg, 73%).  
   
MALDI-TOF-MS:     m/z = 627 [M-4H2O-ClO4]
+
 (100%) 
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CHN:  Found: C: 18.06, H: 3.92, N: 0.00%; Calcd. 
for C12H30Cl3HoO21: C, 18.44; H, 3.87; N, 
0.00%. 
IR (cm
-1
):  3397 (br, O-H), 2955 (w, C-H), 1049 (s, Cl-
O/C-O), 1029 (s, Cl-O/C-O), 951 (m, Cl-O), 
931 (m, Cl-O), 619 (m, Cl-O). 
UV-Vis (MeOH, nm):  λmax = 250 (ε = 57). 
5.5.3.4 Synthesis of [Er(18C6)(H2O)3](ClO4)3 (11.4)  
 
Er(ClO4)3(aq) (50% w/w, 2 eq., 560 μL, 0.757 mmol) and 18-crown-6 (1 eq., 100 mg, 
0.379 mmol) were vigorously stirred in MeOH/CH3CN (1:3, 6 mL) at 55 °C for 18 h. The 
reaction mixture was cooled to room temperature, filtered through cotton wool and left to 
crystallize by slow evaporation. After 6 days, 11.4 was isolated as clear pink crystals 
(140 mg, 47%).    
 
MALDI-TOF-MS:     m/z = 630 [M-4H2O-ClO4]
+
 (100%) 
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CHN:  Found: C: 14.55, H: 4.00, N: 0.15%; Calcd. 
for C12H30Cl3ErO21: C, 17.97; H, 4.02; N, 
0.00%. 
IR (cm
-1
):  3422 (br, O-H), 2951 (w, C-H), 1050 (b, Cl-
O/C-O), 1030 (b, Cl-O/C-O), 952 (m, Cl-O), 
931 (m, Cl-O), 619 (m, Cl-O). 
UV-Vis (MeOH, nm):  λmax = 247 (ε = 62). 
5.6 In vitro and in vivo methods 
5.6.1 In vitro relaxivity measurements 
T1 and T2 relaxation times were measured at 300 and 600 MHz using a Bruker Advance 
AV 300 Digital NMR spectrometer and a Bruker Advance AV 600 Digital NMR 
spectrometer, with the guidance of Razvan Simionescu. Measurements were carried out 
on a series of 5-10 aqueous dilutions between 0 – 5 mM, with a deuterated water insert, 
and processed using Bruker TOPSPIN 2.1 PL6 software. T1 and T2 relaxation times were 
measured at 60 MHz at the STTARR Innovation Centre in Toronto, Canada using a 
Bruker minispec mq60 Contrast Agent Analyzer, with the guidance of Dr. Warren Foltz. 
T1 and T2 relaxation times were measured at 20 MHz at the Bruker Showroom in Milton, 
Canada on a model mq20 Contrast Agent Analyzer. At 60 and 20 Hz, measurements were 
carried out on  a series of 6 aqueous dilutions between 0 – 5 mM.  
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5.6.2 In vitro cytotoxicity study 
The in vitro cytotoxicity study was performed by In Vitro ADMET Laboratories, 
Columbia, MD. 
Reference compound: Gadodiamide (Selleckchem, Lot # 02) was used as the reference 
compound. It is one of the 8 Gd(III)-based MRI agents approved for use in Canada (trade 
name: Omniscan).   
Preparation of test articles and reference compound: The test articles and reference 
compound were weighed and dissolved in the incubation medium to give the highest test 
concentration of 30 mM.  The solution was filter sterilized and diluted to the remaining 
test concentrations of 10 mM, 3.3 mM, 1.1 mM, 0.36 mM, 0.12 mM and 0.04 mM. 
Preparation of cells: Cryopreserved primary rat renal proximal tubule epithelial cells 
(RPTECs) (ScienCell Research Laboratories, Carlsbad, CA) were used for the study. The 
rat RPTECs were thawed completely at 37ºC, and transferred to epithelial cell medium 
(ScienCell Research Laboratores, Carlsbad, CA) followed by plating in poly-L-lysine 
coated 96-well plates. The RPTECs were allowed to recover and grow in a cell culture 
incubator (37°C, humidified atmosphere of 5% carbon dioxide and 95% air) for 3 
additional days with a medium change every alternate day.  
Treatment of cells: Following 3 days of plating, the RPTECs were washed once with 
serum free epithelial cell medium (ScienCell Research Laboratories, Carlsbad, CA) 
followed by treatment with the test, reference or control articles for 2, 4, 10 or 24 h. All 
treatments were performed in triplicate. 
Quantification of cell viability: Cellular viability and metabolic activity were assessed 
by using the 3-(4,5dimethylthiazol- 2-yl)-2,5-diphenyl tetrazolium bromid e(MTT) 
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uptake assay. A 10x stock of the MTT dye was prepared in phosphate buffered saline 
(PBS).  An aliquot of dye was added 2 hrs before the intended time point to achieve a 
final 1x concentration, after which incubation (37°C, humidified atmosphere of 5% 
carbon dioxide and 95% air) continued until the desired time point. For the 2 hr time 
point, the aliquot of dye was added immediately after the test articles. Following 
incubation, all media was aspirated from the wells and the plates were allowed to dry. 
The resulting formazan crystals were dissolved in DMSO using an orbital shaker, and the 
absorbance at 570 nm was measured using a Victor 
3
V multilabel plate reader (reference 
wavelength = 650 nm). 
Data analysis: The inhibitory concentration (IC50, the concentration resulting in 50% 
toxicity) was determined by plotting log concentration vs. relative viability, followed by 
non-linear regression of the curve using Graph Pad Prism 5.0. 
5.6.3 In vivo methods 
Preliminary in vivo studies were performed at the Animal Resource Centre and the 
STTARR Innovation Centre, Toronto, as outlined in UHN AUP 3859.1. Necropsy and 
histopathology were carried out by Mbed Pathology. 
Acute toxicity: Compound 1.1 (aq., 0.0125 mM) was injected intravenously into 4 male 
rats (Sprague Dawley Crl:SD, 315-340 g) at a dosage of 0.02 mmol/kg following 
anaesthesia with 5% isoflurane. The animals were observed for a period of 14 days. Body 
weight measurements and hematology were performed on days 7 and 14. Following 
euthanasia, the heart, lungs, liver, kidneys, spleen, thyroid and pituitary glands were 
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grossly examined during necropsy, and samples of the brain, heart, lungs, liver, kidneys, 
spleen and thymus were microscopically evaluated during histopathological examination.  
Imaging: Compound 1.1 (aq., 0.0125 mM) was injected intravenously into 2 male rats 
(Sprague Dawley Crl:SD, 312-338 g) at a dosage of 0.02 mmol/kg following anaesthesia 
with 5% isoflurane. Anesthesia was maintained at 2-2.5% isoflurane through a nose cone 
for the duration of the scans. Fast-spin-echo images were collected for 45 mins. 
immediately post-injection. The DT1-weighted RARE (Rapid Acquisition Relaxation 
Enhancement) scans were acquired with an echo time of 10 ms, and a repetition time = 
respiratory cycle duration (~1100 ms). 
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7 APPENDIX  
7.1 Crystallographic data 
 9.1 9.2 
Empirical formula C8H28Cl3DyO22 C8H28Cl3HoO22 
Formula weight 745.15 747.59 
Temperature/K 150(2) 150(2) 
Crystal system Monoclinic Monoclinic 
Space group P21/c P21/c 
a/Å 13.1195(7) 13.121(4) 
b/Å 10.2129(6) 10.229(3) 
c/Å 17.5681(10) 17.634(5) 
α/° 90 90 
β/° 93.941(2) 93.558(8) 
γ/° 90 90 
Volume/Å
3
 2348.4(2) 2362.3(12) 
Z 4 4 
ρcalcmg/mm
3
 2.164 2.1018 
/mm-1 3.618 3.786 
F(000) 1524.0 1482.8 
Crystal size/mm
3
 0.43 x 0.27 x 0.28 0.14 x 0.14 x 0.22 
Independent reflections 4806  7160 
Goodness-of-fit on F
2
 1.334 1.161 
Final R indexes [I>=2σ (I)] 
R1 = 0.0208 
wR2 = 0.0514 
R1 = 0.0281 
wR2 = 0.1273 
 
Table 7.1 Crystal data and structure refinement for 9.1 (Dy
III
-12C4) and 9.2 (Ho
III
-12C4). 
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 10.1 10.1b 10.2 
Empirical formula C20H50Cl3DyO27 C8H28Cl3O22Y C10H30Cl3ErO22 
Formula weight 991.45 671.56 775.95 
Temperature/K 150(2) 150(2) 173 
Crystal system Monoclinic Monoclinic Orthorhombic 
Space group P21/n P21/c Pnma 
a/Å 15.8533(14) 13.139(1) 17.6319(11) 
b/Å 14.6908(14) 10.2303(7) 14.7648(8) 
c/Å 16.4867(15) 17.5916(14) 9.5931(6) 
α/° 90 90 90 
β/° 99.409(4) 93.866(3) 90 
γ/° 90 90 90 
Volume/Å
3
 3788.06 2359.2(3) 2497.4(3) 
Z 1 4 4 
ρcalcmg/mm
3
 1.735 1.8906 2.064 
/mm-1 2.278 2.936 3.777 
F(000) 2004.0 1358.8 1540.0 
Crystal size/mm
3
 0.32 x 0.29 x 0.45 0.14 x 0.09 x 0.09 0.09 x 0.05 x 0.11 
Independent reflections 7642 5913 3779 
Goodness-of-fit on F
2
 1.233 1.299 1.081 
Final R indexes  
[I>=2σ (I)] 
R1 = 0.0460 
wR2 = 0.1394 
R1 = 0.0417 
wR2 = 0.1421 
R1 = 0.0250 
wR2 = 0.0616 
 
 
Table 7.2 Crystal data and structure refinement for 10.1 (Dy
III
-15C5), 10.1b (Y
III
-15C5), 
and 10.2 (Er
III
-15C5) 
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 11.1 11.2 
Empirical formula C18H45Cl4.5O31.5Tb1.5 C16H38.67Cl4Dy1.33O28 
Formula weight 1163.46 1037.60 
Temperature/K 150(2) 150(2) 
Crystal system Hexagonal Orthorhombic 
Space group P61 Pbcn 
a/Å 9.9031(5) 13.4884(9) 
b/Å 9.9031(5) 22.4361(16) 
c/Å 44.999(4) 16.9130(12) 
α/° 90 90 
β/° 90 90 
γ/° 120 90 
Volume/Å
3
 3821.8(4) 5118.3(6) 
Z 4 6 
ρcalcmg/mm
3
 2.0219 2.020 
μ/mm-1 3.183 3.325 
F(000) 2319.8 3088.0 
Crystal size/mm
3
 0.07 x 0.11 x 0.06 0.12 x 0.09 x 0.09 
Independent  
reflections 
4245 5268 
Goodness-of-fit  
on F
2
 
0.932 1.019 
Final R indexes  
[I>=2σ (I)] 
R1 = 0.0279 
wR2 = 0.0749 
R1 = 0.0440  
wR2 = 0.1193 
 
 
Table 7.3 Crystal data and structure refinement for 11.1 (Tb
III
-18C6) and 11.2 (Dy
III
-
18C6). 
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 11.3 11.4 
Empirical formula C20H40O20Cl3Ho C30H30N2O20Cl3Er 
Formula weight 776.61 783.97 
Temperature/K 150(2) 150(2) 
Crystal system Monoclinic Monoclinic 
Space group Pc P21/c 
a/Å 9.7970(8) 9.8027(6) 
b/Å 17.8698(15) 17.8702(13) 
c/Å 14.8669(12) 14.8422(11) 
α/° 90 90 
β/° 100.228(3) 100.180(3) 
γ/° 90 90 
Volume/Å
3
 2561.4(4) 2559.1(3) 
Z 4 4 
ρcalcmg/mm
3
 2.0137 2.0347 
μ/mm-1 3.493 3.685 
F(000) 1534.8 1558.4 
Crystal size/mm
3
 
0.62 x 0.09 x 
0.12 
0.03 x 0.09 x 0.55 
Independent  
reflections 
10186  5239 
Goodness-of-fit  
on F
2
 
1.011 1.008 
Final R indexes  
[I>=2σ (I)] 
R1 = 0.0467 
wR2 = 0.1122 
R1 = 0.0339 wR2 = 
0.0896 
 
Table 7.4 Crystal data and structure refinement for 11.3 (Ho
III
-18C6) and 11.4 (Er
III
-
18C6). 
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7.2 Relaxivity plots 
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Figure 7.1 Relaxivity plots for the eight soluble, pure Mn
II
 and Gd
III
 complexes in aqueous solution (37°C, 60 MHz). 
 
y = 7.3626x - 0.0185 
R² = 0.9998 
y = 30.68x + 3.3352 
R² = 0.9978 
0
25
50
75
100
125
150
1
/T
 (
s-
1
) 
Concentration (mM) 
(MnII-N3O2)2 
1/T1
1/T2
y = 5.58x - 0.1598 
R² = 0.9989 
y = 6.7671x + 0.0564 
R² = 0.9999 
0
25
50
0 1 2 3 4 5 6
1
/T
 (
s-
1
) 
Concentration (mM) 
GdIII-N5 
1/T1
1/T2
y = 6.0439x - 0.4079 
R² = 0.999 
y = 7.669x - 0.4163 
R² = 0.9989 
0
25
50
0 1 2 3 4 5 6
1
/T
 (
s-
1
) 
Concentration (mM) 
GdIII-N3O2 
1/T1
1/T2
y = 7.5216x - 0.2959 
R² = 0.9982 
y = 8.6816x + 0.4229 
R² = 0.9995 
0
25
50
0 1 2 3 4 5 6
1
/T
 (
s-
1
) 
Concentration (mM) 
GdIII-dbN3O3 
1/T1
1/T2
